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Tauopathies are neurodegenerative diseases characterised by the pathological 
phosphorylation and accumulation of tau protein within the brain.  Despite considerable 
efforts, the molecular pathways underlying tau pathogenesis have not yet been fully 
elucidated.  This has been partially attributed to the limitations of traditionally used in vitro 
and in vivo models to recapitulate the complex molecular pathways involved in the 
pathogenesis of tau.   
The use of human induced pluripotent stem cell (hiPSC) technology has enabled the 
derivation of disease-relevant cell types from patients with tauopathy.  During this project, 
models of sporadic Alzheimer’s disease (sAD) and frontotemporal dementia with 
Parkinsonism linked to chromosome 17 (FTDP-17) were developed through the derivation of 
vulnerable neuronal subtypes from hiPSC.  Tau-related molecular pathology was assessed in 
these models and compared to that within human brain tissue to determine the ability of 
these models to recapitulate the molecular aspects of the disease niche and to inform on the 
underlying pathways contributing to tau pathogenesis.   
hiPSC derived from a patient carrying Val337Met MAPT were differentiated to produce 
cortical glutamatergic neurons (CGNs) to model FTDP-17.  This model successfully 
recapitulated the abnormal tau phosphorylation characteristic of tauopathy and decreased 
levels of synapsin, indicative of synaptic loss.  Additionally, analysis of alterations in the gene 
expression,  protein levels and activity of tau kinases involved in tauopathy recapitulated 
those seen in the brain, demonstrating the value of this model as a platform for further 
investigation of the pathogenesis of frontotemporal dementia.  
Basal forebrain cholinergic neurons (bfCNs) and CGNs, which are vulnerable in sAD, were 
derived from control human pluripotent stem cell lines and treated with Amyloid-β (Aβ) 
oligomers for 48 hours to probe the molecular mechanisms underlying Aβ-induced tau 
pathology.  While no evidence of abnormal tau phosphorylation or increased levels of tau 
were found, the model was found to recapitulate the development of neuronal varicosities 
and the loss of synapsin.  The knowledge gained from this model serves to inform future 









I gratefully acknowledge the James Tudor Foundation for providing the funding that made 
this project possible.   
I would also like to express my gratitude for the support and tutorage of my supervisors, Dr. 
Shelley Allen and Prof. Maeve Caldwell.  Many thanks to Prof. Maeve Caldwell, who initially 
took me on as her PhD student for this project and has stayed in touch with me throughout 
the process of completing it, providing guidance and support.  My sincere thanks to Dr. 
Shelley Allen for her excellent advice, patience and support during this project. 
I am gratefully indebted to Dr. Lucy Crompton and Dr. Paul Nistor who spent many hours 
helping me to develop cell culture techniques, checking problematic cell cultures with me 
and for providing advice on the neuronal differentiation protocols.  Many thanks to Dr. Lucy 
Crompton for carrying out the reprogramming of hiPSC lines V337M-C and V337M-E.  Many 
thanks also to Dr. Daniel Whitcomb for his help with the preparation of Amyloid-β.  Many 
thanks to Prof. Peter Davies (Albert Einstein College of Medicine, New York, USA)  for 
supplying tau antibodies DA9, PHF-1, CP13, RZ3 and MC1. 
I would like to thank my fellow PhD students in the Regenerative Medicine Labs at the 
University of Bristol.  A special thanks to Jal and Renata, who kept me sane during late 
working hours and brightened challenging days in the lab with their sense of humour.  Many 
thanks also to Petros for his calm attitude, humour and advice on cell culture work.  I would 
also like to thank Aida and Hadil for their lovely cakes.   
I wish to thank my parents, who have instilled in me a sense of resilience; they have 
demonstrated through their own challenges that there is always a way to solve difficult 
problems.  I have always admired their determination and work ethic.  Thank you both so 
much for your support during this project. 
This PhD project has taught me to have resilience and patience.  I feel privileged to have been 






Table of Contents 
 
Declaration ......................................................................................... 2 
Abstract .............................................................................................. 3 
Acknowledgements ............................................................................ 4 
List of Tables ...................................................................................... 16 
List of Figures ..................................................................................... 18 
List of Abbreviations .......................................................................... 21 
Chapter 1  General Introduction ........................................................ 27 
1.1 Tau protein .................................................................................................. 27 
1.1.1  Expression of tau in the brain .............................................................................. 27 
1.1.1.2  Haplotypes .................................................................................................... 28 
1.1.2  The physiological functions of tau ....................................................................... 29 
1.1.2.1  The role of tau as a microtubule binding protein ......................................... 29 
1.1.2.1.1  Regulation of microtubule binding by phosphorylation of tau.............. 31 
1.1.3  Pathological phosphorylation of tau leads to neurodegeneration ...................... 32 
1.2  Tauopathies ..................................................................................................... 34 
1.2.1  Frontotemporal Dementia ................................................................................... 35 
1.2.1.1  Neurodegeneration in frontotemporal dementia associated with tau 
pathology ................................................................................................................... 37 
1.2.1.2  Pick’s Disease ................................................................................................ 38 
1.2.2  Frontotemporal dementia with Parkinsonism linked to chromosome 17 ........... 38 
1.2.2.1  MAPT mutations ....................................................................................... 39 
1.2.2.1.1  The clinical and pathological features of IVS 10+16 C>T MAPT ......... 41 
1.2.2.1.2  The clinical and pathological features of R406W MAPT .................... 42 
6 
 
1.2.3  Alzheimer’s disease .............................................................................................. 42 
1.2.3.1  Neurodegeneration in Alzheimer’s disease .................................................. 43 
1.2.3.1.1  Vulnerable neuronal populations in AD ................................................. 44 
1.2.3.2  Tau and Amyloid-beta pathology in Alzheimer’s disease ............................. 45 
1.2.3.2.1  Propagation of tau pathology ................................................................ 46 
1.2.3.2.2  Generation of Amyloid pathology .......................................................... 48 
1.2.3.2.3  Amyloid toxicity ...................................................................................... 50 
1.2.3.2.4  Phosphorylation of tau in AD ................................................................. 50 
1.2.3.3  Mutations of familial AD ............................................................................... 51 
1.2.3.4  Risk factors of Alzheimer’s disease ............................................................... 52 
1.3  Tau kinases and phosphatases ........................................................................ 53 
1.3.1  GSK3β ................................................................................................................... 54 
1.3.1.1  GSK3β in tauopathy ...................................................................................... 55 
1.3.2  CDK5 ..................................................................................................................... 57 
1.3.2.1  Cdk5 in tauopathy ......................................................................................... 58 
1.3.3  P21 activated kinases ........................................................................................... 60 
1.3.3.1  PAK3 in tauopathy ......................................................................................... 62 
1.4  Models of tauopathy ....................................................................................... 63 
1.4.1  Animal models ..................................................................................................... 64 
1.4.1.1  Murine models .............................................................................................. 64 
1.4.1.3  Drosophila models ........................................................................................ 65 
1.4.1.3  C. elegans models ......................................................................................... 66 
1.4.2  Cell-based models of tauopathy .......................................................................... 66 
1.4.2.1  Primary neuronal cultures............................................................................. 67 
1.4.2.2  Cancer-derived cell lines ............................................................................... 67 
1.4.3  Modelling tauopathy using induced pluripotent stem cells ................................ 68 
1.4.3.1  Stem cells ...................................................................................................... 68 
7 
 
1.4.3.1.1  Embryonic stem cells ............................................................................. 69 
1.4.3.1.2  Induced pluripotent stem cells .............................................................. 70 
1.4.3.1.3  Differentiation of pluripotent stem cells to produce neurons .............. 71 
1.4.3.1.4  The role of dual Smad inhibition in neural induction ............................ 72 
1.4.3.1.5  Modelling tauopathy using induced pluripotent stem cells .................. 72 
1.4.3.1.6  Modelling frontotemporal dementia using induced pluripotent stem 
cells ........................................................................................................................ 73 
1.4.3.1.7  Modelling Alzheimer’s disease using induced pluripotent stem cells ... 76 
Chapter 2  General Methods .............................................................. 80 
2.1  Cell culture ....................................................................................................... 80 
2.1.1  Mouse embryonic fibroblast culture ................................................................... 80 
2.1.1.1  Mouse embryonic fibroblast (MEF) media ................................................... 80 
2.1.1.2  Derivation of mouse embryonic fibroblasts (MEF) ....................................... 80 
2.1.1.3  Mouse embryonic fibroblast (MEF) inactivation .......................................... 81 
2.1.1.4  Plating down inactivated mouse embryonic fibroblasts (iMEFs) as feeders for 
human induced pluripotent stem cells ...................................................................... 81 
2.1.2  Human pluripotent stem cell culture ................................................................... 82 
2.1.2.1  Culturing human pluripotent stem cells on an iMEF feeder layer ................ 82 
2.1.2.1.1  Mechanical passaging of human induced pluripotent stem cells .............. 82 
2.1.2.2  Culturing human pluripotent stem cells (hPSC) within the Essential 8TM 
feeder free system ..................................................................................................... 83 
2.1.2.2.1  Tissue culture plate surface coatings ..................................................... 84 
2.1.2.2.1.1  GeltrexTM ............................................................................................. 84 
2.1.2.2.1.2  MatrigelTM ........................................................................................... 84 
2.1.2.2.1.3  Vitronectin .......................................................................................... 85 
2.1.2.2.1.4  Poly-L-ornithine and laminin ............................................................... 85 
8 
 
2.1.2.2.2  Passaging human pluripotent stem cells using ethylenediamine 
tetraacetic acid ....................................................................................................... 85 
2.1.2.2.3  Passaging human pluripotent stem cells from iMEFs to E8 cell culture 
system .................................................................................................................... 86 
2.1.3  General Cell Techniques ....................................................................................... 86 
2.1.3.1  Counting cells ................................................................................................ 86 
2.1.3.2  Cryopreservation of cells .............................................................................. 88 
2.1.3.2.1  Cryopreservation of MEFs and iMEFs .................................................... 88 
2.1.3.2.2  Cryopreservation of human pluripotent cells grown on an iMEF feeder 
layer........................................................................................................................ 88 
2.1.3.2.3  Cryopreservation of human pluripotent cells cultured within the E8 
system .................................................................................................................... 89 
2.1.3.2.4  Cryopreservation of neurospheres ........................................................ 89 
2.1.3.2.5  Cryopreservation of neural progenitors and neurons at day 20-25 of the 
cortical glutamatergic neuron differentiation protocol ......................................... 89 
2.2  Biomolecular Techniques ................................................................................ 90 
2.2.1  Western Immunoblotting .................................................................................... 90 
2.2.1.1  Protein extraction from neurospheres ......................................................... 90 
2.2.1.2  Protein quantification ................................................................................... 90 
2.2.1.3  Buffers and solutions used during western immunoblotting ....................... 91 
2.2.1.4  Sample Preparation ....................................................................................... 92 
2.2.1.5  Preparation of the loading and stacking gels ................................................ 93 
2.2.1.6  Wet transfer of proteins to a polyvinylidene difluoride membrane ............ 93 
2.2.1.7  Probing the PVDF membrane with antibodies .............................................. 94 
2.2.1.8  Enhanced chemiluminescence (ECL) detection of antibodies ...................... 95 
2.2.1.9  Stripping the western .................................................................................... 95 
2.2.1.10  Densitometric analysis of protein bands .................................................... 96 
2.2.2  Immunocytochemistry ......................................................................................... 96 
9 
 
2.2.2.1  List of solutions ............................................................................................. 96 
2.2.2.2  Preparation of cells for immunocytochemistry ............................................ 96 
2.2.2.3  Probing cells with antibodies ........................................................................ 97 
2.2.2.4  Mounting coverslips ...................................................................................... 97 
2.2.3  Analysis of Gene Expression................................................................................. 97 
2.2.3.1  Extraction and purification of total RNA ....................................................... 98 
2.2.3.2  Quantification of RNA ................................................................................... 98 
2.2.3.3  Reverse Transcription of RNA to cDNA ......................................................... 99 
2.2.3.4  Quantitative Polymerise Chain Reaction .................................................... 100 
2.2.3.5  Analysis of qPCR results .............................................................................. 102 
2.2.4  Statistical analysis of western immunoblotting and gene expression results ... 102 
2.2.5 Definition of technical and biological replicates ................................................. 103 
Chapter 3  Generation of V337M MAPT induced pluripotent stem cell 
lines ................................................................................................. 104 
3.1  Introduction ................................................................................................... 104 
3.2  Methods......................................................................................................... 106 
3.2.1  Human fibroblast culture ................................................................................... 106 
3.2.2  Reprogramming ................................................................................................. 106 
3.2.3  Clonal Selection of hFibs .................................................................................... 106 
3.2.4  Alkaline Phosphatase Staining ........................................................................... 107 
3.2.5  Fluorescent immunocytochemistry ................................................................... 108 
3.2.6  Karyotyping ........................................................................................................ 108 
3.2.7  Genotyping ......................................................................................................... 108 
3.2.8  Maintenance of hiPSC ........................................................................................ 109 
3.3  Results............................................................................................................ 110 
3.3.1  Characterisation of pluripotency ....................................................................... 110 
10 
 
3.3.2  V337M MAPT lines have normal karyotypes ..................................................... 113 
3.3.3  V337M MAPT hiPSC are homozygous H1 .......................................................... 114 
3.3.4  Summary ............................................................................................................ 114 
Chapter 4  The development of a model of frontotemporal dementia 
with Parkinsonism linked to chromosome 17 using induced 
pluripotent stem cell technology ..................................................... 115 
4.1  Introduction ................................................................................................... 115 
4.1.1  Val337Met MAPT ............................................................................................... 116 
4.1.2  Aims .................................................................................................................... 119 
4.2  Methods......................................................................................................... 120 
4.2.1 Use of Tg4510 mice for antibody screening ................................................ 120 
4.2.2  Differentiation of human pluripotent cells to produce cortical glutamatergic 
neurons ........................................................................................................................ 121 
4.2.2.2  Media used during the derivation of cortical glutamatergic neurons ........ 122 
4.2.2.3  Neural Induction ......................................................................................... 123 
4.2.2.4  Neural Rosette Formation ........................................................................... 124 
4.2.2.5  Terminal differentiation and maturation of neurons ................................. 124 
4.2.2.6  Passaging cells at day 20-23 ........................................................................ 124 
4.2.3  Immunocytochemistry ....................................................................................... 125 
4.2.4  Western Immunoblotting .................................................................................. 125 
4.2.4.1 Preparation of mouse brain tissue lysates ............................................... 128 
4.2.5  qPCR ................................................................................................................... 128 
4.3  Results............................................................................................................ 129 
4.3.1  Optimisation of a panel of tau antibodies for western immunoblotting .......... 129 
4.3.2  Characterisation of CGNs derived from pluripotent stem cells ......................... 132 
4.3.3  Tau and phosphorylated tau levels in CGNs ...................................................... 139 
11 
 
4.3.4  Gene expression of MAPT in Shef 6-CGNs and V337M-C CGNs ........................ 145 
4.3.5  Tau kinase levels and activity in hiPSC-CGNs ..................................................... 146 
4.3.6  Gene expression of tau kinases in CGN ............................................................. 154 
4.3.7  Loss of synapsin I in CGN .................................................................................... 155 
4.4  Discussion ...................................................................................................... 156 
4.4.1  Limitations in the use of a V377M MAPT iPSC derived from a single patient ... 156 
4.4.2  Levels of tau and MAPT expression in V337M-CGN .......................................... 156 
4.4.3  Levels of phosphorylated tau in V337M-CGN .................................................... 158 
4.4.4  Protein levels, activity and expression levels of tau kinases in V337M-CGN..... 161 
4.4.5  Levels of synapsin I in V337M-CGN .................................................................... 163 
4.4.6  Summary ............................................................................................................ 164 
Chapter 5  The development of a model of Alzheimer’s disease using 
pluripotent stem cell technology ..................................................... 165 
5.1  Introduction ................................................................................................... 165 
5.1.1  The relationship between Aβ and tau in Alzheimer’s disease ........................... 166 
5.1.2  Rational for sAD hiPSC-model design ................................................................. 167 
5.1.3  Aims .................................................................................................................... 169 
5.2  Methods......................................................................................................... 170 
5.2.1  Differentiation of human pluripotent cells to produce basal forebrain cholinergic 
neurons using a non-adherent, embryoid body based system ................................... 170 
5.2.1.1  Media used during the derivation of basal forebrain cholinergic neurons 171 
5.2.1.2 Formation of embryoid bodies from human pluripotent stem cells ....... 172 
5.2.1.3 Neuralisation of embryoid bodies............................................................ 172 
5.2.1.4 Expansion of neural stem cells within neurospheres .............................. 173 
5.2.1.5 Terminal Differentiation of neural stem cells and progenitors ............... 173 
5.2.2  Application of toxins .......................................................................................... 174 
12 
 
5.3.2.1  Preparation of Aβ42O ................................................................................... 174 
5.2.3  Immunocytochemistry ....................................................................................... 174 
5.2.4  Western Immunoblotting .................................................................................. 174 
5.2.4.1 Stripping and re-probing of western immunoblots ................................. 174 
5.2.4.2 Analysis of western blots ......................................................................... 175 
5.2.5  Quantitative PCR ................................................................................................ 177 
5.3  Results............................................................................................................ 178 
5.3.1  Characterisation of bfCN differentiation ........................................................... 178 
5.3.2  Tau and ptau levels in Shef 6-bfCNs, Nas 2-bfCNs Shef 6-CGNs treated with 
Aβ42O ............................................................................................................................ 183 
5.3.3  Gene expression of MAPT in Shef 6-CGN and Nas 2-bfCNs treated with Aβ42O 192 
5.3.4  Tau kinase levels and activity in Shef 6-CGNs and Nas 2-bfCNs treated with Aβ42O
 ..................................................................................................................................... 193 
5.3.5  Gene expression of tau kinases in Shef 6-CGN and Nas 2-bfCNs treated with 
Aβ42O ............................................................................................................................ 200 
5.3.6  Level of synapsin I in Shef 6 and Nas 2 derived CGNs and bfCNs treated with 
Aβ42O ............................................................................................................................ 202 
5.3.7  Varicosities in Nas 2-bfCN treated with 1 µM Aβ42O ......................................... 204 
5.4  Discussion ...................................................................................................... 207 
5.4.1  Characterisation of hPSC-bfCN .......................................................................... 207 
5.4.2  Aβ42O-induced tau pathology ............................................................................ 208 
5.4.3  Aβ42O-induced alterations in kinase activity, levels and expression ................. 211 
5.4.4  The effects of Aβ42O on synapsin I protein levels .............................................. 213 
5.4.5  Aβ42O-induced varicosities containing pathogenic tau and mitochondria ........ 214 
5.4.6  Summary ............................................................................................................ 216 
Chapter 6  Tau pathology in the brain tissue of ................................ 218 
patients with frontotemporal dementia .......................................... 218 
13 
 
and Alzheimer’s disease................................................................... 218 
6.1  Introduction ................................................................................................... 218 
6.2  Methods and reagents .................................................................................. 220 
6.2.1  Brain tissue samples ........................................................................................... 220 
6.2.2  Western immunoblotting................................................................................... 222 
6.2.2.1  Lysate preparation of brain samples ........................................................... 222 
6.2.2.2  Analysis of western immunoblots ............................................................... 223 
6.2.3  qPCR analysis of gene expression in brain tissue ............................................... 223 
6.2.3.1 RNA extraction, purification and conversion to cDNA ............................. 223 
6.3  Results............................................................................................................ 225 
6.3.1  Tau pathology within the frontal and temporal cortices of patients with FTD . 225 
6.3.2  Levels of MAPT gene expression within the frontal and temporal cortices of 
patients with FTD ......................................................................................................... 233 
6.3.3  Levels and activity of tau kinases within the frontal and temporal cortices of 
patients with FTD ......................................................................................................... 234 
6.3.4  Levels of synapsin I in within the frontal and temporal cortices of patients with 
FTD ............................................................................................................................... 245 
6.3.5  Gene expression of MAPT, CDK5 and PAK3 in basal nucleus of Meynert of 
patients with AD .......................................................................................................... 247 
6.4  Discussion ...................................................................................................... 248 
6.4.1 Rational behind inclusion of sample PiD2 .................................................... 248 
6.4.2  Protein and gene expression levels of tau within the frontal and temporal 
cortices of patients with PiD and FTDP-17 ................................................................... 249 
6.4.3  Levels of phosphorylated tau in the frontal and temporal cortices of patients 
with PiD and FTDP-17 .................................................................................................. 250 
6.4.4  Protein levels and expression of tau kinases in the frontal and temporal cortices 
of patients with PiD and FTDP-17 ................................................................................ 252 
6.4.5  Levels of synapsin I within PiD temporal cortex and FTDP-17 frontal cortex .... 254 
14 
 
6.4.6  Gene expression of MAPT, CDK5 and PAK3 within the nbM of patients with AD 
compared to controls ................................................................................................... 255 
6.5  Chapter Summary .......................................................................................... 256 
Chapter 7  Final discussion and future work ..................................... 258 
7.1  The development of a model of frontotemporal dementia with Parkinsonism 
linked to chromosome 17 using induced pluripotent stem cell technology ....... 259 
7.1.1 The ability of hiPSC-CGNs generated from a patient with V337M MAPT to model 
tau pathology in FTDP-17 ............................................................................................. 260 
7.1.1.1 Comparison of levels of tau protein and MAPT expression in hiPSC and brain 
tissue ........................................................................................................................ 260 
7.1.1.2 Tau phosphorylation in hiPSC-neurons and brain tissue ............................. 261 
7.1.3 Changes in kinase expression, levels and activity in hiPSC-neurons and brain 
tissue ............................................................................................................................ 263 
7.1.4  Comparison of levels of synapsin I in hiPSC and brain tissue ............................ 265 
7.1.5  Summary of results ............................................................................................ 266 
7.2  The development of a model of Alzheimer’s disease using pluripotent stem 
cell technology ...................................................................................................... 267 
7.2.1  The ability of hPSC-neurons treated with Aβ42O to model tau pathology in AD 268 
7.2.1.1  MAPT expression, levels of tau and the phosphorylation of tau ................ 268 
7.2.2  Activity levels and expression of kinases ........................................................... 270 
7.2.3  Comparison of levels of synapsin I in hPSC-neurons treated with Aβ42O .......... 271 
7.2.4  Varicosities ......................................................................................................... 271 
7.2.5  Summary of results ............................................................................................ 272 
7.3  Limitations and future development of models............................................ 273 
7.3.1  Limitations of hiPSC-neuron models to recapitulate the aged phenotype of 
neurons in the brains of patients with tauopathy ....................................................... 273 
7.3.2  Limitations of hiPSC-neuron models to recapitulate the latency of tau 
pathogenesis ................................................................................................................ 274 
15 
 
7.3.3  Limitations in recapitulating the disease niche ................................................. 275 
7.3.4  Overcoming clonal variability between hiPSC-neuron cultures .................. 276 
7.4 Thesis summary ......................................................................................... 277 


















List of Tables 
Table 1.1 hiPSC models of FTDP-17 ................................................................................ 74 
Table 1.2 hiPSC-neuron models of AD ............................................................................ 78 
Table 2.1 Mouse embryonic fibroblast (MEF) media ..................................................... 80 
Table 2.2 Human pluripotent stem cell media ............................................................... 82 
Table 2.3 Components of SDS Sample Buffer (5 X) ........................................................ 91 
Table 2.4 Components of Loading Gel (12 %) ................................................................ 91 
Table 2.5 Components of Stacking Gel (4 %) .................................................................. 91 
Table 2.6 Components of Running Buffer (10x) ............................................................. 92 
Table 2.7 Components of Transfer Buffer (10x) ............................................................. 92 
Table 2.8 Components of TRIS Buffer Saline (TBS) (10x) ................................................ 92 
Table 2.9 Components of blocking/permeabilisation solution ...................................... 96 
Table 2.10 Components of antibody incubation solution ................................................ 96 
Table 2.11 Reaction mix for reverse transcription of RNA to cDNA. ................................ 99 
Table 2.12 Components required per qPCR Taqman® Gene Expression Assay reaction.
 ...................................................................................................................... 101 
Table 2.13 Taqman® probes ........................................................................................... 101 
Table 2.14 Thermal cycling parameters used for qPCR .................................................. 102 
Table 3.1 Transduction Media ...................................................................................... 106 
Table 3.2 Table of cell lines used .................................................................................. 107 
Table 3.3 Antibodies for characterisation of hiPSC ...................................................... 108 
Table 4.1 Components of Neural Maintenance Media (NMM) ................................... 122 
Table 4.2 Components of Neural Induction Media (NIM) ............................................ 123 
Table 4.3 Primary antibodies in immunocytochemistry and western immunoblotting
 ...................................................................................................................... 127 
Table 5.1 Chemically Defined Media (CDM) ................................................................. 171 
17 
 
Table 5.2 Neural Expansion Media (NEM) .................................................................... 171 
Table 5.3 Terminal Differentiation Media (TDM) ......................................................... 171 
Table 5.4 Antibodies used in western immunoblotting and immunocytochemistry ... 176 
Table 6.1 Brain tissue samples ..................................................................................... 221 




List of Figures 
Figure 1.1     Schematic representation of the structure of tau protein ................................ 27 
Figure 1.2     The isoforms of tau............................................................................................ 28 
Figure 1.3     Tau binds to microtubules to regulate the transport of cellular cargo ............. 30 
Figure 1.4      Physiological and pathological phosphorylation of tau ................................... 33 
Figure 1.5      Histological classification of frontotemporal dementias ................................. 36 
Figure 1.6      MAPT mutations in FTDP-17 ............................................................................ 40 
Figure 1.7      Neurodegeneration in Alzheimer’s disease ..................................................... 44 
Figure 1.8      Neurofibrillary tangles and Amyloid plaques in the Alzheimer’s disease brain 45 
Figure 1.9     Schematic representation of amyloid beta precursor protein cleavage via the 
amyloidogenic and non-amyloidogenic pathways ......................................... 49 
Figure 1.10     Schematic representation of totipotent, pluripotent and multipotent stem cell 
differentiation during development ............................................................... 69 
Figure 2.1      Mechanical stem cell colony passaging ............................................................ 83 
Figure 2.2     Schematic demonstrating the grid within the counting chamber of the 
haemocytometer used .................................................................................... 87 
Figure 2.3     Schematic of western transfer .......................................................................... 94 
Figure 3.1     Reprogramming of hFibs to produce hiPSC .................................................... 105 
Figure 3.2     Morphology and immunocytochemical staining of V337M hiPSC and Shef 6 
hESC colonies ................................................................................................ 111 
Figure 3.4      Karyotyping of V337M-C and V337M-E hiPSC ................................................ 113 
Figure 4.1     MRI images of the brains of two patients with V337M MAPT ........................ 117 
Figure 4.2        Schematic detailing the protocol used for the derivation of cortical 
glutamatergic neurons from human pluripotent stem cells ........................ 122 
Figure 4.3      Western immunoblots of Tg4510 mice basal forebrain, cortex and 
hippocampus with tau antibodies ................................................................ 129 
Figure 4.4     Neural progenitors express Pax6 at day 15 ..................................................... 133 
19 
 
Figure 4.5     Neural progenitors express Tbr2 at day 15 ..................................................... 134 
Figure 4.6     Neural progenitors express Tbr1 at day 25 ..................................................... 135 
Figure 4.7     hPSC-CGN express VGlut1 at day 50 ............................................................... 136 
Figure 4.8     Day 50 hPSC-CGN express synapsin I .............................................................. 137 
Figure 4.9     hPSC-CGN express post-synaptic density protein 95 at day 50 ...................... 138 
Figure 4.10     Levels of total tau in CGNs ............................................................................ 140 
Figure 4.11     Levels of tau phosphorylated at pSer396 and pSer404 in V337M-C- and Nas 2-
CGNs.............................................................................................................. 141 
Figure 4.12     Levels of tau phosphorylated at Ser396 and Ser404 in V337M-E-CGNs and 
Shef 6-CGNs .................................................................................................. 142 
Figure 4.13    Levels of tau phosphorylated at pSer202 and pSer205 in V337M-C- and Nas 2-
CGNs.............................................................................................................. 143 
Figure 4.14     Levels of tau phosphorylated at pThr231 in V337M-C- and Nas 2-CGNs ..... 144 
Figure 4.15     Levels of MAPT gene expression in V337M-C-CGN and Shef 6-CGN ............ 145 
Figure 4.16     Level of GSK3β and pTyr216 GSK3β in V337M-C-CGN and Nas 2-CGN ......... 147 
Figure 4.17     Level of GSK3β and pTyr216 GSK3β in V337M-E-CGN and Shef 6-CGN ........ 148 
Figure 4.18     Levels of p35 in hPSC-CGNs ........................................................................... 149 
Figure 4.19     Levels of PAK3 in hiPSC-CGNs ........................................................................ 151 
Figure 4.20    Level of pSer473 Akt in hPSC-CGNs ................................................................ 153 
Figure 4.21     Levels of tau kinase gene expression in V337M-C-CGNs and Shef 6-CGNs .. 154 
Figure 4.22     Levels of synapsin I in hPSC-CGNs ................................................................. 155 
Figure 5.1     Cells within neurospheres express neural stem cell markers at day 30 during of 
expansion phase of Crompton protocol ....................................................... 178 
Figure 5.2     Characterisation of day 35 differentiated bfCNs............................................. 179 
Figure 6.1     Levels of total tau in frontal (A & B) and temporal (C & D) cortex brain tissue 
from PiD patients .......................................................................................... 226 
Figure 6.2     Levels of total tau in frontal brain tissue from PiD patients ........................... 227 
Figure 6.3     Levels of pSer396/404 tau in frontal cortex brain tissue from PiD patients ... 228 
20 
 
Figure 6.4     Levels of pSer396/404 tau in frontal cortex brain tissue from FTDP-17 patients
 ...................................................................................................................... 229 
Figure 6.5     Levels of pSer202 tau in frontal cortex brain tissue from PiD patients .......... 230 
Figure 6.6     Levels of pSer202 tau in temporal cortex brain tissue from PiD patients....... 231 
Figure 6.7     Levels of pSer202 tau in frontal cortex brain tissue from FTDP-17 patients .. 232 
Figure 6.8     Levels of MAPT gene expression in frontal and temporal cortex tissue from 
patients with PiD disease and FTDP-17 ........................................................ 233 
Figure 6.9     Levels of GSK3β and pTyr216 GSK3β in frontal cortex brain tissue from PiD 
patients ......................................................................................................... 235 
Figure 6.10     Levels of GSK3β and pTyr216 GSK3β in temporal cortex brain tissue from PiD 
patients ......................................................................................................... 237 
Figure 6.11     Levels of GSK3β in frontal lobe brain tissue from FTDP-17 ........................... 238 
Figure 6.12     Levels of p25 and p35 in frontal cortex brain tissue from PiD ...................... 239 
Figure 6.13    Levels of p25 in temporal cortex brain tissue from PiD ................................. 240 
Figure 6.14     Levels of PAK3 in frontal and temporal cortex brain tissue from PiD patients
 ...................................................................................................................... 241 
Figure 6.15     Levels of PAK3 in frontal cortex brain tissue from FTDP-17 .......................... 242 
Figure 6.16     Gene expression levels of GSK3β, CDK5 and PAK3 in frontal lobe brain tissue 
from PiD disease and FTDP-17 patients ........................................................ 243 
Figure 6.17    Levels of synapsin I in temporal cortex brain tissue from PiD ....................... 245 
Figure 6.18     Levels of synapsin I in frontal cortex brain tissue from FTDP-17 patients .... 246 
Figure 6.19     Levels of MAPT, CDK5 and PAK3 gene expression, normalised to GAPDH, in 








List of Abbreviations 
 




3D  Three dimensional 
aa Amino acid 
AA Ascorbic acid 
ACh Acetylcholine 
ACID APP intracellular cytoplasmic domain 
AD Alzheimer’s disease 
ADP Adenosine diphosphate 
AGD Argyrophilic grain disease 
AlCl3 Aluminium chloride 
ALS amyotrophic lateral sclerosis 
AP-1 Activator protein 1 
ApoE Apolipoprotein E 
APP Amyloid precursor protein 
ATP Adenosine triphosphate 
Aβ Amyloid-β peptide  
Aβ40 Amyloid-β 1-40 
Aβ42 Amyloid-β 1-42 
Aβ42O Amyloid-β 1-42 oligomers 
AβO Amyloid-β oligomers 
BfCNs Basal forebrain cholinergic neurons 
BIN1 Bridging integrator 1 
BMPs Bone morphogenic proteins 
Bp Base pair 
BSA Bovine serum albumin 
bvFTD  Behavioural variant frontotemporal dementia 
C83 C-terminus fragment of 83aa 
C99 C-terminus fragment of 99aa 
Ca2+ Calcium ion 
CaCl2 Calcium chloride 
cAMP  Cyclic adenosine monophosphate 
CBD Corticobasal degeneration 
22 
 
Cdc42/Rac Cell division control protein 42 homolog/Ras-related C3 botulinum toxin 
substrate 1 
Cdk5 Cyclic dependent kinase 5 
CDK5 Cyclic dependent kinase 5 gene 
CDM Chemically defined media 
cDNA Complementary DNA 
CGN Cortical glutamatergic neurons 
ChAT Choline acetyltransferase 
c-myc Myelocytomatosis viral oncogene homologue 
CR1 Complement receptor 1 
CSF Cerebrospinal fluid 
CT Threshold cycle number 
CTE chronic traumatic encephalopathy 
Cu2+ Copper (II) ion 
DAPT  N-[N-(3,5-diflurorphenacetyl) – l-alanyl]-S-phenylglycine t-butyl ester 
DIV days in vitro 
DMEM Dulbecco’s Modified Eagle medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DTT 1,4-Dithiothreitol 
EB Embryoid body 
EDTA Ethylenediamine tetraacetic acid 
EGF Epidermal growth factor 
EOAD Early-onset Alzheimer’s disease 
ERK Extracellular signal-regulated protein kinase 
ESC  Embryonic stem cell 
fAD Familial AD 
FAM Fluorochrome 6-carboxyfluorescein (FAM) 
FBS Foetal bovine serum 
FGF2 Fibroblast growth factor 2 (also known as basic fibroblast growth factor – 
bFGF) 
FTD Frontotemporal dementia 
FTDP Frontotemporal dementia with Parkinsonism 
FTDP-17 Frontotemporal dementia with Parkinsonism linked to chromosome 17 
FTD-tau Frontotemporal dementia associated with tau pathology 
FTLD Frontotemporal lobar degeneration  
FUS Fused in sarcoma 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
gDNA Genomic DNA 
23 
 
GDNF Glial derived neurotrophic factor 
GFP  Green fluorescent growth factor 
GSK3 Glycogen synthase kinase 3 
GSK3α Glycogen synthase kinase 3 alpha 
GSK3β Glycogen synthase kinase 3 beta  
GSK3β  Glycogen synthase kinase 3 beta gene 
HCl Hydrochloric acid 
HD Huntington’s disease 
hESC  Human embryonic stem cell 
hFib Human fibroblast 
hiPSC Human induced pluripotent stem cell 
HiPSC-bfCNs Basal forebrain cholinergic neurons derived from human induced 
pluripotent stem cells 
HiPSC-CGN Cortical glutamatergic neurons derived from human induced pluripotent 
stem cells 
HIV Human immunodeficiency virus 
hPSC Human pluripotent stem cell 
hPSC-bfCNs Basal forebrain cholinergic neurons derived from human pluripotent stem 
cells 
HPSC-CGN Cortical glutamatergic neurons derived from human pluripotent stem cells 
ICM Inner cell mass 
iMEFs Inactivated mouse embryonic fibroblasts 
IPC Intermediate progenitor cells 
iPSC  Induced pluripotent stem cell 
IRES Internal ribosome response element 
IVS Intervening sequence 
JNK c-Jun N-terminal kinase 
Kb Kilobase pair 
Klf4 Kruppel-like factor 4 
KO Knock-out 
KO DMEM Knock-out DMEM 
LTD Long-term depression 
LTP Long-term potentiation 
M Molar 
mA Milliamps 
MAPs Microtubule associated proteins 
MAPT Microtubule binding protein tau gene 
MARK Microtubule-affinity regulating kinase 
MBD Microtubule binding domain 
24 
 
MBP Microtubule binding protein 
MC1 Mild cognitive impairment 
MEF Mouse embryonic fibroblast 
MEFs Mouse embryonic fibroblasts 
MgCl2 Magnesium chloride 
ml Millilitres  
mM Millimolar 
mRNA  Messenger RNA 
MT Microtubule 
NaCl Sodium chloride 
NAD  Nicotinamide adenosine dinucleotide 
NaHCO3 sodium bicarbonate  
nbM Nucleus Basalis of Meynert 
NEAA Non-essential amino acids 
NEM Neural expansion media 
NFT Neurofibrillary tangle 
NIM Neural induction media 
nM nanomolar 
NMM Neural maintenance media 
NPC Neural progenitor cell 
NTC Non-template control 
OCT4 Octamer binding transcription factor 4 
p Phosphorylated  
PAK P21 activated kinase  
PAK1 P21 activated kinase 1 
PAK1 P21-activated kinase 1 gene 
PAK3 P21 activated kinase 3 gene 
PAK3 P21-activated kinase 3 
Pax6  Paired box protein gene 6 
PBS Phosphate buffered saline 
PBs Pick bodies 
PBS-Tx PBS + 0.1 % Triton-X-100 
PCR Polymerase chain reaction 
PD Parkinson’s disease 
PFA Paraformaldehyde 
PICALM Phosphatidylinositol binding clatherin assembly protein  
PiD Pick’s disease 
PKB Protein kinase B 
25 
 
PMD Post-mortem delay 
PNFA Progressive non-fluent aphasia 
POR Poly-L-ornithine 
PSD95 Post-synaptic protein 95 
PSP Progressive supranuclear palsy 
ptau Phosphorylated tau 
PVDF Polyvinylidene difluoride 
qPCR  Quantitative polymerase chain reaction 
RNA  Ribonucleic acid 
ROCK Rho-associated protein kinase inhibitor, also known as Y-27632 
ROS Reactive oxygen species 
RT Reverse transcription 
S.D. Standard deviation 
S.E.M.  Standard error of the mean 
sAD Sporadic Alzheimer’s disease  
Sarkosyl N-Dodecanoyl-N-methylglycine sodium salt 
SD Semantic dementia 
SDS Sodium dodecyl sulfate 
sFTD Sporadic frontotemporal dementia 
Shh Sonic hedgehog 
SORL1 Sortilin-related receptor 1 
SOX1 Sex determining region Y-box 1 
SOX2 Sex determining region Y box 2 
SSEA4 Stage-specific embryonic antigen 4 
TAMRA Tetramethylrhodamine 
Tau Tau protein 
Tbr1 T-domain transcription factor 1 
Tbr2 T-domain transcription factor 2 
TBS-T 20 mM Tris–Cl pH 7.6, 137M NaCl, 0.1 % Tween 20 
TDM Terminal differentiation media 
TDP-43 Transactive response DNA binding protein of 43 kilodalton molecular weight 
Tg Transgenic  
TGFβ Transforming growth factor beta 
Thr Threonine 
TOD Tangle only dementia  
Tra-1-60 Trafalgar antigen 1-60 
TRIS Tris(hydroxymethyl) aminomethane 




UNG Uracil-N glycosylase 
UP Ultrapure 
UPS Ubiquitin protease system 
V Volts 
VCP Valosin-containing protein 
VGlut1 Vesicular glucose transporter 1 
vGlut2 Vesicular glucose transporter 2 
VPA Valproic acid 
VTN Vitronectin 
VTN-T Truncated vitronectin  
WMT-GGI White matter tauopathy with globular glial inclusions 
Wnt Wingless 
WT Wild type 















1.1  Tau protein 
Tau is a microtubule binding protein present abundantly within the axons and the 
somatodendritic compartments  of neurons, as well as in relatively low levels within glial cells 
(Lee et al., 2001; Trojanowski et al., 1989; Tashiro et al., 1997).  This natively unfolded, 
hydrophilic protein has four main regions:  an N-terminal projection region, a proline-rich 
domain, a microtubule-binding domain and a C-terminal region (Mandelkow et al., 1996) 
(Figure 1.1).  The primary role of tau within neurons is to provide stability to the microtubules 
(Chapter 1.1.2.1).   
 
1.1.1  Expression of tau in the brain 
In humans, tau is encoded by microtubule-associated protein tau gene (MAPT), which is 
situated on chromosome 17q21 and contains 16 exons.  Six isoforms of tau are generated 
through alternative splicing of exons 2, 3 and 10; exons 2 and 3 each encode a 29-residue N-
terminal repeat sequence (N), while exon 10 encodes a microtubule repeat domain (R).  The 
resultant isoforms are denoted according to the number of these sequences that they 
contain, as 3R0N, 3R1N, 3R2N, 4R0N, 4R1N and 4R2N (Lee et al., 2001; Andreadis et al., 1992; 
Goedert et al., 1989) (Figure 1.2).  Although adults express all six isoforms, during the first 
year of neurodevelopment only 3R0N tau, also known as foetal tau, is expressed (Goedert et 
Figure 1.1     Schematic representation of the structure of tau protein 
Schematic representation of the structure of the longest isoform of tau protein (441 amino acids 
(aa)) depicting the N-terminal domains N1 and N2 (blue), the proline rich domain (orange) and 
the microtubule binding domains R1, R2, R3 and R4 (purple).  Tau binds to the microtubules via 
the microtubule binding domains and the N-terminal domains project outwards.   
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al., 1989).  Within the adult brain the ratio of 3R to 4R containing isoforms is approximately 
1:1.  Isoforms containing 0N, 1N and 2N comprise approximately 37 %, 54 % and 9 % of tau, 
respectively (Andreadis et al., 1995; Goedert and Jakes, 1990).  Abnormal alternative splicing 
of exon 10 results in an imbalance in the ratio of 3R:4R tau and is associated with particular 
tauopathies (Dickson et al., 2011).  The regulation of tau expression levels is brain region 
specific; the highest expression of tau in the brain occurs in the frontal and temporal lobes 
(Trabzuni et al., 2012; Majounie et al., 2013; McMillan et al., 2008).   
 
1.1.1.2  Haplotypes 
The locus containing the MAPT gene has two major haplotypes, H1 and H2.  H2 differs in 
comparison to H1 by a 238-base pair (bp) deletion upstream of exon 10, as well as the 
inversion of a 900 kilo base pair (kb) sequence (Pittman et al., 2006; Myers et al., 2007; 
Caillet-Boudin et al., 2015).  Genome wide association studies have associated non-inverted 
H1 haplotypes with increased plasma tau levels (Allen et al., 2016).  This haplotype has also 
been associated with 4R tauopathies (Beevers et al., 2017; Caffreys, 2006), frontotemporal 
dementia (FTD) and Alzheimer’s disease (AD) (Pastor et al., 2015; Pastor et al., 2002; Chen et 
al., 2017; Winder-Rhodes et al., 2015).  The H2 haplotype has been suggested to be 
Figure 1.2     The isoforms of tau 
Alternative splicing of MAPT produces six isoforms of tau; three of these include exon 10 and 
therefore have four microtubule binding domains (4R), three exclude this exon so have three 
microtubule binding domains (3R).  Within these two groups the isoforms differ based on their 
inclusion or exclusion of exons 2 and 3.  Exon 3 can only be included with exon 2, therefore allowing 
for three options; isoforms can have no N-terminal domains (0N), one N-terminal domain (1N) or 
two N-terminal domains (2N). 
Image from Wang and Mandelkow, 2015, with permission. 
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protective in neurodegenerative disease (Allen et al., 2016), however this haplotype has also 
been implicated as a risk factor in the development of Pick’s disease (PiD) (Russ et al., 2001) 
and early onset AD (EOAD) (Kaivorinne et al., 2008). 
1.1.2  The physiological functions of tau  
The most established function of tau is in microtubule stabilisation and as a conduit for the 
regulation of microtubule dynamics (Drubin and Kirschner 1986; Caceres and Kosik 1990; 
Avila et al., 2004) (Chapter 1.1.2.1).  As such tau also plays important roles in axonogenesis 
(Sayas et al., 2015; Dawson et al., 2001), synaptogenesis and synaptic plasticity in long-term 
depression (LTD) (Regan et al., 2015; Kimura et al., 2014).  Increasing evidence has 
demonstrated tau’s role in other cellular functions, unrelated to microtubule dynamics, such 
as in neurodevelopment, DNA repair, the transfer of information between neurons and in 
cell signalling (Hanger et al., 2014; Wang and Mandelkow, 2015).  The phosphorylation-
dependent role of tau in microtubule regulation, however, remains the primary focus when 
considering the pathological roles of tau in tauopathy. 
1.1.2.1  The role of tau as a microtubule binding protein 
Microtubules are cylindrical polymers, comprised of alpha and beta tubulin heteromers, 
which form part of the cytoskeleton in all cells (Kirschner and Mitchison, 1986).  In neurons, 
these linear structures, found grouped into bundles, have important roles in maintaining cell 
morphology, mitosis, scaffolding signalling molecules to form signalling hubs, synaptic 
plasticity and neurite growth (Kadavath et al., 2015).  Together with motor proteins, such as 
dynein and kinesin, which associate with the microtubule through microtubule associated 
proteins (MAPs), they are crucial for the transport of organelles, vesicles, nutrients and other 
cellular cargo in both in anterograde and retrograde directions throughout neurons.  As 
highly polarised cells with great energy demands, efficient cellular transport is particularly 
important for the maintenance of healthy biomolecular functioning within neurons.  




To carry out their functions effectively, microtubules must exist in a state of dynamic 
instability, which means they are constantly being assembled and disassembled.  This state 
is maintained and regulated by a plethora of proteins, including tau (De Forges et al., 2012; 
Roll-Mecak and McNally, 2010; Akhmanova and Steinmetz, 2015).    
 
 
Tau binds to microtubules via its microtubule binding domains, with its N-terminals and C-
terminals projecting outwards, at the interface between tubulin heterodimers (Santarella et 
al., 2004; Kar et al., 2003; Buée et al., 2000) (Figure 1.3).  The binding of specific isoforms of 
tau (Chapter 1.1.2) dictates the degree of microtubule stability of each bound tau molecule 
(Stanford et al., 2003; Kosik et al., 1989; Lu and Kosik, 2001).  4R isoforms have a greater 
affinity for the microtubules compared to 3R isoforms, owing to their possession of an extra 
microtubule-binding repeat domain, which explains their superior efficiency at promoting 
microtubule stability in comparison to 3R isoforms (Utton et al., 2001; Goedert and Jakes, 
1990).  The N-terminals of tau can also bind to microtubules to form part of a membrane-
Figure 1.3     Tau binds to microtubules to regulate the transport of cellular cargo 
Tau binds to the microtubules via its microtubule binding domains (blue rectangles).  The 
binding of tau to the microtubules is regulated by phosphorylation through the activity of 
phosphatases and kinases; phosphate groups are indicated by the pink circles.  Phosphorylation 
of tau regulates axonal transport, which is carried out by motor proteins, such as kinesin. 
Image from Kolarova et al., 2012, with permission.  Copyright © 2012 Michala Kolarova et al. 
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associated complex and to regulate the spacing between microtubules (Maas et al., 2000; 
Frappier et al., 1994; Al-Bassam et al., 2002; Buée et al., 2000; Kadavath et al., 2015).   
The exact mechanism through which tau regulates microtubule transport via the 
microtubules is unclear, however, increased binding of tau to the microtubules is thought to 
inhibit transport (Ebneth et al., 1998; Trinczek et al., 1999; Stamer et al., 2002; Dixit et al., 
2008; Stoothoff et al., 2009; Vossel et al., 2010; Shahpasand et al., 2012).  The amount of tau 
bound to the microtubules influences cellular transport and the concentration of tau exists 
in a gradient throughout mature neurons such that a greater amount of tau is present within 
the synapses to encourage release of cellular cargo (Medina et al., 2016).   
1.1.2.1.1  Regulation of microtubule binding by phosphorylation of tau  
Tau is subject to many modes of post-translational modification including phosphorylation, 
glycosylation, ubiquitination, sumoylation, glycation, polyamination, nitration, cleavage and 
truncation (Martin et al., 2011).  Primarily, however, it is the degree of phosphorylation of 
tau which dictates its binding affinity to the microtubules.  There are 85 possible 
phosphorylation sites within the longest isoform of tau (4R2N), of which 80 are serine or 
threonine residues and five tyrosine (Hanger et al., 2009).  Tau phosphorylation is tightly 
regulated by the activity of tau kinases and phosphatases (Chapter 1.3), to allow for control 
of microtubule function.  
In general, increased phosphorylation of tau results in decreased microtubule binding 
(Lindwall and Cole, 1984; Jenkins and Johnson, 1999; Sontag et al., 1996; Drewes et al., 1995; 
Sengupta et al., 1998).  It is recognised that phosphorylation of particular phosphorylation 
sites has a greater influence on the affinity of tau to the microtubules; for example, 
phosphorylation at Ser262, Ser214 and Thr231 is known to greatly reduce the affinity of tau 
for microtubules compared to phosphorylation at other residues (Sengupta et al., 1998).  
Foetal tau is highly phosphorylated, containing approximately seven moles of phosphate 
compared to the two moles within the adult brain (Kanemaru et al., 1992).  It is thought that 
this is important for neurogenesis; for example, it has been demonstrated that tau must be 
phosphorylated at serine 205 and threonine 205 (Ser202/Thr205) to allow for neurite 
extension (Rösner et al., 1995; Riederer et al., 2001). 
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1.1.3  Pathological phosphorylation of tau leads to neurodegeneration 
Many post-translational modifications of tau (Chapter 1.1.2) have been implicated in 
tauopathy (Martin et al., 2011; Héraud et al., 2014; Zilka et al., 2006; Paholikova et al., 2015; 
Cook et al., 2014; Irwin et al., 2013; Yan et al., 1994; Gong and Iqbal 2008), however, 
hyperphosphorylation of tau at abnormal sites is the hallmark of tauopathies.  It is believed 
that initial phosphorylation events lead to the formation of pathological conformations of 
tau, which are predisposed to become further phosphorylated and to subsequently 
aggregate (Zheng-Fischhöfer et al., 1998; Kimura et al., 1996).  The molecular pathways 
underlying the aberrant phosphorylation and aggregation of tau, leading to 
neurodegeneration, is an area of intense research.  Pathological tau is thought to contribute 
to neurodegeneration through several pathways (Figure 1.4).   
Hyperphosphorylation of tau is known to lead to the detachment of tau from the 
microtubules (Goedert, 1993), which leads to the destabilisation and disassembly of the 
microtubules.  Consequently, the loss of cellular structural integrity as well as cellular 
transport of critically important cargo, such as mitochondria, to distal areas of the neuron 
follows.  This contributes to synapse loss and neuronal death (Spires-Jones and Hyman, 2014) 
(Figure 1.4).  The detachment of tau from the microtubules also leads to an increase in free 
intracellular tau, which is susceptible to further phosphorylation and aggregation.   
The formation of tau with a pathogenic conformation occurs due to hyperphosphorylation 
(Gendron and Petrucelli, 2009; LaPointe et al., 2009) and has been proposed to seed the 
formation of aggregates of tau (Jicha et al., 1999; Jicha et al., 1997).  Hyperphosphorylated 
tau has also been proposed to be more resistant to degradation, thereby contributing to the 
accumulation and subsequent aggregation of the protein (Paglini and Cáceres, 2001).  For 
example, tau aberrantly phosphorylated at Ser422, Ser262 and Ser356 is resistant to 
proteasomal degeneration (Dickey et al., 2006).  Hyperphosphorylated, aggregated tau may 
further impede cellular transport, affect cell signalling and enforce toxicity through 
overloading protein clearance pathways.   
The interaction of tau with other proteins is also altered through increased phosphorylation, 
contributing to dysregulation of critically important biomolecular pathways.  This is 
exemplified by the fact that only hyperphosphorylated tau can interact with the kinesin-
associated protein JUN N-terminal kinase-Murray et al, 2014.  Additionally, abnormal 
phosphorylation of tau at specific sites ‘primes’ tau for further sequential phosphorylation 
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by other tau kinases, which would not usually occur in physiological conditions, establishing 
a pathogenic feed-forward system (Zheng-Fischhöfer et al., 1998; Cho and Johnson, 2003; 
Cho and Johnson, 2004). 
We have not yet completely mapped out which sites are aberrantly phosphorylated in all 
cases of tauopathy, however, mounting evidence supports the role of hyperphosphorylation 
of specific phospho-sites in AD and other tauopathies (Martin et al., 2013; Luna-Muñoz et al., 
2007).  Hanger and collegues have used mass spectrometry to map novel tau 
phosphorylation sites (Hanger et al., 2007).   
 
Interestingly, hyperphosphorylation of tau at sites associated with tauopathy have been 
found in mammals that undergo hibernation.  Hibernation is a physiological state 
Figure 1.4      Physiological and pathological phosphorylation of tau 
In normal physiological function (A and C), kinases and phosphatases work in concert to control the 
phosphorylation of tau, which determines its ability to bind to the microtubules.  Upon 
phosphorylation by kinases, tau detaches from the microtubules and is then dephosphorylated by 
phosphatases (A).  This regulation of tau phosphorylation facilitates stabilisation of the 
microtubules as well as transport of cargo along the microtubules; at the synapses cargo is released 
by phosphorylation of tau by kinases (C).   
Under pathological conditions (B and D), there is an imbalance between the action of kinases and 
phosphatases, leading to hyperphosphorylation of tau.  Hyperphosphorylation of tau causes tau to 
detach from the microtubules, leading to microtubule depolymerisation and the aggregation of 
hyperphosphorylated tau into tau deposits (NFTs) (B), which build-up within the neuron (D).  
Destabilisation of neurons contributes to the impairment of cellular transport and to the loss of 
synapses (D). 
Image adapted, with permission, from Bodea et al., 2016.  Copyright © 1999 - 2017 John Wiley & 
Sons, Inc.  
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characterised by significant decreases in body temperature and oxidative metabolism during 
prolonged inactivity to minimise energy expenditure during inhospitable environmental 
conditions.  Hibernation is accompanied by dramatic decreases in neuronal function (Arendt 
et al., 2003).  Previous studies have demonstrated that hyperphosphorylated tau has been 
found within the entorhinal cortex and hippocampus of European ground squirrals (Arendt 
et al., 2003) and within the brains of Arctic ground squirrels (Su et al., 2008).  The increase in 
tau phosphorylation was found to correspond to changes in the activity of tau kinases and 
phosphatases during hibernation; activity of tau kinases GSK3β and PKA increased and 
activity of tau phosphatase PP2A decreased during hibernation of the Arctic squirrel (Su et 
al., 2008).  This hyperphosphorylation is fully reversible when hibernation ends or during the 
periodic re-warmings of the animals body during hibernation and has been suggested to be 
a neuroprotective mechanism enabling the brain to adapt to dramatically decreased 
metabolism and temperature thus demonstrating a physiological role for 
hyperphosphorylation of tau in the adult mammal brain (Arendt et al., 2003; Su et al., 2008; 
Arendt and Bullmann, 2013).   
Hyperphosphorylation of tau has also been found within in the adult, healthy human brain; 
Matsuo and colleagues demonstrated that healthy, human brain biopsies have tau 
phosphorylated at many of the same sites associated with PHF tau found in patients with AD 
(Matsuo et al., 1994) and later rapid processing of biopsied healthy human and monkey brain 
tissues also revealed tau is hyperphosphorylated at sites associated with pathological tau 
(Garver et al., 1996).  Phosphorylation of tau at certain sites is known to be lost rapidly after 
death and time taken to process post-mortem brain samples has been demonstrated to be 
an important consideration in investigations into tau phosphorylation .  
 
1.2  Tauopathies 
Tauopathies are a group of heterogenous, progressive neurodegenerative diseases 
characterised by the pathological hyperphosphorylation and accumulation of tau within the 
brain.  The most common tauopathy is Alzheimer’s disease (AD), initially described by Alois 
Alzheimer (Alzheimer, 1907).  The second most prevalent is frontotemporal dementia (FTD) 
(Yoshiyama et al., 2001).  Hyperphosphorylated, aggregated tau pathology is also the primary 
culprit underlying many other dementing disorders including progressive supranuclear palsy 
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(PSP), corticobasal degeneration (CBD), argyrophilic grain disease (AGD), Huntington’s 
disease (HD), amyotrophic lateral sclerosis (ALS) and chronic traumatic encephalopathy (CTE) 
(Murray et al., 2014).  
1.2.1  Frontotemporal Dementia 
The highly heterogeneous group of diseases circumscribed by the term frontotemporal 
dementia (FTD) (or frontotemporal lobar degeneration (FTLD)) are characterised by a 
predominant, progressive loss of neurons within the frontal and temporal lobes.  Over time 
and with growing knowledge, our classification of these diseases has been refined.  
Histologically, there are four subtypes within the group; FTD-tau, FTD-TDP, FTD-FUS and FTD-
UPS, which are so called due to their association with the aggregation of tau, transactive 
response DNA-binding protein (TDP), fused in sarcoma (FUS) proteins or ubiquitin protease 
system (UPS) proteins, respectively (Figure 1.5).     
Between 50-80 % of FTD cases are thought to be sporadic, while the rest of the cases are 
accounted for by mutations within a number of genes.  FTD-TDP can be caused by mutations 
in GRN, TARDBP or VCP, which encode progranulin protein, transactive response DNA-
binding protein of 43 kilodalton (kDa) molecular weight (TDP-43) and valosin-containing 
protein, respectively.  Each of the mutations responsible for FTD-TDP cause formation of glial 
and neuronal inclusions of TDP-43, a DNA and RNA binding protein involved in RNA 
processing.  Mutations in CHMP2B, which encodes charged multivesicular body protein 2B 
are associated with FTD-UPS. Mutations in C9orf72, which is important for lysosomal storage 
function (Clayton et al., 2015) and in the regulation of endosomal trafficking (Farg et al., 
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2014), lead to FTD-FUS (Hardy, 2014; Goedert and Spillantini, 2000).  Mutations in MAPT 
cause FTD-tau.   
 
FTD-tau includes sporadic and familial forms of FTD with tau pathology.  The group includes 
Pick’s disease (PiD), frontotemporal dementia with Parkinsonism linked to chromosome 17 
(FTDP-17), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), white 
matter tauopathy with globular glial inclusions (WMT-GGI), argyrophilic grain disease (AGD) 
and tangle only dementia (TOD) (Halliday et al., 2012) (Figure 1.5).  While histologically 
Figure 1.5      Histological classification of frontotemporal dementias 
FTD can be classified due to its association with different protein pathologies.  FTD-tau is 
associated with tau pathology, FTD-fus is associated with ubiquitinated Fused-in-Sarcoma (FUS) 
pathology, FTD-TDP is associated with the presence of ubiquitinated TAR DNA-binding protein 
of 43 kDa (TDP-43) pathology and FTD-UPS includes pathology positive for components of the 
ubiquitin-proteasome system (UPS) but negative for FUS or TDP-43.  Tauopathies are also 
classified according to the predominant isoforms, 3R or 4R, of tau that accumulate.  Depending 
on the specific mutation responsible for FTDP-17, either of these isoforms, or a mixture, can be 
dominant.  PiD is associated with 3R tau accumulation.  Tauopathies known to contain more 4R 
tau include white matter tauopathy with globular glial inclusions (WMT-GGI), argyrophilic grain 
disease (AGD), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD).   
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classified as distinct diseases, these diseases are all highly heterogenous and there are 
extensive histological and clinical overlaps between them (Luna-Muoz et al., 2014). 
In general, the presentation of FTD is associated with cognitive decline heeded by 
disinhibition, behavioural changes and emotional changes, however, the disease is highly 
variable in its clinical presentation.  Clinical presentations of FTD are classified into three main 
groups.  Behavioural variant FTD (bvFTD) accounts for approximately 60 % of all FTD cases 
and includes PiD and FTDP-17, while semantic dementia (SD) accounts for approximately 20 
% of cases and progressive non-fluent aphasia (PNFA) accounts for the remaining 20 % of 
cases.   
bvFTD is recognised by behavioural disinhibition, apathy, loss of empathy, hyperorality, 
dietary changes, executive function deficits and compulsive, perseverative or ritualistic 
behaviours (Piguet et al., 2011).  Memory is relatively spared in bvFTD, however, when 
memory dysfunction does present it is similar in phenotype to that in AD patients.  SD, also 
called temporal variant FTD, is characterised by a loss of language semantics caused by 
degeneration of an area of the left temporal lobe critical for assigning meaning to words.  
Right-sided SD occurs where neurodegeneration begins in the right temporal lobe and is 
characterised by problems remembering the faces of familiar people and loss of empathy.  
Patients with SD usually live longer than those with bvFTD, however, will always develop 
symptoms associated with bvFTD eventually.  Patients with PNFA have difficulty producing 
fluent speech despite their understanding of the meaning of the words remaining intact 
(Goedert et al., 2012).  Classification is further complicated by the co-presentation of motor 
dysfunction similar to that of Parkinson’s disease (PD), termed ‘frontotemporal dementia 
with Parkinsonism’ (FTDP), which most commonly is recognised in cases of bvFTD (Goedert 
et al., 2012). 
1.2.1.1  Neurodegeneration in frontotemporal dementia associated with tau pathology  
The presentation of FTD is influenced by the areas of the brain affected, the underlying 
pathology and the large-scale neural networks involved (Finger, 2016).  Each clinical group is 
associated with different patterns of neurodegeneration; bilateral degeneration of the 
medial frontal lobes and anterior temporal lobes underlies bvFTD, whereas SD is associated 
with more pronounced, usually asymmetric temporal lobe atrophy and PNFA is accompanied 
by atrophy of the left lateral sulcus. 
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Cortical glutamatergic neurons (CGNs) and glutamatergic transmission are particularly 
vulnerable in FTD (Procter et al., 1999; Ferrer, 1999; Sposito et al., 2015), demonstrated by 
reduced numbers of dendritic branches, numbers of dendritic spines and levels of synaptic 
proteins, including synapsin I (Ferrer, 1999).  Surprisingly few studies have been carried out 
aimed at understanding why glutamatergic neurons are selectively lost in the disease.  In AD, 
tau is linked to molecular pathways resulting in glutamate toxicity (Campos-Pea and Antonio, 
2014) and similar pathways may underlie loss of these neurons in FTD.   
1.2.1.2  Pick’s Disease 
Pick's disease (PiD) is a sporadic, progressive and highly heterogenous frontotemporal 
dementia (FTD) that accounts for approximately 2 % of all cases of dementia.  Clinically, PiD 
manifests at around age 40-60 years as bvFTD (Hodges 2001; Luna-Munoz et al., 2014).  
Patients live an average of 10.4 years after diagnosis (Josephs et al., 2005).  Histologically, 
PiD is recognised by frontal and anterior temporal lobe cortical atrophy due to the loss of 
synapses dendrites and neurons, white matter degeneration, achromatic neurons (Pick cells) 
and intraneuronal tau inclusions called Pick bodies (PBs) (Lewis et al., 2001; Kertesz, 2003), 
which have been found in the cerebral cortex, the hippocampus and in selected brainstem 
nuclei (Zhukareva et al., 2002).  Recent studies suggest that neurodegeneration first occurs 
in the frontotemporal limbic regions and neocortical regions before progressing to 
subcortical regions, then the primary motor cortex and pre-cerebellar nuclei and finally the 
visual cortex (Lewis et al., 2001).  Tau aggregations are mainly composed of 3R tau 
(Delacourte et al., 1998; Delacourte et al., 1996; Dickson et al., 2011; Buée and Delacourte 
1999) loosely arranged into straight filaments (Takauchi et al., 1984). 
1.2.2  Frontotemporal dementia with Parkinsonism linked to chromosome 
17 
We have known for a long time that tau is the major component of the intracellular 
filamentous deposits found in the brains of those suffering from many neurodegenerative 
diseases.  In 1998, mutations within MAPT were demonstrated to be the cause of familial 
FTD (Hutton et al., 1998; Poorkaj et al., 1998), emphatically demonstrating that dysfunction 
of tau protein can cause neurodegenerative disease. 
FTD caused by mutations in MAPT account for approximately 30 % of cases of heritable FTD 
and are associated with autosomal dominant inheritance of disease (Hardy, 2014).  These 
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diseases are named frontotemporal dementia with Parkinsonism linked to chromosome 17 
tau (FTDP-17) (Foster et al., 1997) as patients tend to clinically present with Parkinson’s 
disease-like motor symptoms along with bvFTD (Siuda et al., 2014). Patients usually initially 
present with psychiatric symptoms, alongside language dysfunction in some cases, and are 
often misdiagnosed with PiD, primary progressive aphasia, AD, PSP or CBD (Ghetti et al., 
2015).  Memory impairment, as a predominant presenting feature, has been reported in only 
a few cases of FTDP-17 (Doran et al., 2007), however, the phenotype of the memory 
disturbance phenotype is similar to that in AD (Doran et al., 2007).   
The clinical presentation, age of onset and duration of these diseases varies between patients 
with different MAPT mutations, in line with the heterogeneity reflected in the 
neuropathology and patterns of brain atrophy in these patients.  For example, while the 
average age of onset is 49 years and the life expectancy after diagnosis is 8.5 years, patients 
have presented with FTDP-17 in their early 20s as well as in the late 70s and lived for only 1.5 
years or as long as 26 years (Wszolek et al., 2003; Reed et al., 2000).  There is also a high level 
of heterogeneity between families carrying the same mutation and even within families 
(Larner, 2009; Larner and Doran, 2008; Wszolek et al., 2003; Bugiani et al., 1999), 
demonstrating that environmental factors or genetic modifiers play a role in the 
pathogenesis of tauopathies.  Phenotypic differences between patients with the same FTDP-
17 mutation may be explained by the tau haplotype (Chapter 1.1.1.2) (Baba et al., 2005) 
carried by these patients or their ApoE genotype (Mann et al., 2001).  Through understanding 
how each of these mutations, which exert specific changes to tau protein or the splicing of 
tau isoforms, result in different disease pathology and presentation, we can gain insight into 
the importance of particular pathogenic alterations to tau in disease.   
1.2.2.1  MAPT mutations  
Linkage analysIs of 150 families affected by FTDP-17 have led to the identification of 53 
intronic and exonic MAPT mutations (van der Zee and Van Broeckhoven, 2014).  
Approximately half of these are exonic mutations of exons 1, 9, 11, 12 and 13, which affect 
the ability of tau to interact with microtubules or increase its propensity to assemble into 
abnormal filaments (Hasegawa et al., 1998; Deture et al., 2000; Dayanandan et al., 1999; 
Hong et al., 1998; Matsumura et al., 1999; Ghetti et al., 2015).  The other mutations occur 
within exon 10 or in the adjacent introns (Figure 1.6).  Some of these intronic mutations of 
these mutations prevent or disrupt the formation of the stem loop structure of tau’s pre-
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RNA, which forms because the non-mutant sequence is palindromic, thereby preventing the 
splicing machinery from splicing out exon 10 (Wolfe, 2008).  Another mechanism through 
which mutations affect the splicing of exon 10 is by altering linear cis-splicing elements 
(Wolfe, 2008).  This results in the overproduction of 4R tau, thus perturbing the normal ratio 
of 3R:4R tau isoforms (Ghetti et al., 2015).  Disturbances in the normal function and 
expression of tau lead to neurodegeneration due to altered microtubule dynamics.   
 
Different mutations lead to different tau pathology, patterns of atrophy and clinical 
presentations.  For example, Whitwell and colleagues demonstrated that although all cases 
of FTDP-17 exhibit degeneration of the anterior temporal lobes, mutations that alter the 
splicing of tau pre-mRNA lead to grey matter loss focused within the medial temporal lobes, 
including the hippocampus, amygdala, parahippocampal gyrus and fusiform gyrus. On the 
other hand, mutations that lead to altered structure of tau are more commonly associated 
Figure 1.6      MAPT mutations in FTDP-17 
Schematic representation of the positions of MAPT mutations in FTDP-17.  Approximately half of 
these are either intronic or exonic mutations near, or in exon 10; These mutations affect the 
alternative splicing of exon 10.  Other exonic mutations exist in exon 1, 9, 11, 12 and 13 and these 
affect either the binding of tau to the microtubules or the propensity of tau to aggregate.  






with relative sparing of the medial temporal lobes and degeneration of the lateral temporal 
lobes (Whitwell et al., 2009).  
In the studies presented here, hiPSC from patients carrying a missense mutation resulting in 
a change of valine to methionine at 337 (V337M) within MAPT were differentiated into 
neurons.  A more detailed description of the clinical presentation and tau pathology 
associated with this mutation is given in Chapter 4 (Chapter 4.1.1).  Tau pathology within the 
frontal and temporal lobes of patients with a missense mutation resulting in a change of 
arginine to tryptophan at 406 (R406W), and within those with a point mutation resulting in 
a change of cysteine to tyrosine within intron 10 (IVS 10+16 C>T) MAPT, have been 
investigated in Chapter 6. 
1.2.2.1.1  The clinical and pathological features of IVS 10+16 C>T MAPT  
The point mutation from cysteine to tyrosine within intron 10 of MAPT (IVS 10+16 C>T MAPT) 
destabilises the stem-loop structure of intron 10 of MAPT (Figure 1.6), leading to a two- to 
six-fold increase in the ratio of 4R:3R tau mRNA by altering the splicing of exon 10 (Connell 
et al., 2005).  The clinical presentation of individuals with this mutation is heterogenous 
within and between families (Larner and Doran, 2008); patients have been diagnosed with 
FTD (Janssen et al., 2002; Pickering-Brown et al., 2002), AD (Doran et al., 2007; Larner et al., 
2008, 2009) and PSP (Morris et al., 2003).  A range of symptoms have been described 
including those more commonly associated with FTDP-17; motor dysfunction including 
Parkinsonism, anomia, language impairment and disinhibition have been reported 
(Pickering-Brown et al., 2002; Janssen et al., 2002; Larner et al., 2009; Stanford et al., 2004; 
Morris et al., 2003).  Age of onset varies from the late 30’s to the early 60’s of patients 
(Janssen et al., 2002; Pickering-Brown et al., 2002; Morris et al., 2003; Stanford et al., 2004; 
Larner and Doran, 2006; Larner, 2009). 
While the frontal and temporal lobes are affected in patients with this mutation, 
neuropathology, including the loss of neurons, neuropil vacuolation, grey matter gliosis, tau 
phosphorylation and tau aggregation, also varies in location and reports have concluded 
particularly severe loss of temporal lobe tissue (Larner et al., 2009), global loss of cortical 
regions of the brain (Larner et al., 2009) and the severe neurodegeneration of the globus 
pallidus and subthalamic nucleus  (Morris et al., 2003) within the brains of patients with this 
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mutation.  Hyperphosphorylated tau aggregates within the brains of these patients have 
been reported to be diffuse or globular in structure (Morris et al., 2003).   
1.2.2.1.2  The clinical and pathological features of R406W MAPT 
The point mutation arginine to tryptophan at 406 (R406W MAPT), occurs in exon 13 of MAPT.   
The residue it alters is highly conserved, which highlights its probable importance in the 
function of tau.  The mutation results in a change in the structure of tau, which results in 
alterations in the ability of tau to bind to the microtubules (Hong et al., 1998).   
Clinically, patients with this mutation present with AD-like symptoms, including memory 
impairment, as well as FTDP-17 symptoms including Parkinsonism, disinhibition and 
impulsivity (Ostojic et al., 2004; Carney et al., 2014; Van Swieten et al., 1999; Rademakers et 
al., 2003; Ebrahimi 2015; Passant et al., 2004; Hirschbichler et al., 2015; Behnam et al., 2015; 
Ng et al., 2015).  As with those with other FTDP-17 mutations, presentation is heterogenous 
between individuals with the disease.  Language disturbances have been reported in some 
cases (Rademakers et al., 2003; van Swieten et al., 1999), however, this is not the case for all 
cases of R406W MAPT FTDP-17 (Ikeuchi et al., 2008; Hirschbichler et al., 2015; van Swieten 
et al., 1999).  This mutation can result in one of two disease trajectories; in most cases 
reported the disease progresses slowly (Passant et al., 2004; Ostojic et al., 2004; Ikeuchi et 
al., 2008; Lindquist et al., 2008; Rademakers et al., 2003; Carney et al., 2014), however, in 
one patient progression of cognitive decline was observed to be rapid (Carney et al., 2014).  
Onset varies considerably from the 3rd to the 6th decade of the patients’ lives (Rademakers et 
al., 2003; Ostojic et al., 2004; Passant et al., 2004; Ikeuchi et al., 2008; Carney et al., 2014; 
Behnam et al., 2015; Hirschbichler et al., 2015) .  
The pathology associated with this mutation is described as bilateral frontotemporal 
degeneration (Basiri et al., 2015).  As well as the loss of neurons, gliosis and widespread 
aggregation of tau within the cortex are pathological features of this mutation.  Amyloid 
pathology has also been reported in some cases (Ishida et al., 2015).  
1.2.3  Alzheimer’s disease 
Alzheimer’s disease (AD) is responsible for the majority of cases of dementia worldwide 
(Alzheimer’s Association, 2016).  The symptoms of AD are caused by neurodegeneration of 
large scale neuroanatomic networks resulting in severe cortical atrophy (Weintraub et al., 
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2012; Seeley et al., 2009; Dennis and Thompson, 2014).  Neuropathologically, AD is 
hallmarked by the accumulation of intracellular tau protein and extracellular amyloid-beta 
(Aβ) within areas of the brain related to this circuitry.  There are two forms of AD with 
equivalent pathology and symptoms, which are clinically distinguished by their age of onset; 
the majority of cases are sporadic (sAD) and generally present after age 65, while 2-10 % of 
cases are familial (fAD), which present before age 65 (Alzheimer’s Association, 2016; Zhu et 
al., 2015).    
The predominant symptom of AD is memory failure, which is subtle upon initial presentation, 
becoming more severe with progression and is eventually incapacitating.  Patients also 
exhibit a range of other cognitive deficits, language disturbances and neuropsychological 
changes including depression, poor judgement, confusion, sleep disturbance, mutism, 
agitation, withdrawal, hallucinations and seizures (Landes et al., 2001; Peter-Derex et al., 
2015; Weintraub et al., 2012; Caraci et al., 2010; Selkoe 2011; Chi et al., 2014).  In the later 
stages of disease, patients may also experience motor symptoms (Wirths and Bayer, 2008).   
1.2.3.1  Neurodegeneration in Alzheimer’s disease 
Neurodegeneration begins in the basal forebrain and entorhinal cortex, considered an 
invariant focus of pathology in all AD cases, which gives rise to bidirectional projections 
connecting the hippocampus and the cortex (Schmitz et al., 2016).  Degeneration of the 
hippocampus follows and then neurons are lost in other neocortical areas including the 
temporal cortex (Buckner et al., 2008; Jack et al., 1998).  The hippocampus plays a prominent 
role in memory acquisition and consolidation, while the temporal lobe governs language 
function and is also involved in memory functions (Buckner et al., 2008; Jack et al., 1998), 
which explains the prominent memory dysfunction associated with AD.  In the later stages of 
AD, wide-spread neurodegeneration occurs, evidenced by shrinkage of the cerebral cortex 
and enlarged ventricles, precipitating additional symptoms (Braak et al., 2011; Braak and 












1.2.3.1.1  Vulnerable neuronal populations in AD 
The cholinergic and glutamatergic neurotransmission systems are preferentially targeted in 
AD  (Sims et al., 1983; Bartus et al., 1982; Francis et al., 1993; Greenamyre, 1986).  It is 
thought that neurodegeneration in the AD brain occurs in a dichotomous pattern, beginning 
with the basal cholinergic forebrain neurons (bfCNs), which originate from within the basal 
nucleus of Meynert (nbM) and provide cholinergic innervation to the hippocampus and 
cortex (Coyle et al., 1983; Auld et al., 2002; Wicklund et al., 2010; Prado et al., 2016; Duan et 
al., 2014.; Palmer and Gershon 1990; Whitehouse et al., 1982; Kuhn et al., 2015; Arendt et 
al., 1983; Bartus et al., 1982; Schmitz et al., 2016; Candy et al., 1983; Liu et al., 2015).  These 
neurons play important roles in encoding novel information, the regulation of cortical 
plasticity and attention, which are all important processes in memory function (Auld et al., 
2002; Olton, 1990; Zaborszky et al., 2012; Janocko et al., 2012; Schmitz et al., 2010; Schmitz 
et al., 2016; Schmitz et al., 2014; Quigley et al., 2010; McGaughy 2005; Pinto et al., 2013; 
Goard and Dan, 2009).  Aβ plaques occur early in these neurons and degeneration of the 
Figure 1.7      Neurodegeneration in Alzheimer’s disease 
The image above depicts a coronal section through a healthy brain (left hand side) and a late-stage 
AD brain (right hand side).  Upon comparison of the two, gross atrophy of the brain can be 
recognised by shrinkage of the cerebral cortex and ventricle enlargement.    The limbic regions and 
temporal lobes are labelled and demonstrate severe loss of brain tissue. 
Adapted with permission from www.alz.org ©2017 Alzheimer's Association. All rights 
reserved. Illustrations by Stacy Jannis. 
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nbM is correlated with dementia (Kerbler et al., 2015).  BfCNs are very long and project 
elaborate, richly arborised processes (Woolf, 1991).  Consequentially, they have high 
metabolic demands deeming them particularly vulnerable in AD (Wu et al., 2014).   
Glutamatergic neurons, particularly those within the cortex, are also particularly vulnerable 
in AD, leading to severe disruption of glutamatergic neurotransmission within the 
hippocampus and neocortical areas (Francis et al., 1993; Francis, 2003; Lee et al., 2002; 
Greenamyre et al., 1988; Campos-Pea and Antonio, 2014; Palmer and Gershon, 1990; Frisardi 
et al., 2011; Revett et al., 2013).  Since glutamatergic neurotransmission within the medial 
temporal lobes is important in learning and memory functions, the loss of these neurons may 
underlie dementia in AD (Squire and Zola-Morgan, 1991).   
1.2.3.2  Tau and Amyloid-beta pathology in Alzheimer’s disease 
 
Figure 1.8      Neurofibrillary tangles and Amyloid plaques in the Alzheimer’s disease brain 
A)  Schematic representation of the spread of Amyloid plaque (green) and tau tangle (red) 
pathology with disease progression. Darker colours resemble areas of higher concentrations of 
aggregations. Plaques develop profusely within the cortex and later in disease can be found within 
the allocortex, diencephalon and eventually throughout the majority of the brain.  NFTs first 
appear within the basal forebrain and entorhinal cortex, then within the temporal lobes and other 
cortical areas.   Image adapted, with permission, from Candela et al., 2013.   
B) Amyloid plaques immunostained with anti-beta-amyloid antibody (green arrow) and tau 
tangles immunostained with anti-PHF-1 antibody (red arrow) within a hippocampal slice from an 
AD brain.   Image adapted, with permission, from Rohn, 2013. 
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1.2.3.2.1  Propagation of tau pathology 
A study by Braak and colleagues compared tau pathology within the brain using 
immunostaining with antibodies against hyperphosphorylated tau and silver staining at Braak 
stages.  The group found that at Braak stage I, mild tau pathology is confined to the 
transentorhinal region.  At stage II, the density of NFT lesions increases and the pathology 
extends to the entorhinal cortex with pathological hyperphosphorylated tau found within the 
deep entorhinal plexus.  By stage III, tau pathology worsens and lesions extend to the 
hippocampus and the adjoining neocortical association areas.  Stage IV is characterised by 
increased lesion density within the entorhinal region and fusiform gyrus, as well as pathology 
within the medial temporal gyrus and insular cortex.  Lesions widely extend into the occipital 
lobe and the pristriate region in stage V and in stage VI lesions are visible within the 
parastriate and striate areas of the occipital neocortex (Braak et al., 2006).  
The stereotypical, spaciotemporal pattern of tau pathology progression associated with 
certain tauopathies, such as AD and AGD, supports the hypothesis that tau spreads trans-
synaptically in a manner resemblent of the progression of prion protein pathology (Seeley 
et al., 2009; Raj et al., 2012; Zhou et al., 2012; Clavaguera et al., 2015).  Prions are 
infectious agents, which propagate via protein-protein interactions, templating further 
aggregation of normally folded proteins (Prusiner, 1982).  Specific aggregations of tau, or 
stains, distinct in different tauopathies, are thought to conformationally template native tau 
into pathological fibrils.  Prions also stably maintain unique conformations that connect the 
structure of the prion to the pattern of pathology (Sanders et al., 2014), akin to the distinct 
patterns of neuropathology and rates of progression associated with different conformations 
of aggregated tau in specific tauopathies.   
Clavaguera and colleagues were the first to illustrate the transmission of tau pathology in 
prion manner.  The group injected brain extracts derived from P301S tau-expressing mice 
into the hippocampi of Tg mice overexpressing WT human tau and noted that this triggered 
the assembly of WT human tau into filaments.  This pathology spread from the site of 
injection to anatomically connected brain regions (Clavaguera et al., 2009).  Similar 
observations regarding the progression of tau pathology have also been achieved through 
injection of P301S tau-mice (Iba et al., 2013) or WT mice (Sanders et al., 2014) with synthetic 
pre-formed fibrils and within Tg mice expressing human P301S MAPT restricted to the 
entorhinal cortex (de Calignon et al., 2012; Liu et al., 2012).  Further studies involving the 
injection of aggregated tau isolated from patients with AD, PiD, AGD, PSP, TD and CBD 
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(Lasagna-Reeves et al., 2012; Clavaguera et al., 2013; Um et al., 2013; Kaufman et al., 2017; 
Narasimhan et al., 2017) into WT mice support this work, demonstating that tau aggregation 
was initiated through the introduction of pathogenic tau at the site of injection and within 
anatomically connected regions.  Interestingly, in the case of mice injected with tau isolated 
from AGD, PSP and CBD site specific lesions associated with disease were noted (Clavaguera 
et al., 2013), differences in the potency of particular tau stains to induce aggregation of 
endogenous tau was noted (Narasimhan et al., 2017) and different neuronal networks were 
differentially vulnerable to specific stains (Narasimhan et al., 2017), supporting the 
hypothesis of prion-like tau transmission.  Stains from CBD and PSP were found to be capable 
of causing tau aggregation within glial cells, further demonstrating the differences in the 
propensity of particular strains of tau to affect certain cell types (Narasimhan et al., 2017).  
Sanders and colleagues illustrated the faithfully templating of two synthetic pathogenic tau 
stains by inoculating WT mice with one of each strain.  Each stain faithfully produced different 
patterns of tau pathology progression within mice and later tau was purified from these mice 
revealing that the strains were unchanged, further supporting the similarities of tau 
pathology propagation with prion diseases (Sanders et al., 2014).  These observations may 
explain the distinct neuroanatomical patterns of tau aggregation and histopathology of 
different tauopathies. 
Soluble tau has been shown to be released into interstitial space within in vivo models, or 
media within in vitro models, and this release is increased with neuronal activity (Pooler et 
al., 2013; Yamada et al., 2014; Wu et al., 2016).  In vitro and in vivo experimental models 
have demonstrated that both synthetic, misfolded tau fibrils (Frost et al., 2009; Guo and Lee, 
2011) as well as those from AD patients (Santa-Maria et al., 2012) can be taken up by cells, 
seeding fibrillisation of endogenous tau.  Wu and colleages have demonstrated that tau 
misfolds into low molecular weight oligomers before further aggregation into fibrils and that 
these oligomers can be internalised after release by neighbouring cells (Wu et al., 2013).   
Experimental evidence supports several mechanisms by which tau may be released and 
reabsorbed by neighbouring neurons.  Oligomeric, misfolded ‘naked’ tau may be released 
into the interstital space (Chai et al., 2012; Kfoury et al., 2012; Pooler et al., 2013), to be taken 
up directly through the plasma membrane of the neighbouring cell, by macropinocytosis 
(Frost et al.,, 2009; Santa-Maria et al., 2012; Holmes et al., 2013; Wu et al., 2013), a form of 
actin-mediated endocytosis whereby the cell membrane internalises a large intracellular 
vesicle containing extracellular fluid and biomolecules (Lim and Gleeson, 2011).  
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Alternatively, tau may be released within exosomes, which fuse with the membranes of 
neighbouring cells (Saman et al., 2012).  Tunnelling nanotubes, which are membranous, 
tunnel-like structures that connect two cells allowing for cytoplasmic continuity, have been 
demonstrated to be involved in the spreading of prion proteins (Gousset et al., 2009) and 
have recently been implicated in tau transmission (Abounit et al., 2016; Tardivel et al., 2016).  
Additional research is needed to provide clarity on the mechanisms of transmission of 
misfolded ‘seed’ tau strains between neurons and glia of patients with tauopathy. 
1.2.3.2.2  Generation of Amyloid pathology 
Aβ is produced through proteolytic processing of its precursor protein, APP.  APP is a 
transmembrane protein and processing occurs through two pathways, the non-
amyloidogenic and the amyloidogenic pathway.  The amyloidogenic pathway is responsible 
for the production of Aβ.  In this pathway, APP is initially cleaved by β-secretase, generating 
a C-terminus fragment of 99 aa (C99), which remains in the membrane, as well as a soluble 
APP fragment (sAPPβ), which is released extracellularly.  Subsequent cleavage of C99 by γ-
secretase leads to the release of Aβ into the extracellular space and the APP intracellular 
cytoplasmic domain (AICD) is deposited intracellularly.  γ-secretase is a large protein complex 
consisting of at least four main proteins; presenilin 1 or presenilin 2, PEN2, APH1 and 
Nicastrin (Vetrivel et al., 2006).  Different forms of Aβ are produced, most commonly Aβ38, 
Aβ40 and Aβ42.  While the majority of Aβ produced in normal physiology is Aβ40 (Seubert et 
al., 1992), Aβ42 is the most abundant form found to be aggregated which is thought to be due 
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to its increased propensity to aggregate thereby resisting degradation (Roher et al., 1993; 
Snyder et al., 1994).   
 
The non-amyloidogenic pathway does not result in the production of Aβ as APP is first 
cleaved by α-secretase within the Aβ peptide region.  This initial cleavage leads to release of 
sAPPα into the extracellular space, leaving a C-terminus fragment of 83aa (C83) embedded 
in the membrane.  sAPPα is thought to be neuroprotective (Mattson et al., 1993; Furukawa 
et al., 1996; Ma et al., 2009), while sAPPβ lacks these neuroprotective properties (Furukawa 
et al., 1996). C83 is then cleaved by γ-secretase to produce the APP intracellular domain 
(AICD) and a small 3 kDa peptide called p3, both of which are rapidly degraded (Zhang et al., 
2012).  The non-amyloidogenic pathway and the amyloidogenic pathway are depicted in 
Figure 1.9.  
The formation of Aβ into plaques is thought to occur through well-defined sequential 
aggregation events.  Monomers form oligomers, which are most likely the principle toxic 
Figure 1.9     Schematic representation of amyloid beta precursor protein cleavage via the 
amyloidogenic and non-amyloidogenic pathways 
Aβ is produced through cleavage of APP via the amyloidogenic pathway, depicted on the left.  APP 
is first cleaved by β-secretase releasing sAPPβ into the extracellular space and leaving a 99 aa C-
terminus fragment within the membrane (C99).  After further cleavage of C99 by γ-secretase, Aβ 
is released into the extracellular space and AICD is left within cell.  APP is cleaved via the non-
amyloidogenic pathway initially by α-secretase to release sAPPα leaving C83 behind embedded in 
the membrane. Subsequent cleavage of the C-terminus fragment leads by γ-secretase leads to the 
release of p3 leaving AICD within the cell. 
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species of Aβ in AD (Klein, 2013; Verma et al., 2015), and then protofibrils of various sizes.  
Protofilaments then further aggregate to form amyloid fibrils and eventually these fibrils 
compose plaques (Martins et al., 2008).  
1.2.3.2.3  Amyloid toxicity 
In healthy people, the normal physiological levels of Aβ are approximately 1.5 nM, however, 
in AD patients much higher levels of have been reported (Kuo et al., 1996; Höglund et al., 
2008).  Toxic Aβ aggregates in the form of soluble Aβ oligomers, intraneuronal Aβ and 
amyloid plaques impair synapses and ultimately cause neurodegeneration and dementia.  
Aβ42 in comparison to Aβ40, elicits considerably greater toxicity in cell culture studies (Krishtal 
et al., 2015), possibly due to its greater propensity for aggregation (Harada and Kuroda, 2011; 
Vandersteen et al., 2012; Tiiman et al., 2015) and effect on the structure of Aβ aggregations 
(Pauwels et al., 2012).  For example, Aβ42, but not Aβ40, has been reported to decrease the 
functionality of forebrain cholinergic neurons differentiated from mouse embryonic stem 
cells (Wicklund et al., 2010), form ion channels in cell membranes in an immortalised neural 
cell line (Bode et al., 2017) and attenuate synaptic AMPA receptor function in primary CA1 
hippocampal neurons (Parameshwaran et al., 2007).  Oligomers are thought to be able to 
interact with the cell membrane non-specifically through electrostatic force and specifically 
by associating with ligand and receptors on pre- and post-synaptic terminals (Hertel et al., 
1997; Jarosz-Griffiths et al., 2016; Malinow et al., 2011; Spires-Jones and Hyman, 2014).  Aβ42 
oligomers have also been demonstrated to cause membrane disruptions through the 
creation of pores in the membrane (Sepulveda et al., 2010).  
1.2.3.2.4  Phosphorylation of tau in AD 
Over 40 of tau’s phosphorylation sites are phosphorylated in AD and not in controls (Hanger 
et al., 2007; Martin et al., 2013).  We know that for tau to become highly phosphorylated, to 
the degree that it is in the AD brain, certain phosphorylation sites must initially be 
phosphorylated to ‘prime’ for further deleterious phosphorylation (Hashiguchi et al., 2002).  
In a comprehensive study aimed at revealing the sequential phosphorylation of specific sites 
of tau protein during disease progression, the brains of cases with mild cognitive impairment 
(MCI) and AD of different Braak stages were immunostained using 429 antibodies against 
phosphorylated tau (ptau) species. The authors found that the tau phosphorylation site 
Thr231 was initially phosphorylated, followed by Ser202 and Ser205.  Phosphorylation at 
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Ser396 and Ser404 ensued, with Thr214 and Ser212 phosphorylated subsequently (Luna-
Muñoz et al., 2007).   
Many of the sites phosphorylated in AD, including Thr181, Ser202, Ser205, Thr231, Ser396 
and Ser422, have been found to be phosphorylated in vitro as a consequence of AβO 
treatment in human and murine neural cell lines (Busciglio et al., 1995; Billingsley and 
Kincaid, 1997; Iqbal et al., 1998; Wang et al., 2000; Zheng et al., 2002; Johansson et al., 2006; 
Ma et al., 2009; Jin et al., 2011). 
1.2.3.3  Mutations of familial AD 
fAD is caused by highly penetrant mutations within three genes encoding proteins involved 
in the amyloid processing pathways (Zhu et al., 2015) (Figure 1.12), which result in the 
abnormal production of Aβ.  The disease, also called early onset AD (EOAD) owing to the 
unusually young age of onset in comparison to sAD, is diagnosed in patients who present 
before age 65 (Rossor et al., 2010; Zhu et al., 2015), have at least one affected, closely-related 
family member and have a mutation in one of these genes (Bird, 1993).  Over 200 mutations 
(Cruts et al., 2012), which are inherited in an autosomal dominant manner, have been found 
in the genes encoding APP (Goate et al., 1991), PSEN1 (Sherrington et al., 1995) and PSEN2 
(Levy-Lahad et al., 1995).  Pathological mutations within PSEN1 are the most common, 
affecting between 30-70 % of patients, while APP mutations are responsible for 10-15 % of 
cases and PSEN2 mutations account for less than 5 % of cases (Bird, 1993; Janssen et al., , 
2003; Tedde et al., 2003; Rogaeva et al., 2001; Lleó et al., 2002). Different clinical 
presentations are associated with specific mutations (Bird, 1993).   
The realisation that EOAD is caused by mutations these genes resulting in an increased ratio 
of cerebral Aβ42 as opposed to Aβ40 (Scheuner et al., 1996; Price et al., 1998), or by an increase 
in the self-aggregation of Aβ if the mutations are within the Aβ of APP (Selkoe and Hardy, 
2016), was the main contributing factor in the development of the amyloid cascade 
hypothesis of AD (Hardy and Higgins, 1992).  The hypothesis is based on the central role of 
Aβ in initiating the cascade of pathological molecular events resulting in AD (Hardy and 
Selkoe, 2002).  Additional genetic evidence in support of the hypothesis is that patients with 
Down Syndrome, which is caused by a trisomy of chromosome 21 resulting in an additional 
copy of APP, leads to the abnormal deposition of Aβ and early-onset dementia (Hardy and 
Higgins, 1992).   
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Whilst the Amyloid cascade hypothesis is centred around the role of Aβ in pathogenesis, 
studies using tau null mice have demonstrated the critical role of tau in AD.  Roberson and 
colleagueds demonstrated the importance of tau in disease pathogenesis through the 
production of Tg mice each expressing human APP (K670M/N671L/V717F) (hAPP) and either 
two (hAPP/Tau+/+), one (hAPP/Tau+/–) or no (hAPP/Tau–/–) endogenous tau alleles (Roberson 
et al., 2007).  While mice with two endogenous tau alleles were found to have learning and 
memory deficits as well as spacial memory deficits, mice with just one endogenous tau allele 
demonstrated reduced deficits and tau null mice showed no impairment compared to 
controls, indicating the importance of tau as a mediator for disease pathogenesis.  Santacruz 
and colleagues have also demonstrated the amelioration of memory function deficits, 
behavioural impairments and neuronal loss by decreasing levels of tau in mice expressing Tg 
MAPT P301L that could be supressed using doxycycline (Santacruz et al., 2005).  In other 
studies, a 3xTg AD mouse, which expresses APPSwe, tauP301L, and PS1M146V transgenes was 
found to generate Aβ pathology earlier than tau pathology, suggesting a causal relationship 
between the pathogenesis of the two proteins (Oddo et al., 2003).  This mouse model also 
suggests tau as a mediator of the disease as severe cognitive deficits are not observed until 
tau pathology is present (Oddo et al., 2004; Billings et al., 2005).  Additionally, the cognitive 
deficits recognised in the 3xTg AD mouse are only mitigated when immunotherapy is used to 
reduce both Aβ and tau, and not Aβ alone (Oddo et al., 2006).  Further evidence of 
the mediatory role of tau has been found in patients with AD; the presence of neurofibrillary 
tangles more strongly correlates to cognitive decline in comparison to Aβ pathology  (Bennett 
et al., 2004).  
1.2.3.4  Risk factors of Alzheimer’s disease 
The primary risk factor of AD is ageing; however, genetic and environmental risks have also 
been implicated.  Environmental risk factors include obesity (Beydoun et al., 2008), smoking 
(Lee et al., 2010), lack of exercise (Morris et al., 2017), lower levels of education and alcohol 
abuse (Anstey et al., 2009).  Previous medical conditions such as hypertension (Qiu et al., 
2005), diabetes (Lu et al., 2009) and stroke (Savva et al., 2010) also increase the risk of 
developing AD. 
The major genetic risk determinant for sAD is the presence of Apolipoprotein E (ApoE) 
polymorphic alleles ε2, ε3 or ε4.  ApoE is a major cholesterol carrier, which functions in lipid 
transportation, glucose metabolism, neuroinflammation, neuronal signalling and 
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mitochondrial function in the brain.  ApoE isoforms differentially regulate Aβ aggregation and 
clearance in the brain; the ε2 allele decreases risk, ε3 is considered neutral, one copy of ε4 
increases risk by two fold and two copies of ε4 increases risk by 12 fold (Liu et al., 2013).  
Genome wide association studies and next-generation sequencing have revealed over 20 
gene loci associated with AD risk, including those within clusterin (apolipoprotein J) (Harold 
et al., 2009; Lambert et al., 2009), phosphatidylinositol binding clatherin assembly protein 
(PICALM) (Harold et al., 2009; Lambert et al., 2009), complement receptor 1 (CR1) (Lambert 
et al., 2009), bridging integrator 1 (BIN1) (Seshadri et al., 2010; Tan et al., 2013) and sortilin-
related receptor 1 (SORL1) (Rogaeva et al., 2007).  
 
1.3  Tau kinases and phosphatases 
The balanced activities of many tau kinases and phosphatases allow for precise control of the 
phosphorylation status of tau protein within neurons under physiological conditions.  In 
tauopathy, the equilibrium of kinase and phosphatase activity is thought to become 
imbalanced, leading to the accumulation of aberrant changes in tau protein over time due to 
abnormal phosphorylation. Understanding how the levels and activity of tau kinases and 
phosphatases change in tauopathy may allow us to deduce key initiating pathological events 
in tauopathy (Boutajangout et al., 2011; Martin et al., 2013).   
Many tau kinases that have been implicated in tauopathy including glycogen synthase-3 
(GSK3), cyclin-dependent kinase 5 (Cdk5) p21-activated kinase 3 (PAK3), p38, extracellular-
signal related kinase (ERK), c-Jun N-terminal kinase (JNK), Akt and microtubule-affinity 
regulating kinase (MARK) (Lee et al., 2011; Tell and Hilgeroth, 2013).  Protein phosphatase 
2A (PP2A) is the major tau phosphatase in the brain and is reduced within the AD brain (Gong 
et al., 1993), however there are other known phosphatases including  PP1, PP2B, PP2C and 
PP5 (Hanger et al., 2009).   
Glycogen synthase kinase 3β (GSK3β) and cyclin dependent kinase 5 (Cdk5) are considered 
to be particularly important kinases in tau pathogenesis and are considered potential 
therapeutic targets for the treatment of tauopathies (Mazanetz and Fischer 2007; 
Boutajangout et al., 2011; Pandey and DeGrado, 2016; Tell and Hilgeroth 2013; Eldar-
Finkelman and Martinez, 2011; Tolosa et al., 2014; Lovestone et al., 2014; Llorens-Martín et 
al., 2014).  GSK3β has been reported to phosphorylate more aberrantly phosphorylated sites 
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in disease than any other tau kinase (Martin et al., 2013).  There are few studies into the role 
of p21-activated kinase 3 (PAK3) in tau phosphorylation and tauopathy, however, recent 
work suggests that the tau kinase may be upregulated in FTDP-17 and involved in AD (Zhao 
et al., 2006; Ma et al., 2008; Nguyen et al., 2008; Arsenault et al., 2013; Ehrlich et al., 2015; 
Hallmann, et al., 2015). 
1.3.1  GSK3β 
Glycogen synthase kinase 3 (GSK3) is a highly conserved, proline directed serine/threonine 
kinase, which is highly enriched in the brain, especially within the neocortex, hippocampus 
and cerebellum (Yao et al., 2002).   Glycogen synthase kinase 3β (GSK3β) is one of two related 
paralogs that encode GSK3, the other of which is glycogen synthase kinase 3α (GSK3α), which 
produce two highly homologous proteins of 52 and 47 kDa, respectively (Doble and 
Woodgett, 2003).  Both proteins are expressed ubiquitously, although GSK3β is expressed at 
higher levels within the brain, and are distinguished by differences in their C-terminal and N-
terminal domains (Woodgett 1990; Leroy et al., 2002).   
GSK3β is involved in the regulation of a myriad of cellular processes within the brain and is 
recognised as a master regulator in many signalling pathways including insulin signalling and 
glycogen synthesis, neurotransmitter signalling, neurotrophic factor signalling and Wnt 
signalling (Llorens-Martín et al., 2014; Wu and Pan, 2010; An et al., 2010; Hemmings et al., 
1981; Embi et al., 1980).  GSK3β also phosphorylates cytoskeletal proteins, including tau, to 
regulate microtubule architecture and dynamics (Hanger and Noble, 2011; Hashiguchi and 
Hashiguchi 2013; Goold and Gordon-Weeks 2004; Trivedi et al., 2005; Castaño et al., 2010; 
Wu et al., 2011).  Through its role in regulating microtubule dynamics, it is a crucial kinase in 
neurodevelopment, synaptic transmission and synaptic plasticity including the regulation of 
LTP and LTD (Conde and Cáceres, 2009; Geraldo and Gordon-Weeks, 2009; Ciani et al., 2004; 
Purro et al., 2008; Krylova et al., 2000; Salinas, 2005; Lucas et al., 1998; Hall et al., 2000; Lucas 
and Salinas, 1997; Eickholt et al., 2002; Shi et al., 2004; Yoshimura et al., 2005; Jiang et al., 
2005; Davis et al., 2008; Plattner et al., 2006; Clayton et al., 2010; Huang 1998; Peineau et 
al., 2007; Stanton, 1996; Hooper et al., 2007; Lisman 2003; Cai et al., 2008; Malenka and 
Bear, 2004; Giese, 2009; Chen et al., 2006; Zhu et al., 2007; de Barreda et al., 2010).   
GSK3β is an unusual kinase as it is constitutively active, however, due to its involvement in a 
plethora of physiological processes, regulation of GSK3β must be tightly controlled.  GSK3β 
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is primarily regulated by phosphorylation; phosphorylation of Tyr216 can enhance enzyme 
activity and, conversely, phosphorylation of Ser9 is inhibitory (Wang et al., 1994).  Akt, which 
is also a tau kinase and will be discussed later (Chapter 1.3.4), is a kinase involved in the 
PI3K/PKB/Akt signal transduction cascade, stimulated by insulin and growth factors, capable 
of phosphorylating GSK3β at Ser9 (Delcommenne et al., 1998; Cross et al., 1994; Cross et al., 
1995).  The activity of GSK3β can also be inhibited through N-terminal cleavage by calcium-
dependent protease calpain (Goni-Oliver et al., 2007; Jin et al., 2015a).   
GSK3β is capable of phosphorylating at least 36 of tau’s phosphorylation sites (Martin et al., 
2013; Hanger et al., 2007).  However, GSK3β preferably phosphorylates tau at Ser199, 
Ser202, Ser396, Ser400, Ser 412 Ser413 and Thr231 (Billingsley and Kincaid 1997; Imahori 
and Uchida, 1997) and moderately phosphorylates tau at Ser46, Thr50 and Ser202/Thr205 
(Illenberger et al., 1998), while other sites are phosphorylated to a lesser degree.  Tau can be 
phosphorylated by GSK3β in the absence of a previous priming event (Cho and Johnson 
2003), however, many of the sites associated with tauopathy, including Ser404 (Plattner et 
al., 2006; Sengupta et al., 2006) and Thr231 (Li and Paudel, 2006; Li et al., 2006), have been 
demonstrated to require priming by another kinase before phosphorylation of GSK3β can 
occur.  In order for these two particular sites to become phosphorylated Cdk5 primes tau 
before phosphorylation by GSK3β (Li and Paudel, 2006; Li et al., 2006; Plattner et al., 2006; 
Sengupta et al., 2006).  Sites found phosphorylated exclusively in AD by GSK3β include 
Ser422, Ser409, Thr403, Ser368, Ser289, Ser262, Ser238, Ser237, Ser214, Ser210, Ser184, 
Thr175, Thr153 and Thr69 (Martins et al., 2013).  It seems that to affect tau’s MT binding 
ability, tau must be phosphorylated at previously primed sites, indicating the importance of 
priming by other kinases, before GSK3β activity, to affect microtubules (Cho and Johnson, 
2003). 
1.3.1.1  GSK3β in tauopathy 
Since 1992, we have known that GSK3β is an important kinase associated with the abnormal 
hyperphosphorylation of tau leading to NFT formation in tauopathies (Hanger et al., 1992; 
Mandelkow et al., 1992).  Increased GSK3β activity has been observed in the brains of AD 
patients (DaRocha-Souto et al., 2012; Leroy et al., 2007), through the application of AβO to 
primary neuronal cultures (Alvarez et al., 1999; DaRocha-Souto et al., 2012; Takashima et al., 
1996; Takashima et al., 1993) and in murine models of AD (Deng et al., 2014; DaRocha-Souto 
et al., 2012; Shipton et al., 2011).   
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Increased activity and overexpression of GSK3β have been shown to result in increased tau 
phosphorylation at sites consistent with those hyperphosphorylated in AD brains within both 
in vitro (Lovestone et al., 1994; Moreno et al., 1995; Sperbera et al., 1995; Li and Paudel, 
2006; Hanger et al., 1992; Mandelkow et al., 1992) and transgenic (Tg) animal models (Lucas 
2001; Engel et al., 2008; Spittaels et al., 2000; Brownlees et al., 1997).  Inhibition has been 
shown to decrease tau phosphorylation (Malm et al., 2007; Zhang et al., 2011; Shi et al., 
2008; Noble et al., 2005; Crouch et al., 2009; Greco et al., 2009; Kozikowski et al., 2006; 
Leclerc et al., 2001; Takahashi et al., 1999), as well as total tau protein levels (Martin et al., 
2009; Rametti et al., 2008) and MAPT mRNA (Rametti et al., 2008).  The activity of GSK3β has 
also been associated with increased aggregation of tau (Lei et al., 2011; Chun and Johnson 
2007; Engel et al., 2006; Rankin et al., 2007).   
In Tg murine and drosophila models of tauopathy, concurrent overexpression of GSK3β has 
been demonstrated to accelerate neurodegeneration (Lucas 2001; Engel et al., 2008; 
Spittaels et al., 2000; Chun and Johnson 2007) and inhibition of GSK3β has been shown to 
reduce tau-induced neurotoxicity (Nakashima et al., 2005; Pérez et al., 2003; Engel et al., 
2006; Alvarez et al., 1999; Qing et al., 2008; Sofola et al., 2010; Hurtado et al., 2012).   
GSK3β is thought to be intimately related to the pathogenesis of tauopathy and its 
dysregulated activity may participate in pathological feed forward loops in tandem with Aβ 
and tau in AD (Llorens-Martín et al., 2014). One example of a feed-forward loop is the 
activation of GSK3β through hyperphosphorylated tau, mediated by an increase in oxidative 
stress, neuroinflammation and apoptotic processes (Saeki et al., 2011; Shim et al., 2007).  In 
vitro overexpression of GSK3β has been demonstrated to alter the transport of organelles 
along microtubules, microtubule structure and microtubule assembly, alongside abnormal 
phosphorylation of tau (Sang et al., 2001; Lovestone et al., 1996; Cho and Johnson 2003; 
Utton et al., 1997; Cuchillo-Ibanez et al., 2008; Dill et al., 2008; Tatebayashi et al., 2004; 
Reddy, 2013).  Polymorphisms in GSK3β have been demonstrated to occur at over twice and 
thrice the frequency in FTD patients and AD patients, respectively, as in aged healthy subjects 
(Schaffer et al., 2008).   
GSK3β also interacts with different components of the amyloid plaque producing system, 
such as APP and presenilin (Aplin et al., 1996; Terracciano et al., 2010; Kirschenbaum et al., 
2001b; Kirschenbaum et al., 2001; Twomey and McCarthy, 2006) influencing the production 
of greater levels of Aβ (Phiel et al., 2003).  The kinase also influences the expression of β-
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secretase in triple Tg AD murine models, leading to increased Aβ (Ly et al., 2013).   
Reciprocally, mounting evidence in Tg murine and in vitro models carrying mutations 
resulting in increased production of Aβ supports the role of Aβ in increasing GSK3β activity 
(Takashima et al., 1993; Takashima et al., 1996; Hoshi et al., 2003; Takashima et al., 1998; 
Ma et al., 2006; Terwel et al., 2008), representing a pathogenic feed-forward mechanism.  
Furthermore, genetic or pharmacological deactivation of GSK3β in these models prevents 
increased levels and neurotoxicity of Aβ (Takashima et al., 1993; Takashima et al., 1996; Koh 
et al., 2008; Aplin et al., 1997; Ryder et al., 2003; Serenó et al., 2009; Rockenstein et al., 2007; 
Decker et al., 2010; Ly et al., 2013).   
Investigations using tau null mice show these mice are protected against neurotoxicity 
mediated by Aβ (Ittner et al., 2010; Roberson et al., 2007) or GSK3β (de Barreda et al., 2010), 
indicating that tau is required in order for the function of pathogenic feed-forward systems 
established by the complex interactions between GSK3, Aβ and tau. These studies strongly 
implicate GSK3β in AD pathogenesis and have led to the development and clinical testing of 
several GSK3β inhibitors aimed at reducing tau phosphorylation in disease.   
1.3.2  CDK5 
Cyclin dependant kinase 5 (Cdk5) belongs to the cyclin dependant kinase (CDK) family of 
proline-directed serine threonine kinase proteins (Kimura et al., 2014). Many of Cdk5’s 
substrates are involved in the regulation of microtubule dynamics (Shah and Lahiri, 2016; 
Contreras-Vallejos et al., 2014); while tau is the most well-known of these, others include 
collapsing response mediator protein 2  (Brown et al., 2004), axin (Fang et al., 2011), stathmin 
(Hayashi et al., 2006), doublecortin (Tanaka et al., 2004), tubulin polymerization-promoting 
protein (Hlavanda et al., 2007) and microtubule associated protein 1B (Paglini et al., 1998).  
Therefore, the activity of Cdk5 influences neurotransmission, neurogenesis, trafficking of 
cellular cargo, synaptic plasticity, LTP and LTD as these rely on rapid changes in microtubule 
structure (Hawasli et al., 2007; Angelo et al., 2006; Hisanaga and Endo 2010; Nakayama et 
al., 1999; Kawauchi 2014; Kawauchi et al., 2005).   
It is important for Cdk5 activity to be tightly regulated as it functions in so many important 
pathways.  Cdk5 is active when complexed with specific activator proteins, p39 and p35 (Tsai 
et al., 1994; Tang et al., 1997).  The expression of these activator proteins is restricted to the 
neurons, therefore, the activity of Cdk5 is neuron specific (Li et al., 2016; Guidato et al., 1998; 
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Miyajima et al., 1995; Paglini and Cáceres, 2001; Humbert et al., 2000) and developmentally 
regulated such that p39 is expressed in foetal development whereas p35 is expressed in 
adults (Dhariwala and Rajadhyaksha, 2008).  When Cdk5 complexes with its activators p35 or 
p39, which have membrane-targeting motifs, the complex translocates from the cytoplasm 
to the membrane allowing for interaction with its substrates (Asada et al., 2008).  Both p35 
and p39 have short half-lives and are degraded via ubiquitin-mediated proteasome system, 
allowing for tightly regulated Cdk5 activity (Li et al., 2016).   
P35 can be cleaved by calpain to produce p25, which retains the Cdk5 binding domain and 
therefore also complexes with Cdk5 (Tang et al., 1997; Tsai et al., 1994; Lew et al., 1994; 
Uchida et al., 1994; Lee et al., 2000; Patrick et al., 1999).  P25 makes a stronger association 
with Cdk5 and Cdk5-p25 has a half-life estimated to be six times greater than Cdk5-p35 
(Patrick et al., 1998; Angelo et al., 2006).  Cdk5-p25 is also not restricted to the membrane, 
as Cdk5-p35 is, allowing the complex access to additional substrates within the cytoplasm 
and nucleus.  Due to these properties of Cdk5-p25 it is considered hyperactive (Lee et al., 
2000; Noble et al., 2003; Patzke and Tsai 2002).  An increase in Cdk5-p25 is associated with 
neurotoxic events and neurodegenerative disease.   
1.3.2.1  Cdk5 in tauopathy 
Cdk5 is a particularly interesting kinase as all of the 11 serine/threonine sites of tau protein 
that it phosphorylates are found to be phosphorylated in AD brains (Chauhan et al., 2005; 
Hanger et al., 2009; Martin et al., 2013).  Major sites phosphorylated by Cdk5 include Ser404, 
Ser235, Ser202 and Thr205, while minor sites include Ser199, Ser396, Thr153, Thr181, 
Thr212, Thr217 and Thr231 (Kimura et al., 2014; Lund et al., 2001; Wada et al., 1998; Sakaue 
et al., 2005; Kimura et al., 2013).  Cdk5 is deregulated in AD and has been intimately 
associated with the pathological processes leading to neurodegeneration (Chang et al., 2010; 
Kanungo et al., 2009).  The mechanism behind this dysregulation is thought to hinge on 
increased intracellular calcium ([Ca2+]i), which occurs in pathological conditions, including in 
the presence of Aβ1-42 or oxidative stress (Lee et al., 2000; Kusakawa et al., 2000; Patzke 
and Tsai, 2002), within the brains of patients with tauopathy.  Increased [Ca2+]i results in the 
activation of calpain, which subsequently cleaves p35 to produce p25 and leads to increased 
levels of hyperactive Cdk5 (Lee et al., 2000).  Importantly, Cdk5-p25 has a higher tau kinase 
activity than Cdk5-p35 (Hashiguchi et al., 2002; Sakaue et al., 2005; Kimura et al., 2014; 
Patrick et al., 1999; Imahori and Uchida, 1997; Dhavan and Tsai, 2001).   
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Studies that provide support for the hypothesis that Cdk5 is hyperactivated in tauopathy 
brain report increased levels of Cdk5-p25, increased p25 and increased p25/p35 ratios within 
AD brains compared to controls (Tseng et al., 2002; Camins et al., 2006; Lee et al., 1999; 
Grynspan et al., 1997; Liu et al., 2016; Zhu et al., 2001).  Cdk5 protein levels have also been 
reported to be increased two-fold in AD brains compared to age-matched controls (Lee et 
al., 1999; Pei et al., 1998; Zhu et al., 2001).  Increased Cdk5 levels have also been observed 
in pre-tangle neurons isolated from AD brains, suggesting that dysregulation of Cdk5 may be 
an early event in tau pathogenesis  (Pei et al., 2001).   
A transgenic mouse overexpressing p25 in the forebrain has been used to demonstrate that 
increased p25 alone is sufficient to elicit neurofibrillary tangles and subsequent neuronal loss 
in otherwise healthy mice through bolstering Cdk5 activity (Cruz et al., 2003).  Furthermore, 
the pathology observed in these mice occurred in the cortex and hippocampus, which are 
primary regions of neurodegeneration in AD and FTD (Chapter 1.2) suggesting a link between 
aberrantly activated Cdk5 and tauopathy.  In an additional study, this transgenic mouse was 
crossed with FTDP-17 model mice carrying the P301L MAPT mutation and the authors 
reported markedly increased tau phosphorylation, tau pathology and neurodegeneration in 
double transgenic mice compared to mice carrying the tau mutation alone (Noble et al., 
2003).   
Cdk5-p25 phosphorylates the same sites on tau as Cdk5-p35 (Sakaue et al., 2005), therefore, 
it is suspected that Cdk5-p25 is capable of causing hyperphosphorylation of tau as it binds to 
tau with greater affinity (Hashiguchi et al., 2002) and has a longer half-life leading to an 
imbalance in the rate of phosphorylation verses dephosphorylation of tau.  Additionally, as 
Cdk5-p25 can phosphorylate ‘free’ tau within the cytoplasm it increases the propensity for 
tau to become aggregated (Giese, 2014).   Indeed, Cdk5 has been found co-localised with tau 
tangles in AD brains (Augustinack et al., 2002b).   
Increased levels of Aβ are also linked to the activity of Cdk5.  Cleavage of p35 to produce p25 
can be induced by Aβ peptide treatment (Lee et al., 2000; Town et al., 2002; Li et al., 2003).  
Additionally, Cdk5-p25 is involved in the synthesis of amyloid-β (Cruz et al., 2006) via 
increasing levels of β-secretase (Wen et al., 2008) and as APP, presenilin-1 (PSEN1) and 
amyloid-β are among its substrates (Baumann et al., 1993; Morfini et al., 2004; Lau et al., 
2002; Iijima et al., 2000).  Furthermore, Cdk5 has been suggested to play a role in mediating 
tau pathology and neurotoxicity caused by the presence of Aβ in AD.  Numerous in vitro 
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studies involving the application of Aβ peptides have demonstrated increased 
phosphorylation of tau at sites phosphorylated by Cdk5, with concurrent increase in Cdk5-
p25 (Otth et al., 2002; Zempel et al., 2010; Shukla et al., 2012; Hernandez et al., 2009; Han 
2005; Lopes et al., 2007; Zheng et al., 2005; Zheng et al., 2010).  Inhibition of Cdk5 activity 
has been demonstrated to ameliorate Aβ peptide-induced toxicity and tau phosphorylation 
in AD Tg murine models and within cells treated with Aβ peptides (Hernandez et al., 2009; 
Alvarez et al., 1999; Chang et al., 2010; Lopes et al., 2010; Lee et al., 2000).  P35 
overexpression potentiates Aβ-induced apoptosis in neuronal cultures (Utreras et al., 2009).   
Furthermore, overexpression of p25 in cortical neurons not only results in aberrant 
phosphorylation of tau but also cytoskeletal disruption and apoptotic cell death, indicating 
that aberrant Cdk5 activation is neurotoxic. Cdk5-p25 has been demonstrated to increase 
oxidative stress and cause mitochondrial dysfunction (Sun et al., 2008).  Increased levels of 
Cdk5 also promotes neuronal apoptosis (Li et al., 2002; Hamdane et al., 2005; Cheung et al., 
2008).    
CDK5 gene expression has also been proposed to be altered in tauopathy, which could 
explain changes to its activity, however this is controversial.  Liang and colleagues found CDK5 
expression was decreased in the entorhinal cortex, hippocampus, posterior cingulate cortex 
and medial temporal gyrus in patients with AD in comparison to controls (Liang et al., 2008).  
Interestingly, the same study also revealed an increase in p35 expression and it was 
speculated that this may represent a neuroprotective mechanism to prevent further tau 
pathology  (Liang et al., 2008).  Within PC12 cells overexpressing APP, CDK5 expression was 
found to be increased (Czapski et al., 2011).   
1.3.3  P21 activated kinases 
P21 activated kinases (PAKs) are a family of serine/threonine kinases, activated by cell 
division control protein 42 homolog/Ras-related C3 botulinum toxin substrate 1 (Cdc42/Rac), 
which are classified into two groups of isoforms based on their structural and biochemical 
properties.  Group 1 consists of PAKs 1-3, while group 2 includes PAKs 4-6 (Arias-Romero and 
Chernoff 2008; Minden 2012).  All PAKs contain an N-terminal Cdc42/Rac-binding domain 
and a C-terminal protein kinase domain, which are highly conserved (Kelly and Chernoff 
2011).  PAK3 shares 95 % homology with PAK1 and is believed to have many similar, 
redundant functions (Kelly and Chernoff, 2011; Huang et al., 2011).  Both of these tau kinases 
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are expressed throughout the brain, particularly in the hippocampus, and are distributed 
throughout the soma and within the proximal dendrites of differentiated neurons (Allen et 
al., 1998; Huang et al., 2011).  There are two other main differences between these two 
isoforms of PAK, which may allude to unknown functional discrepancies of the two isoforms; 
PAK1 is able to enter the nucleus of neurons, whereas PAK3 cannot (Lightcap et al., 2009), 
and PAK1 requires binding with Rho GTPases to become active, whereas Pak3 does not. The 
binding of Rho GTPases to PAK3 is, however, essential for the translocation of PAK3 to the 
dendrites (Bagrodia and Cerione, 1999).   
These PAKs are known to play roles in the regulation of synapse formation, dendritic spine 
morphology, synaptic transmission, neurite outgrowth, growth cone guidance, apoptosis and 
cell cycle control (Arias-Romero and Chernoff, 2008; Zhao et al., 2006; Hayashi et al., 2004; 
Nakayama et al., 2000; Obermeier et al., 1998; Zhang et al., 2005; Boda et al., 2004; Malinow 
and Malenka 2002; Thévenot et al., 2011; Huang et al., 2011; Ding et al., 2015).  The 
involvement of PAK 1 and 3 in these roles may be due to their ability to regulate actin and 
microtubule dynamics through phosphorylation of cytoskeletal proteins, including tau (Arias-
Romero and Chernoff, 2008; Zhao et al., 2006; Szczepanowska, 2009). 
Several lines of evidence demonstrate that the loss of PAK 1 and 3 functions is detrimental 
to neurogenesis and instrumental in neurodegeneration.  PAK3 mutations that result in loss 
of function cause X-linked non-syndromic mental retardation (Hayashi et al., 2007; Kreis and 
Barnier, 2009; Peippo et al., 2007).  PAK1/PAK3 null mice have severely impaired memory 
and learning functions, major loss of brain volume and hyperactive behaviour as well as 
reduced dendrite lengths and dendrite tip number (Huang et al., 2011).  Both Tg null PAK1 
and Tg null PAK3 mice exhibit changes in synaptic morphology and LTP, however these mice 
are otherwise viable, fertile and healthy probably owing to their function redundancy 
(Hayashi et al., 2004; Meng et al., 2005; Asrar et al., 2009).  PAK3 null rat hippocampal slices 
and primary neuron cultures also exhibit abnormal spine morphology, abnormal activity-
mediated spine dynamics and reduced LTP.  Furthermore, in the prefrontal cortex and 
hippocampus of patients with depression PAK1 and PAK3 expression are decreased, which 
corresponds with decreased volume of these areas in these patients (Fuchsova et al., 2016).   
62 
 
1.3.3.1  PAK3 in tauopathy 
In the hippocampi of early-stage AD patients, increased levels of total and active PAK3 levels 
have been reported (Nguyen et al., 2008), while significantly decreased levels of PAK3 have 
been measured in late-stage AD within the hippocampus, temporal lobes and neocortex (Ma 
et al., 2008; Nguyen et al., 2008; Arsenault et al., 2013; Zhao et al., 2006a).  This disparity in 
PAK3 levels has been replicated in young and aged mutant APP Tg mice (Nguyen et al., 2008).  
The variation in PAK3 levels was demonstrated to be a response to increased Aβ; limiting the 
production of Aβ in these mice, by preventing the cleavage of APP by caspase, prevented the 
increased activity of PAK3 in young mice and the decreased activity in aged mice (Nguyen et 
al., 2008).  This finding was replicated in rat hippocampal neurons treated with Aβ42O, which 
were found to exhibit abnormal activation of PAK3 and translocation of PAK3 from the 
cytosol to the membrane (Ma et al., 2008).  Additionally, in fAD murine models PAK3 has 
been shown to mediate the pathways leading to apoptosis and abnormal DNA synthesis 
through its interaction with the C-terminus of APP (McPhie et al., 2003).  An increase in PAK3 
has been proposed to signify a protective mechanism in early AD as the loss of PAK3 is 
detrimental, evidenced by a more pronounced loss of synaptic proteins and a loss in social 
recognition abilities in Tg AD mice crossed with PAK3 null mice, compared to those with two 
copies of PAK3 (Arsenault et al., 2013). Alternatively, the initial increase in the activation of 
PAK 1 and 3 in AD may be a consequence of microtubule instability, as this has been 
demonstrated to result in PAK1 activation in non-neuronal cell cultures (Zang et al., 2001). 
Comparatively fewer studies have investigated the involvement of PAK3 on tau pathogenesis 
in tauopathy. A high-content siRNA screen revealed PAK3 phosphorylates tau at Ser262 
(Azorsa et al., 2010), however, further investigation is required to understand which other 
sites PAK3 may phosphorylate.  Arsenault and colleagues demonstrated that loss of PAK 
function within a Tg AD murine model corresponds with increased aggregation of tau, 
however, no change in soluble tau levels or tau phosphorylation at Ser202, Ser205, Ser396 
or Ser404 was detected (Arsenault et al., 2013).  In a recent study, however, PAK3 depletion 
in 3xTg-AD mice led to increased pSer202/pSer205 and pSer396/pSer404 tau (Bories et al., 
2017).   
Dysregulation of PAK3 activity may indirectly result in aberrant tau phosphorylation through 
its effects on other tau kinases. Extracellular signal regulated kinase 3 (Erk3), a tau kinase 
implicated in neurodegenerative disease (De La Mota-Peynado et al., 2011), is a substrate of 
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PAK3.  Furthermore, PAK3 forms a complex with the tau phosphatase protein phosphatase 2 
(PP2A) (Westphal et al., 1999), found to be deactivated and expressed at lower levels in 
tauopathy (Torrent and Ferrer, 2012).  Since PP2A is thought to be regulated through 
complexing with other proteins, this may suggest that PAK3 regulates PP2A activity 
(Westphal et al., 1999).    
PAK3 is downregulated is hiPSC dopaminergic neurons carrying mutations N279K and V337M 
MAPT, suggesting that tau pathology resulting from these mutations may influence the 
expression of PAK3 (Ehrlich et al., 2015).  Tau activates AP-1 transcription factor via MAPK 
(Leugers and Lee, 2010) and AP-1 transcription factor is responsible for PAK3 transcription 
(Parker et al., 2013), therefore it is possible that aberrant species of tau affect the expression 
of PAK3.  Furthermore, PAK3 phosphorylates tau kinase GSK3β as well as tau (Killick et al., 
2014; Zhou et al., 2014; Inestrosa and Varela-Nallar, 2014).   
 
1.4  Models of tauopathy 
Investigating the pathogenesis of tauopathy is particularly challenging for several reasons.  
Firstly, these diseases are unique to the aged, human brain, which is inaccessible before 
death. Secondly, tauopathies are clinically, pathologically and biochemically heterogeneous, 
therefore tissue from large cohorts of patients is required to allow us to form firm inferences 
about disease.  Thirdly, the neuropathological phenotypes of various tauopathies are 
distinguished based on the involvement of different anatomical areas, cell types and 
presence of distinct isoforms of tau in the pathological deposits, calling for a multidisciplinary 
approach including biomolecular techniques to understand these diseases.   
Recent progression in imaging techniques, specifically in positron emission tomography, 
computed tomography, magnetic resonance imaging and multiphoton imaging has furthered 
our ability to study the brains of individuals with AD and FTD.  While these techniques provide 
valuable data in living patients, particularly concerning the anatomical location of 
neurodegeneration, they are limited in their ability to provide biomolecular information.  Yet, 
whilst post-mortem histology and biomolecular study of brain tissue allows us to see end-
stage properties of disease, we are unable to study the mechanisms of initial pathogenesis.  
This is particularly important as AD and FTD are progressive diseases, whereby pathology is 
accumulated over a long prodromal period.  Furthermore, it is not feasible to obtain brain 
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tissue from a large cohort of patients with very low post-mortem delay (PMD) and proteins, 
post-translational modifications and mRNA are particularly vulnerable to degradation 
(Matsuo et al., 1994).  Prolonged agonal conditions including hypoxia, coma and ischaemia, 
further complicate assessment of tauopathy-related pathology in these samples as these 
conditions can alter molecular pathways associated with neurodegenerative disease.  To 
address research questions concerning the biomolecular basis of tauopathy, animal models 
and cell-based models, such as those using neuroblastoma cell lines and primary murine 
neuron cultures, have traditionally been used, however, the use of these models have 
limitations. 
1.4.1  Animal models 
The aetiology of idiopathic tauopathy is unknown.  Therefore, animal models have been 
created using transgenic (Tg) and knockout (KO) technology to modulate the expression of 
pathogenetically important proteins, with the intention of replicating the neuropathology 
and clinical phenotypes recognised in humans.  The most popular vertebrate animals used in 
neurodegenerative research are rodents.  Invertebrate animals, including the 
nematode Caenorhabditis elegans (C. elegans) and the fruit fly Drosophila melanogaster 
(Drosophila), are particularly useful for genetic screening.  While each of these have provided 
important insights into tauopathy (Götz and Ittner, 2008), no model is capable of 
recapitulating all aspects of human tauopathy and each of them have limitations.   
1.4.1.1  Murine models 
Murine models of AD are a mainstay of research into tauopathy and have facilitated many 
important discoveries, including those regarding the biology of formation of amyloid plaques 
and neurofibrillary tangles.  Tg technology, coupled with behavioural analysis techniques 
cultivated over decades, has enabled in vivo investigation in animals that have a similar 
number of genes and considerable chromosomal synteny with humans (Chinwalla et al., 
2002).  The structure and function of the circuitry of the hippocampus and entorhinal cortex 
is also largely phylogenetically conserved between humans and mice.  There are limitations, 
however; the use of rodents is costly, time-intensive and restricted by ethical considerations 
due to animal rights laws.  Failed translation of promising therapeutic solutions for 
tauopathies into humans is also a major problem with the use of mice in pre-clinical research 
(Franco and Cedazo-Minguez, 2014; Laurijssens et al., 2013; Windisch, 2014).   
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Murine models of AD successfully recapitulate age-dependent accumulation of amyloid 
plaques, which are structurally similar to those found in humans, as well as memory 
impairment and cognitive deficits that occur before the presence of pathology (Meyer-
Luehmann et al., 2008; Morrissette et al., 2009).  Physiological differences are thought to 
underlie the lack of faithful recapitulation of important features of human tauopathy, such 
as widespread neuronal loss (Sullivan and Young-Pearse, 2015).  Rodents and humans differ 
neurally: human cortical and hippocampal neurons have more elaborate dendritic branching 
and a greater density of dendritic spines compared to mice (Ballesteros-Yáñez et al., 2006; 
Benavides-Piccione et al., 2006; Elston et al., 2011); humans’ astrocytes are larger with more 
complex processes (Oberheim et al., 2006; Oberheim et al., 2009); only humans have Von 
Economo (also known as Spindle) neurons, which are important in pathogenesis of FTD 
(Seeley et al., 2006).  Another important consideration is that the splicing of exon 10 MAPT 
varies in mice and humans with 4R tau predominantly expressed in adult mice (McMillan et 
al., 2008).  There are also disparities between humans and rodents in drug metabolism, drug 
pharmacokinetics and immune system modulation (Geerts, 2009; Seok et al., 2013).   
Another concern is the fact that murine Tg models may in fact be representative of the 
consequences of overexpression of human genes, at levels significantly above those that are 
physiologically relevant, rather than tauopathy.  Indeed, many proteins will become toxic if 
overexpressed at sufficient levels and human genes within a rodent may cause abnormal 
interactions.  While murine models have been invaluable in deciphering the biology of 
amyloid and tau aggregation, the subtle molecular changes that result in pathogenesis in 
human AD and FTD, particularly in sporadic cases, may not be involved in generation of the 
observed pathology in these animals.  Furthermore, many popular murine models 
overexpress multiple mutated genes and this does not occur in people with familial disease.  
Additionally, the majority of cases of tauopathy are sporadic whereas these animal models 
are representative of familial disease.  As we do not yet understand whether the molecular 
mechanisms that instigate sporadic disease are equal to those that cause familial disease 
these models are thought to be limited in their applicability for the study of tau pathogenesis.   
1.4.1.3  Drosophila models 
The genome and neurobiology of Drosophila is well characterised, owing to over 100 years 
of research using these animals.  There are no ethical restrictions according to animal 
protection laws for the use of drosophila, which when coupled with the fact that they are 
66 
 
time and cost effective to maintain makes them a good option for modelling 
neurodegenerative disease.  Drosophila can be genetically modified inexpensively and very 
quickly, which, along with their short-life span deems them particularly applicable to genetic 
screens (Prüßing et al., 2013).  Tg drosophila expressing MAPT mutations do exhibit 
hyperphosphorylation of tau and neurodegeneration, however, they do not demonstrate 
large aggregations of tau (Wittmann, 2001).   
Although drosophila are more complex organisms compared to C. elegans, they are far less 
complex than humans both physiologically and genetically.  The anatomy of the drosophila 
brain, although well characterised, is very different to that of humans.  There is also poor 
conservation of many proteins important in neurodegenerative disease and a lower level of 
genetic redundancy.  They also have a simpler, less adaptive immune system in comparison 
to humans and drug metabolism is likely to be very different.  It is also very difficult to 
measure complex behaviour and cognitive decline in these animals (Prüßing et al., 2013).   
1.4.1.3  C. elegans models 
C. elegans are time-effective, cheap and unrestricted by ethical considerations due to animal 
rights laws.  There are also advantages in using C. elegans for screening, including the ease 
of genetic modification, the ability to generate Tg strains rapidly and the short lifespan of the 
worms.  Kraemer and colleagues developed a tauopathy model using C. elegans expressing 
wild type or FTDP-17 mutant tau, which recapitulated the aggregation of 
hyperphosphorylated tau and age-dependent neuronal degeneration, that was later used 
alongside screening to demonstrate the possible involvement of many unexpected genes in 
tauopathy (Kraemer et al., 2003; Kraemer et al., 2006).  These models are limited, however, 
by their applicability to human tauopathy due to major differences in physiology compared 
to humans (Teschendorf and Link, 2009).  In total, there are just 302 neurons in the nervous 
system of these animals and no active immune system.  Furthermore, it is very difficult to 
carry out electrophysiological studies using C. elegans neurons as these are small and difficult 
to patch clamp (Ramot et al., 2008).   
1.4.2  Cell-based models of tauopathy 
The main advantages of using in vitro models are that these can be used alongside 
biomolecular techniques to study the biomolecular mechanisms involved in tauopathy.  
Traditional cell-based disease modelling approaches rely on animal primary neurons or 
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cancerous cell lines.  To model tauopathy, these cells are most commonly treated with tau 
or Aβ peptides and can be genetically modified to knockout or overexpress genes encoding 
proteins involved in tauopathy.  Whilst these models have provided invaluable contributions 
to neurodegenerative research, they also have limitations.   
1.4.2.1  Primary neuronal cultures 
Primary cortical and hippocampal neuron cultures, which are lost in tauopathy, represent a 
valuable research tool for the study of biomolecular mechanisms underlying tauopathy and 
for electrophysiological studies.  These neurons are usually isolated from either wild type 
(WT) or Tg murine animals, and therefore are limited in their ability to model human 
tauopathy by their physiological differences.  These cells are more likely to recapitulate 
neurons in the body, however, compared to cancer-derived cell lines (Gordon et al., 2013) 
(Chapter 1.4.2.2). Perhaps the most technically challenging aspect faced by researchers 
working with these cultures is the inability of isolated neurons to proliferate; cultures must 
be skilfully established and maintained to ensure a healthy culture is obtained (Gordon et al., 
2013).  Additionally, isolation of these cells from animal tissues is difficult as neurons must 
be separated from other neural cell types and the purity of each culture must be determined.  
The use of primary neuronal cultures is also subject to ethical considerations under animal 
rights laws. 
1.4.2.2  Cancer-derived cell lines 
Models of tauopathy based on cancer-derived cell lines circumvent many of the limitations 
posed by primary cell culture models.  These cells are immortal, banked, easy to culture and 
are not subject to ethical considerations.  These properties, alongside the ability of these 
lines to be rapidly expanded in vitro, facilitates the establishment of unlimited cultures of 
homogenous cells, limiting variablily in experimental design.  It is also easier to genetically 
modify these cells as they are easy to transfect (Gordon et al., 2013).   
Numerous human cancer-derived cell lines exist; NT2 and SH-SY5Y are commonly used and 
are derived from cell lines established from a neuronally committed teratocarcinoma and a 
neuroblastoma, respectively.  Although these cells are derived from humans, they are 
considered to be less representative of human neurons compared to cultured primary 
neurons as these cells lack important neuronal phenotypes such as ion channels, receptors, 
functional synapses and long neuritic processes usually found in neurons.  This has been 
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somewhat overcome by directed differentiation of these cells to produce ‘neuron-like’ cells, 
most commonly using retinoic acid.   
Differentiated SH-SY5Y cells express mature neuronal markers, including tau, and have 
neuritic processes, synaptophysin-positive functional synapses, increased membrane 
excitability, neurotransmitters (NT) and NT receptors (Adem et al., 1987; Påhlman et al., 
1981; Påhlman et al., 1984; Lopes et al., 2010; Tosetti et al., 1998; Encinas et al., 2000; 
Kovalevich and Langford, 2013).  These cultures are nevertheless limited in their ability to 
recapitulate tau pathogenesis due to the interaction of biomolecular pathways with 
expressed cancer genes (Zheng et al., 2010).  An important consideration in the development 
of models of tauopathy using these lines is that neuroblastoma cell lines do not express all 
six isoforms of tau, therefore may not be appropriate for studying molecular aspects of tau 
pathogenesis (Sullivan and Young-Pearse, 2015).   
1.4.3  Modelling tauopathy using induced pluripotent stem cells 
1.4.3.1  Stem cells 
Stem cells are undifferentiated cells of a multicellular organism capable of replicating 
indefinitely to give rise to cells of the same type or differentiating to become other types of 
cells.  The zygote, which is the cell created after fertilisation of an egg, is a totipotent stem 
cell; this cell can give rise to all cells of the body as well as forming the extra-embryonic tissue, 
including the placental and umbilical tissues (Mitalipov and Wolf, 2009).  The blastocyst is 
generated early in embryogenesis and consists of the embryoblast and the trophoblast, 
which are the inner and outer layers of this structure, respectively.   
The inner cell mass forms within the blastocyst and consists of human embryonic stem cells 
(hESC) which can form all the cells of the body, except extra-embryonic tissues, and are thus 
described as pluripotent (Gilbert, 2000).  These cells differentiate to form multipotent stem 
cells restricted to differentiation into one of the three primary germ layers; mesoderm, 
endoderm and ectoderm.  Neural tissue arises from the ectoderm, as does tissue that makes 
up the skin, teeth, hair and many exocrine glands (Gilbert, 2000).  These multipotent cells 
further differentiate to produce progenitor cells with further restricted potential for 
differentiation. This includes the neuroblasts, which differentiate to form neurons, and 
glioblasts, which differentiate to produce glial cells such as oligodendrocytes and astrocytes.  
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The differentiation of totipotent, pluripotent and multipotent cells is schematically 
represented in Figure 1.10.  
 
 
1.4.3.1.1  Embryonic stem cells  
The ability of pluripotent stem cells to replicate indefinitely, coupled with the development 
of protocols allowing directed differentiation to produce cells of the nervous system, 
provided researchers with a non-exhaustive supply of human neurons with which to study 
neurodegenerative disease in vitro.  For use experimentally, hESC are derived from within 
the inner cell mass of the blastocyst of donated embryos (Vazin and Freed, 2010). 
In 2000, the first neurons were derived from hESC (hESC-neurons) (Reubinoff et al., 2000).  
Subsequently protocols for directing differentiation to produce neurons, which involve 
manipulation of the in vitro environment as well as treatment with growth factors and small 
Figure 1.10     Schematic representation of totipotent, pluripotent and multipotent stem cell 
differentiation during development 
Zygotes are totipotent and differentiate to produce embryonic stem cells (hESC), which comprise 
the inner cell mass (ICM) and are pluripotent.  hESC of the inner cell mass differentiate to form 
germ layer specific multipotent stem cells, which give rise to tissue specific progenitors.  Neurons 




molecules, have been refined allowing for the derivation of specific cells including motor 
neurons, dopaminergic neurons, GABAergic neurons, oligodendrocytes, astrocytes, 
glutamatergic neurons and cholinergic neurons (Crompton et al., 2013; Nilbratt et al., 2010; 
Bissonette et al., 2011; Perrier et al., 2002; Gerrard et al., 2005; Yan et al., 2005; Erceg et al., 
2008; Zhang et al., 2006; Wichterle et al., 2002). 
One important limitation of disease modelling using hESC is that these cells are derived from 
embryos, rather than adult humans, therefore we do not know whether this person would 
have developed sporadic tauopathy since we still do not understand every genetic and 
epigenetic factor that contributes to increased risk.  Additionally, donated embryos are rare 
and precious resources, limiting the creation of a large bank of cell lines thought to be 
necessary to account for the heterogeneity in tauopathy.  Furthermore, research using hESC 
is fraught with political and ethical concerns as collection of the inner cell mass obligates the 
destruction of the embryo. 
1.4.3.1.2  Induced pluripotent stem cells 
In 2006, Nobel Laurette Yamanaka demonstrated that terminally differentiated, somatic cells 
can be reprogrammed to produce pluripotent stem cells (Takahashi and Yamanaka, 2006).  
These cells, called induced pluripotent stem cells (iPSC) are identical to embryonic stem cells 
in their pluripotent potential and epigenetic profile (Mallon et al., 2014).  The first human 
induced pluripotent stem cells (hiPSC) were generated in 2007 (Yamanaka et al., 2007) using 
human immunodeficiency virus (HIV) derived lentiviral vectors to transfer genes encoding 
transcription factors that drive pluripotency into fibroblasts.  These factors, commonly 
referred to as ‘Yamanaka’s factors’, include Octamer binding transcription factor 4 (OCT4), 
Kruppel-like factor 4 (Klf4), Sex determining region Y box 2 (SOX2) and myelocytomatosis viral 
oncogene homologue (c-myc).  Further developments in reprogramming led to the use of 
various other combinations of factors to achieve reprogramming, allowing for the elimination 
of c-myc, which is a known oncogene (Yu et al., 2007).   
The hiPSC lines, V337M-C and V337M-E, generated for this project (Chapters 3 and 4) were 
created through reprogramming of fibroblasts using lentiviral vectors.  Whilst the use of 
lentiviral vectors delivers good reprogramming efficiency, the main disadvantage of using 
this method is that the reprogramming vectors are integrated into the infected somatic cell’s 
genome leaving a ‘footprint’.  The presence of this ‘footprint’ may affect experimental results 
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through transient expression of transgenes (Rao and Malik, 2012).  Furthermore, the use of 
retroviral and lentiviral vectors can introduce the risk of deleterious DNA recombination 
associated with viral integration into the nucleus (Vannucci et al., 2013).   
The use of non-integrating viral delivery systems such as sendai viral vectors (Fusaki et al., 
2009), mRNA reprogramming (Warren et al., 2010), PiggyBac transposition (Wang et al., 
2008; Woltjen et al., 2009; Yusa et al., 2009), small molecule reprogramming (Jung et al., 
2014) and episomal factor delivery methods such as lipofection (Okita et al., 2008) and 
nucleofection (Yu et al., 2011; Okita et al., 2010) have vanquished the risk of deleterious DNA 
recombination, improving the reliability of iPSC models (Schlaeger et al., 2015).  
The field is rapidly progressing and has overcome many of the initial limitations recognised.  
Reprogramming efficiency has been vastly improved using small-molecule compounds such 
as valproic acid (Huangfu et. al., 2008), genetic alterations such as knockdown of the p53 
gene (Hong et. al., 2009) and optimisation of the in vitro environment, for example through 
culturing in normoxic conditions (Prado-Lopez et al., 2010).  Techniques enabling 
reprogramming of many other non-invasively obtained cells, including blood cells (Okabe et 
al., 2009; Loh et al., 2009) has been developed.  
1.4.3.1.3  Differentiation of pluripotent stem cells to produce neurons 
The generation of specific subtypes of human pluripotent stem cell (hPSC)-derived neurons 
intended to model tauopathy often begins with generation of forebrain neurons.  Since the 
‘default’ fate for neural differentiation of hiPSC is to become cortical neurons, further 
differentiation into specific neuronal subtypes is achieved through dual SMAD inhibition 
within a monolayer culture (Chambers et al., 2009; Shi et al., 2012), embryoid body (EB) 
culture (Crompton et al., 2013; Eiraku et al., 2008) or in tandem with the development of 
three-dimensional organoid culture system (Lancaster et al., 2012).  Small molecules, growth 
factors and the forced expression of transcription factors (Bissonnette et al., 2011; Duan et 
al., 2014) can be used to modulate developmental patterning pathways to produce specific 
cell types; for example, glutamatergic neurons (Boisvert et al., 2013; Shi et al., 2012; Vazin et 
al., 2014) and bfCNs (Crompton et al., 2013; Bissonnette et al., 2011).  hiPSC-derived 
glutamatergic neurons have been demonstrated to be more vulnerable to Aβ-induced 
pathogenesis compared to hiPSC-GABAergic neurons (Vazin et al., 2014), supporting the 
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utility of hiPSC-neurons for research into the selective vulnerability of neuronal subtypes in 
tauopathy.  
1.4.3.1.4  The role of dual Smad inhibition in neural induction 
Smads are proteins that mediate intracellular signalling triggered by transforming growth 
factor β (TGFβ) ligands, which include TGFβs and bone morphogenic proteins (BMPs) 
(Ueberham and Arendt, 2013).  The TGFβ superfamily signalling pathways have diverse and 
complex roles in the regulation of cell growth, differentiation and development of neural 
cells (Yun et al., 2008). TGFβ signals are transmitted through transmembrane 
serine/threonine (Ser/Thr) kinase receptors, which when activated phosphorylate TβRI-
associated Smads.  These activated Smads form a complex with the co-mediator Smad (Smad 
4), which translocates to the nucleus where it activates or suppresses target gene expression 
(Massagué et al., 2000).   
There are Smads associated with two main pathways; Smad1/5/9 are part of the BMP 
pathway and Smad2/3 are part the TGFβ/activin pathway.  Inhibition of the BMP pathways, 
associated with mesoderm lineage development, have previously been shown to be involved 
in neural induction (Sasai et al., 1994; Hemmati-Brivanlou et al., 1994; Smith et al., 1992) and 
inhibition of either the BMP or TGFβ pathways aids neural induction of hESCs (Smith et al., 
2008; Elkabetz et al., 2008; Lee et al., 2007).  Inhibition of either of these pathways alone is 
not sufficient to induce neural induction, however, dual pathway inhibition has been shown 
to enable neural induction through directed differentiation towards the neuroectoderm in 
human embryonic stem cell cultures (Chambers et al., 2009).   
1.4.3.1.5  Modelling tauopathy using induced pluripotent stem cells 
This advent, when paired with protocols facilitating the derivation of hESC-neurons, invited 
the generation of neurons differentiated from hiPSC that had been reprogrammed from 
disease patient’s somatic cells (hiPSC-neurons), creating a new opportunity for modelling 
disease in vitro.  Patient-derived hiPSC-neurons were first cultured by Dimos and colleagues 
to model ALS (Dimos et. al., 2008) and later Ebert and colleagues demonstrated that iPSC-
motor neurons from spinal muscular atrophy (SMA) patients recapitulated deficits of the 
disease (Ebert et. al., 2009).  The first iPSC model of AD was reported in 2011 (Yagi et al., 
2011) and significant progression has been made since then. 
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There are still limitations in the use of hiPSC as models of tauopathy.  Recent studies have 
revealed heterogeneity between cell lines generated from patients with fAD (Kondo et al., 
2013), sAD (Kondo et al., 2013; Israel et al., 2012) and FTDP-17 carrying the same MAPT 
mutation (Hallmann et al., 2017; Wren et al., 2015), which reflects the heterogeneity noted 
in patients.  This finding calls for studies using hiPSC-neurons derived from larger cohorts of 
patients and although biorepositories, such as The Human Pluripotent Stem Cell (hPSC) 
Repository project (California, USA) have been established, it may take some time before 
large numbers of cell lines are available.  Further to this, the generation of neurons from large 
numbers of cell lines is labour intensive and expensive. Genetic background variability 
between lines may also hinder reliable results (Kim et al., 2010), although the development 
of isogenic lines circumvents this problem (Fong et al., 2013).  As the field advances, 
developments in reprogramming and differentiation efficiency are hoped to overcome 
counter these factors (Ebrahimi, 2015).   
1.4.3.1.6  Modelling frontotemporal dementia using induced pluripotent stem cells 
hiPSC-neuron models have been derived through reprogramming somatic cells from patients 
with various MAPT mutations, including V337M (Ehrlich et al., 2015), N279K (Wren et al., 
2015; Ehrlich et al., 2015; Iovino et al., 2015), P301L (Iovino et al., 2015), A152T (Silva et al., 
2016; Fong et al., 2013), R406W (Imamura et al., 2016), IVS 10+16 (Esteras et al., 2017) and 
IVS 10+14 MAPT (Imamura et al., 2016).  These hiPSC lines have been used to derive mixed 
populations of neurons (Ehrlich et al., 2015; Fong et al., 2013), as well as specific neuronal 
subtypes including cortical neurons (Esteras et al., 2017; Imamura et al., 2016; Wren et al., 
2015; Silva et al., 2016; Iovino et al., 2015; Usenovic et al., 2015), dopaminergic neurons 
(Ehrlich et al., 2015) and astrocytes (Hallmann et al., 2017).  hiPSC-neuron models have also 
been derived through overexpression of P301L MAPT within control hiPSC lines (Verheyen et 
al., 2015).  One model of sFTD-tau has been developed through seeding of control hiPSC-
neurons with oligomeric tau species to initiate tau pathology, rather than through deriving 
hiPSC from patients carrying mutations (Usenovic et al., 2015).  A summary of the key findings 











Mixed Gene-dose-dependent effect of the A152T MAPT 
mutation on neurodegeneration and increased 
tau phosphorylation at Ser202/Thr205.  
Dopaminergic neurons are more susceptible to 
neurodegeneration that other neuronal subtypes.   







N279K and P301L increase levels of tau during 
maturation and cause mitochondrial transport 
dysfunction.  N279K express tau prematurely 
leading to an increased 4R:3R tau ratio, have 
increased pThr212/pSer214 tau and tau 
aggregates. P301L neurons have contorted 
processes with varicosities containing tau and α-
synuclein. 
(Iovino et al., 
2015) 
P301L  Cortical 
glutamatergic 
No tau pathology could be detected in mutant 
neurons, except on priming with pre-formed 
aggregates, which then revealed substantially 
increased pSer202/Thr205 tau, total tau levels and 





N279K increased tau protein, 4R:3R tau ratio and 
cellular stress.  Increased levels of vesicle 
components. 




Cortical Treatment of control neurons with oligomeric tau 
species increased pThr231 and pSer396/404 tau, 












N279K and V337M MAPT hiPSC-neurons exhibit 
increased tau fragmentation, increased 
pSer202/Thr205 tau, activation of the unfolded 
protein response and disease associated changes 
to the gene expression profile.  N279K neurons 
were found to have increased tau aggregation, an 
increased 4R:3R tau ratio, decreased neurite 
extension and increased oxidative stress response 
to inhibition of mitochondrial respiration.   






An increased ratio of 4R:3R tau ratio in IVS 10+16 
MAPT compared to controls was found.  
Additionally, full splicing of tau was recognised 
after prolonged culture of neurons for 1 year. 




Mixed Increased levels of tau and ptau at Ser202/Thr205, 
Ser396/404 and Thr231/235 were found in A152T 
MAPT hiPSC-neurons.  No aggregates were 
detected and MAPT expression was found to be 
unchanged.  A152T MAPT hiPSC-neurons were 
more vulnerability to cellular stress. 









R406W and IVS 10+14 MAPT hiPSC-neurons have 
accumulations of misfolded tau accumulations 
and increased extracellular release of misfolded 
tau.  Cultures of hiPSC-neurons carrying these 
mutations also show increased 





evoked calcium ion (Ca2+) transients are 
dysregulated. IVS 10+14 MAPT neurons also 
exhibited increased 4R tau. 
N279K Astrocytes Astrocytes from one mutant line were larger and 
contained tau, as well as being more vulnerable to 
oxidative stress and having increased levels of 
GFAP indicative of astrocytic activation.  4R1N tau 
expressed early in mutant neurons and astrocytes 







Increased vulnerability of control neurons 
cultured with FTD-astrocytes to cellular stress.  
Altered mitochondrial function.  Overproduction 
in ROS in mitochondria, which leads to oxidative 
stress. Increased cell death in neurons dependent 
on increased ROS in mitochondria.  
(Esteras et al., 
2017) 
 
These studies have demonstrated that hiPSC-neuron FTDP-17 models are capable of 
recapitulating the neuronal pathology found in disease patient brains.  Neuronal pathology, 
including decreased neurite extension in hiPSC-neurons carrying N279K MAPT (Iovino et al., 
2015) and contorted processes with varicosities containing tau and α-Synuclein in P301L 
hiPSC-neurons (Iovino et al., 2015), has been reported. 
Some of these studies have investigated the molecular mechanisms underlying the observed 
neurodegeneration, tauopathy and response to cellular stress.  The results demonstrate that 
these models are useful for probing tau pathogenesis.  For example, N279K and P301L MAPT 
hiPSC-neurons exhibit mitochondrial transport dysfunction (Iovino et al., 2015), which may 
result from these mutations and underlie neurodegeneration.  Increased levels of vesicle 
components have been noted in A152T MAPT neurons (Wren et al., 2015).  N279K and 
V337M MAPT hiPSC-neurons exhibit increased activation of the unfolded protein response 
(Ehrlich et al., 2015), responsible for protein clearance, which may show a compensatory 
increased clearance mechanisms to cope with excess tau within these cells.  Healthy hiPSC-
neurons co-cultured with hiPSC-astrocytes from a patient carrying 10+16 MAPT showed 
reduced mitochondrial function, demonstrating that astrocytes carrying the mutation can 
cause neuronal dysfunction in nearby neurons within the brain (Esteras et al., 2017).  This 
Table 1.1 hiPSC models of FTDP-17  
hiPSC models of FTDP-17 derived from patients, apart from for Verheyen et al., 2015 in which 
control neurons were genetically altered to express 2R4N P301L and for Usenovic et al., 2015, in 
which control neurons were pre-seeded with pre-aggregated tau to induce tau pathology.  ‘Mixed’ 
refers to a mixed population of neuronal subtypes.  In Esteras et al., 2017 control hiPSC neurons 
were cultured with hiPSC-astrocytes carrying the IVS 10+16 MAPT mutation. 
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study demonstrated that these in vitro hiPSC models can be used to probe relationships 
between different cell types in isolation during the development of disease.  The models have 
also demonstrated changes in the levels of tau protein, tau phosphorylation and tau 
aggregation as a result of different mutations within MAPT.   
These studies have also provided insights into the effects of MAPT mutations during neuronal 
maturation.  Tau mutations have been found to have no effect on reprogramming efficiency 
(Fong et al., 2013; Imamura et al., 2016) or the propensity of hiPSC to differentiate into 
neuronal subtypes (Hallman et al., 2015; Ehrlich et al., 2015; Imamura et al., 2016; Fong et 
al., 2013).  However, N279K hiPSC-neurons express 4R1N much earlier than control neurons 
(Iovino et al., 2015).  
These studies have also been used to provide proof-of-principle that these models can be 
used in drug discovery.  For example, hiPSC-dopaminergic neurons from patients with V337M 
MAPT and N279K MAPT were found to have a pronounced oxidative stress response 
compared to controls, which could be rescued through GSK3β inhibition (Ehrlich et al., 2015).  
Imamura and colleagues also demonstrated that treatment of hiPSC-neurons derived from 
patients carrying the 10+14 MAPT mutation with glutamate receptor blockers or genetic 
correction of using CRISPR/Cas9 gene editing ameliorated evidence of pathology in these 
cells (Imamura et al., 2016).  Similarly, Hallmann and colleagues have demonstrated the 
genetic correction of N279K MAPT neurons with CRIPSR/Cas9 (Hallmann et al., 2017).   
1.4.3.1.7  Modelling Alzheimer’s disease using induced pluripotent stem cells 
To date, the majority of AD models established using hiPSC-derived neurons have been 
developed through reprogramming somatic cells from fAD patients carrying mutations in 
genes involved in the production of Aβ i.e. PSEN1, PSEN2 and APP (Chapter 1.2.3.3).   Models 
of sAD have also been developed that rely on both the differentiation of hiPSC-neurons from 
sAD patients (Kondo et al., 2013; Israel et al., 2012; Duan et al., 2014; Young et al., 2015; 
Hossini et al., 2015) and the treatment of control hiPSC-neurons with Aβ peptides (Xu et al., 
2013; Zhang et al., 2014; Vazin et al., 2014; Nieweg et al., 2015).  hiPSCs reprogrammed from 
Down’s syndrome (DS) patients have been developed to study AD (Shi et al., 2012; Chang et 
al., 2015), as DS is caused by a triplication of chromosome 21, which contains the genes for 
APP and some tau kinases, such as dual specificity tyrosine-phosphorylation-
regulated kinase 1A (DYRK1A) (Kimura et al., 2007; Jin, Yin, Gu, et al., 2015), and patients 
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with DS also develop dementia, akin to AD.  Models of AD using hiPSC-neurons have also 
been developed through culture of hiPSC-neurons in three dimensional (3D) scaffolds (Zhang 
et al., 2014; Choi et al., 2015) and the development of hiPSC-derived cerebral organoids (Raja 
et al., 2016).  These studies are summarised in Table 1.2.   
The most common experimental output reported in these studies is a change in the levels of 
either amyloid (Shi et al., 2012; Israel et al., 2012; Yagi et al., 2011; Kondo et al., 2013), or in 
the ratio of Aβ 1-42 to Aβ 1-40 (Aβ42/Aβ40) (Sproul et al., 2014; Duan et al., 2014; Muratore 
et al., 2014; Koch et al., 2012; Moore et al., 2015), both of which are associated with AD.  
Studies have revealed a developmental increase in the production of Aβ (Muratore et al., 
2014; Koch et al., 2012) and provided proof-of-principle that both sAD and fAD hiPSC models 
are capable of recapitulating this aspect of AD pathology.  So far, only three models have 
exhibited Aβ aggregates (Chang et al., 2015; Choi et al., 2014; Raja et al., 2016).   
Increased levels of tau phosphorylation (Yagi et al., 2011; Hossini et al., 2015; Choi et al., 
2014; Shi et al., 2012; Chang et al., 2015; Muratore et al., 2014; Moore et al., 2015; Raja et 
al., 2016; Israel et al., 2012), altered tau kinase activity (Israel et al., 2012; Muratore et al., 
2014), altered tau kinase gene expression (Hossini et al., 2015) and abnormal translocation 
of PAK3 (Zhang et al., 2014) have been described in hiPSC-neurons modelling AD.  Other 
studies have reported altered glutamate metabolism (Hossini et al., 2015), increased 
sensitivity to Ca2+ mediated cell death, increased cell stress after glutamate-induced 
excitation (Duan et al., 2014), production of reactive oxygen species (ROS) (Hossini et al., 
2015; Kondo et al., 2013) and the increased expression of genes involved in oxidative stress 
and in the proteasome (Kondo et al., 2012; Hossini et al., 2015).  These studies indicate that 
hiPSC-neurons can be used to investigate the molecular pathways involved in AD. 
Some of these studies have provided proof-of-principle that hiPSC-neurons can be used to 
screen drugs capable of influencing tau phosphorylation.  Israel and colleagues demonstrated 
that treatment of fAD and sAD hiPSC-neurons with β-secretase inhibitors, but not γ-secretase 
inhibitors, significantly reduced levels of pThr231 tau and active GSK3β (Israel et al., 2012).  
Furthermore, both β- and γ-secretase inhibitors decreased the number of 
APP(K670N/M671L,V717L) or ΔE9 PSEN1 hiPSC-neurons, that were positively stained for 
ptau (Choi et al., 2014).  In a recent study, hiPSC-derived neurons from six controls donors 
and seven sAD patients were used to investigate effects the expression of a protective or AD 
risk variant of SORL1, a gene encoding an endocytic trafficking factor, on Aβ burden.  The 
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group demonstrated that only those with the protective variant responded to brain derived 
neurotrophic factor (BDNF) treatment (Young et al., 2015), demonstrating the usefulness of 
these models to investigate the impact of gene variants on specific pathways.   
 
Table 1.2 hiPSC-neuron models of AD 
sAD/fAD Genetics Neuron 
subtype 
Findings Reference 
fAD N141I PSEN1 
and PSEN2 
Cholinergic Increased production of Aβ42 






Cortical Increased Aβ, increased secreted tau, 
pSer396/pSer404 tau and pSer202/205 
tau. 
(Shi et al., 
2012) 
fAD L166P and 
D385N PSEN1 






Mixed* Increased Aβ40, increased ptau (Thr231), 






sAD, E693 and 
V717L APP 
hiPSC 
Mixed* Accumulation of intracellular AβO (E693 
APP), increased ROS production, 




sAD N/A  Forebrain  Aβ-induced cell cycle re-entry, neuronal 
apoptosis and increased Cdk2. 
(Xu et al., 
2013) 
sAD N/A GABAergic 
and 
glutamatergic 
Increased apoptosis of control hESC- 
and hiPSC-neurons with increasing 







BfCNs Increased Aβ42/Aβ40 ratio increased cell 




fAD V717L APP Cholinergic Increased Aβ42/Aβ40 ratio, two-fold 
increase in tau, increased pSer262 tau 




fAD PSEN1 A246E; 
PSEN1 M146L 
Mixed* Increased Aβ42/Aβ40 ratio. (Sproul et 
al., 2014) 
sAD N/A  Mixed* (3D) Abnormal translocation of PAK3 and 
decreased pre-synaptic protein 






APP or ΔE9 
PSEN1  
Mixed* (3D) Aβ and tau aggregations within neurons, 
beaded neurites, pSer396/404 and 
pSer202/Thr205 tau reduced upon 




sAD  N/A GABAergic 
and 
glutamatergic 
Control hiPSC-neurons were treated 
with Aβ for 8 days, increased pSer202 
and pThr231, impaired synaptic 




















Mixed* SORL1 variant dependant decrease of 
Aβ after treatment with brain derived 
neurotrophic factor (BDNF). 
(Young et 
al., 2015) 
sAD N/A Mixed* Downregulation of GSK3 and CDK5, 
altered gene expression of genes 
involved in the ubiquitin proteasome 
system, treatment with γ-secretase 







Mixed* Aβ, aggregates, increased secreted tau, 




fAD  V717I APP  
APP 
duplication 
ΔI4 PSEN1  







Increased ratio of Aβ42 to Aβ40.  
Increased total tau, pSer396 tau, 
pSer404 tau and pSer202/Thr205 tau in 
hiPSC carrying APP mutants but no 
increase in those carrying PSEN1 
mutations.   
(Moore et 
al., 2015) 
fAD  APP 
duplication 
M136I PSEN1  
A264E PSEN1  
Mixed*  
(3D) 
Increased phosphorylation of tau at  
Ser396 or Thr181 at 90 days.  Increased 




Table 1.2 hiPSC-neuron models of AD 
Models are derived from patients with fAD and sAD patients apart from in the six highlighted 
publications.  Models of sAD developed through treatment of control hiPSC-neurons with Aβ42O 
are highlighted in green.  A fAD model developed through treatment of Tg modified control neurons 
with Aβ42O is highlighted in blue. Tg fAD hiPSC-neurons are highlighted in red.  
*Mixed includes cell cultures derived from hiPSC consisting of many types of neuronal subtypes, 









2.1  Cell culture 
All cell lines were cultured within a humidified incubator at 37 oC and 5 % CO2.  All cell work 
was carried out in a class II cell culture hood.   
2.1.1  Mouse embryonic fibroblast culture 
2.1.1.1  Mouse embryonic fibroblast (MEF) media 
Mouse embryonic fibroblasts (MEFs) and inactivated MEFs (iMEFs) were grown in media 
comprised of the following: 
 
Table 2.1 Mouse embryonic fibroblast (MEF) media 
  
2.1.1.2  Derivation of mouse embryonic fibroblasts (MEF) 
Animals were maintained and treated under the Home Office’s animals (Scientific 
Procedures) act 1986 and in agreement with the University of Bristol Animal Welfare and 
Ethical Review Body guidelines.  Pups were removed from a pregnant mouse at gestational 
day 12-13 (E12-13).  After removal of the yolk sack using a sterile scalpel and forceps, the 
Volume Reagent Product ID  
87 % Dulbecco’s Minimum Essential Medium (DMEM) Sigma, D6546 
10 % Foetal Bovine Serum (FBS) (Heat Inactivated)  Invitrogen, 10500 
1 % GlutaMAX™ (100x) Invitrogen, 35050  
1 % Non-Essential Amino Acids (NEAA) (100x) Invitrogen, 11140 
1 % Penicillin-Streptomycin solution stabilised (Pen-Strep) Sigma, P4458 
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head was removed to kill each foetus.  This is necessary in accordance with Home Office 
Schedule 1 requirement for all foetuses over gestational day 10.  After removal of the internal 
organs of each foetus the remaining tissue was pooled into a 50 ml falcon tube with 20 ml 
TrypLE™ Express (1X) [Life Technologies, 12604-021]. The tissue incubated for 10 minutes in 
the TrypLE™ Express after homogenisation of the tissue through repeated trituration with a 
P1000 pipette tip and a glass aspirating needle.  20 ml of FBS was added to the foetal material 
after completion of the incubation period to quench the TrypLE.  The cell suspension was 
centrifuged (300 g; 5 minutes) before the cells were resuspended in MEF media (Chapter 
2.1.1.1).  The cells were split between 175 cm3 flasks; the same number of flasks as foetuses 
were used.  The cells were allowed to proliferate, cultured in MEF media, until approximately 
80 % confluent before being passaged three times at a ratio of 1:5 to expand the population 
of cells.  To passage the cells, the flasks were washed with PBS three times and incubated 
with 5 ml of TrypLE for 10 minutes at 37 oC within the incubator. 
2.1.1.3  Mouse embryonic fibroblast (MEF) inactivation 
MEFs were inactivated through incubation with mitomycin C for 2 hours within the incubator.  
A 100 μg/ ml stock solution of mitomycin C was first prepared by dissolving 10 mg of 
mitomycin C from Streptomyces Caespitosus [Tocris, 3258] in 100 ml of MEF media (Table 
2.1).  2 ml of the stock solution of mitomycin C was then added to each flask, which contained 
18 ml of MEF media, to give a final concentration of 10 μg/ ml.  After completion of the 
incubation period, each flask was washed three times with phosphate buffered saline (PBS), 
pH 7.2 [Invitrogen, 20012] before being incubated for a further 10 minutes in 4 ml of TrypLE™ 
Express.  The TrypLE™ Express was the quenched with MEF media and the cells were washed 
and collected into 50 ml falcon tubes.  The MEFs were centrifuged (300 g; 5 minutes), 
resuspended in freezing media (10 % DMSO; 90 % FBS) and counted (Chapter 2.1.3.1).   The 
cells were cryopreserved (Chapter 2.3.1.2) and stored within -80 oC freezer in aliquots of 4-8 
x 106 cells per cryovial.  From this point the cells are referred to as iMEFs.   
2.1.1.4  Plating down inactivated mouse embryonic fibroblasts (iMEFs) as feeders for 
human induced pluripotent stem cells  
Tissue culture plates [Corning, 430167] were coated by incubating with 0.1 % gelatin 
(prepared from powder [Sigma, G1890] in ddH20) for 10 minutes within the incubator.  An 
aliquot of iMEFs was thawed, resuspended in 10 ml of MEF media within a 15 ml falcon tube 
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and centrifuged (300 g; 3 minutes).  The iMEFs were resuspended in MEF media.  Once the 
gelatin coating was aspirated from the tissue culture plates, iMEFs were plated at a density 
of 21,000 cells/cm2.  The cells were allowed to adhere to the plates overnight.  The media 
was changed to human pluripotent stem cell (hPSC) media (Table 2.2) at least 2 hours before 
passaging pluripotent cells onto the layer of iMEFs to allow the iMEFs to condition the media. 
2.1.2  Human pluripotent stem cell culture 
2.1.2.1  Culturing human pluripotent stem cells on an iMEF feeder layer 
 
Table 2.2 Human pluripotent stem cell media 
Volume Reagent Product ID 
76.7 % Knock-Out DMEM Invitrogen, 10829 
20 % Knock-Out Serum Replacement  Invitrogen, 10828 
1 % GlutaMAX™ (100x) Invitrogen, 35050 
1 % Non-essential amino acids NEAA (100x) Invitrogen, 11140 
1 % Penicillin-Streptomycin solution stabilised (Pen-Strep) Sigma, P4458 
0.2 % 2-Mercaptoethanol (50 mM) Invitrogen, 991827 
10-20 ng/ ml Human Fibroblast Growth Factor – basic (FGF2) PeproTech, 100-18B 
0.1 % Fungizone Invitrogen, 15290-018 
2.1.2.1.1  Mechanical passaging of human induced pluripotent stem cells  
Differentiated areas of colonies were aspirated before passaging using a P200 pipette tip and 
an aspirator.  A sterile insulin needle [VWR, 613-0740] was used to score colonies into 
squares of approximately equal sizes (Figure 2.1).  This was done within the hood under a 
dissection microscope (Leica).  A new needle was used for each cell line.  The colony pieces 
were then detached and collected from the tissue culture plate using a P1000 pipette.  30-
40 colony pieces were collected and plated onto a tissue culture plate with a layer of iMEFs.  
The colony pieces were allowed to attach to the tissue culture plates for 24 hours and the 
media was changed 48 hours later.  Colonies were allowed to grow for 5-10 days before being 








2.1.2.2  Culturing human pluripotent stem cells (hPSC) within the Essential 8TM feeder free 
system 
Human pluripotent stem cells were grown in Essential 8TM (E8) media within 6-well tissue 
culture plates [Fisher, 10119831], coated with either Vitronectin, MatrigelTM or GeltrexTM.  
Essential 8 TM Medium was developed in the laboratory of James Thomson (Chen et al., 2011) 
before being validated and refined by Cellular Dynamics International.  The E8 system has 
been extensively tested for its ability to support maintenance of pluripotency in various hiPSC 
lines.  The complete media requires combination of Essential 8 TM Medium with a 1:50 v/v of 
Essential 8TM Supplement, to consist of DMEM/F12, 64 mg/L l-ascorbic acid-2-phosphate 
magnesium, 14 µg/L sodium selenium, 100 µg/L FGF2, 19.4 mg/L insulin, 543 mg l−1 sodium 
Figure 2.1      Mechanical stem cell colony passaging 
Mechanical passaging of hESC colonies views under a stereomicroscope.  Once the colony has 
reached an appropriate size for passaging (A), a 20 G needle is used to score the colony, viewed 
under a stereomicroscope within the cell culture hood (B). Next, the colony is scored again 
perpendicularly to the direction of initial scoring (C) to create colony pieces of ideal size for re-
plating.  These colony pieces are collected within a P1000 pipette tip and transferred to a new 
plate, pre-seeded with iMEFs (D). 
Image from Lerou et al., 2008 with permission from © 2017 Macmillan Publishers Limited. All 
Rights Reserved. 
 
(a) Colony that reached adequate size for passaging. (b) Colony has been scored using bent needle. (c) Colony 




bicarbonate (NaHCO3) and 10.7 mg/L transferrin, 2 µg/L TGFβ1 or 100 µg/L Nodal (Chen et. 
al., 2011).   
2.1.2.2.1  Tissue culture plate surface coatings 
The advantages of using the following cell culture substrates for culturing hiPSC are reduced 
variability compared to using an iMEF feeder layer, which results in more stable cultures from 
passage to passage.   
2.1.2.2.1.1  GeltrexTM 
GeltrexTM is a gelatinous substrate composed of a complex mixture of basement membrane 
proteins derived from the spontaneous tumours of Engelbreth-Holm-Swarm mice, which 
provide a physical support for cultured cells to grow on top of.  An aliquot of GeltrexTM [Life 
Technologies] was thawed overnight at 4 oC.  The aliquot was kept on ice during handling.  
The contents of the aliquot were diluted in cold DMEM/F12 [Invitrogen, 31331028] to a 
concentration of 150 μg/ ml.  1 ml of the solution was applied to each well of a 6-well plate.  
The plates were incubated for 1 hour with GeltrexTM within the cell culture incubator before 
being incubated for 1 hour at room temperature.  The GeltrexTM was then aspirated and 2 ml 
of Essential 8 media was added to each well. 
2.1.2.2.1.2  MatrigelTM 
MatrigelTM also consists of basement membrane proteins derived from spontaneous 
Engelbreth-Holm-Swarm mouse tumours, is a gelatinous substrate and provides a physical 
support for the growth of cells in vitro. An aliquot of 300 μl MatrigelTM [BD Bioscience] was 
thawed overnight at 4 oC.  The aliquot was kept on ice during handling.  500 μl of cold KO 
DMEM media, which consists of Knockout DMEM [Invitrogen, 10829] supplemented with 
Knockout Serum Replacer [Invitrogen, 10828] was added to the aliquot to dilute it.  The 
contents of the aliquot were then added to 29.3 ml of cold KO DMEM within a 50 ml falcon.  
After mixing, 1 ml of the solution was applied to each well of a 6-well plate and incubated for 
at least 2 hours within the cell culture incubator.  The MatrigelTM was then aspirated and the 
wells were washed once with KO DMEM.  2 ml of Essential 8 media was added to each well. 
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2.1.2.2.1.3  Vitronectin 
Vitronectin is an abundant, secreted glycoprotein found in serum, the extracellular matrix 
and bone, which promotes cell adhesion and spreading when used as a surface 
coating.  Vitronectin is relatively inexpensive compared to other available synthetic surfaces 
and requires minimal preparation.  The truncated recombinant human vitronectin (rhVTN-N) 
[Life Technologies, A14701SA], corresponding to the amino acid fragment 62–478 of human 
vitronectin expressed in E. coli, is purified from inclusion bodies and refolded for use as a 
substrate for the feeder-free culture of human pluripotent stem cells (hPSCs) in Essential 8™ 
medium.  This form of vitronectin was used at a concentration of 5 μg/ ml.  An aliquot of 
stock vitronectin, at concentration 0.5 mg/ ml, was diluted 1:100 in PBS.  1 ml of vitronectin 
was added to each well of a 6-well plate and incubated at room temperature for 1 hour.  The 
solution was aspirated before Essential 8 media was added to the well.   
2.1.2.2.1.4  Poly-L-ornithine and laminin    
200 μl poly-L-ornithine (POR) hydrochloride [Sigma P2533] was added at stock concentration 
to each well and incubated for 2 hours within the incubator.  The poly-L-ornithine was then 
removed and 250 μl of 10 μg/ ml laminin (diluted from stock [Sigma, L2020] in PBS) was 
added to each well.  The wells were incubated with laminin within the incubator for 2 hours 
or overnight.  Upon completion of the incubation period, the laminin was removed and media 
was added to the wells.  At this point to plates are referred to as POR/L coated. 
2.1.2.2.2  Passaging human pluripotent stem cells using ethylenediamine tetraacetic acid 
UltraPure™ 0.5M EDTA, pH 8.0 [Life Technologies, 15575-020] was diluted to a stock of 0.5 
mM in PBS and warmed in a water bath to 37 oC.  Wells with cells to be passaged within them 
were treated with ROCK inhibitor (Y27632) (10 ng/ ml) [Tocris, 1254], which was added to 
the media, 30 minutes prior to being passaged.  The Essential 8 media was aspirated and 
each well was washed once with the EDTA stock solution.  1 ml of ethylenediamine 
tetraacetic acid (EDTA) was applied to each well before incubating at room temperature for 
6 minutes.  The EDTA was aspirated and 1-2 ml of Essential 8 media was sprayed onto the 
tissue culture surface to dislodge the colonies.  The colonies were gently triturated until they 
had broken up into smaller colony pieces. 20-30 colony pieces were added to a freshly coated 
well of a 6-well plate.  The colonies were allowed to adhere to the tissue culture surface 
86 
 
overnight.  The media was changed after 48 hours.  Colonies growing within the E8 culture 
system were passaged every 4-8 days. 
2.1.2.2.3  Passaging human pluripotent stem cells from iMEFs to E8 cell culture system 
Tissue culture plates with colonies to be passaged within them were treated with ROCK 
inhibitor (10 ng/ ml).  Colonies were scored and 20-30 pieces were collected (Chapter 
2.1.2.1.2) before being transferred to a freshly coated well of a 6-well plate.  The colony 
pieces were allowed to adhere to the tissue culture surface overnight.  The media was 
changed after 48 hours.   
2.1.3  General Cell Techniques 
2.1.3.1  Counting cells 
To calculate the number of cells within a given volume of cell suspension, cells were first 
centrifuged and re-suspended in 1 ml of media, pipetting with a P1000 to ensure the cells 
were evenly suspended. To gain a dilution factor of 10, 10 μl of the cell suspension was 
collected into a 0.5 ml Eppendorf tube before 80 μl of media and 10 μl of 0.4 % Trypan Blue 
[Invitrogen, 15250] was added.  The mixture was pipetted using a P1000 pipette to ensure it 









A coverslip was placed onto a clean haemocytometer and 10 μl of the cell suspension within 
the Eppendorf tube was carefully pipetted at the edge of the coverslip.  Capillary action 
ensured the suspension was taken under the coverslip to fill the counting chamber.  Only live 
cells were counted.  Trypan blue is not absorbed by live cells so these cells appear colourless, 
with a bright, refractive border; the dye transverses the membranes of non-viable cells so 







Figure 2.2     Schematic demonstrating the grid within the counting chamber of the 
haemocytometer used   
Cells brightly stained with Trypan blue within highlighted areas (green) with lettered 
numbers were counted to give a total of five counts.  Within the highlighted areas, only 
cells which crossed over the outer borders on the left-hand side and the top and were 
included in the count.  Each highlighted area represents the number of cells within 1 µl of 
the cell suspension; therefore, the scale factor is 104. The number of live cells was calculated 
using the equation shown in the figure. 
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2.1.3.2  Cryopreservation of cells 
2.1.3.2.1  Cryopreservation of MEFs and iMEFs 
After aspirating the media from the cells, the cells were washed with PBS and an appropriate 
volume of TripLE ExpressTM was added to the cells.  The cells were incubated for 10 minutes 
in the incubator.  After completion of the incubation the TripLE ExpressTM was quenched with 
an equal volume of MEF media and the cells were collected into a falcon tube.  For 
cryopreservation of cells in a volume greater than 10 ml, cells were collected into a 50 ml 
falcon and centrifuged (300 g; 5 minutes); for cryopreservation of cells in a volume less than 
10 ml cells were collected into a 15 ml falcon and centrifuged [300 rpm; 3 minutes].  The cells 
were resuspended in freezing media, consisting of 10 % Dimethyl sulfoxide (DMSO), which 
acts as a cryoprotectant, and 90 % foetal bovine serum (FBS) [Life Technologies, 10500064]) 
and 700 μl of the cell suspension was added into each labelled 1 ml cryovial [Greiner, 
123278]. The cryovials were placed in a Mr FrostyTM , at room temperature, and immediately 
stored at -80 oC.  Mr FrostyTM is a freezing container consisting of a plastic chamber of 
compartments in which to place individual vials of cells, surrounded by 100 % isopropyl 
alcohol, which allows for a uniform cooling rate of approximately 1 oC per minute, 
determined to be ideal for optimal cell survival.   
2.1.3.2.2  Cryopreservation of human pluripotent cells grown on an iMEF feeder layer 
The media was aspirated from the cells and 1 ml of warm 1 mg/ ml collagenase IV [Life Tech, 
17104-019] (made up from stock concentration of 10 mg/ ml diluted in KO DMEM)] was 
added to each tissue culture plate.  The cells were incubated with collagenase IV for 20 
minutes in the incubator before KO DMEM and a P1000 pipette were used to spray the 
colonies from the tissue culture surface.  The colonies were collected into 15 ml falcon tubes 
and topped up to 10 ml with KO DMEM before being centrifuged (1100 g; 3 minutes).  The 
media was removed from the cell pellet and the colonies were gently resuspended in freezing 
media.  For each tissue culture plate, colonies were resuspended in 700 μl of freezing media 
and this volume was added to a labelled, 1 ml cryovial.  The cells were placed into a Mr 
FrostyTM and immediately frozen at -80 oC.   
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2.1.3.2.3  Cryopreservation of human pluripotent cells cultured within the E8 system 
A 2x freezing media consisting of 20 % DMSO and 80 % E8 media was prepared.  An 
appropriate number of cryotubes were labelled.  The media was removed from E8 cells and 
the cells were washed once with warmed EDTA, before being incubated with EDTA for 6 
minutes.  After the incubation period the EDTA was removed and the cells were sprayed from 
the tissue culture well surface with an appropriate volume of E8 media, for example 1 ml for 
each well of a 6-well plate and 0.5 ml for each well of a 12-well plate.  An equal volume of 
freezing media was then added to each well drop wise.  500 μl to 700 μl was pipetted into 
each cryovial and the cryovials were placed into a Mr FrostyTM, which was placed into -80 oC 
freezer.  When hPSC cultured within the E8 system were thawed they were plated in E8 
media supplemented with 10 μg/ ml ROCK inhibitor to limit cell death.   
2.1.3.2.4  Cryopreservation of neurospheres 
Neurospheres to be cryopreserved were collected from within the tissue culture flask into a 
15 ml falcon with 10 ml of media.  The neurospheres were centrifuged (300 g; 3 minutes) and 
the media removed from the falcon.  Freezing media (10 % DMSO in foetal bovine serum 
(FBS)) was added to the spheres.  An average of 40 neurospheres were frozen in a 1 ml 
cryovial with 700 μl of freezing media.  The cryovials were placed in a Mr FrostyTM and 
immediately stored at -80 oC.   
2.1.3.2.5  Cryopreservation of neural progenitors and neurons at day 20-25 of the cortical 
glutamatergic neuron differentiation protocol 
The cells were washed once with PBS before 200 μl of AccutaseTM [Sigma, A6964] was applied 
to each well with cells to be cryopreserved.  The cells were incubated with AccutaseTM for 5 
minutes within the incubator.  After completion of the incubation period the cells were gently 
pipetted, using a P1000 pipette, to dissociate the cells to give a single-cell suspension.  800 
μl of neural maintenance media was added to each well to quench the AccutaseTM, and this 
mixture was transferred to a 15 ml falcon tube.  The cells were centrifuged (200 g; 5 minutes) 
and resuspended at 2 x 106 cells/ ml in neural stem cell freezing media [neural maintenance 





2.2  Biomolecular Techniques 
2.2.1  Western Immunoblotting 
2.2.1.1  Protein extraction from neurospheres  
The media was gently aspirated from the wells containing neurospheres before the 
neurospheres were washed once with ice cold PBS.  100 μl Ice cold RIPA buffer (50 mM Tris 
HCl [pH7.4], 150 mM NaCl,1 % Triton-X-100 (v/v), 0.5 % Sodium deoxycholate (w/v), 0.1 % 
sodium dodecyl sulphate (SDS) (w/v)) plus 1 tablet of Protease Inhibitor [Roche, cOmplete 
Mini, 04693124001] per 10 ml of RIPA buffer and 1 tablet of Phosphatase Inhibitor PhosStop, 
[Roche] per 10 ml was used to dissolve neurospheres within 3 wells.  Neurospheres were 
manually detached from the surface of the wells whilst in RIPA buffer using a P1000 pipette 
tip.  The RIPA buffer and neurospheres from three wells were collected into a sterile, labelled 
1.5 ml Eppendorf and triturated using a P200 pipette tip before being left on ice for 10 
minutes.  The sample was then further homogenised by triturating using a 1 ml syringe and 
18G needle.  The sample was then centrifuged (4 oC; 12,000 g, 15 minutes) and the 
supernatant was collected into a clean, cold Eppendorf.  The sample was immediately stored 
at -80 oC overnight.   
2.2.1.2  Protein quantification 
A bicinchoninic acid (BCA) assay [Pierce, 23225] was used to quantify the concentration of 
protein within each sample.  The manufacturer’s protocol was followed.  A set of standards 
of known protein concentrations comprised of bovine serum albumin (BSA) dissolved in RIPA 
buffer (50 mM tris HCl, 150 mM NaCl, 1 % Triton X-100 (v/v), 1 % sodium deoxycholate (w/v), 
0.1 % sodium dodecyl sulfate (w/v), pH 7.4) were prepared and pipetted in triplicate into 
wells of a 96-well plate, alongside triplicates of each protein sample, and incubated with the 
reaction solution for 30 minutes at 37 oC on a shaking platform.  The protein in the samples 
degrades the Cu2+ within the reaction solution to Cu1+, which forms a complex with BCA 
leading to a colorimetric reaction.  This reaction causes the contents of the wells to change 
colour from green to purple.  The relationship between BSA/Cu1+ complex and the 
concentration of protein is linear, allowing the protein within each well to be then quantified 
by measuring the absorbance, read at 562 nm (1 minute) using a photospectrometer.  The 
values from the BCA assay standards were used to create a standard curve and calculate the 
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equation for this curve, using MS ExcelTM.  The equation can then be used to calculate the 
concentration of protein within each sample.   
2.2.1.3  Buffers and solutions used during western immunoblotting 
 
Table 2.3 Components of SDS Sample Buffer (5 X) 
Reagent Product Concentration 
TRIS-HCl [Tris(hydroxymethyl) aminomethane HCl] Melford, T1513 50 mM – pH 6.8 
Dithiothreitol (DTT) Sigma, D9779 100 mM 
SDS Sigma, L3771 2 % (w/v) 
Bromophenol Blue Sigma, B0126 0.1 % (w/v) 
Glycerol Sigma, G5516 10 % (w/v) 
 
Table 2.4 Components of Loading Gel (12 %)  
Reagent Product Concentration Volume 
(v/v) 
H2O* Sigma, W3500 N/A 32.96 % 
Acrylamide Sigma, A3574 30 % 40.00 % 
TRIS [(hydroxymethy)aminomethane] Melford, B2005 1.5 M – pH 8.8 25.00 % 
SDS Sigma, L3771 10 % (w/v) 1.00 % 
Ammonium Persulfate (APS) Sigma, A3678 10 % (w/v) 1.00 % 
TEMED Fluka BioChemika, RA12027 N/A 0.04 % 
 
Table 2.5 Components of Stacking Gel (4 %) 
Reagent Product Concentration Volume 
(v/v) 
H2O* Sigma, W3500 N/A 68.65 % 
Acrylamide Sigma, A3574 30 % 16.75 % 
TRIS [(hydroxymethy)aminomethane] Melford, B2005 1 M – Ph 6.8 12.50 % 
SDS Sigma, L3771 10 % (w/v) 1.00 % 
Ammonium Persulfate (APS) Sigma, A3678 10 % (w/v) 1.00 % 
TEMED Fluka BioChemika, 
RA12027 





Table 2.6 Components of Running Buffer (10x) 
Reagent Product Amount 
TRIS Melford, B2005 30.2 g 
Glycine Melford, GO709 188.0 g 
SDS Sigma, L3771 0.5 % (w/v) 
H2O* N/A Made up to 2 L using H2O 
 
 






Table 2.8 Components of TRIS Buffer Saline (TBS) (10x) 
Reagent Product Amount 
TRIS Melford, B2005 30 g 
NaCl2 Sigma, S7653 80 g 
KCl Sigma, P9541 2 g 
H2O*  N/A Made up to 2 L using H2O 
*H20 was purified using The Milli-Q Integral System, Millipore. 
 
2.2.1.4  Sample Preparation  
The lysate samples were thawed on ice.  The volume of each lysate required to add 20 μg of 
protein for each sample was calculated, using the concentration of the protein samples 
calculated using the BCA assay (Chapter 2.2.1.2).  The volume of H20 required to prepare the 
samples to a total volume of 20 μl was also calculated.   The water was pipetted into labelled 
PCR tubes before adding the 4 μl sample buffer (Table 2.3) containing dithiothreitol (DTT), 
which is required to denature the protein.  Finally, the correct volume of protein was added 
to the corresponding labelled PCR tube.  The samples were heated to 100 oC for 5 minutes 
Reagent Product Amount 
TRIS Melford, B2005 58 g 
Glycine Melford, GO709 29.2 g 
SDS Sigma, L3771 3.7 % (w/v) 
H2O*  N/A Made up to 2 L using H2O 
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within a heat block to facilitate denaturisation of the protein.  Following this treatment, the 
samples were kept on ice before loading.   
2.2.1.5  Preparation of the loading and stacking gels 
12 % acrylamide loading gel was used for all western blotting experiments (Table 2.4).  The 
apparatus for running the protein and the gels were prepared before the protein samples 
were prepared, to limit the time from thawing the samples to preparation for western 
blotting ensuring minimal sample degradation. 7 ml of the loading gel was pipetted, 
immediately after preparation in a 50 ml falcon tube, between two clean 1.5 mm2 plates, 
secured within the Mini Protean II Apparatus (Biorad).  500 μl of butanol was then pipetted 
on top of the loading gel, to ensure the gel set with an even upper surface to allow all samples 
to run equally through the gel.  The gel was allowed to set for 30 minutes before the butanol 
was removed, and the gel washed with water to remove traces of butanol.  The stacking gel 
was then prepared (Table 2.5) and 2 ml pipetted onto the loading gel.  To create the wells 
within the stacking gel for protein loading, a comb with 10 ‘teeth’ was inserted into the top 
of the gap between the two plates and the gel was allowed to set for 15 minutes.  The plates 
containing the set gel were transferred from the Mini Protein II Apparatus into the running 
cassette and the tank (Mini Trans-Blot® Cell, Biorad) was filled with 1L 1 X running buffer 
(Table 2.6), making sure that the running buffer covered the top of the gel.  The comb was 
removed from the gel and the gel was loaded with the protein samples.  A note of the order 
of the protein samples was taken and the wells created by the comb were checked to ensure 
they had not been distorted in the process.  5 μl of protein ladder (Precision Plus Protein™ 
Kaleidoscope™ Standards, [Bio-Rad 161-0375]) was loaded in a well alongside the protein 
samples.  The samples were run at 100 V until they had passed the stacking gel, at which 
point the voltage was increased to 150 V.  The gel was run until the blue sample buffer could 
be seen at the bottom of the gel, which takes approximately 70 minutes.  The plates were 
removed from the apparatus and separated carefully before the stacking gel was removed 
and discarded, leaving the loading gel. 
2.2.1.6  Wet transfer of proteins to a polyvinylidene difluoride membrane  
Two pieces of sponge and two pieces of blotting paper were soaked in 1 X transfer buffer 
with 10 % methanol (Table 2.7).  Polyvinylidene difluoride (PVDF) membrane was cut into an 
appropriate size and soaked for one minute in methanol, before being transferred to a 
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container with 1 X transfer buffer, with 10 % methanol, to soak for an additional 5 minutes.  
Soaking the membrane in methanol ensures it is ‘active’, while soaking in 1 X transfer buffer 
ensures the membrane is at isotonic equilibrium.  The gel and membrane were layered 
between filter paper and sponge within the transfer cassette as depicted (Figure 2.3) rolling 
each layer upon addition to minimise the chance of air bubbles becoming trapped.  The 
cassette was secured close and placed into the western transfer apparatus.  To limit 
degradation of the protein, an ice block was added into the tank next to the cassette as the 
process of transferring produces heat.  The tank was then filled with 1 X transfer buffer with 
10 % methanol and the lid fitted.  The apparatus was placed into a plastic bucket containing 
ice to minimise heating.  The transfer was performed by passing 200 mA of current through 
the apparatus for 90 minutes.  Upon completion of the transfer, the membrane was removed 
from the apparatus and the gel discarded. The membrane was ‘reactivated’ by soaking in 
methanol for five minutes.   
 
Figure 2.3 Schematic of western transfer 
 
2.2.1.7  Probing the PVDF membrane with antibodies 
The membrane was rolled into a 50 ml falcon tube, ensuring no overlapping, and then 
blocked in 10 ml of 10 % skimmed milk [Marvel] in 1 X TBS (Table 2.8) + 20 % Tween (TBS-T) 
for an hour at room temperature on a roller.   After washing the membrane 3 times (10 
minutes/wash) in 10 ml of TBS-T within a clean falcon tube, the membrane was added to a 
new, clean falcon tube with 5 ml of the prepared primary antibody solution.  The primary 
Figure 2.3     Schematic of western transfer 
The current was passed from the negative anode to the positive anode through the gel and then 
the membrane to transfer the protein.  The sponges and filter paper were arranged such as to 




antibodies were prepared in 5 % milk in 1 x TBS-T to the required concentration.  The 
membrane was incubated with the antibody overnight at 4oC on a roller.  The following day, 
the membrane was removed from the primary antibody and placed into a clean falcon tube 
and washed 3 times as before.  An appropriate secondary horseradish peroxidase (HRP)-
conjugated antibody was diluted 1:5000 in 5 % milk in 1 x TBS-T in a clean falcon tube and 
the membrane was incubated with the secondary antibody for 1 hour at room temperature 
on a roller.  The membrane was washed 3 times as before.   
2.2.1.8  Enhanced chemiluminescence (ECL) detection of antibodies 
The membrane was placed within a plastic folder.  0.75 ml of Luminol Enhancer and 0.75 ml 
Stable Peroxide Buffer were mixed in a 15 ml falcon tube [Supersignal west pico 
chemiluminescent substrate (ECL) kit; Thermo Scientific, 34080] and this solution was added 
to the membrane within the folder.  The solution was spread over the membrane, ensuring 
even coverage, for one minute.  The solution was then removed and the folder sealed 
airtight.  The folder containing the membrane was then affixed within a HypercassetteTM [GE 
Healthcare Amersham].  In a dark room, autoradiograph film (Amersham Hyperfilm ECL, [GE 
Healthcare, 28-9068-40]) was added to the hypercassette to expose the film to the 
membrane.  The film was developed using a Kodak X-OMAT 1000 auto processor. 
2.2.1.9  Stripping the western 
Western blots were re-probed after initial probing with a ‘housekeeping’ antibody to allow 
normalisation of signals.  Before re-probing, the membrane was stripped using western blot 
stripping buffer [Fisher, 21059].  The membrane was incubated with the stripping buffer for 
5-10 minutes at room temperature within a 50 ml falcon tube on a roller, before being 
washed three times (10 minutes/wash) and re-activated by soaking in methanol for five 
minutes.  The membrane was blocked for one hour in 10 % milk in 1 X TBS-T before re-
probing.  Each blot was probed with an antibody against GAPDH before being probed with a 
tau antibody, either DA9, PHF-1 or CP13.  Each western blot was then probed with an 
antibody against a tau kinase, either GSK3β, GSK3β pTyr216, Akt pSer273 or PAK3.  Other 
blots were probed with GAPDH and then either antibodies against synapsin or p25-p35.  This 




2.2.1.10  Densitometric analysis of protein bands 
Densitometric analysis was performed using the software Image J, downloaded from 
http://rsbwb.nih.gov/ij/.  The blot was scanned using an Epsom scanner 1250 and saved as a 
Tiff file.  Each band was individually selected to generate a histogram.  The areas under the 
peaks of each histogram were calculated and imported into an Excel file for processing for 
analysis.  
2.2.2  Immunocytochemistry 
2.2.2.1  List of solutions  
 
Table 2.9 Components of blocking/permeabilisation solution 
Reagent Amount Product 
Triton-X-100 0.1 %-0.4 % Sigma, T8787 
Horse serum 10 % Life technologies, 26050088 
Bovine serum albumin (BSA) 2 % Sigma, A9418 
Phosphate buffered Saline (PBS) + CaCl2 + MgCl2 Up to 10 ml Sigma, D8662 
 
Table 2.10 Components of antibody incubation solution 
Reagent Amount Product 
Primary/secondary antibody Various Various  
Triton-X-100 0.1 % Sigma, T8787 
Horse serum 1 % Life technologies, 26050088 
Bovine serum albumin (BSA) 0.2 % Sigma, A9418 
Phosphate buffered Saline (PBS) + CaCl2 + MgCl2 Up to 10 ml Sigma, D8662 
 
2.2.2.2  Preparation of cells for immunocytochemistry 
Cells were washed with PBS and an appropriate volume of 4 % paraformaldehyde (PFA) at 
room temperature was added to the cells (i.e. 150 μl per well of a 4-well or 24-well plate).  
The cells were incubated at room temperature; 15 minutes for cells in a monolayer, or 20 
minutes for neurospheres.  Cells were then incubated with blocking/permeabilisation 
solution for 2 hours at room temperature, or overnight at 4 oC, on a rocker.  Cells were then 
gently washed 3 times (10 minutes/wash) in PBS + 0.1 % Triton-X-100 (PBS-Tx).   
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2.2.2.3  Probing cells with antibodies 
Cells were incubated with the primary antibody, prepared in antibody incubation solution, 
overnight at 4 oC on a rocker.  The following day the cells were gently washed 3 times (10 
minutes/wash) in PBS-Tx before being incubated with the appropriate fluorescent secondary, 
at a concentration of 1:400, for 2 hours on a rocker, protected from light.  After washing the 
cells 3 times (10 minutes/wash) Hoechst solution at a concentration of 1:1000 in PBS was 
added to the cells for 5 minutes, protected from light.  After the incubation period the cells 
were washed 3 times (10 minutes/wash).   
2.2.2.4  Mounting coverslips  
Cells cultured on coverslips and immunostained were mounted.  The coverslips were 
removed from the cell culture well using forceps and placed inverted onto a ~30 μl drop of 
Vectorshield® Mounting Medium on a slide.  Care was taken to avoid placing any pressure on 
the coverslips.  The coverslips were allowed to rest on the slides for approximately two 
minutes to allow the mounting medium to spread through capillary action.  Any excess 
medium was removed using blotting paper.  A layer of clear nail varnish was painted around 
the edge of the coverslip to seal the coverslip to the slide and contain the mounting medium.  
After allowing 1 hour to dry, a second coat of nail varnish was applied.  A fluorescence 
microscope (Leitz DMRB, Leica) was used to image the cells, captured by a camera (DC 500, 
Leica) and processed using Leica imaging software.   
2.2.3  Analysis of Gene Expression 
The expression of specific genes present within hPSCs, embryoid bodies (EBs), hPSC-derived 
neurons and brain tissue was quantified by quantitative polymerise chain reaction (qPCR) 
using Taqman® probes.  Briefly, total RNA was isolated from the cells, purified and converted 
to cDNA.  The cDNA is representative of the RNA present within the sample and therefore 
can be used to quantify RNA expression. This technique involves the amplification of target 
DNA, representative of the gene in question, using sequence specific Taqman® DNA probes, 
which consist of oligonucleotides labelled with a fluorescent reporter.  Fluorescence is only 
detected after hybridisation of the probe with the complimentary target DNA sequence.  The 
fluorescent sequence was detected using a StepOnePlus™ System [Applied Biosciences] 
and the complimentary software used to quantify the number of cDNA copies present 
within each sample. 
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2.2.3.1  Extraction and purification of total RNA 
RNA extraction and purification was performed by using TRIzol reagent [Ambion, 15596-026] 
with the PureLink® RNA Mini Kit [Ambion, 12183018].  TRIzol® [Ambion] is a monophasic 
solution of phenol and guanidine isothiocyanate, designed to isolate separate RNA, DNA and 
proteins from cell and tissue samples into fractions.   
hiPSC colonies were grown in feeder-free conditions in 9 cm diameter cell culture plates until 
50 % confluent.  Cortical glutamatergic neurons were grown in 6 cm diameter 6-well plates 
until confluent and basal forebrain neurons were grown in 24-well plates.  The media from 
the cells was removed and an appropriate volume of TRIzol®, dependent on the surface area 
of the culture surface, was added to the cells.  hPSC and neurons were homogenised directly 
in the plate by pipetting 20 times with a P1000 pipette tip.  EBs and brain tissue were 
collected into RNAse-free tubes and an appropriate amount of TRIzol® was added to each 
tube.  Embryoid bodies and brain tissue were homogenised within the tubes using a tissue 
homogeniser and then by pipetting 20 times with a P1000 pipette tip.   
After homogenisation the plates or tubes were incubated on ice for 5 minutes.  The 
incubation period ensured the complete homogenisation and extraction of nucleic materials 
from the cells.  After incubation on ice, homogenised hPSC and neurons were transferred to 
RNAse-free tubes.  The samples were frozen immediately at -80 oC or processed using the 
PureLink® RNA Mini Kit to isolate RNA.   
The PureLink® RNA Mini Kit relies on spin column technology.  PureLink® DNase [Ambion, 
12185010] is optimised for use with the PureLink® RNA Mini Kit and was used to remove 
genomic DNA from the RNA samples; this product is an endonuclease that breaks apart 
double- and single-stranded DNA and is free of ribonucleases and proteases.  Briefly, the 
bench area, pipettes and tube stands were cleaned using RNase AWAYTM surface 
decontaminant [Thermo Scientific, 7002] to ensure an RNA-free environment.  The 
manufacturer’s instructions for the PureLink® RNA Mini Kit were followed to complete 
extraction and purification of RNA and to remove any residual DNA.  RNA-free filter pipette 
tips were used throughout the protocol.   
2.2.3.2  Quantification of RNA  
A spectrometer [NanoPhotometerTM, Implen, Pearl Edition] was used to quantify the 
concentration of the RNA within the sample by first vortexing the sample for 2 seconds and 
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then adding 1 μl of the sample to the sensor.  The value of the concentration was recorded, 
along with the absorbance ratio values; absorbance ratio of 260nm/280nm should equate to 
2.0 +/- 0.05, which indicates a pure RNA sample, whereas the ratio 260nm/230nm should be 
between 2.0 and 2.2, indicating pure nucleic acid. If this ratio value deviates from this it 
indicates there may be protein contaminants within the sample, therefore, samples outside 
of these ranges were discounted.   
2.2.3.3  Reverse Transcription of RNA to cDNA   
The High-Capacity cDNA Reverse Transcription (RT) Kit [Applied Biosystems, 4368814] was 
used to convert up to 2 µg of RNA per sample to cDNA.  A 2 X reaction mix was prepared on 
ice according to the manufacturer’s instructions (Table 2.11).  An equal amount of RNA, for 
example 1 µg, for each sample was added to the reaction to allow for accurate quantification 
of gene copy number during qPCR.  To create a negative template control for each sample, 
the protocol was performed without MultiscribeTM Reverse Transcriptase.  When used 
alongside qPCR, the negative template control ensured there was no DNA contamination 
within the samples before reverse transcription.  
 
Table 2.11 Reaction mix for reverse transcription of RNA to cDNA. 
 Component Volume/Reaction (µL) 
 Kit with MultiscribeTM Reverse 
Transcriptase to create a positive 
template 
Kit without MultiscribeTM Reverse 
Transcriptase to create a negative 
template 
5 x RT Buffer 2.0 2.0 
25x dNTP* Mix (100 
nM) 
0.8 0.8 







RNAse Inhibitor 1.0 1.0 
Nuclease-free H2O 3.2 4.2 
Total per Reaction 10.0 10.0 
*dNTPs comprise dATP, dCTP, dTTP and dGTP 
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The manufacturer’s instructions for High-Capacity cDNA Reverse Transcription Kit were 
followed.  Briefly, the volumes of each component (10x RT Buffer, 25x dNTP Mix (100 nM)), 
10 X RT Random Primers, MultiscribeTM Reverse Transcriptase, RNAse Inhibitor and Nuclease-
free H20) (Table 2.11) needed to make up the volume of reaction mixture, was calculated to 
create a positive and negative template for each sample, plus 10 % to account for any 
pipetting error.  The positive template and negative template mixtures were made in RNAse 
free Eppendorf tubes, vortexed to mix, briefly centrifuged and kept on ice.  10 µl of RNA 
mixture for each sample, containing the correct amount of RNA and made up to 10 µl with 
nuclease-free H20, was pipetted into clean, RNAse free tubes.  10 µl of the positive or 
negative reaction mixtures were pipetted into the RNAse-free PCR tubes containing the RNA 
mixture.  The samples were inverted three times to mix before centrifuging briefly.  The tubes 
were placed into the thermal cycler [Biorad, MJ Mini] programmed with the following heat 
cycle:  25 oC for 10 minutes, 37 oC for 120 minutes and 85 oC for 5 minutes.  Once the cycle 
was complete, the synthesised cDNA was stored at 4 oC before being used for qPCR.  
2.2.3.4  Quantitative Polymerise Chain Reaction 
The required volume, plus 10 % to account for pipetting error, of 2X TaqMan® Universal PCR 
Master Mix (Applied Biosystems, 4364340) was determined to perform qPCR reactions for 
all samples, endogenous control assays and non-template controls (NTC) for each gene assay.  
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an endogenous reference 
gene throughout.  The 2X TaqMan® Universal PCR Master Mix contains AmpliTaq Gold® DNA 
Polymerase, UP (Ultra-pure), Uracil‐N glycosylase (UNG), dNTPs with dUTP, dNTPs with dUTP, 
ROX™ Passive Reference and optimized buffer components.  The Taqman® Gene Expression 
Assay (20 X) was added to the master mix (Table 2.12) within an RNAse-free Eppendorf.  
Taqman® Gene Expression Assays for real-time PCR were purchased from Applied Biosystems 
(Table 2.13; at the 5’ end, the probes were conjugated to the fluorochrome 6-







Table 2.12 Components required per qPCR Taqman® Gene Expression Assay reaction. 
Component Volume (µl) 
2X TaqMan® Universal PCR Master Mix 10  
Taqman® Gene Expression Assay (20 X) 1  
cDNA template Varies  
RNase free H20 To 20 
 
Table 2.13 Taqman® probes 
Gene TaqMan® Gene Expression 
Assay Catalog no. ID 
Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) Hs02758991 
Cyclin-Dependent Kinase 5 (CDK5) Hs00358991 
Glycogen synthase kinase 3 beta (GSK3β) Hs01047719 
P21 Protein (Cdc42/Rac)-Activated Kinase 3 (PAK3) Hs00176828 
Repeat Microtubule Associated Protein Tau (MAPT) Hs02758991 
 
Within strip PCR tubes the appropriate volume (Table 2.12) required for a triplicate of each 
assay was measured out.  The appropriate volume of cDNA, consistent between all samples 
and assays, for a triplicate of each assay was then added to each tube.  The tubes were 
vortexed and centrifuged for 5 seconds to ensure adequate mixing of the components.  20 µl 
of each assay and cDNA mixture was then added to the side of a well of a 96-well plate 
(MicroAmp, Applied Biosystems).  This was repeated to ensure a triplicate of each assay.   
Non-template controls (NTC) were also mixed and pipetted in the same way with the same 
volumes, however, in the place of the cDNA template RNAse free H20 was added.  The plate 
was covered with an optical adhesive cover (Applied Biosystems; Cat No. 4313663) to 
prevent evaporation and contamination during the reaction and then centrifuged at 300 g 
for one minute at room temperature in a centrifuge to eliminate any bubbles that may have 
formed during pipetting and ensure the mixture was at the bottom of each well.  The 
instructions in the instrument user guide for the StepOnePlus™ Real‐Time PCR System were 




Table 2.14 Thermal cycling parameters used for qPCR 
Parameter UNG incubation Polymerase activation PCR (40 cycles) 
 Hold Hold Denature Anneal/extend 
Temperature 50 oC 95 oC 95 oC 60 oC 
Time (mm:ss) 02.00 10.00 00.15 01.00 
2.2.3.5  Analysis of qPCR results 
The threshold cycle number for product detection (Δ CT value) for the housekeeping gene 
(GAPDH) and the genes being tested (MAPT, CDK5, GSK3β or PAK3) were calculated within 
the StepOnePlus™ Real‐Time PCR System complimentary software, for both the control 
samples and experimental samples.  These values were copied into Microsoft Excel and the 
average relative gene expression of each gene in comparison to the controls was then 
calculated.  In Chapter 4, control samples were from Shef 6-CGN and experimental samples 
were from V337M-C-CGN.  In Chapter 5, control samples were Nas 2-bfCN or Shef 6-CGN not 
treated with Aβ42O and experimental samples were those treated with Aβ42O.  The average 
of the CT values for each sample in triplicate were averaged.  ΔCT values for the experimental 
(ΔCTE) and control (ΔCTC) conditions were generated subtracting the average CT value of the 
housekeeping gene from the average CT value of the gene being tested for the experimental 
sample.  The difference between ΔCTE and ΔCTC (ΔCTE-ΔCTC) was calculated to work out the 
Double Delta CT Value (ΔΔCT).   The value of 2^-ΔΔCT was then calculated to arrive at the 
value for average relative gene expression.  This value, for each sample, was normalised to 
the average 2^-ΔΔCT value of the control samples.   
2.2.4  Statistical analysis of western immunoblotting and gene expression 
results 
Analysis was carried out to determine the statistical significance of results from western 
immunoblotting densitometry and qPCR.  Graphpad Prism 7 was used to analyse the data 
and statistical tests were recommended by Prism.   
An unpaired Student’s t-test was used to analyse the statistical significance of western 
immunoblotting results in which two groups were compared, as recommended by Graphpad 
Prism 7.  Upon analysis of the effects multiple concentrations of Aβ42O on tau-related 
pathogenesis within Shef 6-bfCN (Chapter 5.3), the Friedman test was used followed by the 
Dunn post-hoc test to allow for comparison of results across separate blots. 
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Statistical analysis of gene expression data was carried out using non-parametric tests as 
sample sizes are too small to reliably confirm normal distribution of data.  Where two groups 
were compared, statistical analysis was carried out using the Mann-Whitney test.  Where 
more than two groups were compared the Kruskal-Wallis test followed by a post-hoc Dunn’s 
test.  *=p ≤ 0.05. **=p ≤ 0.01. ***=p ≤ 0.001. ****=p ≤ 0.0001. 
2.2.5 Definition of technical and biological replicates 
For each biological sample collected for western immunoblotting or gene analysis via qPCR 
of cortical glutamatergic neurons (CGNs), protein lysates were collected from one well of a 
6-well plate (Chapter 4 and Chapter 5).  Lysates from three wells of a 24-well plate were 
pooled for each biological sample collected for western immunoblotting or gene analysis for 
basal forebrain cholinergic neurons (bfCNs) (Chapter 5).  Each western blot was repeated 
three times to account for technical variation.  Three technical replicates of the resultant 








Generation of V337M MAPT induced 
pluripotent stem cell lines 
 
3.1  Introduction 
Val337Met (V337M) MAPT is a rare mutation, otherwise known as the Seattle family A 
mutation, described as a missense, single nucleotide polymorphism within exon 12 of MAPT 
resulting in a change in the amino acid (aa) at 337 from valine to methionine, resulting in 
frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17) (Poorkaj et 
al., 1998).  Four human pluripotent stem cell (hPSC) lines were used during this PhD project: 
Shef 6, a human embryonic stem cell (hESC) line; Nas 2 a human induced pluripotent stem 
cell (hiPSC) line; and two hiPSC lines derived from a patient carrying V337M MAPT.  
Characterisation of the pluripotency of the Nas 2 hiPSC and Shef 6 hESC lines has been carried 
out previously within the Kunath lab (Devine et al., 2011) and by the UK Stem Cell Bank, 
respectively.  The study was approved by National Research Ethics Service (NRES Committee 
– South West) reference 09/H0102/47.  The work in this chapter describes the generation, 
establishment and characterisation of hiPSC lines V337M-C and V337M-E.   
Reprogramming of V337M MAPT lines was carried out previously within the Caldwell lab by 
Dr. Lucy Crompton while clonal selection and characterisation was carried out by the author 
of this thesis, under the supervision of Dr. Lucy Crompton.  A skin biopsy was obtained from 
a 44 year old female with the heterozygous mutation V337M MAPT.  Cells from the skin 
biopsy were cultured in vitro to expand a population of fibroblasts, which were obtained from 
Corriell Biorepository (http://ccr.coriell.org/, catalogue no:  ND40082) (New Jersey, USA), 
where they had been genetically characterised.  These fibroblasts were reprogrammed using 
lentiviral transduction of pluripotency transcription factors (TFs), OCT4, KLF4, SOX2, LIN28 
and NANOG, along with the gene for green fluorescent protein (GFP), to produce human 
induced pluripotent stem cells (hiPSC) carrying the mutation.  Clones were selected for 
expansion and two of these were taken forward for characterisation of pluripotency and 
karyotyping: V337M-C and V337M-E.  After expansion of the clones, the established cell lines 
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were cultured and continually banked up until passage 10.  hESC and hiPSC lines between 
passages 10 and 16 were differentiated to produce cortical glutamatergic neurons (CGNs). 
At the start of this PhD, there were concerns within the scientific community that hiPSC lines 
may not be identical to hESC with regards to their genetic and epigenetic regulation of 
pluripotency, genome integrity and gene expression (Bilic and Belmonte, 2012; Puri and 
Nagy, 2012).  Additionally, concerns over the inability of hiPSC-models to recapitulate certain 
aspects of particular diseases, previously recapitulated in hESC-models, were also raised 
(Halevy and Urbach, 2014).   Potential differences between these two cell types would hinder 
the comparison of the results in such studies to those found within studies using hESC-
models.  To allow for control of these possible differences, the gold standard of the time was 
to use a control hESC line alongside a control hiPSC line within studies involving modelling 
using hiPSC lines derived from patients.  This is no longer deemed necessary as differences 
between these two cell types have been confirmed to be minimal (Bates and Silva, 2017).   
 
Figure 3.1     Reprogramming of hFibs to produce hiPSC 
A skin biopsy was collected from the patient, which was cultured in vitro to expand a population 
of fibroblasts.  Lentiviral vectors were used to transduce reprogramming factors (OCT4, SOX2, 
KLF4), along with GFP, into patient fibroblasts.  The silencing of GFP was used to monitor the 
completion of reprogramming.   
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3.2  Methods 
3.2.1  Human fibroblast culture 
Human fibroblast culture was carried out by Dr. Lucy Crompton within the Caldwell lab to 
gain fibroblasts from a skin biopsy.   
3.2.2  Reprogramming 
Reprogramming of these fibroblasts was originally carried out within the Caldwell lab by Dr. 
Lucy Crompton using lentiviral vectors (pRRL-Sin-cppt-PGK-EGFP, pSin4-EF2-Oct4-Sox2, 
pSin4-EF2-Nanog-Lin28, pWXPL-Klf4) originally from the James Thomson lab (Yu et al., 
2007).  A discussion on the disadvantages of retroviral reprogramming and ‘start-of-the-art’ 
approaches is given in Chapter 1.4.3.1.2. 
 





76.8 % (v/v) Knock-out DMEM [Invitrogen, 10829] 
20 % (v/v) Knock-out serum replacement [Invitrogen, 10828]  
1 % (v/v) GlutaMAX™ (100x) [Invitrogen, 35050] 
1 % (v/v) Non-essential amino acids NEAA (100x) [Invitrogen, 11140] 
1 % (v/v) Penicillin-streptomycin (Pen/Strep).  solution stabilised [Sigma, P4458] 
0.2 % (v/v) 2-Mercaptoethanol (50 mM) [Invitrogen, 991827] 
100 ng/ ml Human fibroblast growth factor – basic (FGF2) [Peprotech, 100-
18B] 
8 μg/ ml Polybrene® (Hexadimethrine bromide) [Sigma, 107689] 
2 mM Valproic acid [Calbiochem, 
676380] 
 
3.2.3  Clonal Selection of hFibs  
Clonal selection of hFibs was carried out by the author supervised by Dr. Lucy Crompton.  
After transduction, the cells were plated onto inactivated mouse embryonic fibroblasts 
(iMEFs), within a 9 cm diameter cell culture plate, in 3 ml transduction media containing 100 
ng/ml of fibroblast growth factor 2 (FGF2) and 20 mM valproic acid (VPA).  Over the following 
107 
 
14 days, the cells were half-fed daily; 1.5 ml of the media was removed and replaced with 
fresh transduction media.  After 7 days, VPA was removed from the media and the cells were 
viewed under a fluorescent microscope [Leica, BS7270] to detect ‘clumping’ of GFP positive 
hFibs.   After a further 14 days, the hFibs had clumped and swirled, forming early colonies 
with defined borders.  The location of these colonies were marked on the bottom of the plate 
using a permanent marker.  GFP positive colonies were manually passaged, viewed under a 
dissection microscope within the tissue culture hood, one colony at a time.  Each colony was 
transferred into one well of a 6-well plate, pre-seeded with iMEFs, and cut into smaller pieces 
using an insulin needle.  From this point, the cells were treated as independent clones and 
labelled by letter A-F.  The passaged colony pieces were allowed to form colonies and 
monitored for morphology and the expression of GFP.  At this point, cells are morphologically 
different compared to hFibs and more similar to a stem cell colony, however, they still 
express GFP indicating incomplete reprogramming.   
The amount of FGF2 was reduced to 50 ng/ml for one week, before being reduced to 20 
ng/ml.  The colonies of each clone were passaged again into 6 wells of a 6-well plate after a 
period of two weeks had passed since the last passage.  GFP expression is silenced at this 
point, identified by a lack of fluorescence, indicating complete reprogramming of the cells.  
The pluripotency was determined by analysis of morphology of the cells and colonies, alkaline 
phosphatase staining and fluorescent immunocytochemistry using pluripotency markers.  
Four of these clones were chosen for cryopreservation and two were finally selected for use 
in modelling FTDP-17 (Chapter 4).   
 
Table 3.2 Table of cell lines used 
 
Name Type Control or carrying mutation Source 
Shef 6 hESC Control UK Stem Cell Bank 
Nas 2 hiPSC Control Prof. Kunath’s lab 
V337M-C hiPSC Carrying mutation V337M MAPT Prof. Caldwell’s lab 
V337M-E hiPSC Carrying mutation V337M MAPT Prof. Caldwell’s lab 
 
3.2.4  Alkaline Phosphatase Staining 
hiPSC were cultured for approximately five days until medium-sized colonies had formed.  
The media was aspirated from the plate and cells were fixed in 4 % paraformaldehyde for 1.5 
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minutes.  The fixative was then aspirated, the plate was washed gently with TBS-T (20 mM 
Tris-HCl, 0.15 M NaCl and 0.05 % Tween-20) and 1.5 ml of alkaline phosphatase stain from 
the alkaline phosphatase staining kit [Sigma, AP0100] was pipetted onto each plate.  The 
plates were incubated with alkaline phosphatase stain, protected from the light, for 15-30 
minutes at room temperature.  The stain was then aspirated off of the cells and the cells 
were rinsed with TBS-T.  Epsom scanning software was used obtain images of the plates.  Pink 
colonies indicate pluripotent cells, whereas non-coloured cells represent differentiated cells.   
3.2.5  Fluorescent immunocytochemistry 
Immunocytochemistry was carried out as detailed in Chapter 2.2.2.   
Table 3.3 Antibodies for characterisation of hiPSC 
 
Antibody Code and manufacturer Concentration Species Details  
SSEA4 ab16287, Abcam 1:300 Mouse IgG3, monoclonal 
Tra-1-60 ab16288, Abcam 1:300 Mouse IgM, monoclonal 
 
3.2.6  Karyotyping 
hiPSC were cultured almost to confluence within a 25cm3 flask in the E8 system and sent live 
to The Doctors Laboratory Ltd. for karyotypic analysis to ensure sound chromosomal integrity 
after reprogramming.  
3.2.7  Genotyping 
A 25 cm3 flask of V337M MAPT hFibs was grown until confluent.  The media was aspirated 
and the cells were washed twice with PBS to remove traces of media.  The 25 cm3 flask was 
stored overnight in a -80 oC freezer to aid the lysis of cells.  The next day lysis buffer [10 mM 
Tris-HCl pH 7.5-8, 10 mM EDTA, 10 mM NaCl, 0.5 % SDS, 18 µg/ml Proteinase K (Roche, 
03115887001)] was added to the cells.  The flask was then incubated overnight in a humified 
incubator set to 55 oC.  2 x the volume of -20 oC ethanol/salt solution (75 mM NaCl in 100%, 
ethanol) was added to the flask and the flask was placed on an orbital rocker for 30 minutes 
to elute the DNA from the cells.  Genomic DNA (gDNA) could be seen, precipitated within the 
liquid in the flask.  The liquid and gDNA was removed from the flask and placed into a 15 ml 
falcon tube and centrifuged at 4000 g for 10 minutes.  The supernatant was removed from 
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the falcon tube leaving a gDNA pellet, which was then washed twice with 100 % ethanol.  The 
gDNA was then carefully removed with a pipette tip and placed into an Eppendorf tube.  All 
excess liquid was removed and the pellet was allowed to air dry within the tube for 15 
minutes at room temperature.  250 µl of TE buffer (Tris 10 mM, EDTA 1 mM, pH 8) was then 
added to the gDNA at room temperature and the DNA was allowed to resuspend after 
pipetting for 1 hour.  Samples were then haplotyped in Dr Roger Barker’s lab, Brain Repair 
Centre, Cambridge, UK.  
3.2.8  Maintenance of hiPSC 
hiPSC were maintained on either iMEFs or within the Essential 8TM system as described in 











3.3  Results 
3.3.1  Characterisation of pluripotency 
Characterisation of hiPSC is essential to verify that pluripotent stem cells have been created.  
This was achieved through observation of the morphology of the cells and the colonies that 
they form.  True hiPSCs should resemble pluripotent hESCs, and both the V337M-E and 
V337M-C hiPSC lines displayed hESC-like morphology; colonies had defined edges and 
consisted of small, round cells with a large proportion of each cell taken up by its nucleus 
(Vallier et al., 2004).  Similar to hESCs, cells within the V337M-E and V337M-C hiPSC lines 
were compact within the colonies (Vallier et al., 2004).  Shef 6 was used to compare the 
morphology of the cells within the colonies of Tau-V337M hiPSC.  All cells within the colonies 
expressed both Tra-1-60 and Stage-Specific Embryonic Antigen-4 (SSEA4) (Figure 3.2), which 
are gold-standard markers of pluripotency.  Colonies of each line also contained cells with a 


































































































































































































































































































































































































Figure 3.3 Colonies of V337M-C and V337M-E hiPSC express high levels of alkaline 
phosphatase 
  
Figure 3.3 Colonies of V337M-C and V337M-E hiPSC express high levels of alkaline 
phosphatase 
Alkaline phosphatase staining demonstrating colonies of V337M-C hiPSC (A) and V337M-E hiPSC (B) 
expressing high levels of alkaline phosphatase, as illustrated by pink colonies.  Non-uniform colonies 
are those that have been manually pruned to remove any cells that may be differentiating to ensure 




3.3.2  V337M MAPT lines have normal karyotypes 
The process of reprogramming carries a small risk of introducing chromosomal abnormalities 
and through the culture of hiPSC culture these can be introduced.  Therefore, the karyotypes 
of these cells were examined.  No abnormalities were seen within the chromosomes of 
V337M-C-hiPSC or V337M-E-hiPSC with karyotyping (Figure 3.4), indicated by matching pairs 







Figure 3.4      Karyotyping of V337M-C and V337M-E hiPSC 
No chromosomal abnormalities were revealed by karyotyping in either V337M-
C (A) or V337M-E (B) hiPSC, as indicated by the presence of matching pairs of 




3.3.3  V337M MAPT hiPSC are homozygous H1 
MAPT can exist as one of two haplotypes, H1 or H2.  Both of these are associated with the 
development of tauopathy and are described in Chapter 1 (Chapter 1.1.1.2).  The patient 
fibroblasts used to generate these hiPSC were genotyped to understand whether they carry 
the H1 or H2 haplotypes of MAPT.  The fibroblasts were found to be homozygous H1, 
therefore, hiPSC carrying V337M MAPT are also homozygous H1.  Shef 6 hESC lines are also 
homozygous H1 (Sposito et al., 2015).   
3.3.4  Summary 
HiPSC lines V337M-C and V337M-E exhibit morphology consistent with pluripotency, express 
hallmark pluripotency markers and have high levels of alkaline phosphatase, indicative of 
pluripotency.  Genotyping of these lines revealed that these hiPSC have the H1 haplotype, 
the significance of which in tauopathy is described in Chapter 1 (Chapter 1.1.1.2).  These 
results indicate that reprogramming was successful and that hiPSC have been derived, 


















The development of a model of 
frontotemporal dementia with Parkinsonism 
linked to chromosome 17 using induced 
pluripotent stem cell technology 
  
4.1  Introduction 
The molecular pathways underlying tau pathogenesis is an area of intense research as 
improved comprehension of these of these may facilitate the development of effective 
therapeutics.  Inferences gained through investigating the pathways affected by specific 
MAPT mutations may provide valuable knowledge on the pathogenesis of tau, applicable to 
sporadic tauopathies as well as to those that are heritable.  Neurodegenerative diseases 
caused by mutations in MAPT are termed frontotemporal dementia with Parkinsonism linked 
to chromosome 17 (FTDP-17).  The clinical presentation, pathology and known mutations of 
FTDP-17 are described in Chapter 1 (Chapter 1.2.2).   
To develop a model with the potential to allow research into the initial pathogenic events 
that occur due to MAPT mutations, induced pluripotent stem cell (iPSC) technology was used 
to develop a model of FTDP-17.  The work in this chapter describes the differentiation of 
hiPSC, derived from a patient carrying V337M MAPT, to produce cortical glutamatergic 
neurons (CGN), which are particularly vulnerable in FTD (Chapter 1.2.2).  Current knowledge 
of the specific pathology and symptoms associated with this mutation are discussed below 
(Chapter 4.1.1).  Two cell lines, V337M-C and V337M-E, were derived from a patient carrying 
the mutation Val337Met (V337M) MAPT (Chapter 3) and differentiated alongside a human 
embryonic stem cell (hESC) control line (Shef 6) and a hiPSC control line (Nas 2), to produce 
these neurons.   
At the start of this project, the gold standard in experiments using iPSC was to include a hESC 
line, which is why an hESC line was included in these experiments.  The western blotting 
results included in this chapter use one control line, Shef 6 hESC or Nas 2 hiPSC, and one line 
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carrying V337M MAPT, V337M-C or V337M-E, on each blot allowing for comparison between 
controls and cells carrying the mutation on the same blot.  Unfortunately, a control was not 
included to allow for comparison of results from western immunoblots containing Shef-6-
CGN and V337M-E-CGN samples with western immunoblots containing Nas-2-CGN and 
V337M-C-CGN samples.  Samples from lines Shef 6 and V337M-C were used for gene 
expression analysis as it was not possible to gain enough CGNs from V337M-E and Nas 2 to 
carry this out. 
To characterise changes in tau protein due to the mutation, the levels of tau protein, 
expression of MAPT and phosphorylation of tau at sites associated with tauopathy were 
investigated.  The levels, activity and gene expression of key tau kinases, thought to be 
involved in deregulated hyperphosphorylation of tau in patients with FTDP-17 and other 
tauopathies (Chapter 1.3), were also investigated to interrogate the molecular pathways 
underlying early pathogenesis.    
4.1.1  Val337Met MAPT 
V337M MAPT is a rare, missense mutation also referred to as the ‘Seattle family A’ mutation 
after the family in which it was first discovered (Poorkaj et al., 1998).  V337M MAPT is caused 
by a change in the amino acid (aa) valine to methionine at position 337 within exon 12.  
Although we do not completely understand how this mutation results in tauopathy, valine at 
337 of MAPT is present in other tau protein homologues and is highly conserved (Poorkaj et 
al., 1998) alluding to its importance in tau’s function.   
Recent research has described patients with this mutation as presenting as young as in their 
30’s but more typically in their 50’s with a disease duration of approximately 10 years (Spina 
et al., 2017; Bird et al., 1997; Poorkaj et al., 1998; Domoto-Reilly et al., 2017; Sumi et al., 
1992).  Patients present initially with irritability, compulsive behaviour and mental 
inflexibility (Spina et al., 2017).  As the disease progresses, hallmark symptoms of behavioural 
variant frontotemporal dementia (bvFTD) are observed including loss of inhibition, antisocial 
behaviour, paranoia and loss of empathy (Ghetti et al., 2015; Spina et al., 2017; Bird et al., 
1997; Poorkaj et al., 1998; Sumi et al., 1992).  In the later stages, language problems become 
apparent alongside dementia, which includes disturbance in memory, episodic function and 
loss of semantic knowledge (Spina et al., 2017). 
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The mutation results in symmetrical frontotemporal atrophy (Connell et al., 2001; Spina et 
al., 2017) (Figure 4.1).  Tau aggregates, including neurofibrillary tangles (NFTs), are present 
in the highest density within the medial frontal lobes and to a lesser extent within the lateral 
temporal lobes (Spina et al., 2017; Sumi et al., 1992; Spillantini et al., 1996).  
Neurodegeneration also has been reported in parahippocampus, amygdala and neocortical 
areas (Sumi et al., 1992; Spina et al., 2017).    
  
 
Degeneration within the hippocampus is spared even when tau aggregates are present 
within the region (Spina et al., 2017).  This suggests that the molecular events resulting in 
degeneration due to this mutation occur before the aggregation of tau.  Indeed, in V337M 
MAPT Tg drosophila, no filamentous tau aggregates could be identified in neurons despite 
neurodegeneration, suggesting that tau-induced neurodegeneration is not dependent on the 
aggregation of filamentous tau (Wittmann, 2001).  Considerable variability in the clinical 
presentation and neuropathology of the disease has been reported, akin to FTDP-17 caused 
by other MAPT mutations (Larner and Doran, 2008).  For example, Spina and colleagues 
demonstrated the presence of amyloid pathology, which is not normally observed, within the 
Figure 4.1     MRI images of the brains of two patients with V337M MAPT 
(A) MRI scan showing coronal section of a 65 year old male patient with FTDP-17 caused by V337M 
MAPT mutation.  His symptoms evolved over 20 years. The MRI shows moderate to marked, 
bilateral frontal and temporal cortical atrophy as well as severe anterior temporal lobe atrophy.  
Image adapted with permission from Ghetti et al., 2015 © 1999 – 2017 John Wiley and Sons, Inc. 
(B) MRI scan showing transverse section of a 58 year old male patient with V337M MAPT.  Image 
adapted with permission from Spina et al., 2017 © 2017 American Academy of Neurology.  
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brain of a member of a V337M MAPT family (Spina et al., 2017).  Additionally, Domoto-Reilly 
and colleagues reported one member of a family with V337M MAPT presenting with an 
unusually long duration of disease and delayed penetrance (Domoto-Reilly et al., 2017).  This 
patient was found to carry the ApoE genotype E2/E3, thought to be protective in 
neurodegenerative disease (Liu et al., 2013), implicating the influence of other genetic 
factors in the heterogeneity of this disease (Domoto-Reilly et al., 2017). 
The NFTs in the brains of individuals with this mutation are composed of straight and paired 
helical filaments (PHF) of tau composed of all six isoforms of tau (Poorkaj et al., 1998; Sumi 
et al., 1992; Spillantini et al., 1996; Ghetti et al., 2015).  Aggregations of tau are found mainly 
in neurons of V337M MAPT patient brains (Brandt et al., 2005) and are similar in structure to 
those recognised in AD (Kidd et al., 1963; Goedert et al., 1989).  The mutation has no effect 
on the splicing of exon 10 of MAPT (Ehrlich et al., 2015; Brandt et al., 2005), therefore, tau 
hyperphosphorylation within the brains of patients with this mutation is not initiated through 
an alteration in the ratio of 4R:3R isoforms of tau.    
The mutation encourages aggregation of tau, which may explain the formation of NFTs in the 
brains of patients with V337M MAPT.  Tau with this mutation forms filaments upon heparin 
treatment, in vitro, after incorporation of 4-6 moles of phosphate per mole of tau protein, 
whereas wild type (WT) tau will not form filaments until approximately 10 moles of 
phosphate per mole of tau have been incorporated (Arawaka et al., 1999).  Tau inclusions in 
the brains of these patients stain for tau within an abnormal conformation associated with 
early tauopathy (Sumi et al., 1992), however, it is not clear how the mutation causes tau to 
become hyperphosphorylated.  Importantly, V337M MAPT does not create additional 
phosphorylation sites in tau protein, therefore, the resultant hyperphosphorylation of tau 
due to this mutation must involve downstream molecular pathways triggered by this 
mutation (Brandt et al., 2005).  These pathways are unclear; however, studies have been 
undertaken to understand whether this mutation can affect the susceptibility of tau to be 
phosphorylated by tau kinases, including GSK3β and Cdk5 (Connell et al., 2001; Han et al., 
2009) or the activity of tau kinases (Lambourne et al., 2005).   
One mechanism through which tau mutations are thought to cause neurodegeneration is by 
impairing the ability of tau protein to stabilise microtubules.  Several studies have been 
carried out to examine the effect of V337M MAPT on the ability of tau to bind and stabilise 
microtubules.  In cell free, in vitro systems, V337M MAPT reduces the affinity and binding 
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capacity of tau to microtubules (Hasegawa et al., 1998; Dayanandan et al., 1999; Rizzu et al., 
1999; Hong et al., 1998) and the ability of tau to facilitate microtubule polymerisation (Hong 
et al., 1998; Hasegawa et al., 1998).  V337M tau has also been shown to disrupt microtubule 
organisation within non-neuronal mammalian (Arawaka et al., 1999) and insect (Frappier et 
al., 1999) cells.  In a baculovirus system, expression of V337M MAPT tau led to fewer 
microtubules per process and altered microtubule spacing (Frappier et al., 1999).  
4.1.2  Aims 
The aim of the work in this chapter was to develop and probe a hiPSC-model of V337M MAPT 
FTDP-17 and to investigate the ability of the model to be used to gain insight into the 
influence of V337M MAPT on total tau levels, tau phosphorylation at sites associated with 
tauopathy and the expression of MAPT.  The protein levels, activity and gene expression 

















4.2  Methods 
4.2.1 Use of Tg4510 mice for antibody screening  
Tg4510 mice were used to optimise tau antibodies used within this thesis project.  Tg4510 
mice overexpress human mutant P301L MAPT 4R0N tau (Ramsden et al., 2005; Santacruz et 
al., 2005).  Expression is mostly restricted to neurons of the forebrain, driven by the Ca2+-
calmodulin kinase II promoter, and can be suppressed by treatment with doxycycline (Denk 
and Wade-Martins, 2009; Santacruz et al., 2005).  Tg4510 mice develop severe NFT pathology 
in the form of pre-tangles from 2.5 months of age and argyrophilic tangle-like inclusions from 
4 months of age onwards, which dramatically worsens with age (Santacruz et al., 2005).   
These mice are ideal for optimisation of a panel of tau antibodies for western 
immunoblotting for number of reasons: firstly, these mice develop prominent tau pathology 
and this tau pathology is well characterised (Ramsden et al., 2005; Santacruz et al., 2005; 
Song et al., 2015); secondly, many of these antibodies have previously been used to 
investigate tau phosphorylation of tissue from these mice allowing for comparison of the 
results obtained in this study (Song et al., 2015; Ramsden et al., 2005; Santacruz et al., 2005); 
thirdly, this transgenic mouse model expresses human tau thereby ensuring that the 
antibodies are capable of detecting human tau. 
A panel of tau antibodies was optimised for probing western blots to ensure their suitability 
for use in the experiments.  Antibodies DA9, PHF-1, CP13 and RZ3 have been used previously 
to establish the pathology within post-mortem brain tissue of Alzheimer’s patients (Luna-
Munoz et al., 2007).  Basal forebrain, hippocampus and cortex tissue from a well-established 
FTDP-17 murine model, Tg4510, at 5 and 10 months of age was western immunoblotted 
alongside tissue from aged matched wild type (WT) mice.   
All animal tissues were supplied from Eli Lily, where animals were maintained and treated 
under the Home Office’s animals (Scientific Procedures) act 1986 and in agreement with the 
University of Bristol Animal Welfare and Ethical Review Body guidelines.  Female animals 
were euthanised at 5 months and 10 months of age according to the schedule 1 method of 
cervical dislocation and brain tissue was immediately removed and frozen for histological or 
molecular analysis.   
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4.2.2  Differentiation of human pluripotent cells to produce cortical 
glutamatergic neurons 
This protocol describing the derivation of cortical glutamatergic neurons (CGNs) from human 
pluripotent stem cells (hPSC) has been adapted from work carried out within the Livesey Lab 
(University of Cambridge) (Shi et al., 2012) to allow for the derivation of these cells from 
hiPSC cultured within the E8 culture system (Chapter 2.1.2.2).   
During neural development, glutamatergic projection neurons, which go on to form the 
cerebral cortices affected in FTD, are formed in a stereotyped temporal order, whereby deep 
layer neurons are produced first and upper layer neurons last (Mountcastle, 1998).  The use 
of dual Smad (Sma and Mad Related family) pathway inhibition in this protocol directs the 
differentiation of hiPSC firstly into cortical stem and progenitor cells, which then undergo the 
same temporal process of differentiation and neurogenesis recognised during development 
to generate projection neurons of all layers of the cerebral cortex, in appropriate proportions 
(Shi et al., 2012).    
LDN-193189 and SB431542 are the two small molecule Smad inhibitors used in this protocol.  
LDN-193189 is a cell permeable inhibitor of BMP type I receptors ALK2 and ALK3  (Yu et al, 
2008).  SB421542 is a potent and selective inhibitor of the TGFβ type I receptor activin 
receptor-like kinase ALK5, and its relatives ALK4 and ALK7 (Inman et al., 2002).  Additional 






4.2.2.2  Media used during the derivation of cortical glutamatergic neurons 
 
Table 4.1 Components of Neural Maintenance Media (NMM) 
 
 
Product Amount Supplier and product code 
Advanced DMEM/F12 47.5 % Life Technologies, 12634028 
Neurobasal 47.5 % Life Technologies, 21103049 
B27 supplement 2 % Life Technologies, 17504044 
N2 supplement 1 % Life Technologies, 17502048 
Penicillin-Streptomycin solution stabilised (Pen-Strep) 1 % Sigma, P4458 
GlutaMAX™ (100x) 1 % Invitrogen, 35050 
2-Mercaptoethanol (50mM) 0.2 % Invitrogen, 991827 
Insulin solution (from bovine pancreas) (stock solution 
10 mg/ml)  
0.025 % Sigma, I0516 
Figure 4.2        Schematic detailing the protocol used for the derivation of cortical glutamatergic 
neurons from human pluripotent stem cells 
Y= Y-27632 (ROCK inhibitor).  The protocol can be divided into five stages; hPSC culture, neural 
induction, neural rosette formation, neural progenitor expansion and neuronal maturation.  hPSC 
are first cultured, on truncated Vitronectin (VTN-T)-coated 6-well plates within the Essential 8 (E8) 
culture system, to gain a culture of healthy pluripotent stem cell colonies at 50-70 % confluency 
and these cells are cultured in neural induction media (NIM) to direct them to differentiate into 
cells a neural lineage. The start of neural induction is considered to be ‘day 1’.  Once a monolayer 
of neuroepithelial cells has formed, the cells are passaged onto plates pre-coated with 
polyornithine-laminin (POL) before being cultured within neural maturation media (NMM) 
supplemented with fibroblast growth factor 2 (FGF2) for 4 days.  After this period, the cells are 
cultured in NMM for the duration of the protocol and are passaged once more at day 20. 
123 
 
Table 4.2 Components of Neural Induction Media (NIM) 
Product Amount Supplier and product code 
Neural Maintenance Media To 100% As above 
LDN-193189  1 ng/ml  [Sigma–Aldrich, SML0559] 
SB431542 (Selective inhibitor of activin 
receptor-like kinase, TGF-beta type I 
receptor)  
10 µM [Tocris, 1614] 
 
4.2.2.3  Neural Induction 
Human pluripotent stem cells (hPSP) were cultured in xeno-free and feeder-free culture 
conditions, within the wells of 6-well plates [Fisher, 10098870].  The cells were cultured in 
the E8 culture system [LifeTechnologies, A1517001], in which cells are cultured within E8 
media on truncated Vitronectin [VTN-N; LifeTechnologies, A14700] (Chapter 2.1.2.2.1.3) 
coated plastic surfaces (Chapter 2.1.2.2.1.3).  Cells were cultured in 2 ml of media, which was 
removed and replaced with fresh media each day.  Once a monolayer of 50-70 % confluence 
had been achieved, which takes approximately 4 days after initial passaging of hiPSC colonies, 
the media was changed to neural induction media (NIM), containing the Smad inhibitors LDN-
193189 and SB431542.  This day of the protocol is referred to as day 1.  Cells were cultured 
within this media for 10 days allowing for the formation of a uniform monolayer of cells 
consisting of cells with small, round nuclei, indicating neuroepithelial cells, as opposed to 
large, round nuclei, indicative of hiPSC and hESC (Shi et al., 2012).   
At this point, cells were dissociated by adding 250 µl of 37 °C Dispase stock, consisting of 10 
mg/ml Dispase [Life Technologies, 17105] in PBS, directly to the cell culture media and 
incubating for 7 minutes at 37 °C.  After incubation, the monolayer was broken into 
aggregates of 300-500 cells by pipetting with a P1000 pipette three times.  The media 
containing the aggregates was collected into a 15 ml falcon tube and the aggregates were 
allowed to settle into the bottom of the tube before the media was aspirated.  The aggregates 
were resuspended in 1 ml of NIM, supplemented with 10 ng/ml Rho-associated protein 
kinase (ROCK) inhibitor (Y-27632) [Tocris, 1524] to inhibit cell apoptosis.  The clumps of cells 
were passaged into wells of a 6-well plate pre-coated with poly-L-ornithine and laminin 
(POR/L) (Chapter 2.1.2.2.1.4) containing 1.7 ml of NIM, supplemented with 10 ng/ml Y-
27632, by adding 330 µl of the resuspended cell aggregate mixture to each well to achieve a 
passaging ratio of 1:3.   
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4.2.2.4  Neural Rosette Formation  
The cells were allowed to adhere onto the cell surface overnight, after passaging on day 10, 
and the next day the media was replaced with neural maintenance media (NMM) 
supplemented with human fibroblast growth factor 2 (FGF2) [PeproTech, 100-18B].  The 
media was replaced every day and FGF2 was kept in the media until day 15.  FGF2 has an 
important role in the differentiation, development and function of the central nervous 
system (CNS) (Woodbury and Ikezu, 2014) and its expression co-occurs with neurogenesis in 
the developing brain (Powell et al., 1991).  In this protocol, it is added to media after neural 
induction to stimulate neurogenesis (Shi et al., 2012).  Neural rosette structures formed 
between days 11-19, observed using an inverted microscope.    
4.2.2.5  Terminal differentiation and maturation of neurons 
The rosettes were allowed proliferate and differentiate to produce neural progenitors and 
neurons for the duration of the protocol, for which they were maintained in NMM and fed 
every day.  Between day 20-30 substantial neurogenesis is observed.  Between days 20-23, 
the cultures were passaged and re-plated to continue differentiation, to plate cells for 
immunocytochemistry and to allow for cryopreservation (Chapter 4.3.1.6).  After day 30, 
2 μg/ml laminin, from Engelbreth-Holm-Swarm murine sarcoma basement membrane 
[L2020, Sigma], was added to the media on one day each week, to prevent detachment of 
neurons from the culture surface (Nistor et al., 2015).  
4.2.2.6  Passaging cells at day 20-23 
Between day 20-23 the neural progenitor and neuron cultures were passaged using 
AccutaseTM [Sigma, A6964], which is a gentle enzyme mixture with proteolytic and 
collagenolytic enzyme activity.  After the media was aspirated from the cells, the cells were 
washed gently with PBS once, and 1 ml of AccutaseTM was added to each well.  The cultures 
were incubated in AccutaseTM for 1-2 minutes at 37 oC.  After the incubation period, 4 ml of 
37 oC NMM, supplemented with Y-27632 to prevent apoptosis, was added to each well to 
quench the AccutaseTM and the media was gently pipetted to detach the cells from the 
culture surface.  The cell suspension was added to a 15 ml falcon tube and centrifuged (200 
g; 5 minutes).  For re-plating, the cells were resuspended in NMM supplemented with 10 
ng/ml Y23532 to inhibit apoptosis, gently pipetting with a P1000 pipette to ensure a fully 
dissociated cell suspension, counted and plated at a concentration of 50000 cells/cm2 onto 
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either POR/L pre-coated 6-well plates or POR/L pre-coated glass coverslips within 4-well 
plates for subsequent immunocytochemistry.  For cryopreservation, the cell pellet collected 
was re-suspended in neural stem cell cryopreservation media (1260 µl E8 media 
supplemented with 10 ng/ml Y23532 and 140 µl Dimethyl sulfoxide (DMSO)) at a 
concentration of 2x106 cells/ml and the cell suspension was divided equally between two 
sterile cryovials [Greiner Bio One, 123278] and frozen at -80 oC within a Mr. FrostyTM freezing 
container (Chapter 2.1.3.2.1).  
4.2.3  Immunocytochemistry 
Cells were washed once with PBS and 200 µl of room temperature, 4 % paraformaldehyde 
(PFA) was added to the cells.  The cells were incubated with PFA for 15 minutes before the 
PFA was removed and the cells were washed gently three times with PBS to ensure residual 
PFA was removed.  Non-specific binding of proteins was blocked by incubation of the cells 
for 1 hour, or overnight, in blocking/permeabilisation solution (Chapter 2.2.2.1).  Upon 
completion of the incubation period the blocking/permeabilisation solution was removed 
and the primary antibody was added.  The cells were incubated with the primary antibody 
(Table 4.4) overnight before being washed gently three times with PBS.  Primary and 
secondary antibodies were prepared and diluted in 1 % HS, in 0.1 % TX-PBS.  The secondary 
fluorophore antibody was then added and incubated for two hours, protected from the light, 
at room temperature on a rocking plate.  After the two hour incubation period, the cells were 
washed with PBS for five minutes on a rocking table, three times.  After the final aspiration 
of the washing liquid, the glass coverslips were carefully lifted from the wells and placed 
facing down-wards onto a droplet of Vectorshield™ on a glass slide. The circumference of the 
coverslips were sealed with clear nail varnish and allowed to dry overnight, protected from 
the light.  
4.2.4  Western Immunoblotting 
A panel of tau antibodies, including PHF-1, DA9, CP13 and RZ3 was first assessed in Tg 4510 
mice (Chapter 4.3.1).  After assessment and optimisation of the western blotting protocols, 
required to achieve clear results using these antibodies, a complement of antibodies was 
used to probe hPSC-neuron lysates via western immunoblotting (Table 4.4).  Western 
blotting protocols described in Chapter 2.2.1 were followed.  The bands analysed by 
densitometry were  normalised to those created through probing with anti-GAPDH for each 
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result.  The western immunoblots shown within figures in this chapter are representatives of 
the three western immunoblots carried out for each result.  For phosphorylated tau 
antibodies, density of bands after normalisation to GAPDH were also compared to those for 
total tau after normalisation to GAPDH.  Where multiple bands were produced through 
probing with anti-tau antibodies, all bands were included in the densitometric analysis.    
Analysis of PAK3 levels included only bands at 65 kDa. For analysis of synapsin levels only 
bands at 75 kDa were included.  For p25 and p35 level analysis, only bands at 25 kDa and 35 
kDa, respectively, were included in analysis.   For analysis of the levels of GSK3β and pTyr216 





































βIII Tubulin Mouse ab6046, 
Abcam 
(Huidong et al., 
2015)  
N/A 1:1000 
CP13 pSer202 tau Mouse Prof. 
Davies* 
(Petry et al., 2014; 
Vingtdeux, et al., 
2011) 
1:1000 N/A 
DA9 Pan-tau Mouse  Prof. 
Davies* 





(de Oliveira et al., 
2017)  
1:5000 N/A 
GSK3β GSK3β Rabbit D5C5Z, Cell 
Signalling 





pTyr216 GSK3β Rabbit ab75745, 
Abcam 
(Porquet et al., 
2015; Rui et al., 
2013) 
1:500 N/A 
p25-p35 p25-p35 Rabbit C64B10, 
Cell 
Signalling 
(Porquet et al., 
2014) 
1:300 N/A 










(Otvos et al., 1994) 1:5000 N/A 
PSD-95 PSD-95 Mouse ab2723, 
Abcam 
(Frandemiche et al., 
2013) 
1:1000 1:300 
RZ3 pThr231 Mouse Prof. 
Davies* 
(Vingtdeux et al., 
2011) 
1:250 N/A 
Synapsin Synapsin I Rabbit ab64581, 
Abcam 
(Stefanova et al., 
2016) 
1:750 1:300 
RD3 3R tau Mouse 05-803, 
Merck 
Millipore 
(de Silva et al., 
2003) 
1:1000 N/A 
RD4 3R tau Mouse 05-804, 
Merck 
Millipore 
(de Silva et al., 
2003) 
1:100 N/A 
*Prof. Peter Davies (Albert Einstein College of Medicine, New York, USA) kindly supplied 
CP13, DA9, PHF-1 and MC1 antibodies.   
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4.2.4.1 Preparation of mouse brain tissue lysates 
Mouse hippocampal or cortical brain areas, from control or Tg4510 mice were homogenised, 
in 10 µl per mg of tissue in ice cold RIPA buffer (Chapter 2.2.1.1) plus one tablet of Protease 
Inhibitor [Roche, cOmplete Mini, 04693] per 10 ml of RIPA buffer and one tablet of 
Phosphatase Inhibitor PhosStop, [Roche] per 10 ml.  To homogenise, the tissue was firstly 
compressed using a sterile plastic disposable 1.5 ml microtube pestle 20 times.  The tissue 
was then passed through a series of sterile, disposable needles of descending size, from 14 
gauge to 20 gauge, attached to a sterile syringe.  The resultant crude homogenate was 
centrifuged at 11,000 g for 15 minutes at 4 oC to clarify it by removing any remaining non-
homogenated brain tissue.  The homogenates were kept on ice throughout this process and 
used immediately in western blotting or stored immediately at -80 oC. 
4.2.5  qPCR 
Shef 6-CGNs and V337M-C-CGNs were cultured after terminal differentiation to maturity 
before being collected and processed to extract and purify RNA.  See Chapter 2.2.3 for details 
of the protocols used for extraction and purification of RNA from hPSC-CGN cultures, 
conversion into cDNA, qPCR and analysis of the results.  A list of the Taqman® probes used 
during this chapter are detailed in Table 2.13 and include probes against GSK3β, CDK5, MAPT, 
PAK3 and also GAPDH, which was used as a quantitative control for analysis.   
To calculate the average relative gene expression, the cycle threshold (CT) values (Chapter 2) 
for each gene were normalised to those gained through qPCR using the probe against GAPDH 
and each result was normalised against the average of Shef 6-CGNs, which was used as the 
healthy control for these experiments.  Statistical analysis of qPCR data in this chapter was 










4.3  Results 
4.3.1  Optimisation of a panel of tau antibodies for western immunoblotting  
 
Figure 4.3 Western immunoblots of Tg4510 mice basal forebrain, cortex and 
hippocampus with tau antibodies  
 
Western immunoblots using antibodies CP13, PHF1, RZ3, DA9, 4R tau, 3R tau and α-Tubulin 
as a control antibody, demonstrate clearly that tau pathology is more prominent in the 
hippocampus, cortex and basal forebrain of Tg mice compared to WT mice (Figure 4.3).  Tau 
pathology in Tg4510 mice begins within the cortex (Santacruz et. al., 2005); therefore, it is 
Figure 4.3      Western immunoblots of Tg4510 mice basal forebrain, cortex and hippocampus 
with tau antibodies 
Western immunoblots of Tg4510 mice and WT mice basal forebrain, cortex and hippocampus at 
ages 5 months and 10 months probed using antibodies CP13, DA9, PHF-1, 3R tau, 4R tau and RZ3 
alongside alpha-Tubulin, which is used as a loading control antibody to allow for the consideration 
of the total amount of protein loaded. 
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unsurprising that the immunoblots indicate the greatest staining, using total and 
phosphorylated tau antibodies, within the cortex of these mice.   
DA9 detects both dephosphorylated and phosphorylated tau, therefore is an antibody used 
to detect total tau.  In 10 month old Tg4510 mice, immunoblotting for DA9 is decreased in 
comparison to 5 month old mice, which likely corresponds to the gross neurodegeneration 
observed at 10 months in a previous study (Spires et al., 2006).   
CP13 detects pSer202 tau, which is associated with early phosphorylated tau pathology 
(Luna-Muñoz et al., 2007) and the immunoblots indicate greater amounts of this form of tau 
especially in the cortex and hippocampus of Tg mice, which corresponds to the increased 
staining seen in CA1 neurons within the hippocampus of Tg4510 mice at 10 months old 
(Ramsden et al., 2005).  In these western blots, CP13 staining is increased in Tg mice 
compared to WT in both 5 month and 10 month old mice and is more pronounced in Tg mice 
of 10 months of age compared to those of 5 months of age.  A similar pattern is found for 
antibodies PHF-1 and RZ3, demonstrating that these western blots are consistent with 
previous reports of increased phosphorylated tau pathology, exacerbated with age, within 
Tg4510 mice compared to controls.   
RZ3 detects pThr231 tau and immunoreactivity is seen in a variety of tau transgenic AD model 
mice and in the brains of patients with AD (Acker et al., 2013).  Although RZ3 has not 
previously been cited as being used on Tg4510 mouse brain tissue, the increased presence 
of pThr231 tau as detected here by this antibody is commensurate with the known increase 
in NFT pathology, in particular in the cortex and hippocampus, of these mice.   
PHF-1 is a well-characterised antibody, which detects pSer396/404 tau and is a marker for 
late-stage NFTs.  Previous studies parallel results from these immunoblots (Ramsden et al., 
2005; Santacruz et al., 2005), which show that PHF-1 staining was increased within 10 month 
old mice in comparison to 5 month old mice and most intense staining was found within the 
cortex.  The antibody MC1 was also included in the panel of antibodies used within this 
project.  MC1 can be used to detect abnormal conformations of tau associated with early 
tangle formation (Gotz et al., 2001).  MC1 loses specificity when used for western 
immunoblotting, therefore, it was not used to probe western blots of hPSC-neurons (Petry 
et al., 2014).   
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Immunostaining with 3R tau and 4R tau antibodies, which detect tau with three C-terminal 
repeats and four C-terminal repeats respectively, indicates that these mice have increased 
amounts of both of these isoform groups of tau in comparison to wild type mice, however, 
this is to be expected due to the increase in total tau detected by DA9.  At the beginning of 
this study, these isoform specific antibodies were intended to be used to understand whether 
tau pathology resulting from V337M MAPT could alter the ratio of 3R:4R tau as changes in 
the ratio are associated with tauopathy.  However, the recent discovery that 4R tau is not 
expressed within hPSC-neurons until they have been cultured for at least 100 days (Sposito 
et al., 2015), with the exception of those hPSC-neurons carrying mutations that are capable 
of altering the splicing of MAPT leading to early expression of 4R tau (Iovino et al., 2015; 
Hallman et al., 2015; Wren et al., 2015), deemed this analysis unnecessary.   
The parallels between previous reports of tau pathology within Tg4510 mice and the western 
immunostaining detected in these immunoblots indicated that this panel of antibodies is 
suitable for the detection of changes in tau and may enable a deeper understanding of the 





4.3.2  Characterisation of CGNs derived from pluripotent stem cells  
During the generation of CGNs from hiPSC, cell cultures pass various milestones during 
differentiation, mimicking cortical neurogenesis during development (Shi et al., 2012).  These 
milestones can be assessed and characterised by immunocytochemistry.  During the 
development of the cortex, cortical glutamatergic neurons (CGNs) are produced from radial 
glia, which are capable of differentiating into intermediate cell types that terminally 
differentiate to form neurons and glia (Heins et al., 2002; Noctor et al., 2001; Miyata et al., 
2001; Malatesta et al., 2000; Englund et al., 2005).  Radial glia express paired box protein 
6 (Pax 6), a homeodomain transcription factor that exerts high-level control over cortical 
development (Manuel et al., 2015).  Radial glia differentiate to produce intermediate 
progenitor cells (IPCs), which express T-domain transcription factor 2 (Tbr2) and are 
committed to a glutamatergic neuron fate (Englund et al., 2005; Hevner et al., 2006).  Pax 6 
and Tbr 2 expression overlaps within cells during development of CGNs (Englund et al., 2005; 
Hevner et al., 2006).  The presence of Pax 6 (Figure 4.4) and Tbr 2 (Figure 4.5) were detected 










Figure 4.4     Neural progenitors express Pax6 at day 15 
Neural progenitors differentiated from Shef 6 (A), Nas 2 (B), V337M-E (C) and V337M-C (D), 




Figure 4.5 Neural progenitors express Tbr2 at day 15 
 
The mixture of neural progenitors and young neurons at day 15 of the protocol express both 
Pax 6 and Tbr 2.  The presence of these two proteins in day 15 cultures indicates the presence 
of both radial glia and IPCs, indicating that the cells are following the correct route for 
differentiation.   
Figure 4.5     Neural progenitors express Tbr2 at day 15 
Neural progenitors differentiated from Shef 6 (A), Nas 2 (B), V337M-E (C) and V337M-C (D), 
express Tbr2 at day 15 of the protocol.  Scale bars indicate 50 µM 
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Figure 4.6 Neural progenitors express Tbr1 at day 25 
 
Later in cortical neurogenesis, T-domain transcription factor 1 (Tbr1) is expressed.  Tbr1 is 
expressed by virtually all post-mitotic glutamatergic cortical neurons (Hevner et al., 2001; 
Hevner et al., 2006; Englund et al., 2005) and is not present in GABAergic neurons (Hevner et 
al., 2001).  At day 25 of the differentiation protocol, the cultures of neurons positively co-
immunostained with an antibodies against βIII Tubulin and Tbr1, indicating that these 





Figure 4.6     Neural progenitors express Tbr1 at day 25 
Neural progenitors differentiated from Nas 2 (A) and V337M-C (B), express Tbr1 at day 22 of the 




Figure 4.7 hPSC-CGN express vGlut1 at day 50
 
 
Vesicular glutamatergic transporter 1 (vGlut1) is a vesicular glutamatergic transporter, 
present within neurons that use the neurotransmitter glutamate and within the cortex, 
hippocampus or cerebellar cortex (Bellocchio et al., 2000).  Mature cortical glutamatergic 
neurons should express vGlut1, therefore, an antibody against this protein was used in 
combination with fluorescent immunocytochemistry to visualise the presence of vGlut1.  Nas 
2-CGN, Shef 6-CGN, V337M-C-CGN and V337M-E-CGN cultures all have neurons, highlighted 
by βIII Tubulin, that co-stain positively with VGlut1 (Figure 4.4).  Positive immunostaining of 
these neurons, therefore, indicates post-mitotic cortical glutamatergic neurons (CGNs).   
Figure 4.7     hPSC-CGN express VGlut1 at day 50 
Nas 2-CGN (A), Shef 6-CGN (B), V337M-C-CGN (C) and V337M-E-CGN (D) immunostained with βIII 
Tubulin (red) and VGlut1 (green). V337M-C-CGN and V337M-E-CGN were also immunostained with 
Hoechst solution (blue) to indicate cell nuclei.   The overlays are depicted in the panels furthest to 
the right.  Scale bar for Nas 2-CGN (A) indicates 50 µm, scale bars for Shef 6-CGN (B), V337M-C-CGN 
(C) and V337M-E-CGN (D) indicate 100 µm. 
137 
 












Dysfunction and loss of synapses precedes neurodegeneration in tauopathy, therefore, it was 
important to confirm the presence of synapses within hPSC-CGNs.  Immunocytochemistry 
using antibodies against synapsin, a pre-synaptic protein important for vesicle trafficking 
within the synapse present within early and mature synapses (Evergren et al., 2007) (Figure 
4.8) and βIII Tubulin, demonstrated the presence of this synaptic protein in hPSC-CGNs at day 
50 of the differentiation protocol.  These hPSC-CGNs also express post-synaptic density 
protein 95 (PSD-95) (Figure 4.9), a protein present within the post-synaptic density of mature 
synapses (Naisbitt et al., 2000).    
Figure 4.8     Day 50 hPSC-CGN express synapsin I 
Shef 6-CGN express synapsin I at day 50 as indicated by positive fluorescent immunostaining 
using antibodies against synapsin I and βIII Tubulin.  Scale bars indicates 50µm. 
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Figure 4.9     hPSC-CGN express post-synaptic density protein 95 at day 50 
Shef 6-CGN express Synapsin at day 50 as indicated by positive fluorescent immunostaining using 




4.3.3  Tau and phosphorylated tau levels in CGNs 
After terminal differentiation, hPSC-CGNs were cultured to maturity, i.e. 50 days, from lines 
Nas 2, Shef 6, V337M-C and V337M-E before the cells were washed, lysed and frozen.  The 
resultant samples were western immunoblotted and probed with total tau antibody, DA9, as 
well as antibodies PHF-1, CP13 and RZ3 to detect tau phosphorylated at Ser396/Ser404, 
Ser202 and Thr231, respectively.  The calculated density and size of each band was 
normalised to bands produced by probing with the housekeeping control antibody GAPDH.  
The bands produced by probing with the phosphorylated tau antibodies were also 
normalised against those revealed by probing with DA9, after normalisation against GAPDH, 
allowing for consideration of total tau variation within sample.  Prepared lysates from 
V337M-C-CGN were western immunoblotted alongside Nas 2-CGN, while V337M-E-CGN 






























Figure 4.10     Levels of total tau in CGNs  
Representative western blots showing CGN derived from V337M-C and Nas 2 (V337M-C-CGN n=4; 
Nas 2-CGN n=3) (A) and from derived from V337M-E and Shef 6 (V337M-E-CGN n=4; Shef 6-CGN 
n=3) (B) probed with GAPDH and DA9 antibodies.  Bar charts represent the density of DA9 bands 
compared to GAPDH bands for CGN derived from (B) V337M-C and Nas 2 (***p=0.0005)  and from 
(C) V337M-E and Shef 6 (*** p=0.0007). 
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Levels of total tau are decreased in neurons carrying the V337M mutation, derived from 
V337M-C (p= 0.0005) and V337M-E (p= 0.0007), compared to control neurons derived from 
Nas 2 and Shef 6, respectively (Figure 4.10).   
To detect the amount of tau phosphorylated at Ser396 and Ser404 within cells carrying 
V337M MAPT compared to control cells, lysates from V337M-C-CGN, V337M-E-CGN, Shef 6-
CGN and Nas 2-CGN were immunoblotted and western blots were probed with PHF-1 
(Figures 4.11 and 4.12).   
 
Figure 4.11 Level of tau phosphorylation Ser396 and Ser404 in V337M-C-CGNs and 
Nas 2-CGNs 
 
Figure 4.11     Levels of tau phosphorylated at pSer396 and pSer404 in V337M-C- and Nas 2-CGNs  
Representative western blot (A) showing CGN derived from V337M-C and Nas 2 probed with GAPDH 
and PHF-1 antibodies (V337M-C-CGN n=4; Nas 2-CGN n=3) and corresponding bar charts 
representing the density of PHF-1 bands normalised to GAPDH bands (***p=0.0005) (B) and then 
normalised to DA9 bands (C).   
 




Levels of pSer396/404 tau are decreased in V337M-C-CGN before normalisation to total tau 
levels (p= 0.0005), however, there was no significant difference in levels of tau 
phosphorylation at these sites between Nas 2-CGN and V337M-C-CGN after normalisation to 
total tau (p= 0.2677).    
 
Figure 4.12 Levels of tau phosphorylated at Ser396 and Ser404 in V337M-E-CGNs and 
Shef 6-CGNs 
 
Levels of pSer396/404 tau are decreased in V337M-E-CGN before normalisation to total tau 
levels (p= 0.0013), and after normalisation to total tau (p= 0.0014).   
Figure 4.12     Levels of tau phosphorylated at Ser396 and Ser404 in V337M-E-CGNs and Shef 6-
CGNs 
Representative western blot (A) showing CGN derived from V337M-E and Shef 6 probed with 
GAPDH and PHF-1 (V337M-E-CGN n=3; Shef 6-CGN n=5).  Bar charts representing the density of (B) 
PHF-1 bands normalised to GAPDH bands (** p= 0.0013) and then (C) normalised to DA9 bands (** 
p= 0.0014).   
 
Data was analysed using an unpaired Student’s t-test.  Error bars indicate +1 S.E.M. 
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Figure 4.13 Level of tau phosphorylation Ser202 in V337M-C-CGNs and Nas 2-CGNs  
 
Before normalisation to total tau, no difference was found in phosphorylation of tau at 
Ser202 between V337M-C-CGN and Nas 2-CGN, however, upon normalisation to total tau 
within the neurons, tau was found to be phosphorylated within V337M-C-CGN compared to 
Nas 2-CGN (p= 0.0019) (Figure 4.13).   
Thr231 phosphorylation of tau is associated with pre-tangle pathology (Augustinack et al., 
2002a) and has been shown to inhibit tau’s ability to bind microtubules by approximately 25 
% (Sengupta et al., 1998).  To investigate the phosphorylation of tau at this site western blots 
of V337M-C-CGN and Nas 2-CGN were probed with RZ3 (Figure 4.14).   
 
Figure 4.13    Levels of tau phosphorylated at pSer202 and pSer205 in V337M-C- and Nas 2-CGNs  
Representative western blot showing CGN derived from V337M-C and Nas 2 probed with GAPDH 
and CP13 (V337M-E-CGN n=4; Nas 2-CGN n=3).  Bar charts representing the density of (B) CP13 
bands normalised to GAPDH bands and (C) then normalised to DA9 bands ( ** p= 0.0019). 
 
Data was analysed using an unpaired Student’s t-test.  Error bars indicate +1 S.E.M. 
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Figure 4.14 Level of tau phosphorylation Thr231 in V337M-C-CGNs and Nas 2-CGNs  
 
pThr231 tau is significantly reduced in V337M-C-CGN compared to Nas 2-CGN both before 
(p≤ 0.0001) and after (p= 0.0002) normalisation to total tau.  Unfortunately, the signal 
generated through probing western blots of V337M-E-CGN and Shef 6-CGN was too weak to 




Figure 4.14     Levels of tau phosphorylated at pThr231 in V337M-C- and Nas 2-CGNs  
Representative western blot (A )showing CGN derived from V337M-C and Nas 2 probed with 
GAPDH and RZ3 (V337M-C-CGN n=4; Nas 2-CGN n=3) and corresponding bar chart representing 
the density of RZ3 bands normalised to GAPDH bands (****  p<0.0001) (B) and then to DA9 (*** 
p=0.0002) (C).   
 




4.3.4  Gene expression of MAPT in Shef 6-CGNs and V337M-C CGNs 
Shef 6-CGNs and V337M-C-CGNs were cultured after terminal differentiation to maturity 
(Chapter 4.2.1), before the cells were collected and processed to extract and purify RNA.  RNA 
was converted to cDNA and qPCR was carried out using Taqman® probes to discern 
expression levels of MAPT (Chapter 2.7).  The average relative gene expression MAPT was 
calculated for V337M-C-CGN and compared to that in Shef 6-CGN. 
 
Figure 4.15 Levels of MAPT gene expression in V337M-C-CGNs and Shef 6-CGNs 
 
While the average relative expression of MAPT is not statistically different in V337M-C-CGN 








Figure 4.15     Levels of MAPT gene expression in V337M-C-CGN and Shef 6-CGN 
Bar chart representing the average MAPT gene expression within V337M-C-CGN and Shef 6-CGN 
(V337M-C-CGN n=4; Shef 6-CGN n=3).  
Data was analysed using a Mann-Whitney test.  Error bars indicate +1 S.E.M. 
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4.3.5  Tau kinase levels and activity in hiPSC-CGNs 
To investigate the levels and activity of GSK3β within hiPSC-CGN carrying the V337M MAPT 
mutation compared to control neurons, western blots were probed with antibodies against 
total GSK3β and GSK3β phosphorylated at pTyr216.  Phosphorylation of GSK3β at this site is 
necessary for GSK3β activity (Chapter 1.3.1) and by comparing levels of pTyr216 GSK3β to 
total GSK3β it is possible to investigate the activity of this kinase. 
Levels of GSK3β (p= 0.2225), pTyr216 GSK3β (p= 0.6334) and the ratio of pTyr216 GSK3β 
normalised to total GSK3β (p= 0.2106), were not significantly different in V337M-C-CGN 
compared to Nas 2-CGN (Figure 4.16).  However, in V337M-E-CGNs levels of GSK3β were 
found to be significantly increased compared to Shef 6-CGN (p= 0.0122) while levels of 
pTyr216 GSK3β were decreased (p= 0.0159) (Figure 4.17).  This was reflected in a decreased 
ratio of pTyr216 GSK3β to total GSK3β (p= 0.0016) (Figure 4.17, E), indicating that while 
GSK3β levels overall rise in cells carrying V337M MAPT compared to Shef 6-CGN, the activity 
of GSK3β is decreased.  Banding patterns varied between western blots for pTyr216 GSK3β 
and total GSK3β for both V337M-C and Nas-2 derived CGNs (Figure 4.16) and V337M-E and 















Figure 4.16 Levels of active GSK3β in V337M-C-CGN and Nas 2-CGNs  
 
 
Figure 4.16     Level of GSK3β and pTyr216 GSK3β in V337M-C-CGN and Nas 2-CGN  
Representative western blots showing CGNs derived from V337M-C and Nas 2 probed with 
antibodies against (A) GAPDH and GSK3β and (B) GAPDH and pTyr216 GSK3β (V337M-C-CGN 
n=4; Shef 6-CGN n=3).   Bar charts representing the density of (C) GSK3β bands normalised to 
GAPDH bands, (D) pTyr216 GSK3β bands normalised to GAPDH bands and (E) pTyr216 GSK3β 
bands normalised to total GSK3β bands, then to GAPDH bands.   
 




Figure 4.17 Levels of active GSK3β in V337M-E-CGN and Shef 6-CGNs  
  
Figure 4.17     Level of GSK3β and pTyr216 GSK3β in V337M-E-CGN and Shef 6-CGN  
Representative western blots showing CGNs derived from V337M-E and Shef 6 probed with 
antibodies against (A) GAPDH and GSK3β and (B) GAPDH and pTyr216 GSK3β (V337M-E-CGN n=3; 
Shef 6-CGN n=4).  Corresponding bar charts represent the density of (C) GSK3β bands normalised 
to GAPDH bands (* p= 0.0122), (D)  pTyr216 GSK3β bands normalised to GAPDH bands (* p= 
0.0159) and (E) pTyr216 GSK3β bands normalised to total GSK3β bands, then to GAPDH bands (** 
p= 0.0016).   
 







To investigate the activity of Cdk5, the relative ratio of p35 to p25 in brain samples was 
examined by probing western blots with an antibody against p25 and p35.  An increase in the 
activity of Cdk5 is indicated by increased levels of p25 and decreased levels of p35 as 
described in more detail in Chapter 1 (Chapter 1.3.2). 
 
Figure 4.18 Levels of p35 in hPSC-CGN 
 
Figure 4.18     Levels of p35 in hPSC-CGNs  
Representative western blots showing CGNs derived from (A) V337M-C and Nas 2 (V337M-C-CGN 
n=4; Nas 2-CGN n=3) and (C) V337M-E and Shef 6 (V337M-E-CGN n=3; Shef 6-CGN n=5) probed 
with antibodies against GAPDH and p25/p35.  Bar charts representing the density of p35 bands 
normalised to GAPDH bands for (B) V337M-C and Nas 2 (** p= 0.0037) and (D) V337M-E and Shef 
6 (*** p= 0.0004).   
Data was analysed using an unpaired Student’s t-test.  Error bars indicate +1 S.E.M. 
150 
 
Levels of p25 were too low to be quantified in these western immunoblots.  Levels of p35 
were significantly decreased in V337M-C-CGN compared to Nas 2-CGN (p= 0.0037) and in 
V337M-E-CGN compared to Shef 6-CGN (p= 0.0004) (Figure 4.18).  
Western blots were probed with anti-PAK3 to investigate the effects of V337M MAPT on 
levels of this tau kinase.  PAK3 levels were significantly decreased in V337M-C-CGN compared 
to Nas 2-CGN (p< 0.0001).  Although PAK3 levels appear to be decreased in V337M-E-CGN 















Figure 4.19     Levels of PAK3 in hiPSC-CGNs  
Representative western blot showing CGNs derived from (A) V337M-C and Nas 2 (V337M-C-CGN 
n=4; Nas 2-CGN n=3) and (C) V337M-E and Shef 6 (V337M-E-CGN n=3; Shef 6-CGN n=5) probed 
with antibodies against GAPDH and PAK3.  Corresponding bar charts representing the density of 
PAK3 bands normalised to GAPDH bands for (B) V337M-C and Nas 2 ( **** p< 0.0001) and (D) 
V337M-E and Shef 6.   
 
Data was analysed using an unpaired Student’s t-test.  Error bars indicate +1 S.E.M. 
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Akt, also known as protein kinase B (PKB), is a serine/threonine protein kinase capable of 
phosphorylating tau directly at Thr212 and Ser214 (Kyoung et al., 2004; Ksiezak-Reding et al., 
2003) and regulating the activity of other tau kinases via phosphorylation; for example, Akt 
phosphorylates GSK3β at Ser9, therefore inhibiting it (Chalecka-Franaszek and Chuang, 1999; 
Doble and Woodgett, 2003; De Sarno et al., 2002).  Phosphorylation of Akt at Ser473 is 
necessary for its activation (Kyoung et al., 2004; Ksiezak-Reding et al., 2003).  The influence 
of V337M MAPT on the activity of Akt were investigated by probing western blots with an 
antibody against this phosphorylated form of Akt.  The levels of pSer473 Akt within V337M-
C-CGN (p= 0.0749) and V337M-E-CGN (p= 0.9459) are not significantly different compared to 






















Figure 4.20    Level of pSer473 Akt in hPSC-CGNs   
Representative western blots showing CGNs derived from (A) V337M-C and Nas 2 (V337M-C-CGN 
n=4; Nas 2-CGN n=3) as well as (C) V337M-E and Shef 6 (V337M-E-CGN n=3; Shef 6-CGN n=4) 
probed with GAPDH and pSer473 Akt antibodies.  Corresponding bar charts represent the density 
of pSer473 Akt bands normalised to GAPDH bands for (B) V337M-C and Nas 2 and (D) V337M-E 
and Shef 6.   
 




4.3.6  Gene expression of tau kinases in CGN  
To determine the effect of V337M MAPT on the expression levels of tau kinases, GSK3β, CDK5 
and PAK3, qPCR was carried out using probes to detect cDNA of these kinases. 
 





GSK3β (p= 0.0571), CDK5 (p= 0.0571) and PAK3 (p= 0.1000) gene expression levels are not 
significantly different in V337M-C-CGN compared to Shef 6-CGN (Figure 4.21), however, 





Figure 4.21     Levels of tau kinase gene expression in V337M-C-CGNs and Shef 6-CGNs 
Bar charts representing the average gene expression of (A) GSK3β, (B) CDK5 and (C) PAK3 within 
V337M-C-CGN and Shef 6-CGN (V337M-C-CGN n=4; Nas 2-CGN n=3).   
 




4.3.7  Loss of synapsin I in CGN 
 
Figure 4.22 Level of synapsin in hPSC-CGNs  
 
Levels of synapsin are significantly decreased in V337M-C-CGN compared to Nas 2-CGN (p= 
0.0018).  Similarly, levels of synapsin are significantly decreased in V337M-E-CGN compared 
to Shef 6-CGN (p= <0.0001) (Figure 4.22).   
Figure 4.22     Levels of synapsin I in hPSC-CGNs 
Representative western blots showing (A) V337M-C-CGN and Nas2-CGN (V337M-C-CGN n=4; Nas 
2-CGN n=3) and (C) Shef 6-CGNs and V337M-E-CGNs probed with antibodies against GAPDH and 
synapsin (control n=5; Aβ 0.5µM n=3).  Corresponding bar charts show the average relative 
density of synapsin I bands normalised to GAPDH bands for (B) V337M-C-CGN and Nas2-CGN (** 
p=0.0018) and (D) Shef 6-CGNs and V337M-E-CGNs (**** p<0.0001).   
 
Data was analysed using an unpaired Student’s t-test.  Error bars indicate +1 S.E.M. 
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4.4  Discussion 
4.4.1  Limitations in the use of a V377M MAPT iPSC derived from a single 
patient  
The work in this chapter compares tau protein levels, MAPT gene expression levels, tau 
phosphorylation levels, tau kinase protein levels, tau kinase protein activity and tau kinase 
gene expression levels between CGNs derived from two iPSC lines derived from a single 
patient and control cell lines.  It is important to recognise the limitations of using a single 
patient to understand the pathological changes involving tau protein due to FTDP-17.  FTDP-
17 is known to be caused by over 53 mutations, each producing different pathological 
phosphorylation of tau, which may involve different pathways to hyperphosphorylation or 
different levels of kinase activity.  As discussed in more depth in Chapter 1, patients with the 
same mutations are also known to present in different ways.  The heterogeneity of these 
diseases is not reflected through the work in this chapter as iPSC-CGN derived from one 
patient was examined.  Further studies, addressing the pathological changes to tau and tau 
kinases assessed in this chapter, within a cohort of patients carrying V337M MAPT would 
shed additional light on the heterogeneity of pathological tau and tau kinases between 
patients carrying this mutation.  Additional studies addressing these within patients carrying 
other mutations would also illuminate the heterogeneity of these within FTDP-17 patients in 
general.  This work is likely necessary before the results gained through this study could 
inform clinical drug discovery efforts (Cabana et al., 1999; Greenfield et al., 2007).  In the 
future, statistical techniques, such as Bayesian and adaptive statistical methods, may be 
employed to pool results gained through single patient studies to understand tau pathology 
in a wider population of FTDP-17 patients (Duan et al., 2013).    
4.4.2  Levels of tau and MAPT expression in V337M-CGN  
The work in this chapter has demonstrated that hiPSC-CGNs carrying V337M MAPT have 
markedly decreased levels of tau protein and MAPT expression compared to controls, 
suggesting that a decrease in MAPT expression contributes to decreased levels of tau.   
The finding of decreased levels of tau within these cells aligns with previously reported 
decreased levels of full-length tau within a mixed population of neurons, comprised mainly 
of GABAergic neurons and dopaminergic neurons, derived from V337M MAPT hiPSC (Ehrlich 
et al., 2015).  In this study, the authors demonstrate increased fragmentation of tau and 
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conclude that this is at the expense of full-length tau, however, increased fragmentation was 
not observed within these V337M MAPT hiPSC-CGNs.  The decrease in tau found within 
V337M MAPT hiPSC-CGNs contrasts increased levels of total tau reported within in N297K 
(Wren et al., 2015), A152T (Silva et al., 2015) and P301L (Verheyen et. al., 2015) MAPT hiPSC-
neurons, indicating that this aspect of tau pathology may be exclusive to this mutation. 
Although levels of tau protein have not yet been investigated within the brains of patients 
with this mutation, a recent study reported similar levels of tau within the CSF of V337M 
MAPT patients compared to controls (Spina et al., 2017).  Similar levels of CSF-tau in 
comparison to controls has also been reported in patients carrying P301L and G272V MAPT 
(Rosso et al., 2003) and within those diagnosed with FTD (Sjögren et al., 2001).  Analysis of 
total tau levels within the brain tissue of a patient carrying IVS 10+3 G>A MAPT (Spillantini et 
al., 1997) and in patients with FTD-tau (Adamec et al., 2001; van Eersel et al., 2009) has also 
revealed similar levels compared to controls.  The decrease in total tau levels within V337M 
MAPT hiPSC-CGNs does not reflect levels reported in the cerebrospinal fluid (CSF) or brain 
tissue of those with FTDP-17 and other sporadic forms of FTD-tau.   
The decrease in MAPT expression found in V337M MAPT hiPSC-CGNs in this study was 
unexpected as Ehrlich and colleagues found that V337M MAPT hiPSC-dopaminergic neurons 
express MAPT at similar levels to controls (Ehrlich et al., 2015).  Furthermore, no difference 
in expression levels were found in Drosophila overexpressing human V337M MAPT 
compared to those expressing WT human MAPT (Haddadi et al., 2016).  In A152T MAPT 
hiPSC-neurons MAPT expression has also been reported to be similar to that within controls 
(Silva et al., 2016).   
Ehrlich and colleagues reported considerable variation in MAPT expression levels between 
FTDP-17 hiPSC-neurons created from different clones (Ehrlich et al., 2015).  Non-disease 
related variation of MAPT expression between hiPSC clones could explain the difference in 
MAPT expression reported by Ehrlich and colleagues compared to those measured here, as 
only one clone was analysed here due to a lack of those derived from V337M-E.  The disparity 
between levels of MAPT expression in this study and within Ehrlich et al., 2015 may also be 
explained by neuronal subtype variability in MAPT expression changes due to V337M MAPT.  
MAPT expression levels and the expression of different isoforms of tau varies between 
different areas of the brain, with the temporal and frontal lobes expressing the highest levels 
of tau (Majounie et al., 2013; Trabzuni et al., 2012).  Liang and colleagues have demonstrated 
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that in AD brains MAPT expression is differentially altered in a regionally specific manner; 
specifically regions particularly targeted in AD express lower levels of MAPT compared to 
healthy brains (Liang et al., 2008).  CGNs are abundantly present within the frontal and 
temporal cortices, therefore, gene expression of MAPT may be decreased in these as they 
represent the areas principally degenerated in FTDP-17, whereas Ehrlich and colleagues 
measured MAPT expression within cells that contained a large proportion of dopaminergic 
neurons, which are not associated in such high numbers within these brain areas.  Further 
investigation into changes in the gene expression of MAPT within brain tissue isolated from 
the frontal and temporal cortices compared to other areas of the brain may help us to 
understand whether the effects of MAPT mutations alter gene expression in a region-specific 
manner.   
The reduced levels of tau protein and MAPT expression within V337M MAPT hiPSC-CGNs 
found in this study may reflect the state of these cells early in disease; before tauopathy has 
become apparent.  A reduction in the levels of tau protein has been demonstrated previously 
to diminish the severity of disease (Cheng et al., 2014; Santacruz et al., 2005).  Therefore, the 
reduction of tau measured in these cells could indicate a protective mechanism.   
4.4.3  Levels of phosphorylated tau in V337M-CGN  
Levels of pSer396/404 tau were found to be increased within CGN derived from one hiPSC 
cell line with the mutation (V337M-E), both before and after normalisation to total tau.   
Within CGN derived from V337M-C, however, levels of pSer396/404 were found to be not 
significantly different in comparison to controls after normalisation to total tau.   
Although phosphorylation of tau at this site has not yet been investigated within hiPSC-
neurons carrying V337M MAPT or within the brain tissue of patients with this mutation, 
increased phosphorylation of tau at this site has been reported within the hippocampal 
neurons of 11 month old V337M MAPT mice (Tanemura et al., 2002).  It has also been 
demonstrated, in vitro, that V337M MAPT tau is more rapidly phosphorylated at Ser396 
and Ser404 and phosphorylated to a greater degree than WT tau at Ser404 upon 
treatment with kinases isolated from the rat brain (Alonso et al., 2004).  In another study, 
pSer396/404 tau was found to be increased in H4 neuroblastoma overexpressing V337M 
tau compared to those overexpressing WT tau (DeTure et al., 2002).  Although tau is 
phosphorylated at pSer396/404 during neurodevelopment (Bramblett et al., 1993), which 
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potentially could be a limitation in the recognition of increased phosphorylation due to MAPT 
mutations in these cells, this site has been found to be more intensely phosphorylated in 
hiPSC-neurons carrying A152T MAPT (Silva et al., 2016) and in hiPSC-neurons seeded with 
pre-aggregated tau oligomers (Usenovic et al., 2015) compared to controls, illustrating that 
hiPSC-neurons are capable of overcoming this limitation. It was, therefore, expected that 
V337M MAPT hiPSC-CGNs would also have increased phosphorylation of tau at these sites. 
Evidence of interclonal variability upon disease specific phenotypic analysis has been 
previously documented within studies involving the derivation of neurons and other cell 
types from hiPSC (Martelli et al., 2012; Ehrlich et al., 2015; Yokobayashi et al., 2017; Sheridan 
et al., 2011), which is suggested to be at least partially due to variability occurring during 
reprogramming and differentiation (Liang and Zhang, 2013; Vitale et al., 2012).  Clonal 
variability may explain the difference in the phosphorylation of tau at pSer396/404 between 
clones V337M-C and V337M-E.   
Levels of tau phosphorylated at pSer202 are increased within V337M-C-CGN after 
normalisation to total tau in comparison to the control line, Nas 2-CGN.  In agreement with 
the results in this present study, widespread pSer202/205 tau positive immunostaining has 
been reported within the midbrains of V337M MAPT patients (Ehrlich et al., 2015,) as well as 
within the hippocampal neurons of Tg V337M MAPT mice at 6-12 months of age compared 
to controls (Lambourne et al., 2005; Tanemura et al., 2002).  These are also supported by 
previous in vitro studies, which have provided evidence to suggest that the mutation may 
increase the propensity for tau to become phosphorylated at these sites.  In a cell-free 
system, V337M MAPT tau is phosphorylated in vitro to a greater degree, upon 
phosphorylation with kinases isolated from the rat brain,  at Ser202 compared to WT tau 
(Alonso et al., 2004) demonstrating that V337M MAPT may result in tau with a greater 
propensity to be phosphorylated at these sites.  Additionally, co-overexpression of V337M 
MAPT and GSK3 in CHO cells has been shown to result in increased pSer202 tau compared to 
CHO cells co-expressing WT tau and GSK3 (Dayanandan et al., 1999).  hiPSC-neuron models 
have so far demonstrated increased pSer202 tau within hiPSC-neurons carrying N279K, 
P301L and A152T MAPT (Ehrlich et al., 2015; Fong et al., 2013; Verheyen et al., 2015, Silva et 
al., 2016) despite pSer202 tau being present at high levels during neurodevelopment 
(Goedert et al., 1993).   
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The banding patterns revealed by probing western blots with CP13 are different for Nas 2-
CGN compared to V337M-C-CGN samples.  In V337M-C-CGN samples, the bands at 68 kDa 
are lower in density compared to the same bands within Nas 2-CGN samples.  Additionally, 
bands at 52 kDa are much more dense in V337M-C-CGN compared to those in Nas 2.  Kimera 
and collegues have previously used phospho-tagging alongside western immunoblotting to 
demonstrate that certain mutations affect the banding pattern produced by phosphorylation 
of tau by Cdk5 when probing with different total tau and phospho-tau antibodies.  Upon 
further investigation, the group did not find R406W MAPT affected major phosphorylation 
sites known to be  phosphorylated by Cdk5 (Ser202, Thr205, Ser235 and Ser404), therefore 
it was concluded that minor phosphorylation sites may be affected by the mutation resulting 
in the altered pattern of phosphorylation.  Whilst Kimura and colleagues found that R406W 
MAPT altered these banding patterns, V337M MAPT was not found to alter the 
phosphorylation of tau by Cdk5 (Kimura et al., 2016).  The altered pattern of phosphorylation 
in V337M-C-CGN compared to Nas 2-CGN may suggest that V337M MAPT alters the order in 
which tau is phosphorylated, possibly resulting in fewer tau species phosphorylated at 
Ser202 being hyperphosphorylated to a degree resulting in the band at 68 kDa.  As other tau 
kinases apart from Cdk5, for example GSK3β, PKC and Erk 1/2 (Martin et al., 2013), are known 
to phosphorylate tau at pSer202 it possible that V337M MAPT alters the propensity for tau 
to become phosphorylated by kinases other than Cdk5; further investigation is needed to 
examine this hypothesis. 
Phosphorylation of tau at Thr231 was found to be markedly decreased in V337M-C-CGN 
compared to Nas 2-CGN, suggesting that the mutation alters tau phosphorylation at this site.  
In support of this result, overexpression of V337M MAPT within H4 neuroblastoma cells 
was shown to decrease phosphorylation of tau at Thr231 tau (DeTure et al., 2002).  
Additionally, V337M MAPT overexpression within HEK-297 cells has been demonstrated to 
increase dephosphorylation of tau at this site by protein phosphatase 2A (PP2A) compared 
to overexpression of WT tau (Han et al., 2009).  This result was unexpected, however, as 
increased phosphorylation at this site is associated with tauopathy (Acker et al., 2013).  
Furthermore, increased pThr231 tau has been detected in Tg V337M MAPT mice at six 
months of age (Lambourne et al., 2005).  In line with these studies, within a cell-free in vitro 
system V337M MAPT tau is phosphorylated more rapidly by rat brain kinases and to a 
greater degree at Thr231 compared to WT tau (Alonso et al., 2004).  In control hiPSC-
neurons seeded with pre-aggregated tau (Usenovic et al., 2015) and in hiPSC-neurons 
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derived from a patient with A152T MAPT increased pThr231 tau has been reported (Silva 
et al., 2016), demonstrating that the decrease in pThr231 tau found in V337M MAPT 
hiPSC-CGNs is likely to be an effect of this specific mutation. The decrease in 
phosphorylation of tau within V337M MAPT hiPSC-CGN in this study may represent the 
effect of the mutation in early disease, possibly due to its influence on the ability of tau 
to be dephosphorylated at this site.   
4.4.4  Protein levels, activity and expression levels of tau kinases in V337M-
CGN 
Levels of GSK3β and active (pTyr216) GSK3β, as well as expression levels of GSK3β in V337M-
C-CGN, are not significantly different compared to Nas 2-CGN.  In V337M-E-CGN, however, 
total GSK3β levels are increased and the amount of active GSK3β is decreased compared to 
Shef 6-CGN, both before and after comparison to total GSK3β.  These results suggest that the 
activity of GSK3β is not increased within V337M MAPT hiPSC-CGNs.  Increased activity of 
GSK3β is associated with neurodegenerative disease and GSK3β is capable of 
phosphorylating the majority of sites phosphorylated in AD, therefore it is considered an 
important therapeutic target (Chapter 1.3.1).   
It is uncertain whether GSK3β levels and activity are altered in V337M MAPT FTDP-17.  No 
change in pTyr216 GSK3β could be found in Tg V337M MAPT mice compared to controls 
(Lambourne et al., 2005) and phosphorylation of V337M MAPT tau by GSK3β within a cell-
free system, in vitro, was similar compared to WT tau (Connell et al., 2001), suggesting that 
this mutation does not alter the propensity of tau to become phosphorylated by this kinase.  
These results, therefore, corroborate existing evidence and suggest that GSK3β is not 
involved in the initial phosphorylation events early in tauopathy resulting from V337M MAPT.  
Therefore, the changes in phosphorylation levels of tau at pSer202, pSer396/404 and 
pThr231, which are sites phosphorylated by GSK3β (Reynolds et al., 2000; Goedert et al., 
1995), in V337M-CGN are unlikely to be due to increased GSK3β activity.   
The banding patterns produced by probing western blots for pTyr216 GSK3β and total GSK3β 
for both V337M-C and Nas-2 derived CGNs and V337M-E and Shef 6 derived CGNs were 
found to vary.  Total GSK3β bands for V337M-C-CGN were found at 48 kDa as well as 52 kDa, 
whereas there was just one total GSK3β band for Nas 2-CGN at 52 kDa.  This may be due to 
the greater levels of protein present within the samples loaded on the blots for V337M-C-
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CGN, allowing for visualisation of the minor band at 48 kDa.  Mukai and colleagues suggested 
that the upper band may indicate GSK3β2, the alternative spliced variant of GSK3β with a 
13 amino acid-insertion, whereas the lower band may indicate GSK3β1 (Mukai et al., 
2002).  An additional band at approximately 46 kDa was also produced by probing western 
blots of V337M-C-CGN and Nas 2-CGN for pThr216 GSK3β, which was not present within 
western blots of V337M-E-CGN and Shef-6-CGN probed with the same antibody.  The 
additional minor bands may indicate non-specific binding and therefore were not included in 
the analysis of these results.  
The protein levels of p35 were found to be decreased in V337M MAPT hiPSC-CGN in 
comparison to control hiPSC-CGN.  The regulation of Cdk5 activity is discussed in detail in 
Chapter 1 (Chapter 1.3.2); to briefly reiterate, Cdk5 must bind to p35 or p25 to become 
active.  It is considered to be ‘hyperactive’ when bound to p25 and increased levels of p25 or 
decreased levels of p35 are associated with neurodegenerative disease (Chapter 1).  While 
the levels of p25 cannot be commented on due to the insufficient staining of western blots, 
the decrease in p35 levels detected within V337M-CGN compared to controls suggests that 
p35 has been cleaved to p25, indicative of increased Cdk5 activity.   
Previous reports of the effects of V337M MAPT on the activity of Cdk5 are controversial.  A 
decrease in p35 was not found via western blotting in cells carrying this mutation, therefore, 
increased activity of Cdk5 may underlie the increased levels of tau phosphorylation 
recognised at pSer396/404, pSer202 and pThr231 in V337M-CGN, as these are sites known 
to be phosphorylated by this kinase (Martin et al., 2013; Imahori and Uchida, 1997).  FTDP-
17 mutations have been shown previously to result in increased levels of caspase 3 (Stanford 
et al., 2003).  Indeed, cultures of V337M MAPT hiPSC-dopaminergic neurons have greater 
numbers of cleaved-caspase 3 positive neurons compared to control neurons after treatment 
with Rotenone, indicating increased vulnerability of neurons with the mutation (Ehrlich et 
al., 2015).  Since p35 is cleaved to p25 by caspase, increased levels of caspase could lead to 
increased Cdk5 activity (Chapter 1.3.2).   
PAK3 protein levels of were found to be significantly decreased in V337M-C-CGN compared 
to Nas 2-CGN.  While levels of PAK3 are not significantly decreased in V337M-E-CGN 
compared to Shef 6-CGN controls, there is a trend towards decreased PAK3 protein in 
V337M-E-CGN compared to Shef 6 controls (p= 0.061).  A decrease in PAK3 protein levels has 
been demonstrated to result in neurodegeneration, specifically involving dysregulation of 
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microtubule dynamics and the loss of synapses (Chapter 1.3.3).  PAK3 protein levels and gene 
expression was expected to be decreased in these cells as expression of PAK3 was found to 
be downregulated in V337M MAPT hiPSC-dopaminergic neurons compared to controls in a 
previous study (Ehrlich et al., 2015).  However, gene expression analysis of PAK3 in these cells 
demonstrated that PAK3 is not expressed at significantly different levels in V337M MAPT 
hiPSC-CGNs compared to controls, which may represent a difference between PAK3 
expression in these two different cell types.  PAK3 has not been found to be expressed at 
lower levels within the midbrains of FTDP-17 patients previously (Ehrlich et al., 2015), 
however, which may be due to the association of decreased PAK3 expression with early 
pathogenesis.  In AD, PAK3 levels have been demonstrated to be low in early stage disease 
only (Nguyen et al., 2008) (Chapter 1.3.3).   
The activity of Akt is not affected by V337M MAPT in these hiPSC-CGNs, as there is no 
significant difference in the levels of pSer473 Akt between hiPSC-CGNs carrying V337M MAPT 
compared to controls.  These results suggest that Akt phosphorylation of tau is not involved 
in early pathogenesis of FTDP-17 caused by this mutation.  Although there have been no 
previous studies on the activity of Akt in V337M MAPT patients or models, in P301S MAPT Tg 
mice, no change in the levels of Akt or its activity were found (Barini et al., 2016), therefore, 
this result agrees with previously published work.   
4.4.5  Levels of synapsin I in V337M-CGN 
Levels of synapsin I were found to be markedly decreased in V337M-CGN compared to 
controls, implicating a loss of post-synaptic densities and impaired synaptic localisation of 
NMDARs (Warmus et al., 2014).  In C. elegans, V337M MAPT causes pre-synaptic dysfunction 
of cholinergic neurons (Kraemer et al., 2003).  Synapses have been demonstrated to be 
affected early in FTDP-17, before evidence of neurodegeneration and in some cases 
tauopathy, in FTDP-17 mouse models (Yoshiyama 2008; Umeda et al., 2013; Crescenzi et al., 
2014; Hoffmann et al., 2013; Eckermann et al., 2007; Harris et al., 2012; Rocher et al., 2010).    
One possible explanation for the loss of synapses could be explained by a disruption of the 
regulation of microtubule dynamics, which has been documented to be associated with 
V337M MAPT (Hong et al., 1998; Hasegawa et al., 1998; Dayanandan et al., 1999; Rizzu et al., 
1999; Frappier et al., 1999; Arawaka et al., 1999; Deture et al., 2000).  These results suggest 
that hiPSC-CGNs may be highly suited for the investigation of synaptopathy in 
neurodegenerative disease.    
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4.4.6  Summary 
This study has provided proof-of-concept that patient derived hiPSC-CGNs can be used to 
investigate changes in tau protein levels, tau phosphorylation, kinase activity and gene 
expression caused by V337M MAPT.  hiPSC-CGNs carrying the mutation have been 
demonstrated to have lower levels of tau protein in comparison to controls.  Furthermore, 
hiPSC-CGNs derived from this patient had increased levels of pSer202 tau and decreased 
levels of pSer231 tau, indicating that this mutation is capable of altering the tau 
phosphorylation at these sites, which are associated with tauopathy.  The hiPSC-CGNs have 
also provided an insight into altered kinase activity due to the mutation; Cdk5 activity is 
decreased, as evidenced by decreased levels of p35, while levels of PAK3 are also decreased.  
Surprisingly, GSK3β activity, a tau kinase considered to be a ‘master regulator’ of tau 
phosphorylation, was not increased in these cells, which suggests that the increase in 
pSer202 was not due to GSK3β but another kinase, possibly Cdk5, which also phosphorylates 












The development of a model of Alzheimer’s 




5.1  Introduction 
An extensive body of experimental evidence from biomarker analysis in Alzheimer’s disease 
(AD) patients, in vitro models and in vivo models supports the hypothesis that pathological 
tau phosphorylation and aggregation is initiated by aberrant accumulation of amyloid-β (Aβ) 
in AD (Stancu et al., 2014).  A therapeutic solution may transpire through precise 
manipulation of the molecular pathways coupling these proteins to prevent prodromal 
pathological events, which occur decades before cognitive symptoms arise.  Currently, the 
molecular pathways that facilitate Aβ-induced tau phosphorylation early in the disease 
remain unclear.  Traditional in vitro and in vivo models cannot accurately represent the subtle 
molecular changes important in early stage AD (Chapter 1.4).  A clinically relevant, human 
model allowing for improved resolution of these pathways would, therefore, be an invaluable 
tool for this line of investigation. 
Chapter 4 described altered tau phosphorylation and kinase activity in V337M MAPT hiPSC-
neurons compared to controls, demonstrating that hiPSC technology can be used to gain 
inferences into frontotemporal dementia with Parkinsonism linked to chromosome 17 
(FTDP-17).  To examine whether neurons derived from human pluripotent stem cells (hPSC-
neurons) can also be used to investigate the early changes in tau phosphorylation in sporadic 
AD (sAD), hPSC-neurons were treated with Aβ 1-42 oligomers (Aβ42O), described as the most 
pathogenic form of Aβ (Chapter 1.2.3.2.2).  Two control hPSC lines were differentiated to 
produce mature basal forebrain cholinergic neurons (bfCNs) and cortical glutamatergic 
neurons (CGNs), which are two particularly vulnerable neuronal subtypes in AD (Chapter 
1.2.3.1.1).  The effects of Aβ42O on the levels of total tau, MAPT expression, tau 
phosphorylation at specific sites associated with AD and tau kinase activity were investigated.   
166 
 
5.1.1  The relationship between Aβ and tau in Alzheimer’s disease 
AD is defined not only by the presence of abnormally phosphorylated tau (ptau) but also Aβ 
pathology.  The pathology and pathogenesis of AD is discussed in detail in Chapter 1, along 
with the pathological processing of amyloid protein and the pathological phosphorylation of 
tau in AD (Chapter 1.3.3).  Deleterious interactions between tau and Aβ seem to be necessary 
for initiation and progression of AD.  Indeed, a recent study using regression models to 
analyse cognitive decline and clinical progression in patients with mild cognitive impairment 
(MCI), with aggregations of both proteins, demonstrated that Aβ and tau interact 
synergistically, rather than additively, to drive AD (Pascoal et al., 2017). 
Evidence from murine AD models, with concurrent Aβ and tau pathology, supports the 
hypothesis that abarent Aβ processing exacerbates tau pathology.  For example, 
intracerebral injection of Aβ42O into transgenic (Tg) mice with mutations in MAPT results in 
greater hyperphosphorylation of tau, as well as higher levels of tau in abnormal 
conformations, not only at the injection site but also in distant regions of the brain (Bolmont 
et al., 2007; Frautschy et. al., 1991; Götz et al., 2001; Sigurdsson et al., 1997; Chabrier et al., 
2004; Lewis et al., 2001; Pooler et al., 2015).  Likewise, the resultant offspring born by 
crossing mice with an APP duplication with mice expressing human P301L MAPT exhibit 
increased neurofibrillary tangle (NFT) pathology within the limbic and olfactory areas of the 
brain compared to P301L MAPT parent mice.  This was despite expressing similar levels of 
tau as P301L MAPT parent mice and similar Aβ pathology to APP parent mice (Lewis et al., 
2001).  Chabrier and colleagues generated a double Tg mouse through crossing a mouse 
overexpressing human MAPT with mice overexpressing human V717L or KM670/671NL APP, 
and reported acceleration of cognitive impairment, tau pathology and dendritic spine loss, in 
comparison to either parent (Chabrier et al., 2014), linking Aβ-dependent acceleration of tau 
pathology with other synaptic and symptomatic AD hallmarks.  Pooler and colleagues also 
reported a dramatic increase in the speed and distribution of tau propagation from the 
entorhinal cortex to synaptically-connected brain regions of the offspring produced by 
crossing mice overexpressing P301L MAPT within layer II of the entorhinal cortex with Tg 
3xfAD (K670M/N671L APP, ΔE9 PSEN1) mice, compared to either parent (Pooler et al., 2015).    
The presence of tau has been demonstrated to be necessary for Aβ-induced changes to 
cytoskeletal structure, neurodegeneration and subsequent cognitive decline recognised in 
AD.  Application of AβO (Aβ oligomers) to tau null MAPT mouse primary hippocampal 
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neurons does not result in the cytoskeletal changes and neurodegeneration, which occur 
when it is applied to WT mouse primary hippocampal neurons (Jin et al., 2011; Rapoport et 
al., 2002).  Furthermore, cross-breeding mutant Tg hAPP(K670M/N671L,V717F) or 5xFAD 
(APP(K670N/M671L,I716V,V717I/PSEN1M146L,L286V) mice with null MAPT mice 
ameliorates cognitive dysfunction and early mortality (Roberson et al., 2007; Leroy et al., 
2012).  In patients with a high cerebrospinal fluid (CSF) Aβ load, the presence of pThr181 tau 
was reported to be necessary for cognitive decline (Desikan et al., 2012), demonstrating the 
requirement of abnormal ptau for the pathogenesis of AD.  Collectively, this body of research 
suggests that Aβ exerts its toxic potential through interactions with tau protein.   
Although we do not yet have a thorough understanding of the mechanisms through which 
Aβ causes pathological phosphorylation of tau protein, evidence collected over the last two 
decades supports numerous pathways, which may work in concert with each other to drive 
disease progression.  Aβ and tau can form soluble complexes in vitro (Guo et al., 2006) and it 
has been hypothesised that the interaction of Aβ with tau seeds an initial structural change 
in tau, which templates further misfolding and hyperphosphorylation of tau thereby 
propagating tau pathology (Guo et al., 2006; Bolmont et al., 2007).  Furthermore, AβO 
interacts with the membranes of neurons initiating molecular cascades associated with 
dyshomeostasis of intracellular calcium concentration ([Ca2+]i), disturbed Wnt signalling and 
neuroinflammation.  These molecular cascades are intimately associated with the 
dysregulation and activation of tau kinases and phosphatases, resulting in the 
hyperphosphorylation of tau.   
5.1.2  Rational for sAD hiPSC-model design 
The glutamatergic and cholinergic systems are especially affected in AD, of which CGNs and 
bfCNs are particularly vulnerable, respectively (Chapter 1.2.3).  This model of sAD benefits 
from hiPSC-technology to produce these specific neuronal subtypes from control hPSC lines.  
The hiPSC line, Nas 2 (Chapter 3), was differentiated alongside the hESC line, Shef 6 (Chapter 
3), and synthetic Aβ42O was applied to mature hiPSC-neurons over a period of 48 hours.  Two 
control lines were used in this study to evaluate the reproducibility of model should different 
hPSC cell lines be used.  hPSC-bfCNs were derived through plating neural stem cells, derived 
from hPSCs, for 35 days and hPSC-CGN were derived by culturing cells for 50 days from the 
first day of differentiation.  The reason for these time points was so that the hPSC-bfCNs and 
hPSC-CGNs would be of similar ‘age’ or maturation point as by approximately day 15 of the 
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protocol for the production of hPSC-CGN hPSC have differentiated to become neural 
progenitors (Chi et al., 2012).   
sAD is a highly heterogenous disease; various environmental and lifestyle factors are thought 
to influence the pathogenesis, alongside the cumulative effects of many unknown genetic 
risk factors (Chapter 1.2.3.4).  Genetic factors are conserved through the process of 
reprogramming and differentiation of hiPSC (Rouhani et al., 2014), however, environmental 
influences and the effects they exert on a patient’s epigenetics, are not (Hewitt and Garlick, 
2013).  Therefore, many of the cumulative factors that impact on the development of sAD 
may be lost in reprogramming, which may explain the lack of clear phenotype in some hiPSC-
neuron lines derived from sAD patients (Kondo et al., 2013; Israel et al., 2011; Duan et al., 
2014).  Molecular pathology within hiPSC-neurons generated from different sAD patients has 
been demonstrated to be highly variable (Duan et al., 2014; Kondo et al., 2013; Israel et al., 
2012) and to model this heterogeneous disease comprehensively hiPSC-neurons will likely 
need to be differentiated from a large cohort of donor sAD patients.  To circumvent these 
challenges, synthetic Aβ42O was applied to hiPSC-neurons created from control cell lines, 
rather than from sAD patient somatic cells, to allow for examination of the effects of Aβ42O 
on tau pathogenesis in isolation of influential environmental and genetic factors.   
Oligomeric Aβ42 is the most toxic form of Aβ in neurodegenerative disease (Chapter 
1.2.3.2.2), therefore, treatment of cells with this form of Aβ was used to model AD.  Previous 
studies are at odds on the effects of Aβ42O at various concentrations upon treatment of 
different cell types, however, the majority of the literature overall suggests that greater 
concentrations of Aβ (e.g., between 5 µM and 10 µM) are acutely toxic to cells, whereas 
concentrations lower than this are more likely to be closer to physiological levels and 
therefore be more representative of AD pathology (Wicklund et al., 2010).  Concentrations 
ranging from 0.1 µM to 1 µM Aβ42 are most commonly used for AD modelling to study 
changes in tau phosphorylation using cell culture systems (Wicklund et al., 2010; Zempel et 
al., 2010; Gilson et al., 2015).  The aggregation of Aβ42 depends on concentration and it has 
been reported that application of concentrations of Aβ 1-42 to cell media in the micromolar 
range result in aggregation of monomers to produce oligomers, whereas application of 
nanomolar to low micromolar concentrations result in aggregation into a mixture of 
monomers and oligomers (Hellstrand et al., 2010).  This study aims to investigate the effect 
of Aβ42O on tau pathology, rather than toxicity; therefore, a range of concentrations from 0.1 
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µM to 1 µM were used in this study.  Cells were incubated with Aβ42O over a period of 48 
hours as many publications have been produced demonstrating application of Aβ42O over 
this time period (Wei et al., 2002; de Felice et al., 2008; Ferreira et al., 1997; Zheng et al., 
2002; Choi et al., 2014) and it was hoped this would allow for comparison of the results from 
this study with those from other publications.   
Unfortunately, it was not possible to generate enough Nas 2-CGNs during this project to 
allow for treatment of these cells with Aβ42O to be evaluated.  It also was not possible to 
generate enough Nas 2-bfCN or Shef 6-CGN to evaluate the effects of 0.1 µM Aβ42O.   
5.1.3  Aims 
The aim of the work in this chapter was to develop a model of sAD and to investigate changes 






















5.2  Methods 
Cortical glutamatergic neurons (CGNs) were derived from control hPSC cell lines, Nas 2 and 
Shef 6 using the protocol described in Chapter 4 (Chapter 4.2.1).   
5.2.1  Differentiation of human pluripotent cells to produce basal forebrain 
cholinergic neurons using a non-adherent, embryoid body based system 
This protocol was developed within the Caldwell lab (Crompton et al., 2013).  The method is 
dependent on a non-adherent, embryoid body based system.  This reductionist approach to 
hPSC differentiation allows the cells to establish their own developmental cues, parallel to 
those recognised during embryonic patterning within the neural tube, to produce basal 
forebrain cholinergic neurons (bfCNs) (Crompton et al., 2013).   
The non-adherent system promotes endogenous sonic hedgehog (SHH) signalling within 
cultures of embryoid bodies, which directs the expression of key transcription factors, 
homeobox protein Nkx 2.1 and Lim homeobox 8 (LHX8), required to drive the fate of the cells 
towards basal forebrain neural progenitors.  Subsequent adherent culture of the 
neurospheres allows the cells to terminally differentiate to produce bfCNs.  This protocol has 
been demonstrated to produce bfCNs capable of releasing acetylcholine and that have a 















5.2.1.1  Media used during the derivation of basal forebrain cholinergic neurons 
 
Table 5.1 Chemically Defined Media (CDM) 
 
Table 5.2 Neural Expansion Media (NEM) 
 
Table 5.3 Terminal Differentiation Media (TDM) 
 
Product Amount Supplier and product code 
IMDM + GlutaMAXTM 49 % Life Technologies, 31980-022 
F12 + GlutaMAXTM 49 % Life Technologies, 31765-027 
Penicillin-Streptomycin solution 
stabilised (Pen-Strep) 
1 % Sigma, P4458 
Albumax® 200 mg/ ml Life Technologies, 11021-029 
Monothioglycerol 100 ng/ ml Sigma M6145 
Insulin 10 mg/ ml Sigma, I6634 
SB431542 20 μM Tocris, 1614 
ROCK inhibitor 10 μM Tocris, 1254 
Product Amount Supplier and product code 
KO DMEM 68 % Life Technologies, 10829018 
F12 + GlutaMAXTM 28 % Life Technologies, 31765-027 
B-27® Supplement 2 % Gibco, A14867-01 
GlutaMAXTM  1 % Invitrogen, 35050 
Penicillin-Streptomycin solution stabilised (Pen-Strep) 1 % Sigma, P4458 
Fibroblast Growth Factor 2 (FGF2) 20 ng / ml Peprotech, 100-18B 
Heparin  5 µg / ml Sigma, H-1349 
Epidermal Growth Factor (EGF) 20ng/ ml Sigma, E-9644 
Product Amount Supplier and product code 
KO DMEM 68 % Life Technologies, 10829018 
F12 + GlutaMAXTM 28 % Life Technologies, 31765-027 
B-27® Supplement 2 % Gibco, A14867-0 
GlutaMAXTM 1 % Invitrogen, 35050 
Penicillin-Streptomycin solution stabilised (Pen-Strep) 1 % Sigma, P4458 
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5.2.1.2 Formation of embryoid bodies from human pluripotent stem cells 
Six 9 cm diameter tissue culture plates, each containing approximately 30 colonies of hPSC, 
grown on a layer of iMEFs, were required for each neuralisation.  Any differentiated areas of 
the colonies were removed using an aspirator before incubating the cells with warm 1X 
collagenase (1 ml per plate) within the cell culture incubator at 37 oC for 20 minutes to detach 
the colonies from the tissue culture surface.  Upon completion of the incubation period the 
collagenase was quenched with DMEM (4 ml per plate) to prevent further activity.  The 
colonies were gently sprayed from the tissue culture surface using a P1000 pipette tip and 
collected in a 50 ml falcon tube.  The colony pieces were allowed to settle at the bottom of 
the falcon tube before the media was aspirated.  The colony pieces were resuspended in 5 
ml of hPSC media without FGF2 to wash and allowed to settle again.  After removing the 
media, the colonies were resuspended in 1 ml hPSC media without FGF2.  The colonies were 
collected using a P1000 pipette and placed in a droplet onto the lid of a 6 cm diameter 
chopping plate.  The excess media was carefully removed using a P200 pipette tip.  A 
McIlwain tissue chopper (Mickle Laboratory Engineering Ltd.) was used to chop the colonies 
in a uniform fashion into 150 μM pieces.  hPSC media, without FGF2 and supplemented with 
10 ng/ ml ROCK inhibitor, was then added to the pieces on the chopping plate and a P200 
pipette tip was used to gently lift the colony pieces and transfer them into a 25 cm3  tissue 
culture flask, pre-coated with poly 2-hydroxyethyl-methacrylate and containing 6 ml of hPSC 
media without FGF2 and supplemented with 10 ng/ ml of the ROCK inhibitor, Y27632 (Tocris, 
1254).  The cells were allowed to form neurospheres for 4 days. 
5.2.1.3 Neuralisation of embryoid bodies 
To begin the neuralisation, the embryoid bodies (EBs) were collected with the media within 
the 25 cm3 flask into a 15 ml falcon tube and centrifuged (300 g; 5 minutes).  The media was 
removed and the EBs were resuspended in 10 ml CDM (Table 5.2), which contains the SMAD 
inhibitor SB431542.  The 25 cm3 tissue culture flask was washed with PBS, before the 
resuspended EBs were added back into the flask.  The EBs were cultured in CDM for 8 days.  
At the end of this period the spheres of cells, which were once EBs, are now referred to as 
neurospheres as they now consist of neural stem cells. 
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5.2.1.4 Expansion of neural stem cells within neurospheres  
After completion of this period the neurospheres were centrifuged (300 g; 5 minutes) and 
re-suspended in NEM (Table 5.3), supplemented with 10 μM ROCK inhibitor and 20 μM 
SB431542 for the first 10 days of expansion.  Every 7 days, the neurospheres were chopped 
into 200 μm uniform pieces using the McIlwain tissue chopper to prevent the neurospheres 
becoming too large and to expand the population of cells.  If a neurosphere becomes too 
large during expansion, the cells at the centre of the spheres will not have adequate access 
to nutrients in the media and will not respire correctly, leading to molecular and possibly 
genetic changes within these cells and cell death.  The cells were also regularly triturated  
with a P1000 pipette to ensure a pure population of NSCs (Crompton et al., 2013).  
5.2.1.5 Terminal Differentiation of neural stem cells and progenitors 
13 mm glass coverslips [VWR, 631-0149], stored in ethanol after sterilisation through 
treatment with nitric acid, were passed through a Bunsen burner flame to ensure sterility 
and remove ethanol. Each coverslip was placed into a well of a 12-well plate and coated with 
poly-L-ornithine and laminin (POR/L) (Chapter 2.1.2.2.1.4) and 250 μl TDM (Table 5.4) was 
added to each well, supplemented with 10 ng/ml N-[(3,5-Difluorophenyl)acetyl]-L-alanyl-2-
phenylglycine-1,1-dimethylethylester (DAPT).  DAPT is an inhibitor of the γ-secretase 
complex, for which Notch is a key target, therefore DAPT indirectly inhibits the Notch 
pathway leading to enhanced neuronal differentiation (Crawford and Roelink, 2007).  
Through inhibition of Notch, 3-5 neurospheres were plated onto each well on the coverslip, 
taking care to ensure space between each sphere.  The spheres were allowed to attach, 
without the plate being disturbed, for 48 hours within the incubator.  The media was then 
fully changed to TDM without DAPT.  The media was changed every 2 days; alternating feeds 
were supplemented with 0.1 % laminin to aid attachment of the spheres to the culture 
surface.  After 3-6 days axons sprouting from the spheres could be seen.  Plated neurospheres 
were cultured for 35 days before processing for protein extraction (Chapter 2.2.1.1) or being 





5.2.2  Application of toxins 
Aβ42O were prepared and added to media as described below.  The cells were incubated for 
48 hours with media containing the Aβ42O in concentrations ranging from 0.1 µM to 1 µM. 
5.3.2.1  Preparation of Aβ42O 
Lyophilised Aβ42 peptide [Anaspec, AS-24224] was dissolved to a concentration of 1.6 M in 
35 % acetonitrile (Ryu et al., 2004) and 10 μl aliquots were stored in clean 0.5 ml Eppendorf 
tubes at -20 oC until required.  The day before application of Aβ42 onto the cells, an aliquot 
was thawed and diluted to 300 mM by addition of knockout (KO) DMEM.  The solution was 
pipetted using a P200 pipette to ensure the solution was mixed.  The solution was stored for 
18 hours, overnight, within the cell culture incubator at 37 oC to allow polymerisation of 
protein monomers to oligomers.  After the 18 hour incubation period, on the day of 
application of the toxin to the cells, warmed cell culture media was prepared within a 15 ml 
falcon tube with the correct concentration of Aβ and mixed thoroughly by inversion of the 
tube five times (van Helmond et al., 2009).  The media was then ready to add to the cells.  
5.2.3  Immunocytochemistry 
Immunostaining was performed as described in Chapter 2 (Chapter 2.2.2).  The antibodies 
used during immunostaining in this chapter are listed in Table 5.5.   
5.2.4  Western Immunoblotting 
Immunostaining was performed as described in Chapter 2 (Chapter 2.2.1) using tau and ptau 
antibodies previously optimised in Tg 4510 mice (Chapter 4.3.1).  The antibodies used during 
western immunoblotting in this chapter are listed in Table 5.5.   
5.2.4.1 Stripping and re-probing of western immunoblots 
Apart from western blots of samples obtained from Shef 6 -CGN treated with 1 μM Aβ42O 
and associated controls, western blots were stripped between probing with each antibody 
using western blot stripping buffer [Fisher, 21059].  Each blot was probed with an antibody 
against GAPDH before being probed with a tau antibody, either DA9, PHF-1 or CP13.  Each 
western blot was then probed with an antibody against a tau kinase, either GSK3β, GSK3β 
pTyr216 or PAK3.  Other blots were probed with GAPDH and then either antibodies again 
synapsin or p25-p35.  DA9, PHF-1 or CP13 bands were analysed on separate blots because 
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stripping of these antibodies was determined to be difficult and bands for these antibodies 
are at similar weights. 
Western blots of samples obtained from Shef 6 -CGN treated with 1 μM Aβ42O and associated 
controls were carried out through probing the same blots as these blots were produced and 
probed early in this PhD project.  The process of probing separate western blots for each tau 
antibody was employed after this set of western blots throughout the PhD project to mitigate 
the risk of traces of previous tau antibodies being left behind on the blot after stripping.  For 
these western blots, westerns were probed with secondary antibody after stripping to ensure 
primary antibodies were fully stripped from the blots before probing with an additional 
antibody.  For this reason, the same GAPDH blot is used to compare results for Shef 6 -CGN 
treated with 1 μM Aβ42O.  These results are depicted in figures 5.6, 5.8, 5.11, 5.14, 5.16 and 
5.17.  
5.2.4.2 Analysis of western blots 
The density of bands was analysed as described in Chapter 2 (Chapter 2.2.1.10).  Each band, 
for a specific antibody, was normalised to its bands for control antibody, GAPDH.  For each 
blot, the result for each case were compared to averaged controls.  For phosphorylated tau 
antibodies, density of bands was also compared to those for total tau, after individual 
normalisation to GAPDH.  Where anti-tau antibodies revealed multiple bands, all bands were 
included in the densitometric analysis.    Analysis of PAK3 and synapsin were determined by 
analysis of only the main predicted bands at 65 kDa and 75 kDa, respectively.  For p35 and 
p25 level analysis, only bands at 35 kDa and 25 kDa, respectively, were included.  For analysis 
of the levels of GSK3β and pTyr216 GSK3β, only bands at 48 kDa and 52 kDa were included 
in analysis. 
Statistical analysis for Nas 2-bfCN and Shef 6-CGN results was carried out using an unpaired 
Student’s t-test.   Statistical analysis for Shef 6-bfCN results was carried out using the 
Friedman test, with multiple comparisons undertaken between each concentration, 
including the controls, using Dunn’s post hoc test.  The Friedman test is a non-parametric test 
used to compared three or more matched or paired groups and allows for comparison of 
bands across different blots.  This statistical test was chosen as samples for each 
concentration for Shef 6-bfCN are spread across three sets of blots.  *=p ≤ 0.05. **=p ≤ 0.01. 
***=p ≤ 0.001.  
176 
 
Table 5.4 Antibodies used in western immunoblotting and immunocytochemistry 
*Prof. Peter Davies (Albert Einstein College of Medicine, New York, USA) kindly supplied 






















Rabbit ab15568, Abcam N/A N/A 1:1000 
CP13 pSer202 
tau 





DA9 Pan-tau Mouse  Prof. Davies* (Petry et al., 
2014) 
1:5000 N/A 
GAPDH GAPDH Mouse AM4300, 
Invitrogen 
(de Oliveira et 
al., 2017) 
1:5000 N/A 
GSK3β GSK3β Rabbit D5C5Z, Cell 
Signalling 







Rabbit Ab75745, Abcam (Porquet et al., 
2015) 
1:500 N/A 
p25-p35 p25-p35 Rabbit C64B10, Cell 
Signalling 
(Porquet et al., 
2015) 
1:300 N/A 








Mouse Prof. Davies* (Otvos et al., 
1994) 
1:5000 N/A 
PSD-95 PSD-95 Mouse ab2723, Abcam (Frandemiche et 
al., 2013) 
1:1000 1:300 
Synapsin Synapsin I Rabbit ab64581, Abcam (Stefanova et 
al., 2016) 
1:750 1:300 
ChAT ChAT Rabbit ab181023, Abcam (Crompton et 
al., 2013) 




Mouse Prof. Davies* (Jicha et al., 
1997; Jicha et 
al., 1999; Petry 
et al., 2014) 
N/A 1:250 
Mushashi Mushashi Rabbit ab154497, Abcam N/A N/A 1:300 





5.2.5  Quantitative PCR 
Quantitative PCR (qPCR) was carried out as described in Chapter 2 using probes to detect the 
gene expression of GAPDH, MAPT, GSK3β, CDK5 and PAK3.  The details of these probes can 
also be found in Chapter 2 (Chapter 2.2.3).  Statistical analysis of qPCR data was performed 
using the Mann-Whitney test where one concentration of Aβ42O was used to treat the same 
cells or a Kruskal-Wallis test followed by a post-hoc Dunn’s test where more than one 















5.3  Results 
5.3.1  Characterisation of bfCN differentiation  
The intermediate cells generated during this differentiation protocol have already been 
characterised in Crompton et al., 2013.  However, to ensure a homogenous population of 
neural stem cells (NSC) were obtained within the neurospheres before plating down for 
terminal differentiation, cells from within neurospheres at day 30 of neural expansion were 
dissociated and plated for two hours before fixing for immunocytochemistry with two NSC 
















Figure 5.1     Cells within neurospheres express neural stem cell markers at day 30 during of 
expansion phase of Crompton protocol  
Dissociated cells from within neurospheres at day 30 of differentiation of Nas 2 line, plated and 
cultured for two hours, immunostain positively for nestin (B, red) and mushashi (C, green), two 
neural stem cell markers as shown in the overlay (D). Hoechst stain was used to highlight the cell 





Choline acetyltransferase (ChAT) is the enzyme responsible for biosynthesis of the 
neurotransmitter acetylcholine (ACh), by catalysing the transfer of an acetyl group from 
acetyl coenzyme A to choline.  ChAT is expressed by cholinergic neurons in the central 
nervous system (CNS) (Oda, 1999) and can be used as a marker for cholinergic neurons.  
Terminally differentiated cells, cultured for 35 days after neurosphere plate down, were fixed 
and immunostained with an anti-ChAT antibody and anti-βIII tubulin.  BfCNs differentiated 
from both Shef 6 and Nas 2 lines positively stain with anti-ChAT (Figure 5.2). 
Terminally differentiated bfCNs were fixed and immunostained to detect synapsin I and post-
synaptic density protein 95 (PSD-95).  Synapsin is a protein integral to the pre-synaptic 
membrane and important for vesicle trafficking within the synapse (Evergren et al., 2007), 
therefore can be used to indicate pre-synaptic membranes.  PSD-95 is a key constituent 
protein of the post-synaptic density, which is associated with the post-synaptic membrane, 
Figure 5.2     Characterisation of day 35 differentiated bfCNs 
Images in the upper panels demonstrate Shef-6 bfCNs immunostained with antibodies against βIII 
tubulin (A, red), ChAT (B, green) and the overlay of these (C). Images in the lower panels show Nas 
2-bfCNs immunostained with antibodies against βIII tubulin (D, red), ChAT (E, green) and the overlay 
of these (F).  Scale bars indicate 50µm. 
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and is therefore used as a post-synaptic marker (Naisbitt et al., 2000).  Distribution of these 




Figure 5.3 Immunostaining demonstrating positive staining for anti-synapsin I and anti-
PSD 95 in Shef 6-bfCN and Nas 2-bfCN 
A, B, C and D show immunostaining of Shef 6-bfCN with Hoechst nuclear stain (A, blue), anti-βIII 
Tubulin (B, red), anti-synapsin I (C, green) and the overlay of these (D).  E and F show enlargements 
of the areas outlined by white boxes in C and D, respectively.  G, H and I show Shef 6-bfCN 
immunostained with anti-βIII Tubulin (G, red), anti-PSD 95 (H, green) and the overlay of these (I).  
J, K and L show Nas 2-bfCN immunostained with anti-βIII Tubulin (J, red), anti-PSD 95 (K, green) 
and the overlay of these (L).  Scale bars for A, B, C and  D indicate 100 µm; scale bars for E and F 
indicate 25 µm; Scale bars for G, H, I, J, K and L indicate 50 µm. 
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Nas 2-bfCN and Shef 6-bfCN both positively stained for synapsin I and PSD-95 (Figure 5.3).  
Confocal microscopy, along with epifluorescence microscopy, was used to demonstrate the 
proximity of puncta stained with anti-synapsin I and anti-PDS-95 (Figure 5.4) indicating 
mature synaptic structure (Nieweg et al., 2015).  Nas 2-CGN and Shef 6-CGN also 
demonstrate positive staining for anti-synapsin I and anti-PDS-95, as described in Chapter 4 







Figure 5.4 Synapsin and PSD-95 puncta are within close proximity to each other in 
mature bfCNs 
Nas 2-bfCNs at day 35 positively immunostain for PSD-95 (green) and synapsin (red) with puncta 
along axons within close proximity to each other as can be seen in enlarged images.  Images in A 
were taken using epifluorescence microscopy, while images in B were taken using confocal 
microscopy.  Scale bars indicate 25 μM for those in A and 5 μM for those in B.   
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5.3.2  Tau and ptau levels in Shef 6-bfCNs, Nas 2-bfCNs Shef 6-CGNs treated 
with Aβ42O 
To investigate the levels of total tau and ptau within mature Shef 6-bfCNs, Nas 2-bfCNs and 
Shef 6-CGNs, cells were cultured after terminal differentiation to maturity, which equates to 
35 days after final plate down for bfCNs and 50 days in culture for CGNs (Chapter 5.2.1), and 
treated with Aβ42O for 48 hours before being washed, lysed and immunoblotted.  Levels of 
total tau and tau phosphorylated at Ser396/404 and Ser202 were detected by probing 
western blots with tau and ptau specific antibodies.  The calculated density and size of each 
band was normalised firstly to bands produced by probing with the housekeeping control 
antibody GAPDH and subsequently to the average of the controls; therefore, these results 
are graphically represented as a ratio of the controls.  To allow for consideration of total tau 
variation within each sample, the bands produced by probing with ptau antibodies  were also 
normalised against those revealed by probing with DA9, which specifies total tau, after 
normalisation to GAPDH levels and before normalisation to the average of the controls.  PHF-















Figure 5.5 Levels of total tau in bfCNs treated with Aβ42O 
Figure 5.5 Level of total tau in bfCNs treated with Aβ42O 
Representative western blots showing Shef 6-bfCNs treated with 0.1 µM, 0.5 µM, 1 µM Aβ42O 
(control n=5; Aβ 0.1 µM n=3; Aβ 0.5 µM n=4; Aβ 1 µM n=4) (A) and Nas 2-bfCNs treated with 0.5µM 
Aβ42O (control n=3; Aβ 0.5 µM n=3) (C), probed with GAPDH and DA9 antibodies.  Graphs 
representing the average relative density of DA9 bands normalised to GAPDH bands for Shef 6-
bfCN (B) and for Nas 2-bfCN (D) treated with Aβ42O.   
 
Data represented in B) was analysed using a Friedman test with post-hoc Dunn’s test. Data 
represented in D) was analysed using an unpaired Student’s t-test.  Error bars indicate +1 S.E.M. 
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Western immunoblots of hiPSC-neurons treated with Aβ42O were probed with DA9, an 
antibody against total tau, to understand whether the oligomers affect the total amount of 
tau within the cells.  Treatment of Shef 6-bfCNs with incrementally increasing concentrations 
of Aβ42O (0.1 µM, 0.5 µM and 1 µM) did not have a statistically significant effect on total tau 
(p= 0.0747) (Figure 5.5, A and B).  Nas 2-bfCNs were treated with 0.5 µM Aβ42O, which did 
not have an effect on total tau levels (p= 0.4509) (Figure 5.5, C and D).  Likewise, no 
statistically significant change in the levels of total tau was caused by treatment of Shef 6-
























Figure 5.6 Level of total tau in Shef 6-CGNs treated with Aβ42O 
Representative western blot (A) showing Shef 6-CGNs treated with 0.5 µM (control n=3; Aβ 0.5 µM 
n=3)  and 1 µM (control n=3; Aβ 1 µM n=3)  Aβ42O, alongside controls, probed with GAPDH and 
DA9.  Representation of the average relative density of DA9 bands normalised to GAPDH bands for 
those treated with 0.5 µM  (B) and 1 µM (C) Aβ42O compared to controls.   
 





Figure 5.7 Levels of tau phosphorylated at pSer396 and pSer404 in Nas 2-bfCNs 









Figure 5.7 Level of tau phosphorylated at pSer396 and pSer404 in Nas 2-bfCNs treated 
with Aβ42O 
Representative western blot (A) showing Nas 2-bfCNs treated with 0.5µM Aβ42O alongside 
controls probed with GAPDH and PHF-1 (control n=3; Aβ 0.5µM n=3) and graphical representation 
of the average relative densities of PHF-1 bands normalised to GAPDH bands (B) and then 
normalised to DA9 bands (C).   
 
Data was analysed using an unpaired Student’s t-test.  Error bars indicate +1 S.E.M. 
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Figure 5.8 Levels of tau phosphorylated at Ser396 and Ser404 in Shef 6-CGNs treated 
with Aβ42O  
 
Figure 5.8 Level of tau phosphorylated at Ser396 and Ser404 in Shef-6 CGNs treated with 
Aβ42O 
Representative western blots (A) of Shef 6-CGNs treated with 0.5µM (control n=3; Aβ 0.5 µM n=3)  
and 1 µM (control n=3; Aβ 1 µM n=3) Aβ42O alongside controls, probed with GAPDH and PHF-1.  
Graphs representing the average relative density of PHF-1 bands normalised to GAPDH bands (B 
and D) and then to DA9 bands (C and E) for Shef 6-CGNs treated with 0.5µM Aβ42O (B and C) and 
1 µM Aβ42O (D and E), compared to controls.  
  




No significant difference in pSer396/404 tau was found in Nas 2-bfCNs treated with 0.5 µM 
Aβ42O compared to controls either before normalisation to total tau (p= 0.2417), or 
afterwards (p= 0.3096) (Figure 5.7).  No statistically significant diffference was found in Shef 
6-CGN treated with 0.5 µM or 1 µM Aβ42O before normalisation to total tau (p= 0.1018 and 
p=4765, respectively) or after normalisation to total tau (p= 0.6089 and p= 0.3808, 
repectively) (Figure 5.8).   
 
Figure 5.9 Levels of tau phosphorylated at Ser202 in Shef 6-bfCNs treated with Aβ42O 
 
Figure 5.9 Level of tau phosphorylated at Ser202 in Shef 6-bfCNs treated with Aβ42O  
Representative western blots showing Shef 6-bfCNs treated with 0.1 µM, 0.5 µM, 1 µM Aβ42O 
(control n=5; Aβ 0.1 µM n=3; Aβ 0.5 µM n=4; Aβ 1 µM n=4) probed with GAPDH and CP13 
antibodies (A).  Graphs representing the average relative density of CP13 bands normalised to 
GAPDH bands (B) and then to DA9 bands (C) for Shef 6-bfCN treated with Aβ42O.   
 














Figure 5.10 Level of tau phosphorylated at Ser202 in Nas 2-bfCNs treated with Aβ42O  
Representative western blot (A) showing Nas 2-bfCNs treated with 0.5 µM Aβ42O and probed with 
GAPDH and CP13 (control n=3; Aβ 0.5 µM n=3).  Graphs representing the density of CP13 bands 
normalised to GAPDH bands (B), then normalised to DA9 bands (C), for Nas 2-bfCN treated with 
Aβ42O. 
 
Data was analysed using an unpaired Student’s t-test.  Error bars indicate +1 S.E.M.  
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Figure 5.11 Levels of tau phosphorylated at Ser202 in CGNs treated with Aβ42O 
 
No statistically significant difference in pSer202 tau levels was found in  Shef 6-bfCN treated 
with 0.1 µM, 0.5 µM or 1 µM Aβ42O compared to controls, either before normalisation to 
total tau (p= 0.7813), or afterwards (p= 0.2449) (Figure 5.9).  Similarly, within Nas 2-bfCN 
treated with 0.5 µM Aβ42O no statistically significant change in levels of tau phosphorylated 
at these sites was detected compared to controls before normalisation to total tau (p= 
0.9405) or following normalisation (p= 0.6862) (Figure 5.10).  Application of 1 µM Aβ42O to 
Shef 6-CGN also did not statistically significantly alter levels of pSer202 tau before 
normalisation to total tau (p= 0.9071) or after normalisation to total tau (p= 0.8817), 
compared to controls (Figure 5.11). 
 
Figure 5.11 Level of tau phosphorylated at Ser202 in Shef 6-CGNs treated with Aβ42O 
Representative western blots (A) of Shef 6-CGNs treated with 1 µM (control n=3; Aβ 1 µM n=3)  
Aβ42O alongside controls, probed with GAPDH and CP13.  Graphs representing the average relative 
density of CP13 bands normalised to GAPDH bands (B) and then to DA9 bands (C). 
 




5.3.3  Gene expression of MAPT in Shef 6-CGN and Nas 2-bfCNs treated with 
Aβ42O 
MAPT expression levels within Shef 6-CGN treated with 1 µM Aβ42O and Nas 2-bfCN treated 
with 0.5 µM Aβ42O were investigated.  The average relative gene expression was calculated 
for cells treated with each concentration of Aβ42O compared to controls.  Neither Nas 2-
bfCNs treated with 0.5 µM Aβ42O (p= 0.2286) or Shef 6-CGNs treated with 1 µM Aβ42O (p= 
0.4000) were found to express significantly higher levels of MAPT compared to controls 
(Figure 5.12). 
 








Figure 5.12 Relative expression of MAPT in Nas 2-bfCN and Shef 6-CGN treated with Aβ42O 
Graphs representing the average relative gene expression of MAPT within Nas 2-bfCN treated with 
0.5 µM Aβ42O (control n=3; Aβ 0.5 µM n=4) (A) and within Shef 6-CGN treated with 1 µM Aβ42O 
(control n=3; Aβ 1 µM n=3) compared to controls.   
 





5.3.4  Tau kinase levels and activity in Shef 6-CGNs and Nas 2-bfCNs treated 
with Aβ42O 
To discern whether the activity of tau kinases GSK3β, Cdk5 and PAK3 are affected by 
treatment of hPSC-neurons with Aβ42O, protein levels of GSK3β, GSK3β pTyr216, p25, p35 
and PAK3 in Nas 2-bfCNs treated with 0.5 µM Aβ42O and Shef 6-CGN treated with 0.5 µM 
Aβ42O or 1 µM Aβ42O were investigated via western immunoblotting.  
Phosphorylation of GSK3β at pTyr216 is necessary for the kinase to become fully active 
(Chapter 1.3.1), therefore levels of GSK3β phosphorylated at this site were compared to total 
GSK3β to distinguish the effects of 0.5μM Aβ42O treatment on GSK3β activity in Nas 2-bfCNs.  
Levels of total GSK3β are unchanged in Nas 2-bfCN treated with 0.5 µM Aβ42O compared to 
controls (p= 0.7450), however, levels of pTyr216 GSK3β are increased (p= 0.0127) and remain 















Figure 5.13 Levels of total and active GSK3β in Nas 2-bfCNs treated with Aβ42O 
Representative western blots of Nas 2-bfCNs treated with 0.5µM Aβ42O alongside controls, 
probed with GAPDH and anti-GSK3β (A) and GAPDH and anti-GSK3β (B) (control n=3; Aβ 0.5 µM 
n=3).  Graphs representing the average relative density of anti-GSK3β bands normalised to 
GAPDH bands (C), of anti-GSK3β pTyr216 bands normalised to GAPDH * p= 0.0127 (D), and of 
anti-GSK3β pTyr216 bands normalised to anti-GSK3β bands * p= 0.0273 (E). 
 




Figure 5.14 Levels of active GSK3β in Shef 6-CGNs treated with Aβ42O 
 
Conversely, statistical analysis revealed levels of GSK3β pTyr216 were reduced in Shef 6-
CGNs treated with 0.5 µM compared to controls and treatment with 1 µM Aβ42O (p= 0.0413) 
(Figure 5.14).  There was no statistical difference in the levels of GSK3β pTyr216 between 
controls and Shef 6-CGNs treated with 1 µM Aβ42O.   
Increased p25, decreased p35 and increased p25:p35 ratio are indicative of increased Cdk5 
activity, as discussed in Chapter 1.3.2.  Therefore, western immunoblots of Nas 2-bfCNs 
treated with 0.5 µM Aβ42O and Shef 6-CGNs treated with 0.5 µM and 1 µM Aβ42O alongside 
Figure 5.14 Levels of active GSK3β in Shef 6-CGNs treated with Aβ42O 
Representative western blot (A) of Shef 6-CGNs treated with 0.5 µM (control n=3; Aβ 0.5 µM n=3)  
and 1 µM (control n=3; Aβ 1 µM n=3) Aβ42O alongside controls, probed with GAPDH and anti-
GSK3β pTyr216.  Graphs representing the average relative density of anti-GSK3β pTyr216 bands 
normalised to GAPDH bands, averaged to the controls, for Shef 6-CGNs treated with 0.5 µM (B) 
and 1 µM (C) Aβ42O.   
 




controls were probed with anti-p25/p35 to investigate Cdk5 activity.  The ratio of each to 
GAPDH was measured, however, p25 levels were too low to be detected for Shef 6-CGN 
treated with 0.5 µM Aβ42O.  Where p25 could be calculated in controls and Shef 6-CGN 
treated with 1 µM Aβ42O on the same blot, and within Nas 2-bfCNs, anti-p25 bands were 
normalised against GAPDH and then normalised to p35 bands to calculate the p25:p35 ratio.    
Levels of p35 (p>0.9999), p25 (p= 0.4111) and the ratio of p25:p35 (p= 0.3327) were not 
significantly changed through the application of 0.5 µM Aβ42O to Nas 2-bfCNs (Figure 5.15). 
Levels of p25 (p= 0.2464) and the ratio p25:p35 (p= 0.1183) were found to be not significantly 
different in Shef 6-CGN treated with 1 µM Aβ42O compared to controls (Figure 5.16, C and 
D), however, levels of p35 were significantly decreased in cells treated with 1 µM or 0.5 µM 







Figure 5.15 Levels of p25 and p35 in Nas 2-bfCNs treated with Aβ42O  
Figure 5.15 Levels of p25 and p35 in Nas 2-bfCNs treated with Aβ42O 
Representative western immunoblot (A) of Nas 2-bfCNs treated with 0.5 µM Aβ42O alongside 
controls, probed with GAPDH and anti-p25/p35 (control n=3; Aβ 0.5 µM n=3).  Graphical 
representations of average relative density of p35 bands normalised to GAPDH bands (B), of p25 
bands normalised to GAPDH bands (C) and of p25 bands normalised to p35 bands (D) for Nas 2-
CGNs.   
 




Figure 5.16 Levels of p25 and p35 in Shef 6-CGNs treated with Aβ42O 
Figure 5.16 Levels of p25 and p35 in Shef 6-CGNs treated with Aβ42O 
Representative western blot of Shef 6-CGNs treated with 0.5µM (control n=3; Aβ 0. 5 µM n=3) and 
1µM (control n=3; Aβ 1 µM n=3) Aβ42O alongside controls, probed with GAPDH and anti-p25/p35 
(A).  Graphs representing the average relative density of anti-p35 bands normalised to GAPDH 
bands for Shef 6-CGN treated with 0.5 µM Aβ42O * p= 0.0419 (B) and 1 µM Aβ42O * p=0.0274 (C).  
Graphs representing the average relative density of anti-p25 bands normalised to GAPDH bands 
(D) and then to p35 bands (E) for Shef 6-CGN treated with 1 µM Aβ42O.   
 
Data was analysed using an unpaired Student’s t-test.  Error bars indicate +1 S.E.M. 
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Figure 5.17 Levels of PAK3 in Shef 6-CGNs and Nas 2-bfCNs treated with Aβ42O 
 
Western blots of Shef 6-CGNs and Nas 2-bfCNs treated with Aβ42O were probed with anti-
PAK3 antibody to investigate the effects of Aβ42O on the levels of this tau kinase within these 
Figure 5.17 Levels of PAK3 in Shef 6-CGNs and Nas 2-bfCNs treated with Aβ42O 
Representative western blots of Shef 6-CGNs treated with 0.5 µM (control n=3; Aβ 0.5 µM n=3) 
and 1 µM Aβ42O (control n=3; Aβ 1 µM n=3) alongside controls (A) and Nas 2-bfCN treated with 
0.5 µM Aβ42O (control n=3; Aβ 0.5 µM n=3) (D) probed with GAPDH and anti-PAK3.  Graphs 
representing the average relative density of anti-PAK3 bands normalised to GAPDH bands for Shef 
6-CGNs treated with 0.5 μM (B) and 1 μM (C).  Graph representing the average relative density of 
anti-PAK3 bands normalised to GAPDH bands for Nas 2-bfCNs treated with 0.5 µM Aβ42O alongside 
controls (E). 
 
Data represented was analysed using an unpaired student’s t-test.  Error bars indicate +1 S.E.M.  
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cells.  PAK3 levels were not significantly different in Shef 6-CGNs treated with 0.5 µM (p= 
0.9379) and 1 µM Aβ42O (p= 0.5859) or Nas 2-bfCNs 0.5 µM Aβ42O (p> 0.9999) treated with 
Aβ42O compared to controls (Figure 5.17). 
5.3.5  Gene expression of tau kinases in Shef 6-CGN and Nas 2-bfCNs 
treated with Aβ42O 
To determine whether changes in expression levels of tau kinases are concomitant with 
altered tau kinase activity or tau phosphorylation in response to Aβ42O treatment within Shef 
6-CGN and Nas 2-bfCN, qPCR was carried out using probes to detect GSK3β, CDK5 and PAK3 
cDNA.   
Whilst GSK3β expression was found to be greater within Nas 2-bfCN treated with 0.5 µM 
Aβ42O compared to those treated with 1 µM Aβ42O (p= 0.0128), there was no significant 
difference in Nas 2-bfCN treated with 0.5 µM Aβ42O (p= 0.2715) or 1 µM Aβ42O (p= 0.0714) 
compared to both controls (Figure 5.18, A).  Similarly, no significant change in expression was 
detected for Shef 6-CGN treated with 1 µM Aβ42O (p= 0.1000) (Figure 5.18, B).  
Expression of CDK5 was not found to be significantly different in Nas 2-bfCN treated with 0.5 
µM Aβ42O (p=0.0571) (Figure 5.18, C) compared to controls, or in Shef 6-CGN treated with 1 
µM Aβ42O (p >0.9999) (Figure 5.18, D).  The expression of PAK3 was not significantly altered 
in Nas 2-bfCN after application of either 0.5 µM Aβ42O (Figure 5.18, E) or 1 µM Aβ42O (p= 
0.4990)  or in Shef 6-CGN treated with 1 µM Aβ42O (p= 0.4000) (Figure 5.18, F) compared to 







Figure 5.18 Relative expression of tau kinases in hiPSC-neurons treated with Aβ42O 
 
 
Figure 5.18 Relative gene expression of tau kinases in hiPSC-neurons treated with Aβ42O 
Graphs representing the average relative gene expression of GSK3β (A)* p= 0.0128 (control n=7; 
Aβ 0.5 µM n=4; Aβ 1 µM n=3); CDK5 (C) (control n=3; Aβ 0.5 µM n=4) and PAK3 (E) (control n=7; 
Aβ 0.5 µM n=4; Aβ 1 µM n=3) within Nas 2-bfCN treated with 0.5 µM and 1 µM Aβ42O alongside 
controls.  
 
Graphs representing the average relative gene expression of GSK3β (B), CDK5 (D) and PAK3 (F)  
within Shef 6-CGN treated with 1 µM Aβ42O compared to controls (control n=3; Aβ 1 µM n=4). 
 
Data represented in A) and E) was analysed using a Kruskal-Wallis with post-hoc Dunn’s test.  Data 





5.3.6  Level of synapsin I in Shef 6 and Nas 2 derived CGNs and bfCNs 
treated with Aβ42O 
To investigate the synaptotoxic effects of treatment with Shef 6-CGNs and Nas 2-bfCNs, 
western blots of lysates from these cells after treatment were probed with anti-synapsin I.  
Shef 6-CGN treated with 0.5 µM Aβ42O had lower synapsin I levels compared to controls (p= 
0.0274) (Figure 5.19, B), however, no change in synapsin I levels was detected in Nas 2-bfCNs 















Figure 5.19 Decrease in protein level of synapsin I in Shef 6-CGNs and Nas 2-bfCNs with 
Aβ42O as indicated by western immunoblotting using anti-synapsin  
 
 
Figure 5.19 Decrease in protein level of synapsin I in Shef 6-CGNs and Nas2-bfCNs  with 
Aβ42O  as indicated by western immunoblotting using anti-Synapsin  
Representative western blots showing Shef 6-CGNs treated with 0.5 µM Aβ42O (control n=3; Aβ 
0.5 µM n=3) (A)  and Nas 2-CGNs treated with 0.5 µM (control n=3; Aβ 0.5 µM n=3) (C), alongside 
controls, probed with GAPDH and anti-synapsin I.  Graphs represent the average relative density 
of anti-synapsin I bands normalised to GAPDH bands for Shef 6-CGN treated with 0.5 µM Aβ42O 
(B) and Nas 2-bfCN treated with 0.5 µM Aβ42O (D).   
 




5.3.7  Varicosities in Nas 2-bfCN treated with 1 µM Aβ42O 
To investigate the presence of pathogenic tau within neurons, Nas 2-bfCN treated with 1µM 
Aβ42O were fixed and immunostained with MC1, an antibody which specifically recognises a 
form of tau with an abnormal conformation associated with early AD (Weaver et al., 2000; 
Jicha et al., 1997).  Nas 2-bfCN treated with 1 µM Aβ42O have greater numbers of neurons 
positively stained with MC1 and axonal varicosities that positively stain with MC1 (Figure 
5.20; B and C, white arrows) compared to controls from the same differentiation set (Figure 
5.20, A).   
Trafficking of vital organelles, including mitochondria, has also been reported to be disrupted 
in tauopathies (Chapter 1.1.2).  Mitochondria have a vital role within neurons and their 
dysfunction is intimately associated with neurodegenerative disease (Cabezas-Opazo et al., 
2015; Moreira et al., 2010).  To investigate the transport of mitochondria with Nas 2-bfCN 
treated with 1 µM Aβ42O, cultures were immunostained with anti-ATPβ, which detects the 
beta subunit of ATP (adenosine triphosphate) synthase, an enzyme responsible for 
phosphorylating ADP (adenosine diphosphate) to ATP.  This enzyme is richly present within 
mitochondria and so anti-ATPβ can be used as a mitochondrial marker (Jonckheere et al., 
2012).  Staining was too dim to use for controls, however, varicosities containing 













Figure 5.20 Nas 2-bfCNs treated with 1 µM Aβ42O contain varicosities containing an 
abnormal conformation of tau 
 
Figure 5.20 Nas 2-bfCNs treated with 1 µM Aβ42O contain varicosities containing an 
abnormal conformation of tau 
Nas2-bfCNs positively immunostained for tau with an abnormal conformation in neuronal 
varicosities, as indicated by positive staining using MC1 antibody (green) and βIII Tubulin antibody 
(red).  Arrows indicate individual neurons with varicosities containing MC1 tau found in neurons 
treated with 1 µM Aβ42O, but not in controls.  Controls are shown stained with antibodies A) MC1, 
B) βIII Tubulin and both C) MC1 and βIII Tubulin.  Nas 2-bfCNs treated with 1 µM Aβ42O are shown 
stained with D) MC1, E) βIII Tubulin and both F) MC1 and βIII Tubulin.  Another example of Nas 2-
bfCNs treated with 1 µM Aβ42O, taken from a different well, are shown stained with G) MC1, H) 
βIII Tubulin and both I) MC1 and βIII Tubulin.  Scale bars indicate 50 µM. 
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Figure 5.21 Nas 2-bfCNs treated with 1 µM Aβ42O have varicosities containing mitochondria  
Nas 2-bfCNs were immunostained with anti-βIII Tubulin (A and D, red) and anti-ATPβ (B and E, 
green).  Overlays (C and F) demonstrate axonal varicosities positively stained with ATPβ along 
axons.  Scale bars indicate 50 µM. 
A B C 
D E F 
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5.4  Discussion 
The work in this chapter was untaken to investigate whether the application of pre-
aggregated, synthetic Aβ42O, within a concentration range of 0.1 μM to 10 μM, to hPSC-bfCNs 
and hPSC-CGNs can recapitulate molecular aspects of early tauopathy recognised in AD.  
Specifically, the levels of tau protein and phosphorylated species of tau have been measured, 
which are reported to be increased in the AD brain and are considered to be indicators of tau 
pathology.  Levels of MAPT expression were also investigated to determine whether altered 
levels contribute to the levels of tau protein.  To investigate the culpability of the tau kinases 
GSK3β, Cdk5 and PAK3, reportedly dysregulated in AD, within the model, the protein levels, 
activity and gene expression of these proteins were also investigated. 
5.4.1  Characterisation of hPSC-bfCN 
BfCNs were differentiated from Nas 2-hiPSC and Shef 6-hESC after the generation of 
neurospheres from these lines.  Acutely plated cells from these neurospheres, from each line, 
positively immunostain for nestin, an intermediate filament protein specific to CNS precursor 
cells (Zimmerman et al., 1994; Fukuda et al., 2003) and RNA-binding protein Mushashi 
homolog 1 (Mushashi), which is highly enriched within mammalian CNS and selectively 
expressed in neural stem cells (NSCs) (Sakakibara et al., 1996; Kaneko et al., 2000).  The 
positive expression of these two markers in acute plate-downs of dissociated neurospheres 
indicates a homogenous population of NSCs, necessary to ensure a population of terminally 
differentiated cells of purely neural lineage.  At 35 days after  plating the neurospheres to 
initiate terminal differentiation, these neurons express the cholinergic marker, ChAT, as 
indicated by positive immunostaining of cultures with anti-ChAT and anti-βIII Tubulin. 
Furthermore, at day 35 of terminal differentiation, these neurons also express synapsin, 
known to be present within early synapses, and PSD-95, a marker for mature synapses.  Since 
synapsin is a pre-synaptic marker and PSD-95 is a post-synaptic marker, the proximity of 
puncta positive for these two proteins indicates the formation of synapses (Micheva et al., 
2010; Pratt et al., 2008).  The presence of mature synapses within in vitro AD models is an 
important consideration as dysfunction and loss of synapses are fundamental elements in 
early AD pathogenesis (Ferreira and Klein, 2011).  Additionally, it has been postulated that 
tau pathology propagates throughout neural networks upon neuronal excitation via release 
of tau at synapses (Kfoury et al., 2012; Wu et al., 2016; Wang et al., 2017; Liu et al., 2012), 
208 
 
therefore the presence of a network of functional neurons is required in order to recapitulate 
AD pathogenesis as accurately as possible in vitro.   
Characterisation of Shef 6-CGNs and Nas 2-bfCNs has been described previously in Chapter 
4.  At 50 days, derived neurons expressed the vesicular glutamate transporter 1 (vGlut1), a 
marker of glutamatergic neurons (Chapter 4.3.2). Immunostaining of hiPSC-CGNs also 
revealed the presence of synapsin I and PSD-95 in neurons. 
5.4.2  Aβ42O-induced tau pathology 
Increased tau and ptau are widely reported in studies in post-mortem brain tissue, CSF and 
blood of AD patients (Sjögren et al., 2001; Iqbal et al., 2010; Zetterberg et al., 2013) (Chapter 
1.3).  AD pathology develops over decades and it is not known if this pathological feature can 
be recapitulated in control hiPSC-neurons treated with Aβ42O, although studies in primary 
neurons suggest this may be feasible (Zheng et al., 2002; Billingsley and Kincaid 1997; Iqbal 
et al., 1998; Busciglio et al., 1995; Johansson et al., 2006; Jin et al., 2011; Ma et al., 2009; 
Wang et al., 2000; Alvarez et al., 1999). 
In an attempt to examine this aspect of pathology in these hiPSC-neurons, levels of tau 
protein were investigated by western immunoblotting and qPCR, respectively.  Tau protein 
levels were not significantly altered through the treatment of Nas 2-bfCNs with 0.5 µM, Shef 
6-CGNs with 0.5 µM or 1 µM Aβ42O, or Shef 6-bfCNs with 0.1 µM, 0.5 µM or 1 µM Aβ42O.  
These results indicate that treatment of hPSC-neurons with these concentrations of Aβ42O 
over 48 hours does not result in altered levels of total tau protein, therefore, this aspect of 
AD pathology was not recapitulated in this model.       
This is predictable as so far, no sAD hiPSC-neuron model has reported increased levels of 
total tau or the presence of NFTs (for references see Table 1.2) and one sAD model based on 
the application of Aβ to hiPSC-neurons reported similar levels of total tau after treatment 
(Nieweg et al., 2015).  There have also been reports of increased tau secretion into the media 
of hiPSC-neurons derived from DS patients (Chang et al., 2015; Shi et al., 2012).  
The cause of increased total tau within the AD brain is unclear; some have hypothesised that 
the increase may be due to the resistance of pathologically phosphorylated and aggregated 
tau to proteasomal degradation and removal through clearance pathways (Paglini and 
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Cáceres, 2001; Moore et al., 2015).  In this hiPSC-models of AD, 48 hour treatment with Aβ42O 
may not allow sufficient time for the accumulation of tau.   
To determine whether increased transcription of MAPT early in disease could play a role in 
the increased levels of tau in AD brains, gene expression was investigated.  MAPT expression 
was not altered by treatment of Nas 2-bfCNs or Shef 6-CGNs with 0.5 µM or both 0.5 µM and 
1 µM Aβ42O, respectively.  These results are in line with results from a previous study in which 
MAPT expression levels were reported to be unchanged within hiPSC-neurons derived from 
fAD patients carrying various mutations (Moore et al., 2015).  Studies examining levels of 
MAPT mRNA in AD brains compared to aged healthy brains have produced controversial 
results.  While Liang and colleagues demonstrated decreased MAPT gene expression within 
the entorhinal cortex, hippocampus, middle temporal gyrus and posterior cingulate cortex of 
AD patients (Liang et al., 2008), no statistically significant change was determined in two 
other studies where expression in specific brain regions was examined (Farnsworth et al., 
2016; Fukasawa et al., 2017).  However, it should be noted that upon amalgamation of results 
obtained from various brain regions, Fukasawa and colleagues did note statistically 
decreased MAPT in AD brains compared to controls (Fukasawa et al., 2017).  Liang and 
colleagues suggested that the decrease in MAPT expression in AD brains may represent a 
neuroprotective mechanism of remaining neurons (Liang et al., 2008).  If so, decreased MAPT 
expression occurs later in disease as hiPSC-neurons are thought to represent the early stages 
of disease pathogenesis.   
An elevated level of ptau is one of the defining molecular features of the AD brain; 
pSer396/404 and pSer202 tau are found in AD brain NFTs.  Phosphorylation of tau at Ser396 
and Ser404 is associated with the later stages of AD, while phosphorylation at Ser202 is 
associated with early AD (Luna-Munoz et al., 2007).  The application of 0.5 µM Aβ42O to Nas 
2-bfCN, or of 0.5 µM or 1 µM Aβ42O to Shef 6-CGN did not result in statistically significant 
changes in tau phosphorylation at sites Ser396/404 compared to controls.  Similarly, pSer202 
tau levels were not significantly altered in Shef 6-CGN or Nas 2-bfCN after treatment with 0.5 
µM Aβ42O, or in Shef 6-bfCN after treatment with 0.1 µM, 0.5 µM or 1 µM Aβ42O.  These 
results indicate that the application of Aβ42O, in concentrations between 0.1 µM and 1 µM, 
to hiPSC-derived CGNs and bfCNs for 48 hours does not cause elevated tau phosphorylation 
at these sites. 
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These results are unsurprising as so far, no sAD hiPSC-neuron model has recapitulated 
increased pSer396/404 tau, although one study has demonstrated increased pSer202 tau 
(Nieweg et al., 2015).  Increased phosphorylation of tau at these sites has been reported in 
previous fAD hiPSC-neuron models, suggesting that models based on fAD mutations may 
reproduce tau hyperphosphorylation at these sites more reliably.  Increased pSer396/404 
and pSer202/205 tau have been detected in V717L APP hiPSC and within hiPSC carrying a 
duplication of APP (Moore et al., 2016).  Increased phosphorylation of tau at Ser396, as well 
as Thr181, has also been reported within hiPSC-derived cerebral organoids carrying APP 
duplication (Raja et al., 2016).  Choi and colleagues reported a dramatic increase in 
pSer396/404 and pSer202/205 tau within select neurons, via immunocytochemistry, within 
3xfAD (K670N/M671L,V717L APP/ΔE9 PSEN1) hiPSC-neurons (Choi et al., 2014).   
In a recent publication, an increase in pSer202/pSer205 tau could not be found in rat primary 
neurons treated with Aβ42O via western immunoblotting, however, increased 
immunostaining at the dendrites of these cells was reported (Tanokashira et al., 2017).  
Mislocalised pSer202/202 and pSer396/404 tau has been detected, via 
immunocytochemistry, in some hiPSC-neuron models derived from DS patients (Chang et al., 
2015).  These studies, along with immunostaining results reported by Choi and colleagues 
(Choi et al., 2014), suggest that the use of immunocytochemistry to detect abnormal 
translocation and increased levels of ptau facilitate identification of early AD pathology in 
hiPSC-neurons in which protein levels are not significantly altered.  While no change in the 
levels of pSer396/404 tau or pThr231 was detected within cells of hiPSC-neurons derived 
from patients with DS, increased levels of tau phosphorylated at these sites was detected 
within the media of these cultures (Shi et al., 2012), which may signify that ptau cannot be 
detected in some hiPSC-neuron models of AD via western immunoblotting due to secretion 
of ptau.   
Further investigation of levels of pThr231 tau in this model may reveal increased tau 
phosphorylation, as increased phosphorylation of tau at this site has been reported in sAD 
hiPSC-neuron models (Hossini et al., 2015; Israel et al., 2013; Nieweg et al., 2015) as well as 
within hiPSC-neurons derived from fAD patients with APP duplication (Israel et al., 2013).  
The age of the neurons in these studies seems to be critical to successful recapitulation of 
increased tau phosphorylation at these sites.  Muratore and colleagues noted that pSer262 
tau levels were not increased at day 35 of culture but were at 100 days (Muratore et al., 
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2013), while Raja and colleagues detected increased ptau at 90 days but not at 60 days (Raja 
et al., 2016).  Choi and colleagues measured phosphorylation within their model at 70 days 
after differentiation of hiPSC-neurons (Choi et al., 2014), while Moore and colleagues 
detected ptau within hiPSC-neurons at day 90 (Moore et al., 2016).  The culture period for 
hiPSC-bfCN and hiPSC-CGN in this study may not be sufficient to allow for detection of 
increased ptau.  
Previous studies involving the application of Aβ to murine primary neurons report increased 
pSer396/404 and pSer202/205 tau levels after treatment (De Felice et al., 2008; Ramser et 
al., 2013; Alvarez et al., 1999; Zempel et al., 2010).  Recapitulating increased increased 
phosphorylation at these sites in hiPSC-neurons appears to be more challenging.  In the foetal 
brain, tau is heavily phosphorylated at sites hyperphosphorylated in AD (Matsuo et al., 1994) 
and recently, we have learned that hiPSC-neurons, once differentiated, mature at a similar 
rate to those within the developing human brain (Sposito et al., 2015).  High levels of 
phosphorylation in young hiPSC-neurons may mask the effects of Aβ42O-induced changes to 
pathways leading to aberrant tau phosphorylation in the hPSC-CGN and hPSC-bfCN used in 
this project.   
5.4.3  Aβ42O-induced alterations in kinase activity, levels and expression 
Levels of GSK3β were not significantly altered by treatment with Aβ42O in Nas 2-bfCNs and 
Shef 6-CGNs, however GSK3β activity, indicated by levels of GSK3β phosphorylated at 
Tyr216, was altered in both cell types.  Treatment of Nas 2-bfCNs with 0.5 μM Aβ42O 
significantly increased GSK3β activity, while the same treatment of Shef 6-CGNs decreased 
activity, as indicated by levels of active (pTyr216) GSK3β.  These results suggest that GSK3β 
activity is differentially affected in these two neuronal subtypes.   
Varying levels of GSK3β activity have been reported in different areas of the brain.  Within 
the frontal cortex of AD brains, pTyr216 GSK3β has been reported to be increased (Leroy et 
al., 2007), while activity has been found to be unchanged within the AD hippocampus (Pei et 
al., 1997).   In another study, the activity of GSK3β was found to be decreased in the pre-
frontal cortex of AD brains (Swatton et al., 2004), indicating that further research is required 
to understand the regional differences in GSK3β activity within the AD brain.  Increased 
activity of GSK3β has previously been reported within V717L APP hiPSC-derived cholinergic 
neurons (Muratore et al., 2014) and in rat cholinergic septal neurons after treatment with 
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AβO (Zheng et al., 2002), in line with the increase in pTyr216 GSK3β in hiPSC-bfCN reported 
in this chapter.  Increased levels of pTyr216 GSK3β have also been found within a mixed 
population of hiPSC-neurons carrying a duplication of APP (Israel et al., 2012).   
The gene expression of GSK3β within Nas 2-bfCN and Shef 6-CGN was not significantly altered 
by treatment with 1 μM Aβ42O or 0.5 μM Aβ42O.  Expression was significantly increased, 
however, in Nas 2-bfCN treated with 0.5 μM Aβ42O compared to those treated with 1 μM 
Aβ42O.  These results suggest that GSK3β expression is not altered by treatment of these 
neurons for 48 hours with concentrations 1 μM Aβ42O or 0.5 μM Aβ42O.   
GSK3β expression has been reported to be upregulated in AD and MCI patients, within the 
hippocampus (Blalock et al., 2004), in post-synaptosomal supernatants (Pei et al., 1997) and 
in peripheral lymphocytes (Hye et al., 2004).  Conversely, decreased expression of GSK3β has 
also been described within the hippocampus, medial temporal gyrus and posterior cingulate 
cortex of AD patients compared to healthy age-matched controls (Liang et al., 2008).   In this 
publication, the authors suggest that healthy neurons that remain in the brains of AD patients 
may respond to the disease by decreasing GSK3β expression as a neuroprotective 
mechanism.  The results in this study align with the decrease in GSK3β expression previously 
reported in hiPSC-cortical neurons derived from a patient with sAD (Hossini et al., 2015).  
These studies do not support thes lack of gene expression difference in Nas 2-bfCN and Shef 
6-CGN treated with Aβ42O in this study.    
As described, greater levels of p35 compared to p25 can be associated with physiological 
activity of Cdk5, while greater levels of p25 indicate hyper-activated Cdk5 (Chapter 1.3.2). 
Levels of p25 and levels of p35 are unchanged in Nas 2-bfCN treated with 0.5 μM Aβ42O, while 
levels of p35 are decreased in Shef 6-CGN treated with either 1 μM or 0.5 μM Aβ42O.  In 
agreement with this, AβO treatment of rat primary cortical neurons has been demonstrated 
to cause decreased levels of p35 (Hsiao et al., 2008).   
CDK5 expression was observed to be unchanged in Nas 2-bfCN treated with 0.5 µM Aβ42O 
and Shef 6-CGN treated with 1 µM Aβ42O compared to controls.  These results differ 
compared to a previous report in which CDK5 expression was demonstrated to be decreased 
in sAD hiPSC-neurons (Hossini et al., 2015).  Conversely, in PC12 cells overexpressing APP 
gene, expression of CDK5 was increased (Czapski et al., 2011).  Two studies have reported 
decreased expression of CDK5 in specific brain areas including the entorhinal cortex, 
hippocampus, posterior cingulate cortex and medial temporal gyrus in patients with AD in 
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comparison to controls (Liang et al., 2008; Fukasawa et al., 2017).  Interestingly, Liang and 
colleagues also reported an increase in p35 expression alongside decreased CDK5 expression 
and hypothesised that these expression changes may represent neuroprotective processes 
in the remaining healthy cells in an attempt to prevent further tau pathology (Liang et al., 
2008).   
PAK3 levels and PAK3 expression are unchanged in Nas 2-bfCN and Shef 6-CGN treated with 
0.5 µM and 1 µM Aβ42O.  While changes in PAK3 levels have not been reported in hiPSC-
neurons via western immunoblotting, the application Aβ42O to hiPSC-neurons within a 3D 
culture system has been shown to stimulate translocation of PAK3 into the somatodendritic 
compartments (Zhang et al., 2014), which agrees with previous research in rat primary 
cortical neurons (Ma et al., 2008).  Elevated levels of PAK3 and phosphorylated PAK3 have, 
however, been reported in rat cortical neurons after treatment with Aβ42O (Ma et al., 2008).  
These results suggest that the pathways affected in AD that result in changes to PAK3 protein 
and gene expression levels, described in Chapter 1 (Chapter 1.3.3), may not be recapitulated 
fully in hPSC-bfCNs and CGNs upon treatment with Aβ42O. 
5.4.4  The effects of Aβ42O on synapsin I protein levels 
The loss of synapses is an early event in AD pathogenesis and is thought to occur before the 
loss of neurons (Scheff et al., 2006; Hong et al., 2016).  Levels of synapsin I have been found 
to be decreased within affected brain regions of AD patients compared to controls, indicating 
the loss of synapses (Hamos et al., 1989; Perdahl et al., 1984).  To investigate the loss of 
synapses within this model of AD, levels of synapsin I within hPSC-CGNs and hPSC-bfCNs 
treated with Aβ42O were investigated. 
In this study, levels of synapsin I were found to be decreased in Shef 6-CGN treated with 1 
μM Aβ42O, indicating that treatment of these cells with this concentration of Aβ42O 
recapitulates this aspect of AD.  No change in synapsin I levels was found in Nas 2-bfCN 
treated with 0.5 μM Aβ42O.  Although functional synaptic impairment has been 
demonstrated in hiPSC-glutamatergic neurons treated with 25-50 ng/ml Aβ42O for 8 days, 
the levels of the pre-synaptic protein vGlut1 were reported to be unchanged in this AD hiPSC-
model (Nieweg et al., 2015).  Similarly, Israel and colleagues demonstrated no change in 
synapsin I within hiPSC-neurons derived from patients with a duplication of APP or sAD 
patients, compared to controls (Israel et al., 2011).  The cultures of hiPSC-neurons 
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differentiated by Israel and colleagues consisted of a mixed population of neurons and were 
estimated to contain 15 % of glutamatergic neurons, therefore, the lack of decreased 
synapsin I in these hPSC-neurons may represent the relative resilience of other neuronal 
subtypes.  Differences in the relative resilience of hPSC-CGN compared to hPSC-bfCN to the 
loss of synapsin could be explained by phenotypic differences or differences in culture 
conditions.  Additionally, these differences may be due to the insufficiency of 0.5 µM Aβ42O 
to cause synapsin I loss relative to the higher concentration of 1 μM. 
Reports on the relative resilience of different neuronal subtypes in AD and models of AD are 
conflicting.  Counts and colleagues examined the protein levels of pre-synaptic proteins, 
synaptophysin and synaptotagmin, alongside post-synaptic drebrin in the hippocampi of 
patients with mild-to-moderate AD compared to those with no cognitive impairment.  They 
found that while drebrin levels were diminished by 40 % in AD, synaptophysin and 
synaptotagmin levels were preserved (Counts et al., 2012).  The same group previously 
demonstrated a loss of approximately 35 % of synaptophysin levels in the temporal cortex of 
patients with MCI compared to controls (Counts et al., 2006), suggesting that the loss of 
specific synaptic proteins in AD may be regionally distinct.  This may explain that while there 
is no loss in synapsin I levels within hiPSC-bfCNs, which represent the basal forebrain 
projecting to the hippocampus, synapsin I levels are reduced in hiPSC-CGN, which represent 
cortical neurons.   
Within an in vitro model of AD, the treatment of KM670/671NL APP mouse primary cortical 
neurons with 1 µM AβO had no effect on levels of synapsin I, while post-synaptic proteins 
were found to be decreased (Almeida et al., 2005).  On the contrary, treatment of control 
mouse primary hippocampal neurons with Aβ40O significantly decreased synapsin (Sepulveda 
et al., 2010).  These reports, coupled with the results in this chapter, highlight the need for 
further clarification of the synaptic proteins loss in different neuronal subtypes in AD.  
5.4.5  Aβ42O-induced varicosities containing pathogenic tau and 
mitochondria 
Axonal varicosities, which can be described as swellings or beading, are well documented in 
AD (Geula et al., 2008; Grutzendler et al., 2007; Notter and Knuesel, 2013; Terwel et al., 
2002).  These varicosities are thought to be caused by impaired transport of vesicles 
containing cargo along the microtubules, caused by aberrant phosphorylation of tau through 
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the interaction of AβO and tau (Mertens et al., 2013; Krstic and Knuesel, 2012; Khan and 
Bloom, 2016).  Individual neurons within cultures of Nas 2-bfCN treated with 1 µM Aβ42O 
were found to have axonal varicosities, which positively immunostained for a pathological 
conformation of tau and mitochondria, in this study.  
Varicosities have been demonstrated before in hiPSC-neuron models of tauopathy.  
Varicosities within hiPSC-neurons, carrying mutations in APP (K670N/M671L and V717L) as 
well as in PSEN1 (ΔE9), have been reported within those neurons exhibiting increased levels 
of tau phosphorylation, identified by immunostaining with antibodies to detect pSer396/404 
and pSer199/202/205 tau (Choi et al., 2014).  Additionally, Iovino and colleagues have 
demonstrated varicosities, which positively immunostain with a 4R tau antibody, within 
P301L MAPT hiPSC-CGNs, which also exhibited impairments in the transport of mitochondria 
(Iovino et al., 2015).  This study suggests a link between pathological tau, varicosities and 
mitochondrial impairment. 
Increased phosphorylation of tau, specifically at Ser396/404 and Ser199/202/205, has also 
been demonstrated to lead to abnormalities in mitochondrial transport in P301L MAPT mice 
and within the human AD brain (Kopeikina et al., 2011).  In PC12 cells, as well as in mouse 
cortical neurons, carrying MAPT mutations associated with increased phosphorylation of tau 
at Ser199, Ser202 and Ser205, individual neurons within cultures that were positively 
immunostained with MC1 also exhibited reduced mitochondrial transport, indicating a link 
between tau phosphorylation, the formation of tau with an abnormal conformation and 
reduced transport of mitochondria (Shahpasand et al., 2012).  Furthermore, acute 
application of synthetic AβO to rat hippocampal neurons has been previously shown to result 
in prompt and severe disruption of mitochondrial transport, indicating that this treatment 
can be used to recapitulate this aspect of pathology (Rui et al., 2006). 
These results suggest that Nas 2-bfCN treated with 1 µM Aβ42O may, therefore, be a suitable 
model for investigating the pathways through which Aβ causes changes to tau protein 
resulting in a pathogenic conformation of tau.  The model may also be suitable for 
investigating microtubule transport deficits.  Since it has been previously demonstrated that 
varicosities and impaired axonal transport occur before overt AD pathology in the AD brain 
(Stokin, 2005), the varicosities recognised in this study may be representative of early, 
prodromal pathology linked to AD.   
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5.4.6  Summary 
This study has shown that bfCN neurons respond to Aβ42O with changes in kinase activity of 
GSK3β and Cdk5.  The development of varicosities in response to Aβ42O in Nas 2-bfCN and 
reduction of synapsin I levels in Shef 6-CGN also indicate early pathological changes.  
Furthermore, the differences in the responses of the two types of neurons examined 
suggests that distinct neuronal subtypes have different responses to Aβ42O, which may relate 
to the progression of neurodegeneration through specific pathways in the brain. 
This model failed to recapitulate key changes in tau pathology on a molecular level; increased 
levels of tau protein and tau phosphorylation were not observed.  Although this is not 
unexpected, based on the literature, this limitation of the model may affect its utility for drug 
discovery.  It is hoped that further development of the model could overcome these 
limitations.   
One important consideration when modelling with hiPSC-neurons is that these cells are 
relatively immature, despite being cultured for a long time in vitro, compared to those of the 
AD brain. HiPSC-neurons are thought to mature at a similar rate to that recognised in the 
developing human brain and since the most significant risk factor in AD is age, these neurons 
may not recapitulate molecular changes recognised in aging.  For example, NFTs in the AD 
brain are made up of all six isoforms and development of tau pathology may depend on 
interactions between tau isoforms.  Due to the relative immaturity of these cells, only one of 
the six isoforms of tau is expressed; 3R0N.  Furthermore, it has been shown that AβO more 
readily bind to the surface of aged neurons and have a greater effect on membrane stability 
compared to younger neurons (Ungureanu et al., 2016).   Therefore, the relative immaturity 
of these hiPSC-neurons may contribute to a lack of complete AD phenotype.   
A review of AD hiPSC models to date has revealed some possible avenues for improvement 
of this model.  Three publications detailing 3D AD hiPSC-neuron models have demonstrated 
AD phenotypes that could not be observed in equivalent 2D models.  Zhang and colleagues 
treated hiPSC-neurons within a 3D culture system with 0.1 μM Aβ42O for 24 hours and 
demonstrated abnormal translocation of PAK within neurons in their 3D system, but not in a 
2D system (Zhang et al., 2014).  The only hiPSC-neuron models reported to develop tau 
aggregations were created through 3D culture system (Choi et al., 2014; Raja et al., 2016).  
Recently, the use of layered hydrogels for 3D modelling has been demonstrated to accelerate 
the maturation of neurons and allow for co-culture of different cell types (Zhang et al., 2016). 
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Co-culturing neurons with glial cells has also been shown to advance neuronal maturation 
(Qi et al., 2017).    At 365 days in vitro, hiPSC-CGNs begin to express the adult isoforms of tau 
(Sposito et al., 2015), therefore culturing cells for longer periods after terminal 
differentiation may allow more complete modelling of AD. 
The work in this chapter contributes to the base level research that must be carried out to 
understand the behaviour of tau in hiPSC-neurons to move towards creating improved 

























Tau pathology in the brain tissue of  
patients with frontotemporal dementia  
and Alzheimer’s disease 
 
6.1  Introduction 
Frontotemporal dementia (FTD) is a clinically and pathologically diverse group of progressive 
neurodegenerative diseases (Chapter 1.2.1), the majority of which are sporadic.  In this 
project, hiPSC-neurons have been derived from a patient carrying a mutation that causes 
FTDP-17 (Chapter 4) to model FTD.  Although we do not yet understand the initial causative 
events that instigate pathogenesis in sporadic cases of FTD, we do know that mutations in 
MAPT result in FTDP-17, therefore it is logical to create hiPSC-models based on these 
mutations.  Mutations of MAPT only make up an estimated 10 % of FTD cases (Hardy, 2014), 
however; for this reason it would be valuable to understand how closely these models 
represent the sporadic cases of FTD, as well as FTDP-17.  PiD is a sporadic FTD (sFTD) covering 
a variety of symptoms and pathology, although it has many important features in common 
with FTDP-17 (Chapter 1.2.1).  Both PiD and FTDP-17 most commonly clinically present as 
behavioural variant FTD (bvFTD), are classified as FTD-tau (Figure 1.4) and follow similar 
patterns of neurodegeneration (Chapter 1.2.1).   
Accordingly, the work described in the first part of this chapter was carried out to investigate 
post-mortem tau-related pathology within the frontal and temporal cortices of patients with 
FTDP-17 and PiD, using the same molecular tools used to investigate tau pathology in hiPSC-
neurons (Chapter 4.2) to limit variability during comparison.  Western immunoblotting was 
carried out to determine soluble tau protein levels and their phosphorylation status, 
alongside the protein levels and activity of the tau kinases glycogen synthase kinase 3β 
(GSK3β), cyclic dependent kinase 5 (Cdk5) and p21 activated kinase 3 (PAK3), in six controls, 
three PiD patients and three FTDP-17 patients.   Two of the three patients with FTDP-17 
carried the mutation IVS 10+16 MAPT, while one carried the mutation R406W MAPT.  Below 
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the known pathology and clinical presentations of these mutations are discussed (Chapter 
6.1.1).  
Tau within hiPSC-neurons carrying MAPT mutations has been demonstrated to be soluble, 
with no aggregates of tau (Silva et al., 2016; Hallmann et al., 2017; Ehrlich, Hallmann, et al., 
2015; Wren et al., 2015); therefore, to allow for comparison of tau pathology in human brains 
with hiPSC-models the levels and phosphorylation status of soluble tau protein was 
investigated.  This project focuses on tau pathogenesis since phosphorylated, soluble tau has 
been suggested to be the precursor of tau aggregates (Šimić et al., 2016).   
This knowledge will further our understanding regarding whether hiPSC-models created 
using patients with mutations in MAPT can be used to model not only FTDP-17 but also 
sporadic FTD, and to what extent.  An evaluation of the ability of V337M MAPT hiPSC-neurons 
to recapitulate the pathology found in these tissues is discussed in Chapter 8 (Chapter 8.1).   
In the second part of this chapter, the gene expression levels of MAPT and two selected tau 
kinases were determined within the basal forebrain nucleus basalis of Meynert (nbM) in 
patients with Alzheimer’s disease (AD) compared to controls, using qPCR.  This area of the 
brain is affected early in AD and is particularly vulnerable, as discussed in Chapter 1 (Chapter 
1.2.3).  An evaluation of the ability of the hiPSC-neuron model of AD described in Chapter 5 










6.2  Methods and reagents 
6.2.1  Brain tissue samples 
Temporal and frontal brain tissue from three FTDP-17 patients, with either R406W MAPT or 
IVS 10+16 MAPT mutations, along with three control patients tissue, was obtained from the 
Queen’s Square Brain Bank for Neurological Disorders (QSBB) (London, UK) (Ethics ref 
08/H0718/54+5].  Temporal and frontal brain tissue was obtained from three patients with 
PiD and three control patients, and compared with tissue from four patients with AD (nbM) 
from the South West Dementia Brain Bank (SWDBB) [Ethics ITA074].  Table 6.1 lists the 
known, relevant details regarding these patients.  Brain tissue from patients carrying the rare 
V337M MAPT mutation proved very difficult to find and could not be obtained for this 
project.  An alternative mutation, R406W MAPT, was obtained instead.  Both R406W and 
V337M are nonsense, exonic mutations, which increase tau aggregation, reduce tau 
microtubule binding (Hutton et al., 1998; Poorkai et al., 1998), do not affect splicing of exon 
10 of MAPT and have equal numbers of 3R and 4R tau isoforms within aggregations of tau 
(Hong et al., 1998).  Tissue from only one patient with R406W MAPT was available, therefore, 
frontal and temporal cortex tissue of patients with IVS 10+16 MAPT was also obtained.  
Details of the pathology and clinical presentation of patients with these two mutations are 
























































































































































































































































































6.2.2  Western immunoblotting 
6.2.2.1  Lysate preparation of brain samples 
This method was adapted from Mair et al., 2016 and buffer recipes selected for their ability 
to prevent degradation changes to post translational modifications (PTM) during processing.  
300 mg of frozen brain tissue was weighed out and homogenised in 1.5 ml of Buffer 1 (Table 
6.2).  The tissue was homogenised firstly by compressing 20 times using a sterile plastic 
disposable 1.5 ml microtube pestle, then by passing the tissue through a series of sterile, 
disposable needles of descending size, from 14 gauge to 20 gauge, attached to a syringe.  
After centrifuging 15 minutes; 11,000 g; 4 oC to clarify the crude homogenate, 1 % Sarkosyl 
(Sigma, L9150) was added to each sample from a 10 % stock solution and the samples were 
incubated on a vertically rotating platform for 60 minutes at 4 oC.  The samples were then 
centrifuged at 100,000 g for 120 minutes at 4 oC.  The supernatant was removed and kept in 
a clean Eppendorf labelled ‘soluble fraction’.  Samples were stored at -80 oC and thawed on 
ice just before preparation of western immunoblotting samples.       
 
Table 6.2 Reagents for Buffer 1 
Reagent Manufacturer and code Concentration 
Tris HCl pH 7.4 Melford, T1513 25 mM 
NaCl Melford, S0520 150 mM 
EDTA Sigma, E6758 10 mM 
EGTA Sigma, E3889 10 mM 
DTT Thermal Fisher, R0862 1 mM 
Nicotinamide Sigma, 72340 10 mM 
Trichostatin A Selleck Chemicals, S1045 0.002 mM or 2 µM 
PhosStop™ phosphatase 
inhibitor tablet 
Roche, 04906845001 1 tablet/10 - 50 ml ddH2O 
cOmplete™ protease 
inhibitor cocktail tablet 
Roche, 11697498001 1 tablet/ 10 - 50 ml ddH2O 
 
Western immunoblotting samples were prepared as described in Chapter 2 (Chapter 2.2.1).  
30 µg of protein was loaded into each well, as measured by bicinchoninic acid (BCA) assay 
(Chapter 2.2.1.2).  The samples were run on 12 % SDS-page gels and the antibodies for pan-
tau and phospho-tau were run on separate western blots to avoid any residual staining, 
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which could affect the results as analysed by densitometry.  All tau kinase antibodies were 
also run on separate blots.  Each western blot was performed three times.  Densitometric 
analysis and other western immunoblotting steps were carried out as described in Chapter 2 
(Chapter 2.2.1).  The details for the antibodies used to probe western immunoblots in this 
chapter are as detailed in Table 5.5 (Table 5.5; Chapter 5.2.4). 
6.2.2.2  Analysis of western immunoblots 
Upon completion of densitometric analysis of western bands for tau antibodies, analysed as 
described in Chapter 2 (Chapter 2.2.1.10), bands were normalised against those measured 
for GAPDH, a housekeeping protein.  All bands revealed by western immunoblotting using 
anti-tau antibodies were included in densitometric analysis, for each sample.  The statistical 
significance of differences, calculated as a P value, between patient and control groups was 
calculated using a Student’s T-test.  Analysis of PAK3 levels included only bands at 65 kDa. 
For analysis of synapsin levels only bands at 75 kDa were included.  For p25 and p35 level 
analysis, only bands at 25 kDa and 35 kDa, respectively, were included in analysis.   For 
analysis of the levels of GSK3β and pTyr216 GSK3β, only bands at 41 kDa to 52 kDa were 
included in analysis.  Graphs were annotated with asterisks to denote the level of 
significance; * with P < 0.05, ** with P < 0.01 and *** with P < 0.001.    
6.2.3  qPCR analysis of gene expression in brain tissue 
6.2.3.1 RNA extraction, purification and conversion to cDNA 
1 ml of TRIzol® reagent (Thermo Fisher, 15596026) was added to 100 mg of brain tissue.  The 
tissue was then homogenised as described above (Chapter 6.3.1) before being incubated for 
5 minutes at room temperature to allow for complete dissociation of nucleoprotein 
complexes.  0.2 ml of chloroform was then added to each sample and the samples were 
vigorously mixed for 15 seconds before being left to incubate for 2-3 minutes at room 
temperature.  The samples were then centrifuged at 12,000 g at 4 oC for 5 minutes.  The 
sample separated into three layers; a lower red phenol-chloroform layer, a white interphase 
and a colourless upper aqueous phase containing RNA.  A wide 200 µl pipette tip was used 
to carefully extract the upper layer ensuring none of the interphase was collected with it.  
The aqueous phase was transferred into a clean, RNAse-free Eppendorf and either immediate 
frozen within a -80 oC freezer or processed to purify and concentrate the RNA, as described 
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in Chapter 2 (Chapter 2.2.3.1).  The concentration and purity of the resultant RNA samples 
were measured using the NanoPhotometer™ Pearl (Implen) as outlined in Chapter 2 (Chapter 
2.2.3.2).  Reverse transcription of RNA to cDNA was performed as detailed in Chapter 2 
(Chapter 2.2.3.3) and qPCR was carried out in triplicate as described previously (Chapter 
2.2.3.4).  The analysis of qPCR was also carried out as detailed in chapter 2 (Chapter 2.2.3.5).  
The threshold cycle (CT) values for MAPT, GSK3β, CDK5 or PAK3 were normalised against the 
CT values for the housekeeping gene, GAPDH.  The statistical significance of differences, 
between patient and control groups, was calculated using the Mann-Whitney test where 
expression within brain tissue of controls were compared to brain tissue of AD patients 
(Chapter 6.3.5) and the Kruskal-Wallis test followed by a post-hoc Dunn’s test where 
expression within the brains of controls, FTDP-17 patients and PiD patients were compared 


















6.3  Results 
6.3.1  Tau pathology within the frontal and temporal cortices of patients 
with FTD 
To investigate the total levels of tau protein within the frontal and temporal cortices of 
patients with PiD, compared to controls, western immunoblots were probed with the 







Figure 6.1  Levels of total tau in frontal and temporal cortex brain tissue from PiD patients 
 
No statistically significant change in levels of total tau were detected in frontal (p= 0.2952) 
or temporal (p= 0.2976) cortices of PiD compared to controls.  The total levels of tau protein 
within the frontal cortices of patients with FTDP-17, compared to controls, were also 
detected by probing western immunoblots with DA9 (Figure 6.1). 
Figure 6.1     Levels of total tau in frontal (A & B) and temporal (C & D) cortex brain tissue 
from PiD patients 
Representative western blots showing frontal cortex tissue (A) and temporal cortex tissue (B) 
from PiD patients alongside healthy controls probed with GAPDH and DA9 (Control n=3; PiD 
n=3).  Graphs representing the density of DA9 bands normalised to GAPDH bands for frontal 
cortex tissue (C) and temporal cortex tissue (D). 
 




Figure 6.2  Levels of total tau in frontal cortex brain tissue from FTDP-17 patients 
 
No change in levels of total tau were detected in the frontal cortices of patients with FTDP-
17 compared to controls (p= 0.5155) (Figure 6.2).   
Figure 6.2     Levels of total tau in frontal brain tissue from PiD patients 
Representative western blot (A) showing frontal cortex tissue from patients with FTDP-17 
alongside healthy controls probed with GAPDH and DA9 (Control n=3; FTDP-17 n=3).  Graph 
representing the density of DA9 bands normalised to GAPDH bands (B). 
 
Data was analysed using an unpaired Student’s t-test.  Error bars indicate +1 S.E.M. 
228 
 
Figure 6.3 Levels of pSer404/pSer396 tau in frontal cortex brain tissue from PiD 
patients 
 
In the frontal cortices of patients with PiD pSer396/404 tau levels were not significantly 
increased before normalisation to DA9 (p= 0.0717) but were found to be increased after 






Figure 6.3     Levels of pSer396/404 tau in frontal cortex brain tissue from PiD patients 
Representative western blot (A) showing frontal cortex tissue from patients with PiD alongside 
healthy controls probed with GAPDH and PHF-1 (Control n=3; PiD n=3).  Graphs representing 
the density of PHF-1 bands normalised to GAPDH bands (B) and of PHF-1 bands normalised to 
DA9 bands  ** p= 0.0049 (C). 
 
Data was analysed using an unpaired Student’s t-test.  Error bars indicate +1 S.E.M. 
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Levels of pSer396/404 tau were also investigated in the frontal cortices of patients with 
FTDP-17 compared to controls by probing western blots with the antibody PHF-1. 
 
Figure 6.4 Levels of pSer396/404 tau in frontal cortex tissue from FTDP-17 patients 
 
pSer396/404 tau was significantly increased in the frontal cortices of patients with FTDP-17 
compared to controls both before (p= 0.0059) and after comparison to DA9 (p= 0.0221) 
(Figure 6.4).   
To investigate the levels of pSer202 tau within the frontal and temporal cortices of patients 
with PiD, compared to controls, western immunoblots were probed with the antibody CP13.   
Figure 6.4     Levels of pSer396/404 tau in frontal cortex brain tissue from FTDP-17 patients 
Representative western blot (A) showing frontal cortex tissue from patients with FTDP-17 
alongside healthy controls probed with GAPDH and PHF-1 (Control n=3; FTDP-17 n=3)  Graphs  
representing the density of PHF-1 bands normalised to GAPDH bands ** p= 0.0059 (B) and of 
PHF-1 bands normalised to DA9 bands *p= 0.0221 (C). 
 
Data was analysed using an unpaired Student’s t-test.  Error bars indicate +1 S.E.M. 
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Figure 6.5  Levels of pSer202 tau in frontal cortex brain tissue from PiD patients 
 
No significant difference was detected in the total levels of pSer202 tau within the frontal 
cortices of patients with PiD compared to controls, either before (p= 0.0775) or after 
normalisation to DA9 (p= 0.2766) (Figure 6.5).   
Similarly, no significant difference in levels of tau phosphorylated at these sites was detected 
in the temporal cortices of PiD patients compared to controls either before (p= 0.4680) or 
after (p= 0.4306) normalisation to total tau (Figure 6.6).   
 
Figure 6.5     Levels of pSer202 tau in frontal cortex brain tissue from PiD patients 
Representative western blot (A) showing frontal cortex tissue from patients with PiD alongside 
healthy controls probed with GAPDH and CP13 (Control n=3; PiD n=3).  Graphs representing the 
density of CP13 bands normalised to GAPDH bands (B) and of CP13 bands normalised to DA9 
bands (C). 
 




Figure 6.6 Levels of pSer202 tau in temporal cortex brain tissue from PiD patients 
 
Within the temporal cortices of patients with PiD total levels of pSer202 tau are not 
significantly different compared to controls either before comparison to total tau (p= 0.9639) 
or after (p= 0.4896) (Figure 6.6).   
The levels of pSer202 tau were also investigated within the frontal cortices of patients with 
FTDP-17 compared to controls by probing western blots with CP13.   
 
 
Figure 6.6     Levels of pSer202 tau in temporal cortex brain tissue from PiD patients 
Representative western blot (A) showing temporal cortex tissue from patients with PiD alongside 
healthy controls probed with GAPDH and CP13 (Control n=3; PiD n=3).  Graphs representing the 
density of CP13 bands normalised to GAPDH bands (B) and CP13 bands normalised to DA9 bands 
(C). 
 




Figure 6.7 Levels of pSer202 tau in frontal cortex brain tissue from FTDP-17 patients 
 
 
No significant difference was detected in the levels of pSer202 in frontal cortex tissue from 
controls and FTDP-17 patients either before normalisation to total tau (p= 0.2591) or after 
(p= 0.2721) (Figure 6.7).   
 
 
Figure 6.7     Levels of pSer202 tau in frontal cortex brain tissue from FTDP-17 patients 
Representative western blot (A) showing frontal cortex tissue from patients with FTDP-17 
alongside healthy controls probed with GAPDH and CP13 (Control n=3; FTDP-17 n=3).  Graph 
representing the density of CP13 bands normalised to GAPDH bands (B) and CP13 bands 
normalised to DA9 bands (C). 
 
Data was analysed using an unpaired Student’s t-test.  Error bars indicate +1 S.E.M. 
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6.3.2  Levels of MAPT gene expression within the frontal and temporal 
cortices of patients with FTD 
The levels of MAPT gene expression within the frontal and temporal cortices of patients with 
PiD and FTDP-17, compared to controls, were determined using qPCR.   
 
6.8 Levels of MAPT gene expression in frontal and temporal cortex tissue from 
patients with PiD and FTDP-17 
 
Gene expression of MAPT was found to be significantly greater in the frontal cortices (p= 
0.0348) (Figure 6.8, A) but not the temporal cortices (p= 0.2948) (Figure 6.8, B) of patients 
with PiD.  MAPT expression was not found to be significantly different in the frontal cortices 
(p=0.2147) (Figure 6.8, A) or temporal cortices of patients with FTDP-17 (p= 0.2948) (Figure 
Figure 6.8     Levels of MAPT gene expression in frontal and temporal cortex tissue from patients 
with PiD disease and FTDP-17  
Graphs representing the average MAPT gene expression within frontal cortex tissue *p= 0.0348  
(A) and within temporal cortex tissue **p= 0.0094 (B) from patients with FTDP-17 and PiD disease 
(Control n=6; PiD n=3; FTDP-17 n=3).  
Data was analysed using a Kruskal-Wallis test followed by a Dunn’s post hoc test.  Error bars 




6.8, B) compared to controls.  However, MAPT expression was lower within the temporal 
cortices of patients with FTDP-17 compared to those with PiD (p= 0.0094) (Figure 6.8, B). 
6.3.3  Levels and activity of tau kinases within the frontal and temporal 
cortices of patients with FTD 
To explore the potential roles of tau kinases in PiD and FTDP-17, the levels and activity of 
GSK3β, CDK5 and PAK3 were investigated within the frontal and temporal cortices of PiD 
patients compared to controls, as well as in the frontal cortices of patients with FTDP-17 
compared to controls.  The total levels of GSK3β and the levels of GSK3β phosphorylated at 
Tyr216, necessary for the kinase to be maximally active (Chapter 1.3.1), were investigated 




Figure 6.9 Levels of GSK3β and pTyr216 GSK3β in frontal cortex brain tissue from PiD 
patients 
 
Figure 6.9     Levels of GSK3β and pTyr216 GSK3β in frontal cortex brain tissue from PiD patients 
Representative western blots showing frontal cortex tissue from patients with PiD alongside 
healthy controls probed with GAPDH and GSK3β (A) and GAPDH and pTyr216 GSK3β (C) (Control 
n=3; PiD n=3).  Graphs representing the density of GSK3β bands normalised to GAPDH bands (B), 
of pTyr216 GSK3β normalised to GAPDH bands (D) and of pTyr216 GSK3β normalised to GSK3β 
bands * p= 0.0464 (E).  
Data was analysed using an unpaired Student’s t-test.  Error bars indicate +1 S.E.M. 
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No significant difference in the levels of GSK3β (p= 0.3279) or pTyr216 GSK3β (p= 0.1523) 
were detected in the frontal cortices of patients with PiD compared to controls.  However, 
after normalisation of pTyr216 GSK3β levels to total GSK3β, the frontal cortices of patients 
with PiD were found to have increased levels of active GSK3β (p= 0.0464) (Figure 5.10).  
Similarly, within the temporal cortices of PiD patients there was no significant difference in 
GSK3β (p= 0.6749) or pTyr216 GSK3β (p= 0.9815) levels compared to controls.  Furthermore, 
there is no significant difference in pTyr216 GSK3β levels after normalisation to total GSK3β 




















Figure 6.10 Levels of GSK3β and pTyr216 GSK3β in temporal cortex brain tissue from 
PiD patients  
 
 
Figure 6.10     Levels of GSK3β and pTyr216 GSK3β in temporal cortex brain tissue from PiD 
patients 
Representative western blots showing temporal cortex tissue from patients with PiD alongside 
healthy controls probed with GAPDH and GSK3β (A) or pTyr216 GSK3β (C) (Control n=3; PiD n=3). 
Graphs representing the density of GSK3β bands normalised to GAPDH bands (B), of pTyr216 
GSK3β normalised to GAPDH bands (D) and of pTyr216 GSK3β normalised to GSK3β bands (E).   
 




Figure 6.11 Levels of GSK3β in frontal cortex brain tissue from FTDP-17 patients 
 
There was no significant difference in the levels of GSK3β in the frontal cortices of patients 
with FTDP-17 compared to controls (p= 0.5268) (Figure 6.11). 
To investigate the activity of Cdk5 in PiD and FTDP-17, western immunoblots were probed 
with an antibody against p25 and p35, the activator proteins of Cdk5.  Increased p25 protein 
levels and decreased p35 protein levels are associated with aberrant hyperactivity of Cdk5, 












Figure 6.11     Levels of GSK3β in frontal lobe brain tissue from FTDP-17 
Representative western blot (A) showing frontal cortex tissue from patients with FTDP-17 
alongside healthy controls probed with GAPDH and GSK3β (Control n=3; FTDP-17; n=3).  Graph 
representing the density of GSK3β bands normalised to GAPDH bands (B). 
 
Data was analysed using an unpaired Student’s t-test.  Error bars indicate +1 S.E.M. 
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Figure 6.12 Levels of p25 and p35 in frontal cortex brain tissue from PiD 
 
Figure 6.12     Levels of p25 and p35 in frontal cortex brain tissue from PiD 
Representative western blot (A) showing frontal cortex tissue from patients with PiD alongside 
healthy controls probed with GAPDH and p25/p35 (Control n=3; PiD n=3).  Graph representing 
the density of p25 bands normalised to GAPDH bands * p= 0.0126 (B), p35 bands normalised to 
GAPDH bands (C) and p25 bands normalised to p35 bands. 
 




Levels of p25 were increased (p= 0.0126) while levels of p35 were unchanged (p= 0.4367) in 
the frontal cortices of PiD patients compared to controls as indicated by densitometric 
analysis of the p25 and p35 bands, respectively, normalised to GAPDH bands (Figure 6.12).  
There was no change in the ratio of p25/p35 levels within the frontal cortices of patients with 
PiD compared to controls, calculated by normalising p25 bands to p35 bands (Figure 6.12, D).   
 
Figure 6.13 Levels of p25 in temporal cortex brain tissue from PiD 
 
Levels of p25 are not significantly different within the temporal cortices of PiD patients 
compared to controls (p= 0.4415) as indicated by densitometric analysis of p25 bands 
normalised to GAPDH bands.  Levels of p35 could not be detected in these samples as the 
immunoreactivity was not sufficient (Figure 6.13).   
 
Figure 6.13    Levels of p25 in temporal cortex brain tissue from PiD 
Representative western blot (A) showing frontal cortex tissue from patients with PiD alongside 
healthy controls probed with GAPDH and p25 (Control n=3; PiD n=3).  Bar chart representing 
the density of p25 bands normalised to GAPDH bands (B). 
 




Figure 6.14 Levels of PAK3 in frontal and temporal cortex brain tissue from PiD patients 
 
PAK3 is not changed in PiD patients compared to control patients within the frontal cortices 
(p= 0.5016) as indicated by densitometric analysis of PAK3 bands normalised to GAPDH bands 
(Figure 6.14).  PAK3 levels could not be compared within in the temporal cortices of patients 
with PiD compared to controls as the band for PAK3 expected at 65 kDa was not present and 
an additional band was present at 35 kDa. 
Figure 6.14     Levels of PAK3 in frontal and temporal cortex brain tissue from PiD patients 
Representative western blots showing frontal cortex PiD (A) and temporal cortex (C) tissue from 
patients with and alongside healthy controls probed with GAPDH and PAK3 (control n=3; PiD 
n=3).  Graph representing the density of PAK3 bands normalised to GAPDH bands for frontal 
cortex brain tissue (B). 
 




Figure 6.15 Levels of PAK3 in frontal cortex brain tissue from FTDP-17 patients 
 
Densitometric analysis of PAK3 normalised to GAPDH bands demonstrate that PAK3 is 







Figure 6.15     Levels of PAK3 in frontal cortex brain tissue from FTDP-17 
Representative western blot (A) showing frontal cortex tissue from patients with FTDP-17 
alongside healthy controls probed with GAPDH and PAK3 (Control n=3; FTDP-17; n=3).  Graph 
representing the density of PAK3 bands normalised to GAPDH bands  * p= 0.0201.   
 




Figure 6.16 Gene expression levels of GSK3β, CDK5 and PAK3 in frontal and temporal 
cortices of patients with PiD and FTDP-17 
Figure 6.16     Gene expression levels of GSK3β, CDK5 and PAK3 in frontal lobe brain tissue from 
PiD disease and FTDP-17 patients 
Graphs representing the average GSK3β (A),  CDK5 (C) and PAK3 * p= 0.0494 (E) gene expression 
within frontal cortices of patients with PiD and FTDP-17 (Control n=6; PiD n=3; FTDP-17 n=3).  
Graphs representing the average GSK3β *p= 0.0415 (B),  CDK5 (D) and PAK3 (F) gene expression 
within temporal cortices of patients with PiD and FTDP-17 (Control n=6; PiD n=3; FTDP-17 n=3).   
 
Data was analysed using a Kruskal-Wallis test followed by a Dunn’s post hoc test.  Error bars 
indicate +1 S.E.M. 
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Gene expression of GSK3β was not found to be significantly different in the temporal cortices 
(p= 0.2795) or frontal cortices (p= 0.7430) of patients with PiD compared to controls (Figure 
6.16, B and A).  In the frontal (p= 0.8492) and temporal cortices (p= 0. 0.4339) of patients 
with FTDP-17, gene expression of GSK3β was not significantly different compared controls 
(Figure 6.16, A and B).  GSK3β gene expression was found to be significantly lower within the 
temporal cortices of patients with FTDP-17 compared to PiD (p= 0.0415), however, this was 
not found to be true within the frontal cortices (p= 0.0580).   
CDK5 expression levels were not found to be significantly different within the frontal (p= 
0.1093) and temporal cortices (p= 0.4511) of FTDP-17 patients compared to controls (Figure 
6.16, C and D).  Similarly, levels of CDK5 expression were not found to be significantly 
different within the frontal (p >0.9999) and temporal cortices (p >0.9999) of PiD patients.  
There is also no significant difference in CDK5 expression within the frontal (p= 0.7726) or 
temporal cortices (p= 0.5227) between PiD and FTDP-17 patients. 
In the frontal cortices of patients with FTDP-17 PAK3 expression levels were found to be 
decreased compared to controls (p= 0.0494), although this was not found to be the case in 
the temporal cortices of these patients (p= 0.4511).  In PiD patients, no significant difference 
was found within the frontal (p >0.9999) or temporal cortices (p >0.9999).  There was also no 
significant difference in PAK3 expression in the temporal cortices of patients with FTDP-17 











6.3.4  Levels of synapsin I in within the frontal and temporal cortices of 
patients with FTD 
 
Figure 6.17 Levels of synapsin I in temporal cortex brain tissue from patients with PiD 
 
Levels of synapsin I, indicated by the top two bands at approximately 75 kDa, in the temporal 
cortices of patients with PiD are significantly decreased compared to controls (p= 0.0004).   
 
 
Figure 6.17    Levels of synapsin I in temporal cortex brain tissue from PiD 
Representative western blot (A) showing temporal cortex tissue from patients with PiD alongside 
healthy controls probed with GAPDH and synapsin I (Control n=3; PiD n=3).  Bar chart representing 
the density of synapsin I bands normalised to GAPDH bands  *** p= 0.0004 (B). 
 
Data was analysed using an unpaired Student’s t-test.  Error bars indicate +1 S.E.M. 
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Figure 6.18 Levels of synapsin I in frontal cortex brain tissue from patients with FTDP-
17 
 
Levels of synapsin I in the frontal cortices of patients with FTDP-17 are unchanged compared 




Figure 6.18     Levels of synapsin I in frontal cortex brain tissue from FTDP-17 patients 
Representative western blot (A) showing frontal cortex tissue from patients with FTDP-17 
alongside healthy controls probed with antibodies against GAPDH and synapsin I (Control n=3; 
FTDP-17 n=3).  Graph representing the density of synapsin I bands normalised to GAPDH bands (B). 
 
Data was analysed using an unpaired Student’s t-test.  Error bars indicate +1 S.E.M.  
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6.3.5  Gene expression of MAPT, CDK5 and PAK3 in basal nucleus of 
Meynert of patients with AD 
 
Figure 6.19 Levels of MAPT, CDK5 and PAK3 gene expression in basal nucleus of 
Meynert from patients with AD 
 
Relative gene expression levels of MAPT (p <0.9999), CDK5 (p= 0.4000) and PAK3 (p= 0.7000) 
are unchanged within basal forebrain of AD patients compared to controls.   
Figure 6.19     Levels of MAPT, CDK5 and PAK3 gene expression, normalised to GAPDH, in basal 
nucleus of Meynert (nbM) of patients with AD. 
Graphs representing the average MAPT (A), CDK5 (B) and PAK3 (C) gene expression within nbM of 
patients with AD compared to controls (Control n=4; AD n=3).  
Data was analysed using a Mann-Whitney test.  Error bars indicate +1 S.E.M. 
248 
 
6.4  Discussion 
6.4.1 Rational behind inclusion of sample PiD2 and sample heterogeneity 
Unlike cell-based experiments, there is a great deal of heterogeneity in biological 
measurements in post-mortem human tissues.  To establish statistically significant difference 
between disease and control brain tissue it is therefore necessary to use a large cohort.  
Tissue obtained from FTD individuals is rare and there are also multiple sub-types of FTD 
which may have differing pathological presentation; together this makes it difficult to 
determine highly significant similarities or differences from other diseases or even control 
brain tissue.  For this study it was only possible, unfortunately, to obtain small numbers of 
samples.  Nevertheless, the results have highlighted certain aspects which may inform the 
rationale for further studies.  Therefore, particularly because it seems that the PiD samples 
are heterogenous, all samples, including apparent outliers (for instance PiD2), have been 
included here.    
Examples of this heterogeneity are given here.  For instance, in Figure 6.1, lower levels of 
total tau is evident not only within both frontal and temporal cortex of PiD2, compared with 
PiD1 and PiD3, but also in the temporal cortex for control 1, compared with the other 2 
controls.  Given this heterogeneity appears to be a part of the natural heterogeneity of 
human samples, all have been included.  Additionally, in Figure 6.3, p396/404 tau levels are 
much higher in the frontal cortex tissue of PiD1 and PiD3 than controls and PiD2 levels, 
although PiD2 levels are still increased in comparison to controls.  Considerable variation was 
also seen in p396/404 tau levels between samples MAPT 10+16 (1) and MAPT 10+16 (2) 
(Figure 6.4) indicating the variability of tau phosphorylated at this site even between 
different patients with the same tauopathy.  Interestingly, western blots indicating pSer202 
tau banding patterns, particularly those at approximately 35kDa and 52kda, that varied 
considerably for PiD 2 within the frontal (Figure 6.4) and temporal cortex (Figure 6.5), 
compared to both controls and PiD 1 and PiD 3 samples.  In Figure 6.7, pSer202 levels in 
MAPT 10+16 (1) and MAPT 10+16 (2) vary especially in the bands at 52 kDa and 40 kDa.  
Interestingly, western blots probed with CP13, indicating pSer202 tau, demonstrated 
banding patterns that varied considerably for PiD 2 within the frontal and temporal cortex 
compared to both controls and PiD 1 and PiD 3 samples.  Specifically, a band at approximately 
35kDa has much greater density compared to the other samples, whereas the band at 
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approximately 52kda is much less dense.  Additionally, the 40 kDa band revealed by probing 
with CP13 in MAPT 10+16 (1) is denser than the band at 52 kDa, whereas in MAPT 10+16 (2) 
the band at 52 kDa is denser than the one at 40 kDa (Figure 6.7).   
Additionally, in western blots probed with both antibodies against GSK3β and pTyr216 
GSK3β, PiD2 samples of both frontal and temporal lobes, show a different banding pattern 
compared to the other PiD samples. In particular, 48 and 52kda pTyr216 GSK3β bands are 
much fainter, whereas the 41 kDa band is much darker.  Further to these results, 
heterogeneity in banding patterns has also been described by others, in samples taken from 
different patients with tauopathy (Espinosa et al., 2008) 
Western blots probed with anti-PAK3 of controls and PiD patient temporal cortex tissue 
revealed that the expected band for PAK3 at 65 KDa was missing for PiD2 and an additional 
major band at 35 kDa was present.  Unfortunately, it was only possible to obtain three 
samples from PiD patients, therefore statistical analysis could not be carried out on the 
results gained from probing western blots from the temporal lobes using PAK3 antibody.  For 
this reason, quantification and statistical analysis of this result has been omitted.  The reason 
for this unexpected result remains unclear, however, may be attributed to the heterogeneity 
of the disease.  One possible explanation is that PAK3 may have been cleaved within the 
temporal cortex of PiD2.  Caspase 3 is known to be able to cleave another isoform of PAK, 
hPAK65, at a single site, between the N-terminal regulatory p21-binding domain and the C-
terminal kinase domain, to produce a smaller protein of approximately 35 kDa (Lee et al., 
1997).  Although PAK1 is known to unaffected by caspase 3 cleavage (Lee et al., 1997), it is 
possible that PAK3 may be cleaved by caspase 3, which is known to have increased activity 
and to play multiple roles in neurodegenerative disease (Zhang, 2013). 
6.4.2  Protein and gene expression levels of tau within the frontal and 
temporal cortices of patients with PiD and FTDP-17 
Western immunoblots of lysates from the frontal and temporal cortices of controls, patients 
with PiD and patients with FTDP-17, probed using an antibody against total tau, revealed six  
bands at approximately 48-68 kDa, indicating the presence of the six adult isoforms of tau 
protein in these patients, as well as lower molecular weight bands indicating products of tau 
degradation (Adamec et al., 2001; Goedert et al., 1989).  In the frontal and temporal cortices 
of patients with PiD, and the frontal cortices of patients with FTDP-17, total levels of soluble 
tau are not significantly different compared to controls.  These results are in line with 
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previously reported levels of soluble tau within the frontal cortex tissue of patients with PiD 
and FTLD associated with tau pathology compared to those within controls (van Eersel et al., 
2009; Adamec et al., 2001).   
MAPT expression levels were found to be higher in the frontal cortices of patients with PiD 
but not FTDP-17, or within the temporal cortices of patients with either disease.  Previously, 
MAPT expression in patients with FTLD associated with tau pathology has been previously 
shown to be similar to controls, therefore the higher levels of expression within the frontal 
cortices of PiD patients were unexpected.  Although the levels of MAPT expression have not 
been evaluated in the brains of patients with the mutations carried by these FTDP-17 
patients, previous studies in hiPSC-neurons derived from patients with FTDP-17 (Ehrlich et 
al., 2015) and Tg drosophila models of FTDP-17 (Haddadi et al., 2016) have reported similar 
levels of MAPT mRNA.  Furthermore, MAPT expression levels have been demonstrated to 
largely correlate with tau protein levels within the brain (Trabzuni et al., 2012) whereas here 
soluble protein levels of tau do not reflect MAPT expression.  The higher levels of expression 
within the frontal cortices of patients with PiD may be explained by the fact that here only 
soluble levels of tau were measured, and additional tau may have been aggregated and so 
insoluble.  Further investigation into the insoluble levels of tau may provide insight into this.   
MAPT expression levels and the expression of different isoforms of tau have been 
demonstrated to be brain region specific (McMillen et al., 2008; Majounie et al., 2013; 
Trabzuni et al., 2012), suggesting distinctions in the regulation of MAPT expression between 
brain areas.  Therefore, in these PiD patients, the higher levels of MAPT expression in the 
frontal cortices, in contradiction to the similar levels of expression compared to controls 
found in the temporal cortices, could be explained by the different effects of the MAPT 
mutations on the pathways that regulate MAPT expression within these areas.   
6.4.3  Levels of phosphorylated tau in the frontal and temporal cortices of 
patients with PiD and FTDP-17 
In this study, pSer396/404 tau levels were found to be increased within the frontal cortices 
of patients with PiD and FTDP-17, compared to controls, after normalisation to total tau.  This 
was expected as increased phosphorylation at this site has previously been reported in PiD 
cases in which Pick bodies positively stain with anti-pSer396/404 tau antibodies (van Eersel 
et al., 2009; Zhukareva et al., 2002; Love et al., 1988; Ishizawa et al., 2000; Sparks et al., 
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1994).  Furthermore, in cortical tissue of patients with IVS 10+16 MAPT and other FTDP-17 
mutations, tau is phosphorylated at Ser396/404 (Irwin et al., 2013).  While phosphorylation 
of R406W MAPT tau at Ser396/404 has been reported to be decreased into Chinese hamster 
ovary cells compared to controls, in Tg R406W MAPT mice, pSer396/404 tau is increased 
(Ikeda et al., 2005). 
No difference was found in the phosphorylation of tau at pSer202 in PiD and FTDP-17 frontal 
and temporal cortices in comparison to controls.  Interestingly, levels of tau phosphorylated 
at this site have been shown by others to be increased within the brains of patients with PiD 
(Zhukareva et al., 2002; Espinoza et al., 2008; Koga et al., 2017; van Eersel et al., 2009; Nölle 
et al., 2013) and also FTDP-17 patients carrying G272V MAPT (Nölle et al., 2013). Sections of 
the midbrains of patients carrying V337M MAPT also immunostain more intensely with an 
antibody against pSer202/Thr205 tau, indicating increased levels (Ehrlich et al., 2015).  
Furthermore, increased tau phosphorylation at Ser202 has been reported in Tg R406W MAPT 
mice (Ikeda et al., 2005), as well as Tg P301L MAPT mice (de Calignon et al., 2012).   
Shiarli and colleagues demonstrated, via immunohistochemistry using AT8, an antibody that 
recognises tau phosphorylated at pSer202 as well as Thr205, that the levels of tau 
phosphorylated at pSer202 are approximately 90 % lower in frontal cortex tissue of PiD and 
FTDP-17 patients, including those with R406W and IVS 10+16 MAPT mutations, compared to 
those in AD patients (Shiarli et al., 2006).  Furthermore, this publication mentions the 
significant decrease in western blot immunoreactivity using AT8 observed via western 
immunoblotting in FTDP-17 and PiD patients compared to AD patients (Hasegawa, 
unpublished data).  As FTDP-17 and PiD are heterogenous diseases and variation in the 
phosphorylation of tau at these sites has been demonstrated between patients (Shiarli et al., 
2006), tissue from a larger cohort of patients may be required to gain statistically significant 
results to confirm changes in the levels of pSer202 tau.  
Phosphorylation of tau at Thr231 could not be detected in the temporal and frontal cortices 
of controls or patients with either PiD of FTDP-17 using RZ3 antibody.  Tau phosphorylated 
at Thr231 is associated with AD as brain lysates from healthy human controls do not react 
with this antibody via western blotting (Acker et al., 2013).  Previously, pThr231 tau has been 
demonstrated to be significantly decreased in the frontal cortices of patients with PiD and 
FTDP-17, including those with mutations in R406W and IVS 10+16, compared to patients with 
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AD (Shiarli et al., 2014).  These studies, along with the results in this study, suggest that 
hyperphosphorylation of this site may be specific to AD and not present in all tauopathies.   
6.4.4  Protein levels and expression of tau kinases in the frontal and 
temporal cortices of patients with PiD and FTDP-17 
Within the frontal and temporal cortices of patients with PiD as well as the frontal cortices 
of patients with FTDP-17, there was no significant difference in the levels of total GSK3β 
protein.  GSK3β levels have not been investigated in PiD or FTDP-17, although no change has 
been seen in the brains of patients with AD (Leroy et al., 2007).  GSK3β enzyme activity was 
not measured here, however, an indication of this can be seen by the levels of pTyr216 GSK3β 
present.  In that respect, GSK3β activity within the temporal cortices of patients with PiD was 
comparable to that within controls. Within the frontal cortices of PiD patients, however, 
pTyr216 GSK3β was found to be increased.  Previous studies have reported an increase in 
GSK3β activity within the brains with those with tauopathy.  Leroy and colleagues 
demonstrated an increase in pTyr216 GSK3β via western immunoblotting, in the frontal 
cortices of AD patients compared to controls (Leroy et al., 2007).  Another group 
demonstrated decreased inhibition of GSK3β, determined by increased phosphorylation of 
GSK3β at its inhibitory site Ser9 (Chapter 1.3.1), in the temporal cortices of AD patients 
(DaRocha-Souto et al., 2012).  The differences in activation of GSK3β within the frontal and 
temporal cortices of PiD patients could be due to differences in the regulation of GSK3β, of 
which little is known, in various brain areas, which has previously been demonstrated in mice 
overexpressing GSK3β (Fuster-Matanzo et al, 2011). 
GSK3β gene expression was not found to be significantly different in the frontal cortices or 
temporal cortices of patients with both PiD and FTDP-17 compared to controls.  These results 
reflect the similar protein levels of total GSK3β in the frontal and temporal cortices of PiD 
patients, as well as the frontal cortices of FTDP-17 patients, compared to controls.  
Additionally, these results are in line with previous studies, which overall suggest that, after 
development, GSK3β is rarely regulated through increased or decreased expression (Beural 
et al., 2015).   
Contrary to the results within this study, upregulation of GSK3β has previously been 
demonstrated within the temporal and frontal cortices of patients with ALS, a tauopathy 
related to PiD (Luna-Morenz et al., 2007), although not within the cerebellum or 
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hippocampus (Yang et al., 2008).   Another study also described altered expression of GSK3β 
within the medial temporal gyrus and the hippocampus of AD patients, although difference 
in gene expression was found within the superior frontal gyrus or visual cortex (Liang et al., 
2008).  
While there was no significant difference in the levels of p25 within the temporal cortices of 
PiD patients, p25 levels were found to be increased in the frontal cortices in comparison to 
controls.  This indicates increased activity of Cdk5 within the frontal cortices but not the 
temporal cortices of these patients.  In the frontal cortices, levels of p35 were found to be 
unchanged compared to controls.  Immunoreactivity indicating p35 was very faint and, 
unfortunately, levels within the temporal cortices could not be detected.  This is in line with 
previous reports demonstrating the rapid cleavage of p35 within a short post-mortem delay 
(PMD) in human AD and control brains (Taniguchi et al., 2001; Patrick et al., 2001), which 
would explain the low levels of p35 protein. 
The increase of p25 within the frontal cortices of PiD patients is in disagreement with a 
previous study reporting no difference in the protein levels of p25 or p35 within this area in 
PiD and FTD patients in comparison to controls (Tandon et al., 2003).  It should be mentioned, 
however, that reports of these protein levels in AD patients vary; two publications mention 
the increase of p25 in AD brains (Tseng et al., 2002; Patrick et al., 1999), whilst others were 
unable to reproduce this (Tandon et al., 2003; Taniguchi et al., 2001).  The variation in Cdk5 
activity in the frontal and temporal cortices of PiD patients compared to controls may be 
indicative of different pathological mechanisms in these two parts of the brain and could 
provide an important clue to help us to understand why certain brain regions are more 
susceptible to different neurodegenerative disease pathways.   
No significant difference in the gene expression levels of CDK5 within the frontal and 
temporal cortices of patients with PiD or FTDP-17 compared to controls was found.    
Decreased CDK5 expression has not been reported in FTD before, however, it has been 
reported in brain regions susceptible to neurodegeneration in AD patients (Liang et al., 2008, 
Liang et al., 2010). 
Levels of PAK3 protein are unchanged within the frontal cortices of patients with PiD.  
However, they are decreased within the frontal cortices of patients with FTDP-17.  Decreased 
levels of PAK3 are associated with neurodegeneration and the loss of synapses (Chapter 
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1.3.3).  Although levels of PAK3 protein have not been investigated in PiD or FTDP-17 patient 
brains, in AD levels of PAK3 have been reported to be decreased (Nguyen et al., 2008; Zhao 
et al., 2006).  These results indicate that decreased PAK3 levels are not common to all 
tauopathies, at least in the frontal or temporal cortices, and that there are regional protein 
level differences in the brains of patients with FTDP-17.   
Expression levels of PAK3 were also found to be decreased in the frontal cortices of FTDP-17 
patients compared to controls, however, were not significantly changed in the temporal 
cortices of these patients or within either cortex in PiD patients.  Although levels of PAK3 
gene expression have not been investigated within the frontal or temporal cortices of 
patients with PiD, decreased gene expression has been reported in hiPSC-dopaminergic 
neurons derived from patients with V337M MAPT and N279K MAPT (Ehrlich et al., 2015).  
Contrarily, within the midbrains of FTDP-17 patients carrying either N279K MAPT or P301L 
MAPT, PAK3 levels were found to be unchanged in comparison to controls.   Taken together, 
these results may indicate region specific alterations in PAK3 gene expression in FTDP-17, 
which is in line with region specific changes in other tau kinases in AD (Liang et al., 2008; 
Liang et al., 2010).  For example, CDK5 expression is known to vary between different brain 
regions in normal physiological function (Wu et al., 2000), AD patients (Liang et al., 2008; 
Liang et al., 2010) and in opiate users with AD-like brain changes (Anthony et al., 2010). 
6.4.5  Levels of synapsin I within PiD temporal cortex and FTDP-17 frontal 
cortex 
Levels of synapsin I in the temporal cortices of patients with PiD were significantly decreased 
compared to controls, which implicates the loss of pre-synaptic proteins in PiD.  This finding 
was expected, as the loss of synaptic proteins and synaptic dysfunction is a well recorded co-
occurrence with tauopathy.  Decreased levels of synapsin have been found in PiD patients’ 
temporal cortices (Clare et al, 2010), frontal cortices (Ferrer, 1999) and hippocampi (Lippa, 
2004).  Furthermore, decreased pre-synaptic density was reported in the frontal cortices of 
patients with FTD (Brun et al., 1995; Ferrer, 1999), although this group later reported no such 
change in the temporal cortices of these patients (Liu and Brun, 1996).   
Unexpectedly, the level of synapsin I in the frontal cortices of patients with FTDP-17 was not 
significantly different compared to controls, suggesting no loss in pre-synaptic proteins.  
Synapses have been demonstrated to be lost in the frontal cortices of FTDP-17 patients (Brun 
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et al., 1995; Clare et al., 2010; Liu and Brun, 1996; Mackenzie et al., 2009).  Counts and 
colleagues have provided evidence of varying levels of pre- and post-synaptic proteins across 
different brain regions of patients with AD and mild cognitive impairment MCI, compared to 
controls.  The group demonstrated that while synaptophysin levels were reduced by 35 % in 
the temporal cortex but not the frontal cortex, drebrin levels were reduced in the temporal 
cortex but increased in the frontal cortex in patients with MCI (Counts et al., 2006).  This 
study, carried out by Counts and colleagues, suggests a disparity in the frontal and temporal 
cortices in terms of the loss of synaptic proteins and may explain why temporal cortical 
functions, such as memory and language, are lost early in AD, while frontal cortical functions 
such as executive function, are preserved in the early stages of disease.  As the temporal 
cortices are primarily subject to neurodegeneration in patients with FTDP-17 caused by 
R406W and IVS 10+16, synaptic loss in the frontal cortices may be relatively spared.  It is 
noted that these results contain an outlier in that control 5 (lane 5; Figure 6.18) (Table 1) has 
very low band density compared to the other two controls.  Further research with a greater 
cohort of patients is required to confirm this result, which does not align with previous 
research.  Unfortunately, due to a lack of tissue it was not possible to carry out western blots 
for frontal cortex PiD patients and controls, or for temporal cortex FTDP-17 patients. 
6.4.6  Gene expression of MAPT, CDK5 and PAK3 within the nbM of patients 
with AD compared to controls 
No change in the gene expression of MAPT was detected in AD patient nbM compared to 
controls.  Previous reports on MAPT expression in AD are controversial as some studies 
report lower levels of MAPT expression (Fukasawa et al., 2017), while others report no 
change in MAPT expression levels in AD brains (Farnsworth et al., 2016; Fukasawa et al., 
2017).  MAPT mRNA has previously been found to be decreased within the entorhinal cortex, 
hippocampus, middle temporal gyrus and posterior cingulate cortex of AD patients (Liang et 
al., 2008).   
Although gene expression of CDK5 in the AD nbM was 40 % of that of controls, this result was 
not statistically significant.  CDK5 expression has been demonstrated to be decreased within 
the brains of AD patients (Liang et al., 2008, Liang et al., 2010; Fukasawa et al., 2017), 
although this is debated (Tandon et al., 2003; Borghi et al., 2002).  It should be noted 
however, that cohort sizes in the studies performed by Liang and colleagues were much 
greater than those performed by Tandon and colleagues (n=3 for both AD patients and 
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controls) and within the study published by Borghi and colleagues.  The lack of statistically 
significant change in PAK3 expression levels between AD patients and controls was also 
surprising, as PAK3 levels within the hippocampus have been demonstrated to be decreased 
with AD brains, animal models and cell-based models (Zhao et al., 2006; Nguyen et al., 2008).  
These results may be explained by variation between patients within the small cohort of 
patients examined in this study.  Indeed, CDK5 expression has previously been demonstrated 
to vary considerably between patients with AD (Tandon et al., 2003).  It may be necessary for 
increased numbers of patients to be included in studies investigating the expression of 
kinases which are known to be variable between patients to achieve a statistically significant 
result. 
 
6.5  Chapter Summary 
The results demonstrate that PiD and FTDP-17 share similarities in tau-related molecular 
pathology.  Levels of total soluble tau protein were found to be unchanged in the frontal and 
temporal cortices of PiD patients, as well as within the frontal cortices of patients with FTDP-
17, compared to controls.  Additionally, MAPT gene expression levels were increased in the 
frontal cortex in both PiD and FTDP-17 patients compared to controls.  Compared to controls, 
phosphorylation of tau at Ser396/404 was significantly increased, while phosphorylation at 
Ser202 was not significantly different, in both diseases.  In both PiD frontal and temporal 
cortices, as well as FTDP-17 frontal cortices, total GSK3β protein levels and GSK3β expression 
were not significantly different to controls. 
On the contrary, there are differences in tau-related molecular pathology between the two 
disease groups.  In the frontal cortices, PAK3 expression and protein levels were found to be 
significantly decreased in FTDP-17 patients but not in PiD patients.  Significantly decreased 
levels of synapsin I were found in patients with PiD but not within patients with FTDP-17.  
These differences in kinase expression, kinase level and synapsin I may provide insight into 
the pathogenesis of both sporadic and familial FTD.   
Brain region specific differences in protein levels and gene expression were also found in 
each disease and these differences were found to be unique to each form of FTD.  PiD 
patients, MAPT expression levels and GSK3β activity levels were increased only within the 
frontal cortices, while PAK3 expression levels were found to be decreased only in the frontal 
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cortices of FTDP-17 patients.  These specific differences in MAPT expression, as well as PAK3 
expression and GSK3β activity levels may facilitate understanding into the area of 
pathogenesis initiation in the brains of these patients. 
The limitations of using human brain tissue in research have been outlined in Chapter 1 
(Chapter 1.4.1), however, it is worth reiterating that FTD is a particularly heterogenous 
disease and therefore a large cohort of patients is preferable for use alongside biomolecular 
investigation.  While each sample from FTD patients came from either the frontal or temporal 
cortices, it is also important to note that some variability in this work may have been 
introduced through variation in the exact sampling area.  To overcome this, future studies 
should be carried out on tissue from multiple sampling areas within each cortex.  The western 
immunoblotting results in this chapter inform on the Sarkosyl soluble tau-related pathology 
in PiD and FTDP-17.  Sarkosyl insoluble fractions typically include NFTs and other entangled 
proteins, including kinases such as Cdk5 and GSK3β.  Future work carried out on Sarkosyl 
insoluble fractions, coupled with the work in this chapter, would allow a more 


















Final discussion and future work 
 
Despite decades of research and the thorough characterisation of tau pathology within the 
brains of patients with tauopathies, our knowledge of the molecular pathways involved in 
the etiopathology of these diseases remains inadequate.  The complete elucidation of these 
pathways may be critical for the development of therapies capable of overcoming the 
progression of these diseases.  One obstruction to progress is the lack of readily-available 
models that faithfully recapitulate the biomolecular pathways involved in the development 
of tauopathy in humans.  Traditional animal models of tauopathy have failed to faithfully 
recapitulate human disease, resulting in the failure of many promising drugs to clinically 
translate (Sasaguri et al., 2017).  Biomolecular studies of the human brain can be carried out 
using post-mortem tissue, however this represents end-stage disease rather than the state 
of the brain during pathogenesis. 
Models of tauopathy have been developed through the differentiation of patient-derived 
human induced pluripotent stem cells (hiPSC) to produce disease-relevant cell types.  While 
these models promise to facilitate investigation of the biomolecular pathways involved in 
early-stage disease, during which time we may be able to intercept therapeutically, the field 
is still in its infancy and it is important to research the applicability of these models. 
The purpose of this PhD project was to investigate the ability of hiPSC models of tauopathy 
to inform on tau-related molecular pathology.  hiPSC models of frontotemporal dementia 
with Parkinsonism linked to chromosome 17 (FTDP-17) and sporadic Alzheimer’s disease 
(sAD) were developed through the derivation of vulnerable neuronal subtypes from hiPSC.  
The levels of tau protein and MAPT expression were determined alongside levels of tau 
phosphorylation at sites known to be aberrantly phosphorylated in tauopathy.  The protein 
levels, activity and gene expression of three tau kinases previously implicated in tauopathy, 
GSK3β, Cdk5 and PAK3 (Chapter 1.3), were also investigated to understand the changes that 
occur in these during pathogenesis.  Levels of synapsin I were also determined to understand 
whether the loss of synaptic proteins recognised in tauopathy is recapitulated in these 
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models.  These changes in pathology were compared to those investigated within brain tissue 
in this study, and within the literature.   
It should be noted that upon the inception of this project, it was not known that only foetal 
tau is expressed within hiPSC-neurons until approximately one year of culture has passed 
(Sposito et al., 2015), which will likely affect tau pathogenesis as these diseases occur in 
adults and involve all six tau isoforms.  
 
7.1  The development of a model of frontotemporal dementia 
with Parkinsonism linked to chromosome 17 using induced 
pluripotent stem cell technology 
The causal importance of tau protein in the pathogenesis of neurodegenerative disease was 
highlighted by the discovery that mutations of MAPT result in FTDP-17.  As the underlying 
cause of sporadic tauopathy remains unclear, the development of models of tauopathy 
based on the expression of MAPT mutations offers the opportunity to investigate the 
molecular pathways involved in tau pathogenesis.  To model FTDP-17, two hiPSC clones 
(V337M-C and V337M-E), derived from a patient carrying the missense mutation valine to 
methionine at 337 (V337M) MAPT, were differentiated to produce cortical glutamatergic 
neurons (CGNs) and cultured for 50 days. 
It is not known whether tau pathogenesis in sporadic frontotemporal dementia (FTD) occurs 
through the same molecular pathways as at that within FTDP-17.  Therefore, the tau-related 
molecular pathology discovered in this model was compared to that within the frontal and 
temporal cortices of patients with both FTDP-17 and Pick’s disease (PiD).   It is hoped that 
insights gained through the study FTDP-17 pathogenesis will also be applicable to sporadic 







7.1.1 The ability of hiPSC-CGNs generated from a patient with V337M MAPT 
to model tau pathology in FTDP-17 
7.1.1.1 Comparison of levels of tau protein and MAPT expression in hiPSC and brain tissue 
Chromosomal microdeletions, microduplications and microtriplications involving MAPT have 
been demonstrated to cause syndromes involving mental retardation, thereby 
demonstrating the importance of changes in MAPT expression levels in neurological disease 
(Caillet-Boudin et al., 2015).  Despite this knowledge, few studies have examined the gene 
expression of MAPT in tauopathy.   
In this study, hiPSC-CGNs derived from a patient carrying V337M MAPT were not found to 
have significantly different MAPT gene expression levels compared to controls, in line with 
the similar levels of MAPT gene expression found within the frontal and temporal cortices of 
FTDP-17 patients and temporal cortices of patients with PiD in this study.  These results are 
in agreement with previous reports reporting similar levels of MAPT expression (van Eersel 
et al., 2009; Adamec et al., 2001).  Therefore, levels of tau protein within V337M MAPT hiPSC-
CGNs represent levels within the brain.  MAPT expression was increased within the frontal 
cortices of patients with PiD, suggesting that alterations in MAPT expression, at least in the 
temporal cortex, are also distinguished between different frontotemporal dementias.    
The expression of MAPT is regulated epigenetically by methylation.  Generally, 
hypermethylation of MAPT, leading to decreased levels of tau protein, is associated with 
neuroprotective mechanisms; in reverse, hypomethylation of MAPT is associated with 
increased levels of tau protein and neurodegeneration (Caillet-Boudin et al., 2015).  Previous 
studies have shown that MAPT DNA methylation is altered within the brains of patients with 
tauopathy in a region-specific manner.  For example, within the brains of patients with 
Parkinson’s disease, in which tau pathology is recognised, hypermethylation of MAPT is 
associated with decreased tau protein and relative sparing (Coupland et al., 2014).  
Additionally, the majority of MAPT methylation changes in the AD brain were found to occur 
within the temporal lobes, an area particularly vulnerable in this disease, and when modelled 
in vitro these changes brought about increased expression of tau (Iwata et al., 2014).  Liang 
and colleagues have also reported region-specific reductions in MAPT expression within 
vulnerable areas of the brain, including the temporal cortex, of AD patients and this has also 
been hypothesised to be neuroprotective (Liang et al., 2008).  These studies suggest that in 
tauopathy, MAPT gene expression may vary in specific brain regions compared to healthy 
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brains and that this variation contributes to pathology.  Further research into MAPT 
methylation changes due to disease would be useful to understand if this form of epigenetic 
regulation is affected in FTDP-17 and PiD.  Indeed, highly reproducible DNA methylation 
changes are associated with human ageing (Koch et al., 2011) and may provide the link 
between age and tauopathy.  Mice are often used in epigenetic studies, however, hiPSC-
neuron models may be more ideal for this investigation due to the differences between 
mouse and human epigenetic regulation (Wagner, 2017).  
In a previous study levels of MAPT expression were shown to correlate with tau protein 
expression (Trabunzi et al., 2012).  Levels of soluble tau in the frontal cortices of patients with 
PiD may not represent MAPT expression because these protein levels do not take into 
account potential levels of excess, Sarkosyl-insoluble, aggregated tau.  Further investigation 
into the insoluble levels of total tau protein, coupled with the reported levels of insoluble 
tau, may reveal a correlation in changes in tau protein levels with changes in MAPT 
expression in the frontal cortices of these patients.   
7.1.1.2 Tau phosphorylation in hiPSC-neurons and brain tissue 
The hallmark of tauopathies is the accumulation of hyperphosphorylated tau within the 
brain.  Abnormal phosphorylation of tau initiates a pathological sequence of events, which 
ultimately leads to neurodegeneration.  These include the loss of microtubule stability, 
dysfunction in cellular transport, the aggregation of tau, the loss of synapses and the 
dysregulation of critically important cellular pathways.  Phosphorylation of tau in tauopathy 
is thought to occur sequentially.  The sequential phosphorylation has been investigated 
within AD, but not FTD.  In AD, phosphorylation at pThr231 is thought to be a very early event, 
which is followed by phosphorylation at pSer202 and subsequently pSer396/Ser404 (Luna-
Munoz et al., 2007).  Phosphorylation of tau at Ser396/404 is a well-known indicator of tau 
pathology and is associated with later stages of tau phosphorylation (Luna-Munoz et al., 
2007).  Tau was found to be abnormally phosphorylated in hiPSC-neurons carrying MAPT 
mutations compared to controls.   
In FTDP-17 and PiD frontal cortices, levels of pSer396/404 were predictably increased.  While 
increased phosphorylation at pSer396/404 was found in hiPSC-CGN derived from one clone, 
V337M-E, levels were not found to be significantly altered in the other ,V337M-C, indicating 
clonal variability.   
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Phosphorylation at Ser202 was found to be increased in V337M MAPT hiPSC, in line with 
previous studies demonstrating increased phosphorylation of tau within the midbrains of 
patients with this mutation (Ehrlich et al., 2015), PiD patient brains (Zhukareva et al., 2002; 
Espinoza et al., 2008; Koga et al., 2017; van Eersel et al., 2009; Nölle et al., 2013) and within 
the brains of patients with FTDP-17 caused by G272V MAPT (Nölle et al., 2013).  Surprisingly, 
in this study, no significant change in pSer202 tau was determined in the frontal cortices of 
patients with FTDP-17, as well as the frontal and temporal cortices of PiD patients, contrary 
to previous reports.  In each case the mean of the levels was found to be greater than that 
of controls, however, and there was a trend towards increased phosphorylation at this site 
within the frontal cortex of PiD patients. As discussed in Chapter 6  (Chapter 6.4.2), this may 
be due to heterogeneity and an increased cohort size may provide clarity on this result.  
Another reason for the lack of significantly increased phosphorylation at this site may be the 
fact the tau investigated was Sarkosyl-soluble tau, and tau phosphorylated at this site may 
have been sequestered into Sarkosyl-insoluble aggregations of tau, as it has been shown to 
decorate Pick Bodies previously (Zhukareva et al., 2002; Espinoza et al., 2008; Koga et al., 
2017; van Eersel et al., 2009; Nölle et al., 2013).   
In V337M MAPT hiPSC-CGNs, tau phosphorylation at Thr231 was considerably decreased 
compared to controls while staining was too weak to detect levels on western immunoblots 
of lysates derived from brain tissue of controls, FTDP-17 patients or PiD patients.  This was 
surprising, as increased levels of pThr231 tau within the brains of patients with AD are widely 
reported (Acker et al., 2013; Beurger et al., 2002) and tau aggregations in FTLD patients 
positively immunostain with antibodies against pThr231 tau (Moszczynski et al., 2017).  
Interestingly, levels of pThr231 tau in the brains of patients with FTDP-17 (Shiarli et al., 2014) 
and in the CSF of patients with FTD (Buerger et al., 2002) are much closer to that of controls 
than AD and levels in CSF can be used to discriminate between the two diseases  (Buerger et 
al., 2002).  While further research into the levels of pThr231 tau within the brains of patients 
with FTDP-17 and PiD would be useful to understand if levels are decreased compared to 
controls, the results in V337M MAPT hiPSC-CGN suggest that in early disease tau 
phosphorylation at this site is decreased.  Interestingly, phosphorylation of tau at Thr231 has 
been demonstrated to be a consequence of increased GSK3β activity leading to the 
detachment of tau from the microtubules (Moszczynski et al., 2014; Cho and Johnson, 2004).   
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7.1.3 Changes in kinase expression, levels and activity in hiPSC-neurons and 
brain tissue 
The abnormal phosphorylation of tau occurs through dysregulation of tau kinases and 
phosphatases in tauopathy (Bodea et al., 2015; Dolan et al., 2010; Martin et al., 2013).  The 
molecular pathways responsible for these alterations in these kinases and phosphatases are 
not well understood.  Despite this, the involvement of GSK3β and Cdk5 in tauopathy is well 
reported (Dolan et al., 2010; Martin et al., 2013) and therapeutics targeting the activity of 
both kinases have been developed to limit tau phosphorylation; whilst promising in murine 
models of disease, the intended effects of these did not translate in humans (Vell et al., 2013; 
Tolosa et al., 2014; Lovestone et al., 2015).  Comparatively little research has been carried 
out on the involvement of PAK3 in tauopathy, however, recently this kinase has been shown 
to be downregulated in V337M MAPT hiPSC-dopaminergic neurons (Ehrlich et al., 2015), 
indicating that it may be involved in pathogenesis.   
The gene expression, protein levels and activity of Cdk5 and GSK3β were investigated, 
alongside the gene expression and protein levels of PAK3 to understand if these are altered 
in V337M MAPT hiPSC-CGNs and patient brain tissue.  Through elucidating the mechanism, 
and time-frame (i.e. early-stage disease verses late-stage disease), during which these 
kinases become dysregulated in tauopathy we may be able to further refine therapeutics to 
render them effective. 
CDK5 expression was not found to be significantly altered in V337M MAPT hiPSC-CGN or 
within both the frontal and temporal cortices of those with FTDP-17 and PiD, demonstrating 
that hiPSC carrying V337M MAPT recapitulate this lack of expression change.  The activity of 
Cdk5, determined by an increase in p25 or a decrease in p35, was found to be increased in 
both V337M-hiPSC CGNs and within the frontal cortex of patients with PiD, demonstrating 
that Cdk5 activity in PiD is recapitulated in this model.  Unfortunately, due to a lack of tissue 
p25 and p35 levels within the frontal cortex of FTDP-17 patients could not be examined.  
These results implicate alterations in Cdk5 kinase activity both in the pathogenesis and later 
stages of FTD-tau. 
V337M MAPT hiPSC-CGN recapitulate altered protein levels of PAK3 within FTDP-17 brain 
tissue.  PAK3 protein levels were significantly decreased in V337M MAPT hiPSC-CGNs derived 
from one hiPSC clone (V337M-C) and there was a trend towards decreased levels in CGNs 
derived from the other (V337M-E) (p= 0.0601).  Reduced PAK3 levels were also found within 
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R406W and IVS 10+16 MAPT patient frontal and temporal cortices, demonstrating that a 
reduction in PAK3 protein levels is not specific only to FTDP-17 caused by the V337M MAPT 
mutation.  Recently, it has been demonstrated that downregulation of PAK1 activity, which 
shares functional overlap with PAK3, during the treatment of dopaminergic neurons to 
induce oxidative stress, correlates with neurodegeneration (Kim et al., 2016).  In light of this 
study, these results suggest that decreased PAK3 levels, within hiPSC-CGNs and cortex tissue, 
may be representative of neurodegenerative pathways.  The recapitulation of these protein 
and gene expression changes demonstrate the suitability of this model for further 
investigation into this pathway and the activity levels of PAK3 in FTDP-17.On the other hand, 
in the frontal and temporal lobes of patients with PiD, levels of PAK3 protein were not found 
to be statistically different to those within controls, suggesting that changes in the protein 
levels of PAK3 are not involved in pathogenesis in this disease.   
The gene expression of PAK3 was not found to be statistically different in V337M MAPT 
hiPSC-CGNs, contrasting previously reported findings by Ehrlich and colleagues on expression 
levels within hiPSC-dopaminergic neurons (Ehrlich et al., 2015).  Similarly, within the frontal 
and temporal cortices of PiD patients, as well as the temporal cortices of patients with FTDP-
17, PAK3 expression was not significantly different compared to controls.  In line with these 
results, the expression of PAK3 in the midbrains of V337M MAPT FTDP-17 patients has been 
measured previously and the authors concluded no change in gene expression within the 
midbrains of these patients (Ehrlich et al., 2015).   
PAK3 expression was, however, found to be decreased within the frontal cortex of patients 
with FTDP-17, which may suggest that PAK3 expression levels are altered in a regionally 
specific manner within the brains of these patients.  One possible pathway through which 
MAPT mutations could cause a reduction in PAK3 expression is through tau’s role in the 
potentiation of activating protein 1 (AP-1) activity, which occurs in response to nerve growth 
factor (Leugers and Lee, 2010); AP-1 regulates the activity of PAK3 such that overexpression 
of AP-1 leads to increased levels of PAK3 expression (Parker et al., 2013).  Mutations in MAPT 
may hinder the ability of tau to influence the activity of AP-1, thereby resulting in decreased 
levels of PAK3.   
Within V337M MAPT hiPSC-CGN, gene expression of GSK3β was not found to be significantly 
different in comparison to controls, recapitulating the gene expression levels found within 
the frontal and temporal cortices of patients with FTDP-17 or patients with PiD, in which 
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GSK3β gene expression was not found to be significantly different compared to controls.  
Total levels of GSK3β within V337M-CGN were found to be significantly increased within one 
clone, V337M-E, although unchanged within the other, V337M-C, indicating clonal variability 
in this model.  Additionally, no significant differences compared to controls were found in 
the total levels of GSK3β within the frontal cortices of patients with FTDP-17 or PiD.  
Together, these results suggest that changes in the protein levels of GSK3β are not likely to 
be involved in disease pathogenesis or progression.   
The activity of GSK3β was found to be decreased in V337M-E-CGN compared to controls, 
whereas it was found to be increased in the frontal cortices of PiD patients and unaltered in 
the temporal cortices of these patients.  Additional research is required to understand 
whether GSK3β activity plays a role in disease pathogenesis or progression in FTD, however, 
these results indicate that GSK3β activity within PiD patient brain tissue is not recapitulated 
in this hiPSC model of FTDP-17. 
The phosphorylated form of Akt, another tau kinases, was also investigated within the cells 
of this hiPSC-neuron and levels were found to similar compared to controls, suggesting that 
increased levels of the active, phosphorylated form of this tau kinase are not involved in 
FTDP-17. 
7.1.4  Comparison of levels of synapsin I in hiPSC and brain tissue  
The dysfunction and loss of synapses is thought to be an early event in tauopathy and to 
contribute to the dichotomous loss of neurons throughout the brain as functional 
connections between neurons are lost (Selkoe et al., 2002; Bodea et al., 2016).  
Hyperphosphorylated tau causes the loss of synapses through several pathways (Zhao et al., 
2017; Spire-Jones et al., 2014).  The levels of synapsin I, a pre-synaptic protein demonstrated 
previously to be lost in neurodegenerative disease, were determined within V337M MAPT 
hiPSC-CGNs to investigate the ability of these to recapitulate this aspect of disease.  Levels of 
synapsin I were found to be decreased in hiPSC-CGNs, indicative of tauopathy and 
demonstrating that the loss of synaptic proteins is affected very early in disease 
pathogenesis, since these neurons are thought to be equivalent to foetal neurons in age.  
Although this is also strongly replicated in the PiD post-mortem temporal cortex, the 
reduction seen in the tissue from the FTDP-17 patients was not significant due to an outlier 
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in one of the controls.  Replicate values from the controls were unsatisfactory but there was 
not enough tissue to replicate this experiment.   
7.1.5  Summary of results 
V337M MAPT hiPSC-CGNs recapitulated important tau-related pathology found in FTD 
patients, including the abnormal phosphorylation of tau and the loss of the pre-synaptic 
protein, synapsin I.  This indicates that this model would be a useful tool for investigating the 
biomolecular pathways involved in aberrant tau phosphorylation and the early loss of 
synapses in FTD.   
This study has also demonstrated the value of using hiPSC-CGN derived from patients with 
MAPT mutations to investigate biomolecular differences in disease, which may underlie the 
pathological phosphorylation of tau.  The protein levels of PAK3, a tau kinase under-
investigated in tauopathy, were found to be decreased within V337M MAPT hiPSC-CGNs as 
well as within the frontal and temporal cortices of patients with FTDP-17.  Since PAK3 
expression was not found to be downregulated in V337M MAPT hiPSC-CGNs or the temporal 
cortices of patients with FTDP-17 this suggests that PAK3 levels are reduced through a 
pathological mechanism that does not target PAK3 gene expression.  Similarly, the results 
gained from V337M MAPT hiPSC-CGNs and the frontal cortices of patients with PiD in this 
study suggest the activity of the Cdk5 is increased, in FTD-tau.   
Although protein levels of GSK3β and GSK3β gene expression were not significantly different 
compared to controls within the frontal and temporal cortices of FTDP-17 and PiD patients, 
or within V337M MAPT hiPSC-CGN, the activity of this kinase within V337M MAPT hiPSC-
CGNs did not mirror that observed within tissue from either PiD or FTDP-17 patients.  The 
inability of the model to replicate this aspect of tauopathy could be attributed to a number 
of limitations inherent in modelling with hiPSC-neurons.  GSK3β is involved in neural 
development and these cultures of hiPSC-neurons, at day 50, are now thought to be 
equivalent in age to those within the developing foetus, exemplified by the production of 
only foetal tau isoforms in hiPSC-neurons before day 365 of culture (Sposito et al., 2015).  
The pathways altered in adults due to pathological tau leading to increased GSK3β activity 
may respond differently in these ‘young’ neurons.  The limitation of age in hiPSC-neuron 
modelling is discussed later (Chapter 7.3.1).  Furthermore, GSK3β is involved in a concert of 
cellular signalling pathways within the brain, some of which may be influenced by the 
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presence of other cell types within the brain.  Increased GSK3β activity may not be 
recapitulated in this model, therefore, due to a lack of faithful recapitulation of the disease 
niche.  This limitation is discussed later (Chapter 7.3.3).  Levels of active GSK3β varied 
between the two clones indicating clonal variation, which is a limitation of hiPSC-models that 
is well reported (Hallman et al., 2015; Liang and Zhang, 2013) and discussed later (Chapter 
7.3.4).   
GSK3β activity is also regulated by phosphorylation of GSK3β at Ser9, which inhibits its 
activity (Hanger and Noble, 2011).  It is possible that a more accurate depiction of GSK3β 
activity may be gained through analysis of levels of GSK3β phosphorylated at Ser9.   
The lack of difference between MAPT expression in V337M MAPT hiPSC-CGNs mirrors MAPT 
expression within the FTDP-17 frontal and temporal cortices, as well as within the PiD 
temporal cortices, but not within the PiD frontal cortices where greater levels of MAPT 
expression were measured compared to controls. Further study is also required to 
understand the mechanisms behind region-specific and disease-specific MAPT expression 
changes in PiD frontal and temporal corticies.    
 
7.2  The development of a model of Alzheimer’s disease using 
pluripotent stem cell technology 
Most AD models, including those developed using hiPSC technology, have been developed 
through the expression of mutations associated with familial AD (fAD), which is much more 
rare compared to sAD.  sAD remains particularly difficult to model due to the unknown 
aetiology of the disease.  Studies in which sAD has been modelled using patient derived 
hiPSC-neurons, have reported large phenotypic variation between lines from different 
patients; in studies by Israel and colleagues (Israel et al., 2012) as well as Kondo and 
colleagues (Kondo et al., 2013) only one out of two sAD lines studied demonstrated 
phenotypes comparable to those observed in hiPSC-neurons derived from patients with fAD.  
As sAD does not have a genetic cause, the use of gene editing techniques to create isogenic 
lines are not helpful here.    
The aberrant molecular pathways involved in sAD are numerous, exceedingly complex and 
poorly understood; however, previous research has provided substantial evidence 
suggesting Aβ pathology initiates and exacerbates tau pathology through various pathways.  
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Therefore, during this project, a model of sAD was developed to investigate Aβ-induced tau 
pathogenesis and the same tau-related molecular pathology measured within V337M MAPT 
hiPSC-derived neurons was investigated in this model.  The presence of neuronal varicosities 
was also investigated.  These results were compared to those within the literature, while 
changes in gene expression levels of MAPT, CDK5 and PAK3 were also compared to those 
within the basal forebrain nucleus of Meynert (nbM) of AD patients compared to healthy 
patients.   
To model sAD, the control hESC line Shef 6 and the control hiPSC line Nas 2 were 
differentiated to produce both bfCNs and CGNs, which are particularly vulnerable in this 
disease.  Aβ 1-42 oligomers (Aβ42O) were applied to the hPSC-neurons for 48 hours, at 
concentrations of 0.1, 0.5 and 1 μM, to investigate the molecular tau-related pathology 
induced by this treatment.   
The following paragraphs review the molecular tau-related pathology found within these 
models and compare this to that observed within the nbM tissue of AD patients and to 
previously reported pathology. 
7.2.1  The ability of hPSC-neurons treated with Aβ42O to model tau 
pathology in AD 
7.2.1.1  MAPT expression, levels of tau and the phosphorylation of tau  
The presence of increased levels of tau and abnormal hyperphosphorylation of tau are 
considered the hallmarks of AD pathology alongside Aβ pathology (Luna-Munoz et al., 2007) 
but these are not recapitulated within this sAD model.  Levels of total tau were not increased 
within Nas 2-bfCNs, Shef 6-bfCNs or Shef 6-CGNs after the application of any concentration 
(0.1, 0.5 or 1 μM) of Aβ42O over 48 hours.  While this was not surprising since no other sAD 
hiPSC-model has replicated the increased levels of tau found in the AD brain, recapitulation 
of increased tau levels has been achieved in two fAD hiPSC-models (Moore et al., 2015; Choi 
et al., 2014).   
Through determining the properties of models in which increased total tau was 
demonstrated, we may be able to understand how this sAD model can be improved upon in 
the future.  One sAD model, based on the application of Aβ to hiPSC-neurons over 8 days, 
reported similar levels of total tau after treatment (Nieweg et al., 2015), which suggests that 
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the lack of recapitulation of increased total tau would not be overcome by lengthening the 
period of Aβ treatment from 48 hours up to 8 days.  It remains to be determined whether 
treatment with Aβ42O throughout the differentiation and maturation of hiPSC-neuron 
cultures could bring about an increase in total tau.  Additionally, hiPSC-CGNs within the 
model reported by Nieweg and colleagues were matured for approximately 14 weeks after 
the start of the differentiation protocol as opposed to 50 days for hiPSC-CGNs in this study, 
suggesting that further ‘ageing’ of the cells through prolonged culture would not coax the 
appearance of increased levels of tau either.   
Moore and colleagues reported increased levels of total tau in V717L APP or APP duplication 
hiPSC-forebrain neurons cultured for 90 days.  These cultures were described as three 
dimensional (3D) as these had developed into thick monolayer cultures over a culture period 
of 90 days (Moore et al., 2015).   Choi and colleagues also reported increased total tau within 
3xfAD (K670N/M671L,V717L APP/ΔE9 PSEN1) hiPSC-neurons cultured for approximately 70 
days within a 3D culture system (Choi et al., 2014).  As other hiPSC-models based on fAD 
mutations have also failed to demonstrate increased levels of tau protein, these models 
suggest that culture of hiPSC-neurons within 3D culture systems may allow for this aspect of 
AD to be replicated.   One explanation for this, given by Moore and colleagues, could be that 
3D culture systems allow for the accumulation of tau within neurons.   
No statistically significant changes in tau phosphorylation levels at sites Ser202 or Ser396/404 
were brought about through the treatment of hPSC-bfCNs with 0.1, 0.5 or 1 μM Aβ42O or of 
hPSC-CGNs treated with 0.5 μM Aβ42O, over a period of 48 hours.  Nieweg and colleagues 
reported increased levels of pSer202/Thr205 tau, as well as pThr231 tau, within hiPSC-
neurons cultured for 14 weeks and treated with Aβ for 8 days (Nieweg et al., 2015), 
suggesting that increased ‘ageing’ of neurons through longer culture periods or the 
application of Aβ over a longer period may be necessary to achieve changes in ptau within 
sAD hiPSC-neuron models based on the application of Aβ to otherwise healthy neurons.  
Indeed, within studies using hiPSC-neurons derived from patients with fAD long-term culture 
has been demonstrated to be necessary before observed ptau levels significantly exceed 
those of controls.  For example, Raja and colleagues detected increased ptau at 90 days but 
not at 60 days (Raja et al., 2016).   
No significant change in the expression of MAPT was found within hPSC-bfCNs and hPSC-
CGNs treated with Aβ42O, which reflects levels of MAPT expression within AD patient nucleus 
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basalis of Meynert (nbM) tissue found in this study.  These results align with recently 
reported levels within AD brain tissue (Fukasawa et al., 2017; Farnsworth et al., 2016) and 
fAD hiPSC-glutamatergic neurons (Moore et al., 2015).   
7.2.2  Activity levels and expression of kinases 
The levels, activity and gene expression of tau kinases GSK3β, Cdk5 and PAK3 were 
investigated within these hPSC-neurons after treatment with Aβ42O.  The purpose of this 
work was to investigate the AD-related pathways through which Aβ influences the tau 
kinases GSK3β, Cdk5 and PAK3.  
Within Shef 6-CGN treated with 1 μM Aβ42O and Nas 2-bfCN treated with 0.5 or 1 μM Aβ42O, 
no significant difference in the gene expression of GSK3β was found compared to controls, 
in line with levels found in AD patient nbM tissue.  These results disagree with reported 
downregulation of GSK3β within hiPSC-neurons derived from a patient with sAD (Hossini et 
al., 2015).   The activity of GSK3β has been demonstrated to be increased in V717L APP hiPSC-
CGNs and a within mixed population of hiPSC-derived neurons carrying a duplication of APP 
(Muratore et al., 2014; Israel et al., 2012).  In contrast, decreased GSK3β activity was 
indicated in Shef 6-CGN treated with 0.5 μM Aβ42O, while no difference in activity was noted 
for Shef 6-CGN cultures treated with 1 μM Aβ42O in comparison to controls.   
Similarly, in Nas 2-bfCN treated with 0.5 μM Aβ42O and Shef 6-bfCN treated with 1 μM Aβ42O 
CDK5 gene expression was unchanged by treatment compared to controls.  These results 
recapitulate CDK5 expression levels within AD nbM tissue, which were found to be not 
significantly different to controls, despite a decrease of 40% in mean value of gene expression 
compared to controls.  Within the literature, CDK5 expression has been reported to be 
downregulated in studies using large cohorts of patients (Fukasawa et al., 2017; Liang et al., 
2008), and within hiPSC-neurons derived from a sAD patient (Hallmann et al., 2015).  
However, no change in CDK5 expression has also been reported upon comparison of AD 
brains and health patient brains (Tandon et al., 2002).  Further investigation into the 
expression of CDK5 is required to clear this point of contention within the literature.  Within 
Shef-6 CGN treated with 1 μM Aβ42O, levels of p35 were decreased, suggesting increased 
Cdk5 activity, however, this was not found within Nas2-bfCN treated with 0.5 μM Aβ42O.   
These results suggest that Cdk5 and GSK3β activity is affected in different ways within these 
two cell types; bfCNs and CGNs.  As these represent the basal forebrain and cerebral cortex, 
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respectively, investigation using these may provide insight into the progression of AD.  
Additional research using these two hPSC-derived neuronal subtypes in tandem within 
investigations using hiPSC-neuron models would allow for further characterisation of their 
differences in response to Aβ42O.  Additionally, concurrent differentiation of hiPSC-bfCNs and 
hiPSC-CGNs from fAD patients would also be useful to confirm changes recognised through 
treatment with Aβ42O as fAD and sAD are generally associated with the same pattern of 
progression of aggregated Aβ and tau pathology in the brain.   
The levels of PAK3 were unaltered by treatment of Shef 6-CGN or Nas 2-bfCN with 1 μM and 
0.5 μM Aβ42O, respectively.  Additionally, gene expression of PAK3 was also unaltered by 
these treatments.  This result reflects gene expression within AD nbM tissue.  These results 
disagree with previous research demonstrating that PAK3 levels are decreased within the AD 
brain, however, these were examined within the hippocampus (Nguyen et al., 2008; Zhao et 
al., 2006).  It would be useful to carry out this investigation again with a larger cohort of 
patient brain tissue to rule out heterogeneity in the non-significant result.   
7.2.3  Comparison of levels of synapsin I in hPSC-neurons treated with 
Aβ42O  
Tau and Aβ pathology have been linked to the loss of synapses in AD mouse models and 
within AD patient brains, a parameter that correlates with cognitive decline in this disease 
(Palop and Mucke, 2010; Palop et al., 2006).  Treatment of Shef 6-CGN with 1 μM Aβ42O 
replicated the loss of synaptic proteins reported in AD, indicating that this particular 
treatment of hPSC-derived CGNs would be useful for investigating the mechanisms 
underlying synaptic loss in this disease.  Treatment of Nas 2-bfCN with 0.5 μM Aβ42O, 
however, failed to replicate this important feature of neuropathology.  This disparity could 
be due to differences in the reaction of the two cell types studied to the application of Aβ, 
discussed in Chapter 5 (Chapter 5).  Aβ42O bring about missorting of tau into the dendrites, 
which leads to the loss synapses (Zempel et al., 2010). 
7.2.4  Varicosities  
In Nas 2-bfCNs, treatment with 1 μM Aβ42O resulted in the development of varicosities within 
the lengths of select neurons containing mitochondria and an abnormal conformation of tau 
associated with tau pathology in AD.   Axonal varicosities are well documented in AD (Geula 
et al., 2008; Grutzendler et al., 2007; Notter and Knuesel, 2013; Terwel et al., 2002) and are 
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thought to represent microtubule transport dysfunction, leading to accumulation of cell 
organelles and pathological conformations of tau (Mertens et al., 2013; Krstic and Knuesel, 
2012; Khan and Bloom, 2016).  These varicosities are found in AD and have been previously 
replicated in AD hiPSC-neurons (Choi et al., 2014).   
7.2.5  Summary of results  
This model failed to replicate reported hyperphosphorylation of tau in AD at phosphorylation 
sites pSer202 and pSer396/404.  Since phosphorylation of tau is an important and invariable 
aspect of AD pathology this model may not be suitable for the investigation of pathology 
downstream of overt phosphorylation in tau.  No changes in total tau levels, usually found to 
be increased within AD brains, was observed deeming this model unsuitable for studying the 
causal mechanisms of tau accumulation in AD. 
The inability of this model to recapitulate important, previously reported AD pathology may 
be explained by more general limitations in modelling tauopathy using hiPSC-neuron models, 
described below (Chapter 7.3).  However, it is possible that these limitations also arise from 
the limitations of 48-hour treatment with Aβ42O to model AD.  This acute treatment may not 
be sufficient to induce changes that in human disease, culminate over decades to result in 
the pathogenic hallmarks of AD.   
Nevertheless, treatment of Nas 2-bfCNs with 1μM Aβ42O did cause the appearance of 
varicosities in neurons, recapitulating these found within the AD brain and suggesting that 
microtubule transport was affected by the treatment.  This model may, therefore, provide 
insights into microtubule transport deficits in AD within these human neurons.  Furthermore, 
treatment of Shef 6-CGNs with 1μM Aβ42O replicated the loss of pre-synaptic proteins, 
through decreased levels of synapsin I, recognised as an early event in AD pathology.   
Aβ-induced alterations in the activity of kinases were also recognised; levels of GSK3β activity 
were increased in Nas 2-bfCNs treated with 0.5 μM Aβ42O.  Additionally, decreased p35 
levels, indicative of decreased Cdk5 activity, were found within Shef 6-CGN treated with 1 
μM Aβ42O.  These results indicate that while overt changes in tau were not discovered, this 
model may be suitable for studying early changes in the molecular pathways that contribute 
to aberrant tau phosphorylation. 
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Finally, comparison of the different responses, in activity of tau kinases Cdk5 and GSK3β, to 
Aβ42O within these two cell types demonstrates that culture of specific neuronal subtypes 
derived from hiPSC may be used to understand the different behaviours of these cell types 
in AD.  These differences in kinase activity may explain the regional progression of AD with 
further research. 
 
7.3  Limitations and future development of models 
7.3.1  Limitations of hiPSC-neuron models to recapitulate the aged 
phenotype of neurons in the brains of patients with tauopathy 
Identifying phenotypes in hiPSC-neurons modelling tauopathies, where aging is the main risk 
factor, is challenging due to the current limitations of these models.  Upon the inception of 
hiPSC-neuron models it was suggested that the epigenetic profile of the donor patient cells, 
also known as ‘age memory’, may be retained by these cells allowing for the production of 
‘aged’ neurons.  Since then, it has become apparent that the ‘age memory’ is lost during 
hiPSC-reprogramming (Miller et al., 2013), therefore, the neurons derived from patient 
hiPSC-neurons are equivalent in age to those found during foetal development.  In terms of 
modelling tauopathy this property of hiPSC-neurons is particularly problematic; firstly, it is 
believed younger neurons may be more resilient to neurodegeneration caused by tauopathy 
and so the changes brought on over decades within human aged-neurons may not be 
recapitulated in these; and secondly these neurons produce only the foetal isoform of tau 
(3R0N) until day 365 (Sposito et al., 2015), whereas in AD and FTD all six isoforms of tau are 
involved in pathogenesis (Ghetti et al., 2015) preventing faithful recapitulation of disease.  
Additionally, foetal tau is heavily phosphorylated at many of the same sites found to be 
hyperphosphorylated in tauopathy, which may restrict identification of changes in 
phosphorylation of tau due to disease processes in these models.   
Currently, we do not have an ideal solution enabling this challenge to be overcome as the 
neurobiology of aging is poorly understood and therefore cannot be accurately replicated in 
vitro.  Protocols involving direct conversion of fibroblasts to neurons are reported to allow 
the production of neurons that retain the age-specific transcriptional profile of donor cells, 
which may support the development hiPSC-neuron models which are more susceptible to 
tau pathology (Mertens et al., 2015).  Miller and colleagues have expressed progerin, to 
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induce premature aging in hiPSC-neurons (Miller et al., 2013); when paired with genetic 
alterations resulting in tauopathy, this may allow for overt tau pathology to be replicated in 
these models, however, it is unknown whether tau pathology will occur through alternate 
molecular pathways to those which occur within the human brains of patients with these 
diseases.  Further optimisation of culture methods, for example through three dimensional 
(3D) culture, co-culture with other neural cell types and the use of optimised media 
compositions (Bardy et al., 2015), have been demonstrated to support earlier maturation of 
neurons, which may also improve the ability of these models to recapitulate tau pathology.   
7.3.2  Limitations of hiPSC-neuron models to recapitulate the latency of tau 
pathogenesis 
In these age-related tauopathies, pathology develops and progresses over decades.  
Furthermore, there is evidence suggesting that, during the progression of disease, pathways 
responsible for tau pathogenesis become modulated; for example, levels of PAK3 are 
reduced in early AD, and increased in late-stage AD (Chapter 1.3.3).  This may explain why 
tau hyperphosphorylation has not been observed in many hiPSC-models of tauopathy and 
why Raja and colleagues reported a lack of tau hyperphosphorylation in their hiPSC-model of 
AD at 60 days of culture, while at 90 days hyperphosphorylation of tau at Thr181 and Ser396 
was detected (Raja et al., 2016).  
Although the ability to culture hiPSC-neurons for extended periods has been recently 
drastically improved, with hiPSC-neurons reportedly cultured for 365 days (Sposito et al., 
2015), this time period of culture falls short of the 30 or so years required for the 
development of tau pathology within the human brain.  Furthermore, extended maintenance 
of these cultures is costly and technically challenging.  One solution to overcome this 
challenge may involve subjecting the cultures to environmental stressors to coax the early 
appearance of overt pathology, however, this may lead to the development of models that 
recapitulate the overt pathology of disease through different molecular pathways to those 
that occur in the adult brain, further obscuring the development of therapeutics aimed at 
interrupting these pathways.  This limitation of hiPSC-neuron modelling may constrain the 
use of the models for investigation of early-stage tau pathogenesis.   
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7.3.3  Limitations in recapitulating the disease niche 
A conspicuous limitation in the use of hiPSC-neurons to model tauopathy is the difficulty in 
replicating the complex disease niche of the human brain.  Some aspects of disease pathology 
have been demonstrated to be replicated in vitro, within this study and in previous studies 
detailed in Chapter 4.1 and Chapter 5.1, using hiPSC-neurons; however, the complex 
cytoarchitecture of the brain and the effects of interactions with other cell types in the brain 
are not modelled by monolayer cultures of pure hiPSC-neurons.  While these limitations of 
in vitro modelling are challenging to overcome, recent advancements presage the possibility 
of more physiologically accurate cultures in the future.   
Glial cells have important roles in tauopathy.  In AD, astrocytes associate with Aβ plaques 
(Rinaldi and Caldwell, 2013), are capable of internalising and degrading Aβ (Wyss-Coray et 
al., 2003; Koistinaho et al., 2004) and exhibit cellular stress, which is thought to contribute 
to neurodegeneration through decreased antioxidant support of neurons (Abramov et al., 
2003).  Microglial cells are important components of the inflammatory response recognised 
in AD pathology and microglial inflammatory activity has been demonstrated to be increased 
in AD, while protein clearance mechanisms are reduced (Sarlus and Heneka, 2017).  Microglia 
also play important roles in the molecular pathways that transduce Aβ-induced tau 
hyperphosphorylation, illustrated by Figure 1.2.3 (Figure 8.1, Chapter 1.2.3), through 
increased inflammatory response.  Future models of tauopathy would, therefore, benefit 
from the development of co-cultures of neurons with glial cells, aimed at replicating the 
disease niche more faithfully.   
Culturing hiPSC-neurons with primary murine and human astrocytes supports long-term 
culture, shortens the maturation period of neurons and supports maturation of functional 
synaptic connections (Kuijlaars et al., 2016; Odawara et al., 2014).  Astrocytes have now been 
derived from healthy, AD (Kondo et al., 2013) and FTDP-17 (Hallmann et al., 2017) patient 
hiPSC, which have also been demonstrated to improve the ability of neurons to produce 
mature action potentials and reduce variability associated with introducing astrocytes from 
different species or patients (Gunhanlar et al., 2017).   Recently, protocols for the derivation 
of microglia from hiPSC have been published (Haenseler et al., 2017; Douvaras et al., 2017; 
Muffat et al., 2016); one of these studies exhibited greater physiological accuracy in these 
models, demonstrating a decreased  pathogen-response pathway (Haenseler et al., 2017).  
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Future research using these models may help us to understand more clearly the molecular 
influence of these glial cells in tau pathogenesis in neurons.   
3D models of tauopathy have also been developed, which employ 3D scaffolds culture and 
the generation of cerebral organoids, described as miniature brain models, with discrete 
areas representing brain regions, in attempt to model the complexity of neural connectivity 
in the brain.  Four publications detailing 3D AD hiPSC-neuron models have been published 
(Lee et al., 2016; Zhang et al., 2014; Choi et al., 2014; Raja et al., 2016), which demonstrated 
AD phenotypes that could not be observed in 2D models.  Zhang and colleagues observed 
abnormal translocation of PAK within hiPSC-neurons in their 3D system, but not in a 2D 
system (Zhang et al., 2014), while Choi and colleagues, along with Raja and colleagues, have 
developed the only hiPSC-models of AD in which aggregates of tau and Aβ within neurons 
were observed (Raja et al., 2016; Choi et al., 2014).   
7.3.4  Overcoming clonal variability between hiPSC-neuron cultures 
Clonal variability, which affects the disease phenotype modelled by hiPSC-neurons created 
from the same person’s hiPSC, is well reported throughout the literature on modelling 
neurodegenerative disease using hiPSC-neurons (Hallmann et al., 2015; Martelli et al., 2012; 
Ehrlich et al., 2015; Yokobayashi et al., 2017; Sheridan et al., 2011).  A number of reasons 
have been suggested for this including sources of variation that occur during reprogramming 
and differentiation of these cells (Liang and Zhang, 2013; Vitale et al., 2012).   
It is possible to use gene editing techniques, such as zinc finger nuclease editing technology 
(Hockemeyer et al., 2009) and CRISPR/Cas9 (Seah et al., 2015) to create isogenic lines to 
overcome this, provided the disease being modelled has a genetic basis.   Future approaches 
to modelling may involve either genome editing or screening for clonal variability between 








7.4 Thesis summary 
During this project a model of FTDP-17 was produced that is capable of recapitulating 
important aspects of tau-related molecular pathology found within the brains of patients 
with this disease, indicating that this model is useful for the investigation of tau pathogenesis 
within FTDP-17, and to a lesser extent PiD.   
Within the hiPSC-neurons treated with Aβ42O to sAD, tau hyperphosphorylation or increased 
levels of tau found in AD were not recapitulated.  These did recapitulate the appearance of 
varicosities within neurons and the loss of synaptic proteins due to the presence of Aβ.  
Interestingly, bfCNs and CGNs derived from pluripotent stem cells, that were treated with 
the same concentration of Aβ42O, revealed different responses in the activity of tau kinases 
GSK3β and Cdk5.  These differences, which occurred in the absence of tau 
hyperphosphorylation, suggest that early in disease the dysregulation of tau kinases may vary 
between specific cell types.  Further clarification of these differences may inform on the 
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